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Preamble
The medical profession should play a central role in evalu-
ating the evidence related to drugs, devices, and procedures
for the detection, management, and prevention of disease.
When properly applied, expert analysis of available data on
the benefits and risks of these therapies and procedures can
improve the quality of care, optimize patient outcomes, and
favorably affect costs by focusing resources on the most
effective strategies. An organized and directed approach to a
thorough review of evidence has resulted in the production of
clinical practice guidelines that assist physicians in selecting
the best management strategy for an individual patient.
Moreover, clinical practice guidelines can provide a founda-
tion for other applications, such as performance measures,
appropriate use criteria, and both quality improvement and
clinical decision support tools.
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly
produced guidelines in the area of cardiovascular disease
since 1980. The ACCF/AHA Task Force on Practice Guide-
lines (Task Force), charged with developing, updating, and
revising practice guidelines for cardiovascular diseases and
procedures, directs and oversees this effort. Writing commit-
tees are charged with regularly reviewing and evaluating all
available evidence to develop balanced, patient-centric rec-
ommendations for clinical practice.
Experts in the subject under consideration are selected by
the ACCF and AHA to examine subject-specific data and
write guidelines in partnership with representatives from
other medical organizations and specialty groups. Writing
committees are asked to perform a literature review; weigh
the strength of evidence for or against particular tests,
treatments, or procedures; and include estimates of expected
outcomes where such data exist. Patient-specific modifiers,
comorbidities, and issues of patient preference that may
influence the choice of tests or therapies are considered.
When available, information from studies on cost is consid-
ered, but data on efficacy and outcomes constitute the
primary basis for the recommendations contained herein.
In analyzing the data and developing recommendations and
supporting text, the writing committee uses evidence-based
methodologies developed by the Task Force.1 The Class of
Recommendation (COR) is an estimate of the size of the
treatment effect, with consideration given to risks versus
benefits as well as evidence and/or agreement that a given
treatment or procedure is or is not useful/effective or in some
situations may cause harm. The Level of Evidence (LOE) is
an estimate of the certainty or precision of the treatment
effect. The writing committee reviews and ranks evidence
supporting each recommendation, with the weight of evi-
dence ranked as LOE A, B, or C according to specific
definitions that are included in Table 1. Studies are identified
as observational, retrospective, prospective, or randomized as
appropriate. For certain conditions for which inadequate data
are available, recommendations are based on expert consen-
sus and clinical experience and are ranked as LOE C. When
recommendations at LOE C are supported by historical
clinical data, appropriate references (including clinical re-
views) are cited if available. For issues for which sparse data
are available, a survey of current practice among the clini-
cians on the writing committee is the basis for LOE C
recommendations, and no references are cited. The schema
for COR and LOE is summarized in Table 1, which also
provides suggested phrases for writing recommendations
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within each COR. A new addition to this methodology is
separation of the Class III recommendations to delineate
whether the recommendation is determined to be of “no
benefit” or is associated with “harm” to the patient. In
addition, in view of the increasing number of comparative
effectiveness studies, comparator verbs and suggested
phrases for writing recommendations for the comparative
effectiveness of one treatment or strategy versus another have
been added for COR I and IIa, LOE A or B only.
In view of the advances in medical therapy across the
spectrum of cardiovascular diseases, the Task Force has
designated the term guideline-directed medical therapy
(GDMT) to represent optimal medical therapy as defined by
ACCF/AHA guideline (primarily Class I)–recommended
therapies. This new term, GDMT, will be used herein and
throughout all future guidelines.
Because the ACCF/AHA practice guidelines address pa-
tient populations (and healthcare providers) residing in North
America, drugs that are not currently available in North
America are discussed in the text without a specific COR. For
studies performed in large numbers of subjects outside North
America, each writing committee reviews the potential influ-
ence of different practice patterns and patient populations on
the treatment effect and relevance to the ACCF/AHA target
population to determine whether the findings should inform a
specific recommendation.
The ACCF/AHA practice guidelines are intended to assist
healthcare providers in clinical decision making by describ-
Table 1. Applying Classification of Recommendations and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines
do not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is
useful or effective.
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior
myocardial infarction, history of heart failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve
direct comparisons of the treatments or strategies being evaluated.
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ing a range of generally acceptable approaches to the diag-
nosis, management, and prevention of specific diseases or
conditions. The guidelines attempt to define practices that
meet the needs of most patients in most circumstances. The
ultimate judgment about care of a particular patient must be
made by the healthcare provider and patient in light of all the
circumstances presented by that patient. As a result, situations
may arise in which deviations from these guidelines might be
appropriate. Clinical decision making should involve consid-
eration of the quality and availability of expertise in the area
where care is provided. When these guidelines are used as the
basis for regulatory or payer decisions, the goal should be
improvement in quality of care. The Task Force recognizes
that situations arise in which additional data are needed to
inform patient care more effectively; these areas will be
identified within each respective guideline when appropriate.
Prescribed courses of treatment in accordance with these
recommendations are effective only if followed. Because lack
of patient understanding and adherence may adversely affect
outcomes, physicians and other healthcare providers should
make every effort to engage the patient’s active participation
in prescribed medical regimens and lifestyles. In addition,
patients should be informed of the risks, benefits, and
alternatives to a particular treatment and should be involved
in shared decision making whenever feasible, particularly for
COR IIa and IIb, for which the benefit-to-risk ratio may be
lower.
The Task Force makes every effort to avoid actual,
potential, or perceived conflicts of interest that may arise as a
result of industry relationships or personal interests among
the members of the writing committee. All writing committee
members and peer reviewers of this guideline were required
to disclose all such current health care-related relationships,
including those existing 24 months (from 2005) before
initiation of the writing effort. The writing committee chair
may not have any relevant relationships with industry or other
entities (RWI); however, RWI are permitted for the vice chair
position. In December 2009, the ACCF and AHA imple-
mented a new policy that requires a minimum of 50% of the
writing committee to have no relevant RWI; in addition, the
disclosure term was changed to 12 months before writing
committee initiation. The present guideline was developed
during the transition in RWI policy and occurred over an
extended period of time. In the interest of transparency, we
provide full information on RWI existing over the entire
period of guideline development, including delineation of
relationships that expired more than 24 months before the
guideline was finalized. This information is included in
Appendix 1. These statements are reviewed by the Task Force
and all members during each conference call and meeting of
the writing committee and are updated as changes occur. All
guideline recommendations require a confidential vote by the
writing committee and must be approved by a consensus of
the voting members. Members who recused themselves from
voting are indicated in the list of writing committee members,
and specific section recusals are noted in Appendix 1.
Authors’ and peer reviewers’ RWI pertinent to this guideline
are disclosed in Appendixes 1 and 2, respectively. Compre-
hensive disclosure information for the Task Force is also
available online at http://www.cardiosource.org/ACC/About-
ACC/Who-We-Are/Leadership/Guidelines-and-Documents-
Task-Forces.aspx. The work of the writing committee is
supported exclusively by the ACCF, AHA, American College
of Physicians (ACP), American Association for Thoracic
Surgery (AATS), Preventive Cardiovascular Nurses Associ-
ation (PCNA), Society for Cardiovascular Angiography and
Interventions (SCAI), and Society of Thoracic Surgeons
(STS), without commercial support. Writing committee
members volunteered their time for this activity.
The recommendations in this guideline are considered
current until they are superseded by a focused update or the
full-text guideline is revised. Guidelines are official policy of
both the ACCF and AHA.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
1. Introduction
1.1. Methodology and Evidence Overview
The recommendations listed in this document are, whenever
possible, evidence based. An extensive evidence review was
conducted as the document was compiled through December
2008. Repeated literature searches were performed by the
guideline development staff and writing committee members
as new issues were considered. New clinical trials published
in peer-reviewed journals and articles through December
2011 were also reviewed and incorporated when relevant.
Furthermore, because of the extended development time
period for this guideline, peer review comments indicated that
the sections focused on imaging technologies required addi-
tional updating, which occurred during 2011. Therefore, the
evidence review for the imaging sections includes published
literature through December 2011.
Searches were limited to studies, reviews, and other evi-
dence in human subjects and that were published in English.
Key search words included but were not limited to the
following: accuracy, angina, asymptomatic patients, cardiac
magnetic resonance (CMR), cardiac rehabilitation, chest
pain, chronic angina, chronic coronary occlusions, chronic
ischemic heart disease (IHD), chronic total occlusion, con-
nective tissue disease, coronary artery bypass graft (CABG)
versus medical therapy, coronary artery disease (CAD) and
exercise, coronary calcium scanning, cardiac/coronary com-
puted tomography angiography (CCTA), CMR angiography,
CMR imaging, coronary stenosis, death, depression, detec-
tion of CAD in symptomatic patients, diabetes, diagnosis,
dobutamine stress echocardiography, echocardiography, el-
derly, electrocardiogram (ECG) and chronic stable angina,
emergency department, ethnic, exercise, exercise stress test-
ing, follow-up testing, gender, glycemic control, hyperten-
sion, intravascular ultrasound, fractional flow reserve (FFR),
invasive coronary angiography, kidney disease, low-density
lipoprotein (LDL) lowering, magnetic resonance imaging
(MRI), medication adherence, minority groups, mortality,
myocardial infarction (MI), noninvasive testing and mortal-
ity, nuclear myocardial perfusion, nutrition, obesity, out-
comes, patient follow-up, patient education, prognosis, prox-
imal left anterior descending (LAD) disease, physical
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activity, reoperation, risk stratification, smoking, stable is-
chemic heart disease (SIHD), stable angina and reoperation,
stable angina and revascularization, stress echocardiogra-
phy, radionuclide stress testing, stenting versus CABG, un-
protected left main, weight reduction, and women. Appendix
3 contains a list of abbreviations used in this document.
To provide clinicians with a comprehensive set of data, the
absolute risk difference and number needed to treat or harm,
if they were published and their inclusion was deemed
appropriate, are provided in the guideline, along with confi-
dence intervals (CIs) and data related to the relative treatment
effects, such as odds ratio (OR), relative risk (RR), hazard
ratio, or incidence rate ratio.
1.2. Organization of the Writing Committee
The writing committee was composed of physicians, cardiovas-
cular interventionalists, surgeons, general internists, imagers,
nurses, and pharmacists. The writing committee included repre-
sentatives from the ACP, AATS, PCNA, SCAI, and STS.
1.3. Document Review and Approval
This document was reviewed by 2 external reviewers nomi-
nated by both the ACCF and the AHA; 2 reviewers nomi-
nated by the ACP, AATS, PCNA, SCAI, and STS; and 19
content reviewers, including members of the ACCF Imaging
Council, ACCF Interventional Scientific Council, and the
AHA Council on Clinical Cardiology. Reviewers’ RWI
information was collected and distributed to the writing
committee and is published in this document (Appendix 2).
Because extensive peer review comments resulted in substan-
tial revision, the guideline was subjected to a second peer
review by all official and organizational reviewers. Lastly,
the imaging sections were peer reviewed separately, after an
update to that evidence base.
This document was approved for publication by the gov-
erning bodies of the ACCF, AHA, ACP, AATS, PCNA,
SCAI, and STS.
1.4. Scope of the Guideline
These guidelines are intended to apply to adult patients with
stable known or suspected IHD, including new-onset chest
pain (ie, low-risk unstable angina [UA]), or to adult patients
with stable pain syndromes (Figure 1). Patients who have
“ischemic equivalents,” such as dyspnea or arm pain with
exertion, are included in the latter group. Many patients with
IHD can become asymptomatic with appropriate therapy.
Accordingly, the follow-up sections of this guideline pertain
to patients who were previously symptomatic, including those
who have undergone percutaneous coronary intervention
(PCI) or CABG.
This guideline also addresses the initial diagnostic ap-
proach to patients who present with symptoms that suggest
IHD, such as anginal-type chest pain, but who are not known
to have IHD. In this circumstance, it is essential that the
practitioner ascertain whether such symptoms represent the
initial clinical recognition of chronic stable angina, reflecting
gradual progression of obstructive CAD or an increase in
supply/demand mismatch precipitated by a change in activity
or concurrent illness (eg, anemia or infection), or whether
they represent an acute coronary syndrome (ACS), most
likely due to an unstable plaque causing acute thrombosis.
For patients with newly diagnosed stable angina, this guide-
line should be used. Patients with ACS have either acute
myocardial infarction (AMI) or UA. For patients with AMI,
the reader is referred to the “ACCF/AHA Guidelines for the
Management of Patients With ST-Elevation Myocardial In-
farction” (STEMI).2,3 Similarly, for patients with UA that is
believed to be due to an acute change in clinical status
attributable to an unstable plaque or an abrupt change in
supply (eg, coronary occlusion with myocardial supply
through collaterals), the reader is referred to the “ACCF/AHA
Guidelines for the Management of Patients With Unstable
Angina/non–ST-Elevation Myocardial Infarction” (UA/
NSTEMI).4,4a There are, however, patients with UA who can
be categorized as low risk and are addressed in this guideline
(Table 2).
A key premise of this guideline is that once a diagnosis of
IHD is established, it is necessary in most patients to assess
their risk of subsequent complications, such as AMI or death.
Because the approach to diagnosis of suspected IHD and the
assessment of risk in a patient with known IHD are concep-
tually different and are based on different literature, the
writing committee constructed this guideline to address these
issues separately. It is recognized, however, that a clinician
might select a procedure for a patient with a moderate to high
pretest likelihood of IHD to provide information for both
diagnosis and risk assessment, whereas in a patient with a low
likelihood of IHD, it could be sensible to select a test simply
for diagnostic purposes without regard to risk assessment. By
separating the conceptual approaches to ascertaining diagno-
Asymptomatic
(SIHD)
Asymptomatic 
Persons 
Without 
Known IHD
(CV Risk)
Stable Angina 
or Low-Risk 
UA*
(SIHD; PCI/CABG)
Acute Coronary 
Syndromes
(UA/NSTEMI; STEMI;
PCI/CABG)
Patients 
with 
Known IHD
Noncardiac 
Chest Pain
New Onset 
Chest Pain
(SIHD; UA/NSTEMI; STEMI)
Sudden Cardiac Death
(VA-SCD)
Noninvasive
Testing
*Features of low risk unstable angina:
•Age, 70 y
•Exertional pain lasting <20 min. 
•Pain not rapidly accelerating
•Normal or unchanged ECG
•No elevation of cardiac markers
Figure 1. Spectrum of IHD. Guidelines relevant to
the spectrum of IHD are in parentheses. CABG
indicates coronary artery bypass graft; CV, cardio-
vascular; ECG, electrocardiogram; IHD, ischemic
heart disease; PCI, percutaneous coronary inter-
vention; SCD, sudden cardiac death; SIHD, stable
ischemic heart disease; STEMI, ST-elevation myo-
cardial infarction; UA, unstable angina;
UA/NSTEMI, unstable angina/non–ST-elevation
myocardial infarction; and VA, ventricular
arrhythmia.
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sis and prognosis, the goal of the writing committee is to
promote the sensible application of appropriate testing rather
than routine use of the most expensive or complex tests
whether warranted or not. It is not the intent of the writing
committee to promote unnecessary or duplicate testing, al-
though in some patients this could be unavoidable.
Additionally, this guideline addresses the approach to
asymptomatic patients with SIHD that has been diagnosed
solely on the basis of an abnormal screening study, rather
than on the basis of clinical symptoms or events such as
anginal symptoms or ACS. The inclusion of such asymptom-
atic patients does not constitute an endorsement of such tests
for the purposes of screening but is simply an acknowledg-
ment of the clinical reality that asymptomatic patients often
present for evaluation after such tests have been performed.
Multiple ACCF/AHA guidelines and scientific statements
have discouraged the use of ambulatory monitoring, treadmill
testing, stress echocardiography, stress myocardial perfusion
imaging (MPI), and computed tomography (CT) scoring of
coronary calcium or coronary angiography as routine screen-
ing tests in asymptomatic individuals. The reader is referred
to these documents for a detailed discussion of screening,
which is beyond the scope of this guideline (Table 3).
Patients with known IHD who were previously asymptom-
atic or whose symptoms were stable can develop new or
recurrent chest pain or other symptoms suggesting ACS. Just
as in the case of patients with new-onset chest pain, the
clinician must determine whether such recurrent or worsening
pain is consistent with ACS or simply represents symptoms
more consistent with chronic stable angina that do not require
emergent attention. As indicated previously, patients with
AMI or moderate- to high-risk UA fall outside of the scope of
this guideline, whereas those with chronic stable angina or
low-risk UA are addressed in the present guideline.
When patients with documented IHD develop recurrent
chest pain, the symptoms still could be attributable to another
condition. Such patients are included in this guideline if there
is sufficient suspicion that their heart disease is a likely source
of symptoms to warrant cardiac evaluation. If the evaluation
demonstrates that IHD is unlikely to cause the symptoms, the
evaluation of noncardiac causes is beyond the scope of this
guideline. If the evaluation demonstrates that IHD is the
likely cause of their recurrent symptoms, subsequent man-
agement of such patients does fall within this guideline.
The approach to screening and management of asymptom-
atic patients who are at risk for IHD but who are not known
Table 2. Short-Term Risk of Death or Nonfatal MI in Patients With UA/NSTEMI
Feature
High Risk Intermediate Risk
Low Risk
No high- or intermediate-risk
features are present, but patient may
have any of the following:
At least 1 of the following features must
be present:
No high-risk features are present, but patient
must have 1 of the following:
History Accelerating tempo of ischemic symptoms
in preceding 48 h
Prior MI, peripheral or cerebrovascular disease,
or CABG
Prior aspirin use
N/A
Characteristics of pain Prolonged ongoing (.20 min) rest pain Prolonged (.20 min) rest angina, now resolved,
with moderate or high likelihood of CAD
Rest angina (.20 min) or relieved with rest or
sublingual NTG
Nocturnal angina
New-onset or progressive CCS Class III or IV
angina in previous 2 wk without prolonged
(.20 min) rest pain but with intermediate or
high likelihood of CAD
Increased angina frequency, severity,
or duration
Angina provoked at a lower
threshold
New-onset angina with onset 2 wk
to 2 mo before presentation
Clinical findings Pulmonary edema, most likely due to
ischemia
New or worsening mitral regurgitation
murmur
S3 or new/worsening rales
Hypotension, bradycardia, or tachycardia
Age .75 y
Age .70 y N/A
ECG Angina at rest with transient ST-segment
changes .0.5 mm
Bundle-branch block, new or presumed
new
Sustained ventricular tachycardia
T-wave changes
Pathological Q waves or resting ST-depression
,1 mm in multiple lead groups (anterior,
inferior, lateral)
Normal or unchanged ECG
Cardiac markers Elevated cardiac TnT, TnI, or CK-MB (ie,
TnT or TnI .0.1 ng/mL)
Slightly elevated cardiac TnT, TnI, or CK-MB (ie,
TnT .0.01 but ,0.1 ng/mL)
Normal
Estimation of the short-term risks of death and nonfatal cardiac ischemic events in UA or NSTEMI is a complex multivariable problem that cannot be fully specified
in a table such as this. Therefore, the table is meant to offer general guidance and illustration rather than rigid algorithms.
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; CK-MB, creatine kinase-MB fraction; ECG,
electrocardiogram; MI, myocardial infarction; NTG, nitroglycerin; N/A, not available; TnI, troponin I; TnT, troponin T; and UA/NSTEMI, unstable angina/non–ST-elevation
myocardial infarction.
Modified from Braunwald et al.6
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to have IHD is also beyond the scope of this guideline, but it
is addressed in the “ACCF/AHA Guideline for Assessment of
Cardiovascular Risk in Asymptomatic Adults.”5 Similarly,
the present guideline does not apply to patients with chest
pain symptoms early after revascularization by either percu-
taneous techniques or CABG. Although the division between
“early” and “late” symptoms is arbitrary, the writing com-
mittee believed that this guideline should not be applied to
patients who develop recurrent symptoms within 6 months of
revascularization. Pediatric patients are beyond the scope of
this guideline, because IHD is very unusual in such patients
and is related primarily to the presence of coronary artery
anomalies. Patients with chest pain syndromes after cardiac
transplantation also are not included in this guideline.
1.5. General Approach and Overlap With Other
Guidelines or Statements
This guideline overlaps with numerous clinical practice
guidelines published by the ACCF/AHA Task Force on
Practice Guidelines; the National Heart, Lung, and Blood
Institute; and the ACP (Table 3). To maintain consistency, the
writing committee worked with members of other committees
to harmonize recommendations and eliminate discrepancies.
Some recommendations from earlier guidelines have been
updated as warranted by new evidence or a better understand-
ing of earlier evidence, whereas others that were no longer
accurate or relevant or were overlapping were modified;
recommendations from previous guidelines that were similar
or redundant were eliminated or consolidated when possible.
Most of the topics mentioned in the present guideline were
addressed in the “ACC/AHA 2002 Guideline Update for the
Management of Patients With Chronic Stable Angina—
Summary Article,”7 and many of the recommendations in the
present guideline are consistent with those in the 2002
document. Whereas the 2002 update dealt individually with
specific drugs and interventions for reducing cardiovascular
risk and medical therapy of angina pectoris, the present
document recommends a combination of lifestyle modifica-
tions and medications that constitute GDMT. In addition,
recommendations for risk reduction have been revised to
reflect new evidence and are now consistent with the “AHA/
ACCF Secondary Prevention and Risk Reduction Therapy for
Patients With Coronary and Other Atherosclerotic Vascular
Disease: 2011 Update.”8 Also in the present guideline,
recommendations and text related to revascularization are the
result of extensive collaborative discussions between the PCI
and CABG writing committees, as well as key members of
the SIHD and UA/NSTEMI writing committees. In a major
undertaking, the PCI and CABG guidelines were written
concurrently with input from the STEMI guideline writing
committee and additional collaboration with the SIHD guide-
line writing committee, allowing greater collaboration be-
tween these writing committees on revascularization strate-
gies in patients with CAD (including unprotected left main
PCI, multivessel disease revascularization, and hybrid proce-
dures).9,10 Section 5 is included as published in both the PCI
and CABG guidelines in its entirety.
In addition to cosponsoring practice guidelines, the ACCF
has sponsored appropriate use criteria (AUC) documents for
imaging testing, diagnostic catheterization, and coronary
revascularization since 2005.11–16 Practice guideline recom-
mendations are based on evidence from clinical and obser-
vational trials and expert consensus; AUCs are complemen-
tary to practice guidelines and make every effort to be
concordant with their recommendations. In general, the rec-
ommendations in this guideline and current AUCs are con-
sistent. Apparent discrepancies usually reflect differing
frameworks or imaging methodologies. Moreover, where
guidelines leave “gaps” (ie, unaddressed applications), AUCs
can provide additional clinical guidance based on the best
Table 3. Associated Guidelines and Statements
Document Reference(s) Organization Publication Year
Guidelines
Chronic Stable Angina: 2007 Focused Update (19) ACCF/AHA 2007
Valvular Heart Disease (20) ACCF/AHA 2008
Heart Failure: 2009 Update (21) ACCF/AHA 2009
STEMI (2, 3, 22) ACCF/AHA 2009
Assessment of Cardiovascular Risk in Asymptomatic Adults (5) ACCF/AHA 2010
Coronary Artery Bypass Graft Surgery (9) ACCF/AHA 2011
Percutaneous Coronary Intervention (10) ACCF/AHA/SCAI 2011
Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other
Atherosclerotic Vascular Disease
(8) AHA/ACCF 2011
UA/NSTEMI: 2007 and 2012 Updates (4, 4a) ACCF/AHA 2012
Statements
NCEP ATP III Implications of Recent Clinical Trials (18, 24) NHLBI 2004
National Hypertension Education Program (JNC VII) (17) NHLBI 2004
Referral, Enrollment, and Delivery of Cardiac Rehabilitation/Secondary Prevention Programs
at Clinical Centers and Beyond: A Presidential Advisory From the AHA
(25) AHA 2011
ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; ATP III, Adult Treatment Panel 3; JNC VII, The Seventh Report of the
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; NHLBI, National Heart, Lung and Blood Institute; and SCAI,
Society for Cardiovascular Angiography and Interventions.
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available clinical evidence and use a prospective, expert
consensus methodology.16 Specifically, AUCs provide de-
tailed indications for testing and procedures to aid clinical
decision making, categorizing each indication as appropriate,
uncertain, or inappropriate. Thus, ACCF AUCs provide an
additional means to identify candidates for testing or proce-
dures as well as those for whom they would be inappropriate
or for whom the optimal approach is uncertain. Inappropriate
candidates are those for whom compelling evidence indicates
that testing is not indicated or, in some cases, results in
reduced accuracy. Uncertain indications are those with either
published evidence or lack of expert consensus on testing use.
AUCs also include relevant clinical scenarios not ad-
dressed by these guidelines,11 such as the issue of testing
during follow-up of patients with SIHD with stress echocar-
diography,15 single-photon emission computed tomography
(SPECT) MPI,12 CMR, and CCTA.13,14 These AUC docu-
ments address the intervals between testing for various stress
imaging indications. As with all standards documents, ongo-
ing evaluation is required to update the recommendations on
the value, limitations, timing, costs, and risks of imaging as
an adjunct to clinical assessment during follow-up of patients
with established SIHD. Review of these AUCs is beyond the
scope of the present document, and the reader is referred to
the most recent AUC documents to complement the guide-
lines provided here.
As the scientific basis of the approach to management of
cardiovascular disease has rapidly expanded, the size and
scope of clinical practice guidelines have grown commensu-
rately to a point where they have become too unwieldy for
routine use by practicing clinicians. The most current national
guidelines for management of hypertension (Joint National
Committee VII)17 and hyperlipidemia (Adult Treatment Panel
III)18 combined comprise nearly 400 pages. Thus, the writing
committee recognized that it would be unfeasible to produce
a document that would be simultaneously practical and
exhaustive and, therefore, has tried to create a resource that
provides a comprehensive approach to management of SIHD
for which the relevant evidence is succinctly summarized and
referenced. The writing committee used current and credible
meta-analyses, when available, instead of conducting a sys-
tematic review of all primary literature.
1.6. Magnitude of the Problem
IHD remains a major public health problem nationally and
internationally. It is estimated that 1 in 3 adults in the United
States (about 81 million) has some form of cardiovascular
disease, including .17 million with coronary heart disease
and nearly 10 million with angina pectoris.26,27 Among
persons 60 to 79 years of age, approximately 25% of men and
16% of women have coronary heart disease, and these figures
rise to 37% and 23% among men and women $80 years of
age, respectively.27
Although the survival rate of patients with IHD has been
steadily improving,28 it was still responsible for nearly 380
000 deaths in the United States during 2010, with an
age-adjusted mortality rate of 113 per 100 000 population.29
Although IHD is widely known to be the number 1 cause of
death in men, this is also the case for women, among whom
this condition accounts for 27% of deaths (compared with
22% due to cancer).30 IHD also accounts for the vast majority
of the mortality and morbidity of cardiac disease. Each year,
.1.5 million patients have an MI. Many more are hospital-
ized for UA and for evaluation and treatment of stable chest
pain syndromes. Beyond the need for hospitalization, many
patients with chronic chest pain syndromes are temporarily
unable to perform normal activities for hours or days and thus
experience a reduced quality of life. Among patients enrolled
in the BARI (Bypass Angioplasty Revascularization Investi-
gation) study,31 about 30% never returned to work after
coronary revascularization, and 15% to 20% of patients rated
their own health as “fair” or “poor” despite revascularization.
Similarly, observational studies of patients recovering from
an AMI demonstrated that 1 in 5 patients, even after intensive
treatment at the time of their AMI, still suffered angina 1 year
later.32 These data confirm the widespread clinical impression
that IHD continues to be associated with considerable patient
morbidity despite the decline in cardiovascular mortality rate.
Patients who have had ACS, such as AMI, remain at risk for
recurrent events even if they have no, or limited, symptoms
and should be considered to have SIHD.
In approximately 50% of patients, angina pectoris is the
initial manifestation of IHD.27 The incidence of angina rises
continuously with age in women, whereas the incidence of
angina in men peaks between 55 and 65 years of age before
declining.27 Despite angina’s clinical importance and high
frequency, modern, population-based data are quite limited,
and these figures likely underestimate the true prevalence of
angina.33
The annual rates per 1000 population of new episodes of
angina for nonblack men are 28.3 for ages 65 to 74 years,
36.3 for ages 75 to 84 years, and 33.0 for age $85 years. For
nonblack women in the same age groups, the rates are 14.1,
20.0, and 22.9, respectively. For black men, the rates are 22.4,
33.8, and 39.5, and for black women, the rates are 15.3, 23.6,
and 35.9, respectively.30 In a study conducted in Finland, the
age-standardized, annual incidence of angina was 2.03 in men
and 1.89 in women per 100 populations.33
Further estimates of the prevalence of chronic, symptom-
atic IHD can be obtained by extrapolating from data on ACS
and, more specifically, AMI. About one half of patients
presenting to the hospital with ACS have preceding angina.27
One current estimate is that about 50% of patients who suffer
an AMI each year in the United States survive until hospi-
talization.27 Two older population-based studies from Olm-
sted County, MN, and Framingham, MA, examined the
annual rates of MI in patients with symptoms of angina and
reported similar rates of 3% to 3.5% per year.34,35 On this
basis, it can be estimated that there were 30 patients with
stable angina for every patient with infarction who was
hospitalized, which represents 16.5 million persons with
angina in the United States. However, since the data reported
in these studies were collected, it is likely that the much
greater use of effective medical therapies, including antiangi-
nal medications and revascularization procedures, has re-
duced the proportion of patients with symptomatic angina—
although there are still many patients whose symptoms are
poorly controlled.36–38
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The costs of caring for patients with IHD are enormous,
estimated at $156 billion in the United States for both direct
and indirect costs in 2008. More than one half of direct costs
are related to hospitalization. In 2003, the Medicare program
alone paid $12.2 billion for hospitalizations for IHD, includ-
ing $12 321 per discharge for AMI and $11 783 per discharge
for admissions for coronary atherosclerosis.39
Another major expense is for invasive procedures and
related costs. In 2006 in the United States, there were 1 313
000 inpatient PCI procedures, 448 000 inpatient coronary
artery bypass procedures, and 1 115 000 inpatient diagnostic
cardiac catheterizations.27,40 In addition, $13 million outpa-
tient visits for IHD occur in the United States annually.41 It
was estimated that the costs of outpatient and emergency
department visits in 2000 by patients with chronic angina
were $922 million and $286 million, respectively, and pre-
scriptions accounted for $291 million. Long-term care
costs—including skilled nursing, home health, and hospice
care—were $2.6 billion, which represented 30% of the total
cost of care for chronic angina.42
Although the direct costs associated with SIHD are sub-
stantial, they do not account for the significant indirect costs
of lost workdays, reduced productivity, long-term medica-
tion, and associated effects. The indirect costs have been
estimated to be almost as great as the direct costs27,43 (Table
4). The magnitude of the problem can be summarized
succinctly: SIHD affects many millions of Americans, with
associated annual costs that are measured in tens of billions of
dollars.
1.7. Organization of the Guideline
The overarching framework adopted in constructing this
guideline reflects the complementary goals of treating pa-
tients with known SIHD, alleviating or improving symptoms,
and prolonging life. This guideline is divided into 4 basic
sections summarizing the approaches to diagnosis, risk as-
sessment, treatment, and follow-up. Five algorithms summa-
rize the management of stable angina: diagnosis (Figure 2),
risk assessment (Figure 3), GDMT (Figure 4), and revascu-
larization (Figures 5 and 6). We readily acknowledge, how-
ever, that in actual clinical practice, the elements comprising
the 4 sections and the steps delineated in the algorithms often
overlap and are not always separable. Some low-risk patients,
for example, might require only clinical assessment to deter-
mine that they do not need any further evaluation or treat-
ment. Other patients might require only clinical assessment
and further adjustment of medical therapy if their preferences
and comorbidities preclude revascularization, thus obviating
the necessity for risk stratification. The stress testing/angiog-
raphy algorithm might be applicable for diagnostic purposes
in patients with symptoms that suggest SIHD or to perform
risk assessment in patients with established SIHD.
1.8. Vital Importance of Involvement by an
Informed Patient: Recommendation
Class I
1. Choices about diagnostic and therapeutic options
should be made through a process of shared decision
making involving the patient and provider, with the
provider explaining information about risks, bene-
fits, and costs to the patient. (Level of Evidence: C)
In accordance with the principle of autonomy, the healthcare
provider is obliged to solicit and respect the patient’s prefer-
ences about choice of therapy. Although this principle, in the
setting of cardiovascular disease, has received only limited
study, the concept of shared decision making increasingly is
viewed as an approach that ensures that patients remain
involved in key decisions. This approach leads to higher
quality of care.44,45
To ensure that the patient is able to make the most
informed decisions possible, the provider must give sufficient
information about the underlying disease process, along with
all relevant diagnostic and therapeutic options—including
anticipated outcomes, risks, and costs to the patient.46 This
information should be provided in a manner that is readily
comprehensible and permits the opportunity for dialog and
questions.
Patients should be encouraged to seek additional informa-
tion from other sources, including those on the Internet, such
as those maintained by the National Institutes of Health, the
Centers for Disease Control and Prevention, and the ACCF/
AHA. Substantial research indicates that when informed
about absolute or marginal benefit, patients often elect to
postpone or forego invasive procedures. Two patients with
similar pretest probabilities of IHD could prefer different
approaches because of variations in personal beliefs, eco-
nomic situation, or stage of life. Because of the variation in
symptoms and clinical characteristics among patients, as well
as their unique perceptions, expectations, and preferences,
there is often no single correct approach to any given set of
clinical circumstances. In assisting patients to reach an
Table 4. Estimated Direct and Indirect Costs (in Billions of
Dollars) of Heart Disease and Coronary Heart Disease: United
States: 2010
Heart Disease
($ in Billions)
Coronary Heart
Disease ($ in Billions)
Direct costs
Hospital 110.2 56.6
Nursing home 24.7 13.0
Physicians/other professionals 24.7 13.9
Drugs/other
Medical durables 22.5 10.0
Home health care 8.3 2.5
Total expenditures 189.4 96.0
Indirect costs
Lost productivity/morbidity 25.6 11.3
Lost productivity/mortality* 101.4 69.8
Grand totals 316.4 177.1
All estimates prepared by Thomas Thom, National Heart, Lung, and Blood
Institute.
*Lost future earnings of persons who will die in 2010, discounted at 3%.
Reproduced from Lloyd-Jones et al.27
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Figure 2. Diagnosis of patients with suspected ischemic heart disease.* *Colors correspond to the class of recommendations in the
ACCF/AHA Table 1. The algorithms do not represent a comprehensive list of recommendations (see text for all recommendations).
†See Table 2 for short-term risk of death or nonfatal MI in patients with UA/NSTEMI. ‡CCTA is reasonable only for patients with inter-
mediate probability of IHD. CCTA indicates computed coronary tomography angiography; CMR, cardiac magnetic resonance; ECG,
electrocardiogram; Echo, echocardiography; IHD, ischemic heart disease; MI, myocardial infarction; MPI, myocardial perfusion imaging;
Pharm, pharmacological; UA, unstable angina; and UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction.
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informed decision, it is essential to elicit the breadth of their
knowledge, values, preferences, and concerns.
The healthcare provider has a responsibility to ensure that
patients understand and consider both the upside and down-
side of available options, in both the near and long terms. All
previous guidelines reviewed by the writing committee have
recognized the crucial role that patient preferences play in the
selection of a treatment strategy.9,10,47–49 It is essential that
these discussions be conducted in a location and atmosphere
that permits adequate time for discussion and contemplation.
Initiating a discussion about the relative merits of PCI or
CABG while a patient is in the midst of a procedure, for
example, is not usually consistent with these principles.
In crafting a diagnostic strategy, the objective is to ascer-
tain, as accurately as possible, whether the patient has IHD
while minimizing the expense, discomfort, and potential
harms of any tests or procedures. This includes avoiding
procedures that are likely to yield false positive or false
negative results or that are unnecessary or inappropriate. The
objective for procedures intended to assess prognosis is
similar.
Treatment options should be emphasized, especially in
cases where there is no substantial advantage of one strategy
over others. For most patients, the goal of treatment should be
to simultaneously maximize survival and to achieve prompt
and complete (or nearly complete) elimination of anginal
chest pain with return to normal activities—in other words, a
functional capacity of Canadian Cardiovascular Society
(CCS) Class I angina.50 For example, for an otherwise
healthy, active patient, the treatment goal is usually the
complete elimination of chest pain and a return to vigorous
physical activity. Conversely, an elderly patient with more
severe angina and several serious coexisting medical prob-
lems might be satisfied with a reduction in symptoms that
permits limited activities of daily living. Patients with anat-
omy that would ordinarily favor the choice of CABG could
have comorbidities that make the risk of surgery unaccept-
able, in which case PCI or medical therapy is a more
attractive option.
In counseling patients, the healthcare provider should be
aware of, and help to rectify, common misperceptions. Many
patients assume, for example, that opening a partially blocked
artery will naturally prevent a heart attack and prolong life
irrespective of other anatomic and clinical factors. When
there is little expectation of an improvement in survival from
revascularization, patients should be so informed. When
evidence points to probable benefit from either revascular-
ization or medical therapy, it should be quantified to the
extent possible, with explicit acknowledgment of uncertain-
ties, and should be discussed in the context of what treatment
option is best for that particular patient. When possible, the
relative time course of response to therapy should be de-
scribed for therapeutic choices. Some patients might, for
example, initially opt for PCI over medical therapy because
relief of symptoms is typically more rapid. However, when
informed of the immediate risk of complications of PCI, some
Figure 3. Algorithm for risk assessment
of patients with SIHD.* *Colors corre-
spond to the class of recommendations
in the ACCF/AHA Table 1. The algo-
rithms do not represent a comprehen-
sive list of recommendations (see text
for all recommendations). CCTA indi-
cates coronary computed tomography
angiography; CMR, cardiac magnetic
resonance; ECG, electrocardiogram;
Echo, echocardiography; LBBB, left
bundle-branch block; MPI, myocardial
perfusion imaging; and Pharm,
pharmacological.
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patients could prefer conservative therapy. Similarly, many
patients choose PCI over CABG because it is less invasive
and provides for quicker recovery, despite the fact that repeat
revascularization procedures are performed more frequently
after PCI. Patients’ preferences in these circumstances often
are influenced by their attitudes toward risk and by the
tendency to let immediate smaller benefits outweigh larger
future risks, a phenomenon termed “temporal discounting.”51
2. Diagnosis of SIHD
2.1. Clinical Evaluation of Patients With
Chest Pain
2.1.1. Clinical Evaluation in the Initial Diagnosis of
SIHD in Patients With Chest Pain: Recommendations
Class I
1. Patients with chest pain should receive a thorough
history and physical examination to assess the prob-
ability of IHD before additional testing.52 (Level of
Evidence: C)
2. Patients who present with acute angina should be
categorized as stable or unstable; patients with UA
should be further categorized as being at high,
moderate, or low risk.4,4a (Level of Evidence: C)
2.1.2. History
The clinical examination is the key first step in evaluating a
patient with chest pain and should include a detailed assess-
ment of symptoms, including quality, location, severity, and
duration of pain; radiation; associated symptoms; provocative
factors; and alleviating factors. Adjectives often used to
describe anginal pain include “squeezing,” “grip-like,” “suf-
focating,” and “heavy,” but it is rarely sharp or stabbing and
typically does not vary with position or respiration. On
occasion the patient might demonstrate the classic Levine’s
sign by placing a clenched fist over the precordium to
describe the pain. Many patients do not, however, describe
angina as frank pain but as tightness, pressure, or discomfort.
Figure 4. Algorithm for guideline-directed medical therapy for patients with SIHD.* *Colors correspond to the class of recommendations
in the ACCF/AHA Table 1. The algorithms do not represent a comprehensive list of recommendations (see text for all recommenda-
tions). †The use of bile acid sequestrant is relatively contraindicated when triglycerides are $200 mg/dL and is contraindicated when
triglycerides are $500 mg/dL. ‡Dietary supplement niacin must not be used as a substitute for prescription niacin. ACCF indicates
American College of Cardiology Foundation; ACEI, angiotensin-converting enzyme inhibitor; AHA, American Heart Association; ARB,
angiotensin-receptor blocker; ASA, aspirin; ATP III, Adult Treatment Panel 3; BP, blood pressure; CCB, calcium channel blocker; CKD,
chronic kidney disease; HDL-C, high-density lipoprotein cholesterol; JNC VII, Seventh Report of the Joint National Committee on Pre-
vention, Detection, Evaluation, and Treatment of High Blood Pressure; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular;
MI, myocardial infarction; NHLBI, National Heart, Lung, and Blood Institute; and NTG, nitroglycerin.
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Other patients, in particular women and the elderly, can
present with atypical symptoms such as nausea, vomiting,
midepigastric discomfort, or sharp (atypical) chest pain. In
the WISE (Women’s Ischemic Syndrome Evaluation) study,
65% of women with ischemia presented with atypical
symptoms.54
Anginal pain caused by cardiac ischemia typically lasts
minutes. The location is usually substernal, and pain can
radiate to the neck, jaw, epigastrium, or arms. Pain above the
mandible, below the epigastrium, or localized to a small area
over the left lateral chest wall is rarely angina. Angina is often
precipitated by exertion or emotional stress and relieved by
rest. Sublingual nitroglycerin also usually relieves angina,
within 30 seconds to several minutes. The history can be used
to classify symptoms as typical, atypical, or noncardiac chest
pain6 (Table 5). The patient presenting with angina must be
categorized as having stable angina or UA.4,4a UA is defined
as new onset, increasing (in frequency, intensity, or duration),
or occurring at rest50 (Table 6). However, patients presenting
with UA are subdivided by their short-term risk (Table 2).
Patients at high or moderate risk often have experienced
rupture of coronary artery plaque and have a risk of death
higher than that of patients with stable angina but not as great
as that of patients with AMI. These patients should be
transferred promptly to an emergency department for evalu-
ation and treatment. The short-term prognosis of patients with
low-risk UA, however, is comparable to those with stable
angina, and their evaluation can be conducted safely and
expeditiously in an outpatient setting.
After thorough characterization of chest pain, the presence
of risk factors for IHD55 should be determined. These include
smoking, hyperlipidemia, diabetes mellitus, hypertension,
obesity or metabolic syndrome, physical inactivity, and a
family history of premature IHD (ie, onset in a father, brother,
or son before age 55 years or a mother, sister, or daughter
before age 65 years). A history of cerebrovascular or periph-
eral artery disease (PAD) also increases the likelihood of
IHD.
2.1.3. Physical Examination
The examination is often normal or nonspecific in patients
with stable angina56 but could reveal related conditions such
as heart failure, valvular heart disease, or hypertrophic
cardiomyopathy. An audible rub suggests pericardial or
Potential revascularization procedure 
warranted based on assessment of 
coexisting cardiac and noncardiac factors 
and patient preferences?
Perform 
coronary 
angiography
Yes
Heart Team concludes that 
anatomy and clinical factors 
indicate revascularization may 
improve survival (Table 18)
Determine optimal method of 
revascularization based upon 
patient preferences, anatomy, other 
clinical factors, and local resources 
and expertise (Table 18)
Yes
No
No
Noninvasive testing 
suggests high-risk 
coronary lesion(s)
from Figure 2
Continued Guideline-
Directed Medical 
Therapy with 
ongoing patient 
education
Go to Figure 4
Guideline-Directed Medical Therapy 
continued in all patients
Figure 5. Algorithm for revascularization
to improve survival of patients with
SIHD.* *Colors correspond to the class
of recommendations in the ACCF/AHA
Table 1. The algorithms do not represent
a comprehensive list of recommenda-
tions (see text for all recommendations).
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pleural disease. Evidence of vascular disease includes carotid
or renal artery bruits, a diminished pedal pulse, or a palpable
abdominal aneurysm. Elevated blood pressure (BP), xantho-
mas, and retinal exudates point to the presence of IHD risk
factors. Pain reproduced by pressure on the chest wall
suggests a musculoskeletal etiology but does not eliminate
the possibility of angina due to IHD.
2.1.4. Electrocardiography
2.1.4.1. Resting Electrocardiography to Assess
Risk: Recommendation
Class I
1. A resting ECG is recommended in patients without
an obvious, noncardiac cause of chest pain.57–59
(Level of Evidence: B)
Patients with SIHD who have the following abnormalities on
a resting ECG have a worse prognosis than those with normal
ECGs57–59: evidence of prior MI, especially Q waves in
multiple leads or an R wave in V1 indicating a posterior
infarction60; persistent ST-T-wave inversions, particularly in
leads V1 to V361–64; left bundle-branch block (LBBB),
bifascicular block, second- or third-degree atrioventricular
Figure 6. Algorithm for revascularization
to improve symptoms of patients with
SIHD.* *Colors correspond to the class
of recommendations in the ACCF/AHA
Table 1. The algorithms do not represent
a comprehensive list of recommenda-
tions (see text for all recommendations).
CABG indicates coronary artery bypass
graft; PCI, percutaneous coronary
intervention.
Table 5. Clinical Classification of Chest Pain
Typical angina
(definite)
1) Substernal chest discomfort with a characteristic quality
and duration that is 2) provoked by exertion or
emotional stress and 3) relieved by rest or nitroglycerin
Atypical angina
(probable)
Meets 2 of the above characteristics
Noncardiac
chest pain
Meets 1 or none of the typical anginal characteristics
Adapted from Braunwald et al.6
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(AV) block, or ventricular tachyarrhythmia65; or left ventric-
ular (LV) hypertrophy.62,66
2.1.5. Differential Diagnosis
Although the symptoms of some patients might be consistent
with a very high probability of IHD, in others, the etiology
might be less certain, and alternative diagnoses should be
considered (Table 7). However, even when angina seems
likely to be related to IHD, other coexisting conditions can
precipitate symptoms by inducing or exacerbating myocardial
ischemia, by either increased myocardial oxygen demand or
decreased myocardial oxygen supply (Table 8). When severe,
these conditions can cause angina in the absence of signifi-
cant anatomic coronary obstruction. Chest pain in women is
less often due to IHD than in men, even when the pain is
typical. Nevertheless, pain in women can be related to
vascular dysfunction in the absence of epicardial CAD.
Entities that cause increased oxygen demand include hyper-
thermia (particularly if accompanied by volume contrac-
tion),67 hyperthyroidism, and cocaine or methamphetamine
abuse. Sympathomimetic toxicity, due, for example, to co-
caine intoxication, not only increases myocardial oxygen
demand but also induces coronary vasospasm and can cause
infarction in young patients. Long-term cocaine use can cause
premature development of IHD.68,69 Severe uncontrolled
hypertension increases LV wall tension, leading to increased
myocardial oxygen demand and decreased subendocardial
perfusion. Hypertrophic cardiomyopathy and aortic stenosis
can induce even more severe LV hypertrophy and resultant
wall tension. Ventricular or supraventricular tachycardias are
another cause of increased myocardial oxygen demand, but
when paroxysmal these are difficult to diagnose.
Anemia is the prototype for conditions that limit myocar-
dial oxygen supply. Cardiac output rises when the hemoglo-
bin drops to ,9 g/dL, and ST-T-wave changes (depression or
inversion) can occur at levels ,7 g/dL.
Hypoxemia resulting from pulmonary disease (eg, pneu-
monia, asthma, chronic obstructive pulmonary disease, pul-
monary hypertension, interstitial fibrosis, or obstructive sleep
apnea) can also precipitate angina. Polycythemia, leukemia,
thrombocytosis, and hypergammaglobulinemia are associated
with increased blood viscosity that can decrease coronary
artery blood flow and precipitate angina, even in patients
without significant coronary stenoses.
2.1.6. Developing the Probability Estimate
When the clinical evaluation is complete, the practitioner
must determine whether the probability of IHD is sufficient to
recommend further testing, which is often a standard exercise
test. When the probability of disease is ,5%, further testing
is usually not warranted because the likelihood of a false-
positive test (ie, positive test in the absence of obstructive
CAD) is actually higher than that of a true positive. On the
other hand, when the exercise test is negative in a patient who
has a very high likelihood of IHD on the basis of the history,
there is a substantial chance that in reality the result is falsely
negative. Thus, further testing is most useful in patients in
whom the cause of chest pain is truly uncertain (ie, the
probability of IHD is between 20% and 70%). It is necessary
to note, however, that these probabilities relate solely to the
presence of obstructive CAD and do not pertain to ischemia
due to microvascular disease or other causes. They also do
not reflect the likelihood that a nonobstructing plaque could
become unstable and cause ischemia.
A landmark study52 showed how information about the
type of pain and age and sex of the patient can provide a
reasonable estimate of the likelihood of IHD. For instance, a
64-year-old man with typical angina has a 94% likelihood of
having significant coronary stenosis. A 32-year-old woman
with nonanginal chest pain has a 1% chance of coronary
stenosis.70–72 Other clinical characteristics that improved the
accuracy of prediction include active or recent smoking,
Q-wave or ST-T-wave changes on the ECG, hyperlipidemia
(defined at the time of study as a total cholesterol level .250
mg/dL), and diabetes mellitus (defined at that time as a
fasting glucose level .140 mg/dL). Of these characteristics,
Table 6. Three Principal Presentations of UA
Rest angina Angina occurring at rest and usually prolonged .20 min,
occurring within 1 wk of presentation
New-onset
angina
Angina of at least CCS Class III severity with onset
within 2 mo of initial presentation
Increasing
angina
Previously diagnosed angina that is distinctly more frequent,
longer in duration, or lower in threshold (ie,
increased by $1 CCS class within 2 mo of initial presentation
to at least CCS Class III severity)
CCS indicates Canadian Cardiovascular Society.
Reproduced from Braunwald.50
Table 7. Alternative Diagnoses to Angina for Patients With Chest Pain
Nonischemic Cardiovascular Pulmonary Gastrointestinal Chest Wall Psychiatric
Aortic dissection Pulmonary embolism Esophageal
Esophagitis
Spasm
Reflux
Costochondritis
Fibrositis
Rib fracture
Sternoclavicular arthritis
Herpes zoster (before the rash)
Anxiety disorders
Hyperventilation
Panic disorder
Primary anxiety
Pericarditis Pneumothorax
Pneumonia
Pleuritis
Biliary
Colic
Cholecystitis Choledocholithiasis
Cholangitis
Peptic ulcer
Pancreatitis
Affective disorders (ie, depression)
Somatiform disorders
Thought disorders (ie, fixed delusions)
Reproduced from Gibbons et al.7
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diabetes mellitus had the greatest influence on increasing the
probability of IHD. The presence of hypertension or a family
history of premature IHD did not provide additional predic-
tive accuracy. The results of the aforementioned landmark
study subsequently were replicated with data from CASS
(Coronary Artery Surgery Study)73 and were within 5% of the
original estimates for 23 of 24 patient groupings. The single
major exception was the category of adults who were #50
years of age with atypical angina, for whom the CASS
estimate was 17% higher. On the basis of this high degree of
concordance, the data from these studies were merged in the
2002 Chronic Stable Angina guideline7,52,73 (Table 9).
Additional validation studies were conducted with data
from the Duke Databank for Cardiovascular Disease, which
also incorporated electrocardiographic findings (Q waves or
ST-T changes) and information about risk factors (smoking,
diabetes mellitus, hyperlipidemia).71 Table 10 presents the
Duke data for mid-decade patients (35, 45, 55, and 65 years
of age). Two probabilities are given. The first is for a low-risk
patient with no risk factors and a normal ECG. The second is
for a high-risk patient who smokes and has diabetes mellitus
and hyperlipidemia but has a normal ECG. A key contribu-
tion of the Duke Databank is the value of incorporating data
about risk factors into the probability estimate.
A limitation of these predictive models, however, is that
because they were developed with data from patients referred
to university medical centers, they tended to overestimate the
likelihood of IHD in patients at lower risk. It is possible to
correct this referral (or ascertainment) bias by using the
overall prevalence of IHD in the primary-care population,72
although these adjustments are themselves subject to error if
the prevalence estimates are flawed.
An additional limitation of these models is that they were
derived from populations of patients #70 years of age. Yet
another drawback is that they perform less well in women, in
part because the prevalence of obstructive CAD is lower in
women than in men. As shown in Table 9, the Diamond-
Forrester model substantially overestimates the likelihood of
CAD compared with the prevalence observed in the WISE
study.52,74
After integrating data from the clinical evaluation, model
predictions, and other relevant factors to develop a probabil-
ity estimate, the clinician must then engage the patient in a
process of shared decision making, as noted in Section 1.8, to
determine whether further testing is warranted.
2.2. Noninvasive Testing for Diagnosis of IHD
2.2.1. Approach to the Selection of Diagnostic Tests to
Diagnose SIHD
Functional or stress testing to detect inducible ischemia has
been the “gold standard” and is the most common noninva-
sive test used to diagnose SIHD. All functional tests are
designed to provoke cardiac ischemia by using exercise or
pharmacological stress agents either to increase myocardial
work and oxygen demand or to induce vasodilation-elicited
heterogeneity in induced coronary flow. These techniques
Table 8. Conditions Provoking or Exacerbating Ischemia
Increased Oxygen Demand Decreased Oxygen Supply
Noncardiac Noncardiac
Hyperthermia
Hyperthyroidism
Sympathomimetic toxicity
(ie, cocaine use)
Hypertension
Anxiety
Arteriovenous fistulae
Anemia
Hypoxemia
Pneumonia
Asthma
Chronic obstructive pulmonary
disease
Pulmonary hypertension
Interstitial pulmonary fibrosis
Obstructive sleep apnea
Sickle cell disease
Sympathomimetic toxicity (ie, cocaine
use, pheochromocytoma)
Hyperviscosity
Polycythemia
Leukemia
Thrombocytosis
Hypergammaglobulinemia
Cardiac Cardiac
Hypertrophic cardiomyopathy
Aortic stenosis
Dilated cardiomyopathy
Tachycardia
Ventricular
Supraventricular
Aortic stenosis
Hypertrophic cardiomyopathy
Significant coronary obstruction
Microvascular disease
Modified from Gibbons et al.7
Table 9. Pretest Likelihood of CAD in Symptomatic Patients
According to Age and Sex* (Combined Diamond/Forrester and
CASS Data)
Age, y
Nonanginal Chest Pain Atypical Angina Typical Angina
Men Women Men Women Men Women
30–39 4 2 34 12 76 26
40–49 13 3 51 22 87 55
50–59 20 7 65 31 93 73
60–69 27 14 72 51 94 86
CAD indicates coronary artery disease; and CASS, Coronary Artery Surgery
Study.
* Each value represents the percent with significant CAD on catheterization.
Adapted from Forrester and Diamond.52,73
Table 10. Comparing Pretest Likelihood of CAD in Low-Risk
Symptomatic Patients With High-Risk Symptomatic Patients
(Duke Database)
Age, y
Nonanginal Chest Pain Atypical Angina Typical Angina
Men Women Men Women Men Women
35 3–35 1–19 8–59 2–39 30–88 10–78
45 9–47 2–22 21–70 5–43 51–92 20–79
55 23–59 4–21 45–79 10–47 80–95 38–82
65 49–69 9–29 71–86 20–51 93–97 56–84
Each value represents the percentage with significant CAD. The first is the
percentage for a low-risk, mid-decade patient without diabetes mellitus,
smoking, or hyperlipidemia. The second is that of a patient of the same age
with diabetes mellitus, smoking, and hyperlipidemia. Both high- and low-risk
patients have normal resting ECGs. If ST-T-wave changes or Q waves had been
present, the likelihood of CAD would be higher in each entry of the table.
CAD indicates coronary artery disease; and ECG, electrocardiogram.
Reprinted from Pryor et al.71
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rely on the principles embodied within the ischemic cascade
(Figure 7), in which graded ischemia of increasing severity
and duration produces sequential changes in perfusion, relax-
ation and contraction, wall motion, repolarization, and, ulti-
mately, symptoms, all of which can be detected by an array of
cardiovascular testing modalities.75 The production of ische-
mia, however, depends on the severity of stress imposed (ie,
submaximal exercise can fail to produce ischemia) and the
severity of the flow disturbance. Coronary stenoses ,70%
are often undetected by functional testing.
Because abnormalities of regional or global ventricular
function occur later in the ischemic cascade, they are more
likely to indicate severe stenosis and, thus, demonstrate a
higher diagnostic specificity for SIHD than do perfusion
defects, such as those seen on nuclear MPI. Isolated perfusion
defects, on the other hand, can result from stenoses of
borderline significance, raising the sensitivity of nuclear MPI
for underlying CAD but lowering the specificity for more
severe stenosis.
The recent availability of multislice CCTA allows for the
noninvasive visualization of anatomic CAD with high-
resolution images similar to invasive coronary angiography.
As would be expected, CCTA and invasive angiography
exhibit a high degree of concordance, as they are both
anatomic tests, and CCTA is more sensitive in detecting
obstructive CAD, especially at diameter stenosis #70%, than
is nuclear MPI.76
The accuracy of a CCTA reader in estimating coronary
stenosis within a vessel is hindered by the presence of dense
coronary calcification and a tendency to overestimate the
severity of lesions relative to invasive angiography.77 No
direct comparisons of the effectiveness of a functional ap-
proach with inducible ischemia or an anatomic approach
assessing coronary stenosis have been completed in the
noninvasive setting, although several randomized controlled
trials (RCTs) are under way, which will directly or indirectly
compare test modalities: PROMISE (Prospective Multicenter
Imaging Study for Evaluation of Chest Pain; clinicaltrials.gov
identifier NCT01174550), RESCUE (Randomized Evalua-
tion of Patients With Stable Angina Comparing Diagnostic
Examinations; clinicaltrials.gov identifier NCT01262625),
and ISCHEMIA (International Study of Comparative Health
Effectiveness with Medical and Invasive Approaches; clini-
caltrials.gov identifier NCT01471522).
In 2010, the United Kingdom’s National Institute for
Clinical Excellence Guidance for “Chest pain of recent onset:
Assessment and diagnosis of recent onset chest pain or
discomfort of suspected cardiac origin” provide, for a health-
care system that allocates resources differently from that of
the United States, recommendations for an initial assessment
of CAD. This Guidance recommends beginning in people
without confirmed CAD with a detailed clinical assessment
and performing a 12-lead ECG in those in whom stable
angina cannot be diagnosed or excluded on the basis of
clinical assessment alone. The Guidance suggests that there is
no need for further testing in those with an estimated
likelihood ,10%. In those with an estimated likelihood of
CAD of 10% to 29%, the National Institute for Clinical
Excellence document recommends beginning with CT coro-
nary artery calcium (CAC) scoring as the first-line diagnostic
investigation, whereas the present SIHD guideline provides a
Class IIb recommendation for several reasons, as outlined in
Section 2.2.4.2.
2.2.1.1. Assessing Diagnostic Test Characteristics
A hierarchy of diagnostic test evidence has been proposed by
Fryback and Thornbury78 and ranges from evidence on
technical quality (level 1) through test accuracy (sensitivity
and specificity associated with test interpretation), to changes
in diagnostic thinking, effect on patient management, and
patient outcomes, to societal costs and benefits (level 6). A
similar framework has been proposed for biomarkers by
Hlatky et al.79 In practice, although knowledge of the effect of
diagnostic testing on outcomes would be highly desirable, the
vast majority of available evidence is on diagnostic or
prognostic accuracy. Therefore, this information most com-
monly is used to compare test performance.
Diagnostic accuracy is commonly represented by the terms
sensitivity and specificity, which are calculated by comparing
test results to the “gold standard” of the results of invasive
coronary angiography. The sensitivity of any noninvasive test
to diagnose SIHD expresses the frequency that a patient with
angiographic IHD will have a positive test result, whereas the
specificity measures the frequency that a patient without IHD
will have a negative result. In addition, predictive accuracy
represents the frequency that a patient with a positive test
does have IHD (positive predictive value) or that a patient
with a negative test truly does not have IHD (negative
predictive value). The predictive accuracy may be used for
both diagnostic and prognostic accuracy analyses; in the latter
case, the comparison is to subsequent cardiovascular events.
It is important to note that apparent test performance can be
altered substantially by the pretest probability of IHD,52,80,81
making the accurate assessment of pretest probability and
proper patient selection essential for diagnostic interpretation
statements on IHD prevalence by test results. The positive
predictive value of a test declines as the disease prevalence
decreases in the population under study, whereas the negative
predictive accuracy increases.82 Finally, the performance of
noninvasive tests also varies in certain patient populations,
Figure 7. The Ischemic Cascade. Reproduced with permission
from Shaw et al.75
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such as obese patients, the elderly, and women (Section 5.12),
who often are underrepresented in clinical studies.
Estimates of all test characteristics are subject to workup
bias, also known as verification or posttest referral bias.81,83,84
This bias occurs when the results of stress testing are used to
decide which patients undergo the standard reference proce-
dure (invasive coronary angiography) to establish a definitive
diagnosis of IHD (ie, patients with positive results on stress
testing are referred for coronary angiography, whereas those
with negative results are not). This bias has the effect of
raising the measured sensitivity and lowering the measured
specificity in relation to their true values. Mathematical
corrections can be applied to estimate corrected values.84–86
Diagnostic testing is most valuable when the pretest
probability of IHD is intermediate—for example, when a
50-year-old man has atypical angina, and the probability of
IHD is approximately 50% (Table 9). The precise definition
of intermediate probability (ie, between 10% and 90%, 20%
and 80%, or 30% and 70%) is somewhat arbitrary. In addition
to these boundaries, other factors are important in the deci-
sion to refer a patient to testing, including the degree of
uncertainty acceptable to the physician and patient; the
likelihood of an alternative diagnosis; the accuracy of the
diagnostic test selected (ie, sensitivity and specificity), test
reliability, procedural cost, and the potential risks of further
testing; and the benefits and risks of treatment in the absence
of additional testing. A definition of 10% and 90%, first
advocated in 1980,87 has been applied in several studies.88,89
Although broad, this range still excludes several sizable
patient groups (eg, older men with typical angina and younger
women with nonanginal pain). When the probability of IHD
is high, a positive test result is merely confirmatory, whereas
a negative test result might not diminish the probability of
disease sufficiently to be clinically useful and could even be
misleading because of the possibility that it is a false negative
result. When the probability of IHD is very low, however, a
negative test result is simply confirmatory, whereas a positive
test result might not be clinically useful and could be
misleading if falsely positive. The importance of relying on
clinical judgment and refraining from testing in very low-risk
populations is well illustrated by a thought experiment
proposed by Diamond and Kaul in a letter to the editor of The
New England Journal of Medicine:
“As an example, suppose we have a test marker with
80% sensitivity and 80% specificity (typical of car-
diac stress tests). Given 100 individuals with a 10%
disease prevalence, there will be 8 true positives
(10030.130.8) and 18 false positives
(10030.930.2). If we refer only these 26 positive
responders for angiography, the observed “diagnostic
yield” is only 31% (8/26). Moreover, the test’s
sensitivity will appear to be 100% (all diseased
subjects having a positive test), and its specificity will
appear to be 0% (all non-diseased subjects also
having a positive test). Hence, the more we rely on a
test, the less well it appears to perform.”(p. 93)90
The likelihood of CAD proposed above differs substantially
from that in the populations from which the estimates of
noninvasive test performance were derived; the overall prev-
alence of CAD from a meta-analysis was 60%.91 Instead,
contemporary age-, sex-, and symptom-based IHD probabil-
ity estimates can be gleaned from a multicenter cohort of
14 048 patients with suspected IHD undergoing CCTA.92
2.2.1.2. Safety and Other Considerations Potentially
Affecting Test Selection
All forms of noninvasive stress testing carry some risk.
Maximal exercise testing is associated with a low but finite
incidence of cardiac arrest, AMI, and even death. Pharmaco-
logical stress agents fall into 2 broad categories: beta-agonists
such as dobutamine, which increase heart rate and inotropy,
and vasodilators such as adenosine, dipyridamole, or regade-
noson, which act to increase blood flow to normal arteries
while decreasing perfusion to stenotic vessels. Each of these
pharmacological stress agents also carries a very small risk of
drug-specific adverse events (dobutamine: ventricular ar-
rhythmias; dipyridamole/adenosine: bronchospasm in chronic
obstructive pulmonary disease).
Nuclear perfusion imaging and CCTA use ionizing radia-
tion techniques for visualizing myocardial perfusion and
anatomic CAD, respectively. Risk projections are based
largely on observations from atomic bomb survivors exposed
to higher levels of ionizing radiation. The Linear-No-
Threshold hypothesis states that any exposure could result in
an increased projected cancer risk and that there is a dose–
response relationship to elevated cancer risk with higher
exposures. Considerable controversy exists surrounding the
extrapolation of projected cancer risk to low-level exposure
in medical testing, and no reported evidence links low-level
exposure to observed cancer risk. Even when the Linear-No-
Threshold hypothesis is used, the projected incident cancer is
estimated to be very low for nuclear MPI and CCTA.93–95
Nevertheless, general agreement exists that the overriding
principle of caution and safety should apply by projecting the
Linear-No-Threshold hypothesis.
The principle of As Low as Reasonably Achievable
(ALARA) should be applied in all patient populations. For
CCTA performed with contemporary equipment in accor-
dance with the Society of Cardiovascular Computed Tomog-
raphy recommendations, average estimated radiation dose
ranges from 5 to 10 mSv.96 For stress nuclear MPI, when the
American Society of Nuclear Cardiology–recommended rest-
stress Tc-99m SPECT or Rb-82 positron emission tomogra-
phy (PET) protocol97 is used, the estimated radiation dose is
approximately 11 or 3 mSV, respectively.97,98 On the basis of
American Society of Nuclear Cardiology guidelines, dual-
isotope or rest-stress Tl-201 imaging is discouraged for
diagnostic procedures because of its high radiation exposure.
The use of new high-efficiency nuclear MPI cameras results
in a similar or lower effective dose for both dual-isotope and
rest-stress Tc-99m imaging.99–101 For both CT and nuclear
imaging, the AHA, Society of Cardiovascular Computed
Tomography, and American Society of Nuclear Cardiology
recommend widespread application of dose-reduction tech-
niques whenever possible.96–98 Clinicians should apply the
concept of benefit-to-risk ratio when considering testing.
When testing is used appropriately, the clinical benefit in
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terms of supportive diagnostic or prognostic accuracy ex-
ceeds the projected risk such that there is an advantage to
testing.13,14 When it is used inappropriately or overused, the
benefit of testing is low, and the risk of exposure is unac-
ceptably high. Of note, care should be taken when exposing
low-risk patients to ionizing radiation. This is particularly of
concern in younger patients for whom the projected cancer
risk is elevated.102
Use of contrast agents with CCTA can cause allergic
reactions. Contrast agents also can affect renal function and
therefore should be avoided in patients with chronic kidney
disease. CMR might be contraindicated in patients with
claustrophobia or implanted devices, and use of gadolinium
contrast agents is associated rarely with nephrogenic systemic
fibrosis. For this reason, gadolinium is contraindicated in
patients with severe renal dysfunction (estimated glomerular
filtration rates ,30 mL/min per 1.73 m2), and the dose should
be adjusted for patients with mild to moderate dysfunction
(estimated glomerular filtration rates 30 to 60 mL/min per
1.73 m2). As with all safety considerations, the potential risks
need to be considered carefully in concert with the potential
benefits from the added information obtained to guide care.
In addition to pretest likelihood, a variety of clinical factors
influence noninvasive test selection.103–105 Chief among these
are the patient’s ability to exercise, body habitus, cardiac
medication use, and ECG interpretability. The decision to add
imaging in patients who have an interpretable ECG and are
capable of vigorous exercise is important because imaging
and nonimaging testing have different diagnostic accuracies,
predictive values, and costs. Most, but not all, studies
evaluating cohorts of patients undergoing both exercise ECG
and stress imaging have shown that the addition of imaging
information provides incremental benefit in terms of both
diagnostic and prognostic information with an acceptable
increase in cost (Section 2.2.1.5).106–117
Other factors affecting test choice include local availability
of specific tests, local expertise in test performance and
interpretation, the presence of multiple diagnostic or prog-
nostic questions better addressed by one form of testing over
another, and the existence of prior test results (especially
when prior images are available for comparison). Finally,
although echocardiographic, radionuclide, and CMR stress
imaging can have complementary roles for estimating patient
prognosis, there is rarely a reason to perform multiple tests in
the same patient, unless the results of the initial imaging test
are unsatisfactory for technical reasons or the findings are
equivocal or require confirmation.
2.2.1.3. Exercise Versus Pharmacological Testing
When a patient is able to perform routine activities of daily
living without difficulty, exercise testing to provoke ischemia
is preferred because it often can provide a higher physiolog-
ical stress than would be achieved by pharmacological
testing. This can translate into a superior ability to detect
ischemia as well as providing a correlation to a patient’s daily
symptom burden and physical work capacity not offered by
pharmacological stress testing. In addition, exercise capacity
alone is a very strong prognostic indicator.118,119
The goal of exercise testing for suspected SIHD patients is
1) to achieve high levels of exercise (ie, maximal exertion),
which in the setting of a negative ECG generally and reliably
excludes obstructive CAD, or 2) to document the extent and
severity of ECG changes and angina at a given workload (ie,
demand ischemia) so as to predict the likelihood of underly-
ing significant or severe CAD. Thus, candidates for exercise
testing must possess sufficient functional capacity to attain
maximal, volitional stress levels. Because there is high
variability in age-predicted maximal heart rate among sub-
jects of identical age,120 achieving 85% of age-predicted
maximal heart rate might not indicate sufficient effort during
exercise testing and should not be used as a criterion to
terminate a stress test.121 Failure to reach peak heart rate (if
beta blockers have been held as recommended) or to achieve
adequate levels of exercise in the setting of a negative ECG
is consistent with functional disability and results in an
indeterminate estimation of CAD. Female-specific age-
predicted maximal heart rate and functional capacity mea-
surements are available.118,122
Standard treadmill protocols initiate exercise at 3.2 to 4.7
metabolic equivalents (METs) of work and increase by
several METs every 2 to 3 minutes of exercise (eg, modified
or standard Bruce protocol). Most activities of daily living
require approximately 4 to 5 METs of physical work to
perform. Thus, reported limitations in activities of daily
living identify a patient who might be unable to perform
maximal exercise. Gentler treadmill protocols, with incre-
mental stages of 1 MET, or bicycle stress can help some
patients achieve maximal exercise capacity.
Optimal candidates with sufficient physical functioning
may be identified as those capable of performing at least
moderate physical functioning (ie, performing at least mod-
erate household, yard, or recreational work and most activi-
ties of daily living) and with no disabling comorbidity
(including frailty, advanced age, marked obesity, PAD,
chronic obstructive pulmonary disease, or orthopedic limita-
tions). Patients incapable of at least moderate physical func-
tioning or with disabling comorbidity should be referred for
pharmacological stress imaging. In the setting of submaximal
exercise and a negative stress ECG, consideration should be
given to performing additional testing with pharmacological
stress imaging to evaluate for inducible ischemia.
2.2.1.4. Concomitant Diagnosis of SIHD and Assessment
of Risk
Although the primary goal of testing among patients with
new onset of symptoms suggesting SIHD is to diagnose or
exclude obstructive CAD, the various modalities also can
provide additional information about long-term risk (Section
3.3.2), and this prognostic ability may influence the selection
of an initial test. Exercise capacity remains one of the
strongest indicators of long-term risk (including death) for
men and women with suspected and known CAD.118,123–125 In
addition, information derived from treadmill exercise (eg,
Duke treadmill score126,127 and heart rate recovery) provides
incremental diagnostic and prognostic information. For this
reason, it is preferable to perform exercise stress if the patient
is able to achieve a maximal workload. For the exercise-
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capable patient with a normal baseline ECG, the decision to
perform imaging with nuclear or echocardiographic tech-
niques along with stress ECG should be based on many
factors, including the likelihood of garnering substantial
incremental prognostic information that is likely to alter
clinical and therapeutic management.
2.2.1.5. Cost-Effectiveness
Estimates of cost-effectiveness of various testing strategies in
symptomatic patients have been used to inform responses to
rising healthcare costs. However, to be of value, estimates of
cost-effectiveness must use contemporary estimates of effec-
tiveness that incorporate considerations of disease prevalence
and test accuracy. Furthermore, costs must reflect not only
the index test but also the episode of care and the longer-term
induced costs and outcomes of diagnosed and undiagnosed
SIHD. Ideally, these data would be derived from RCTs or
registries designed to compare the effectiveness of testing
strategies and observed associated costs. However, in the
interim until such evidence is available, mixed methods and
decision analytic models provide general estimates of the
cost-effectiveness of various forms of testing. Mixed methods
use observational evidence of index and downstream proce-
dures, hospitalization, and drug costs and apply cost weights
to estimate cumulative costs,128–130 whereas decision analytic
models simulate clinical and financial data.131–137 Regardless
of the approach, inherent assumptions and uncertainties with
regard to the data and incomplete consideration of risks and
benefits require that such calculations be considered as
estimates only.138
In most studies, stress imaging is estimated to provide a
benefit over exercise ECG at a reasonable cost, commensu-
rate with accepted values for cost effectiveness (ie, at the
threshold for economic efficiency of ,$50 000 per added
year of life), a result driven primarily by more frequent
angiography and adverse cardiovascular events for those with
a negative exercise ECG. Results of decision analytic and
mixed modeling approaches comparing stress echocardiogra-
phy with myocardial perfusion SPECT vary, with some
favoring exercise echocardiography and others favoring ex-
ercise nuclear MPI.128,133
The patient’s pretest likelihood of CAD also influences
cost-effectiveness such that exercise echocardiography is
more cost-effective in lower-risk patients (with annual risk of
death or MI ,2%) than in higher-risk patients, in whom
nuclear MPI is more cost-effective. Use of invasive coronary
angiography as a first test is not cost-effective in patients with
a pretest probability ,75%.139,140 Finally, it is important to
note that as the reimbursement for stress imaging decreases
(it is now less than half the value used in older studies), the
relative cost-effectiveness (dollars/quality-adjusted life-year
saved) of stress imaging is more favorable than that of
exercise ECG, and the comparative advantage of lower- to
higher-cost imaging procedures is minimized.
The cost-efficiency of CCTA is less well studied but also
depends on disease prevalence.139,140 Data conflict as to
whether patients undergoing CCTA as initial imaging modal-
ity are less or more likely to undergo invasive coronary
angiography or revascularization, although it appears that
they have similar or lower rates of adverse cardiovascular
events.128,130,141,142 As a result, CCTA performed alone or in
combination with functional testing minimizes adverse car-
diac events, maximizes quality-adjusted life-years,140,143 and
is estimated to be cost-effective.
Although data on cost-effectiveness and patient satisfac-
tion for CMR are limited, evidence suggests that CMR can
improve patient management. The German Pilot/European
Cardiovascular Magnetic Resonance (EuroCMR) registry of
11 040 consecutive patients evaluated for cardiomyopathy,
ischemia, and myocardial viability found that CMR satisfied
all requested imaging needs in 86% of patients so that no
further imaging was required.144 In the 3351 stress CMR
cases, invasive angiography was avoided in 45%, compared
with 18% in patients who underwent nuclear imaging.
2.2.2. Stress Testing and Advanced Imaging for Initial
Diagnosis in Patients With Suspected SIHD Who Require
Noninvasive Testing: Recommendations
See Table 11 for a summary of recommendations from this
section.
2.2.2.1. Able to Exercise
Class I
1. Standard exercise ECG testing is recommended for
patients with an intermediate pretest probability of
IHD who have an interpretable ECG and at least
moderate physical functioning or no disabling co-
morbidity.114,145–147 (Level of Evidence: A)
2. Exercise stress with nuclear MPI or echocardiogra-
phy is recommended for patients with an intermedi-
ate to high pretest probability of IHD who have an
uninterpretable ECG and at least moderate physical
functioning or no disabling comorbidity.91,132,148–156
(Level of Evidence: B)
Class IIa
1. For patients with a low pretest probability of ob-
structive IHD who do require testing, standard
exercise ECG testing can be useful, provided the
patient has an interpretable ECG and at least mod-
erate physical functioning or no disabling comorbid-
ity. (Level of Evidence: C)
2. Exercise stress with nuclear MPI or echocardiogra-
phy is reasonable for patients with an intermediate
to high pretest probability of obstructive IHD who
have an interpretable ECG and at least moderate
physical functioning or no disabling comorbid-
ity.91,132,148–156 (Level of Evidence: B)
3. Pharmacological stress with CMR can be useful for
patients with an intermediate to high pretest prob-
ability of obstructive IHD who have an uninterpre-
table ECG and at least moderate physical function-
ing or no disabling comorbidity.153,157,158 (Level of
Evidence: B)
Class IIb
1. CCTA might be reasonable for patients with an
intermediate pretest probability of IHD who have at
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least moderate physical functioning or no disabling
comorbidity.158–166 (Level of Evidence: B)
2. For patients with a low pretest probability of ob-
structive IHD who do require testing, standard
exercise stress echocardiography might be reason-
able, provided the patient has an interpretable ECG
and at least moderate physical functioning or no
disabling comorbidity. (Level of Evidence: C)
Class III: No Benefit
1. Pharmacological stress with nuclear MPI, echocar-
diography, or CMR is not recommended for patients
who have an interpretable ECG and at least moder-
ate physical functioning or no disabling comorbid-
ity.155,167,168 (Level of Evidence: C)
2. Exercise stress with nuclear MPI is not recom-
mended as an initial test in low-risk patients who
have an interpretable ECG and at least moderate
physical functioning or no disabling comorbidity.
(Level of Evidence: C)
2.2.2.2. Unable to Exercise
Class I
1. Pharmacological stress with nuclear MPI or echo-
cardiography is recommended for patients with an
intermediate to high pretest probability of IHD who
are incapable of at least moderate physical function-
ing or have disabling comorbidity.148–150,152–156 (Level
of Evidence: B)
Class IIa
1. Pharmacological stress echocardiography is reason-
able for patients with a low pretest probability of
Table 11. Stress Testing and Advanced Imaging for Initial Diagnosis in Patients With Suspected SIHD Who Require Noninvasive
Testing
Test
Exercise
Status
ECG
Interpretable
Pretest Probability
of IHD
COR LOE ReferencesAble Unable Yes No Low Intermediate High
Patients able to exercise*
Exercise ECG X X X I A (114, 145–147)
Exercise with nuclear MPI or Echo X X X X I B (91, 132, 148–156)
Exercise ECG X X X IIa C N/A
Exercise with nuclear MPI or Echo X X X X IIa B (91, 132, 148–156)
Pharmacological stress CMR X X X X IIa B (153, 157, 158)
CCTA X Any X IIb B (158–166)
Exercise Echo X X X IIb C N/A
Pharmacological stress with nuclear
MPI, Echo, or CMR
X X Any III: No Benefit C (155, 167, 168)
Exercise stress with nuclear MPI X X X III: No Benefit C N/A
Patients unable to exercise
Pharmacological stress with nuclear
MPI or Echo
X Any X X I B (148–150, 152–156)
Pharmacological stress Echo X Any X IIa C N/A
CCTA X Any X X IIa B (158–166)
Pharmacological stress CMR X Any X X IIa B (153, 157, 158, 169–172)
Exercise ECG X X Any III: No Benefit C (91, 132, 148–156, 161)
Other
CCTA
If patient has any of the following:
a) Continued symptoms with prior
normal test, or
b) Inconclusive exercise or
pharmacological stress, or
c) Unable to undergo stress with
MPI or Echo
Any Any X IIa C (173)
CAC score Any Any X IIb C (174)
CAC indicates coronary artery calcium; CCTA, cardiac computed tomography angiography; CMR, cardiac magnetic resonance imaging; COR, class of
recommendation; ECG, electrocardiogram; Echo, echocardiography; IHD, ischemic heart disease; LOE, level of evidence; MPI, myocardial perfusion imaging; N/A, not
available; and SIHD, stable ischemic heart disease.
*Patients are candidates for exercise testing if they are capable of performing at least moderate physical functioning (ie, moderate household, yard, or recreational
work and most activities of daily living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predicted maximum heart rate.
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IHD who require testing and are incapable of at least
moderate physical functioning or have disabling
comorbidity. (Level of Evidence: C)
2. CCTA is reasonable for patients with a low to
intermediate pretest probability of IHD who are
incapable of at least moderate physical functioning
or have disabling comorbidity.158–166 (Level of Evi-
dence: B)
3. Pharmacological stress CMR is reasonable for pa-
tients with an intermediate to high pretest probabil-
ity of IHD who are incapable of at least moderate
physical functioning or have disabling comorbid-
ity.153,157,158,169–172 (Level of Evidence: B)
Class III: No Benefit
1. Standard exercise ECG testing is not recommended
for patients who have an uninterpretable ECG or
are incapable of at least moderate physical function-
ing or have disabling comorbidity.91,132,148–156,161
(Level of Evidence: C)
2.2.2.3. Other
Class IIa
1. CCTA is reasonable for patients with an intermedi-
ate pretest probability of IHD who a) have continued
symptoms with prior normal test findings, or b) have
inconclusive results from prior exercise or pharma-
cological stress testing, or c) are unable to undergo
stress with nuclear MPI or echocardiography.173
(Level of Evidence: C)
Class IIb
1. For patients with a low to intermediate pretest
probability of obstructive IHD, noncontrast cardiac
CT to determine the CAC score may be consid-
ered.174 (Level of Evidence: C)
See Online Data Supplement 1 for additional data on diag-
nostic accuracy of stress testing and advanced imaging for
the diagnosis of suspected SIHD.
2.2.3. Diagnostic Accuracy of Nonimaging and Imaging
Stress Testing for the Initial Diagnosis of
Suspected SIHD
2.2.3.1. Exercise ECG
The exercise ECG has been the cornerstone of diagnostic
testing of SIHD patients for several decades. The diagnostic
endpoint for an ischemic ECG is $1 mm horizontal or
down-sloping (at 80 ms after the J point) ST-segment
depression at peak exercise. ST-segment elevation (in a
non–Q-wave lead and excluding aortic valve replacement)
during or after exercise occurs infrequently but represents a
high-risk ECG finding consistent with an ACS. The diagnos-
tic accuracy of exertional ST-segment depression has been
studied extensively in several meta-analyses, systematic re-
views, large observational registries, and RCTs.114,145–147,175
The composite diagnostic sensitivity and specificity, unad-
justed for referral bias, is 61% and ranges from 70% to 77%,
but it is lower in women146,147,175 and lower than that for
stress imaging modalities. A similar accuracy has been
reported for correlation of ECG ischemia with anatomic CAD
by CCTA.176 Diagnostic accuracy is improved when consid-
eration is given to additional non-ECG factors, such as
exercise duration, chronotropic incompetence, angina, ven-
tricular arrhythmias, heart rate recovery, and hemodynamic
response to exercise (ie, drop in systolic BP), or when
combination scores such as the Duke treadmill or Lauer
scores are applied.118,177–180
Multiple factors in addition to the patient’s inability to
achieve maximal exercise levels influence the accuracy of the
ECG during exercise testing to diagnose obstructive CAD.
Resting ECG abnormalities preclude accurate interpretation
of exercise-induced changes and reduce test accuracy; these
include abnormalities affecting the ST segment, such as LV
hypertrophy, LBBB, ventricular-paced rhythm, or any resting
ST-segment depression $0.5 mm. Although some have
proposed calculating the difference from rest to exercise of
changes $1 mm for patients with significant resting ST-
segment changes, the accuracy of this approach has been less
extensively studied and validated. The interpretation of ST-
segment changes in patients with right bundle-branch block
can be limited, especially in the precordial leads. Certain
medications, including digitalis, also influence ST-segment
changes and can produce ischemic ECG changes that are
frequently false positive findings. In addition, anti-ischemic
therapies can reduce heart rate and myocardial workload, and
therefore, a lack of ischemic ECG changes can reflect false
negative findings when the test is used to diagnose SIHD. It
is routine practice to withhold beta-blocker therapy for 24 to
48 hours before testing. Patients who are candidates for an
exercise ECG must be able to exercise and must have an
interpretable ECG, which is defined as a normal 12-lead ECG
or one with minimal resting ST-T-wave abnormalities
(,0.5 mm).
2.2.3.2. Exercise and Pharmacological
Stress Echocardiography
The diagnostic endpoint of exercise and pharmacological
stress echocardiography is new or worsening wall motion
abnormalities and changes in global LV function during or
immediately after stress. In addition to the detection of
inducible wall motion abnormalities, most stress echocardi-
ography includes screening images to evaluate resting ven-
tricular function and valvular abnormalities. This information
can be helpful in a symptomatic patient without a proven
diagnosis.
Pharmacological stress echocardiography in the United
States is performed largely by using dobutamine with an
endpoint of inducible wall motion abnormalities (Table 11).
Vasodilator agents such as adenosine are used rarely in the
United States but are used more commonly in Europe. The
diagnostic accuracy of exercise and pharmacological stress
echocardiography has been studied extensively in multiple
meta-analyses, systematic reviews, and large, multicenter,
observational registries.91,148–152,154,175 In several contempo-
rary meta-analyses, the diagnostic sensitivity (uncorrected for
referral bias) ranged from 70% to 85% for exercise and
85% to 90% for pharmacological stress echocardiogra-
phy.91,150,152,154 The uncorrected diagnostic specificity ranges
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from 77% to 89% and 79% to 90% for exercise and
pharmacological stress echocardiography, respectively. The
use of intravenous ultrasound contrast agents can improve
endocardial border delineation and can result in improved
diagnostic accuracy.181 Myocardial contrast echocardiogra-
phy also has been examined for determination of rest and
stress myocardial perfusion, with the results showing compa-
rability to myocardial perfusion SPECT findings in small
patient series.182 However, the technique is currently in
limited use in the United States.
The diagnostic accuracy of all imaging modalities is
influenced by technical factors that could be inherent in the
technique (ie, variable correlation between perfusion and wall
motion abnormalities and CAD extent and severity) or that
result from physical characteristics of the patient that reduce
image quality. For echocardiography, reduced image quality,
defined as reduced LV endocardial visualization, has been
reported for obese individuals and those with chronic lung
disease, although the use of intravenous contrast enhance-
ment results in sizeable improvement in endocardial border
delineation.
2.2.3.3. Exercise and Pharmacological Stress Nuclear
Myocardial Perfusion SPECT and Myocardial
Perfusion PET
Myocardial perfusion SPECT generally is performed with
rest and (for exercise or pharmacological stress) with stress
Tc-99m agents, with Tl-201 having limited applications (eg,
viability) because of its higher radiation exposure.97 Pharma-
cological stress generally is used with vasodilator agents
administered as a continuous infusion (adenosine, dipyridam-
ole) or bolus (regadenoson) injection. The diagnostic end-
point of nuclear MPI is reduction in myocardial perfusion
after stress. Nonperfusion high-risk markers include a mark-
edly abnormal ECG, extensive stress-induced wall motion
abnormalities, reduced post-stress left ventricular ejection
fraction (LVEF) $5% or global LVEF (rest or post-stress)
,45%, transient ischemic LV dilation, increased lung or right
ventricular uptake, or abnormal coronary flow reserve with
myocardial perfusion PET.183–186
The diagnostic accuracy for detection of obstructive CAD
of exercise and pharmacological stress nuclear MPI has been
studied extensively in multiple meta-analyses, systematic
reviews, RCTs, and large, multicenter, observational regis-
tries.91,114,132,147,148,152,155,156,175 From these reports, the uncor-
rected diagnostic sensitivity ranged from 82% to 88% for
exercise and 88% to 91% for pharmacological stress nuclear
MPI. The uncorrected diagnostic specificity ranged from 70%
to 88% and 75% to 90% for exercise and pharmacological
stress nuclear MPI, respectively.
Diagnostic image quality is affected in obese patients, as
well as in women and men with large breasts. Reductions in
breast tissue artifact have been reported with the use of the
Tc-99m agents as well as with attenuation-correction algo-
rithms or prone imaging.187–190 For myocardial perfusion
SPECT, global reductions in myocardial perfusion, such as in
the setting of left main or 3-vessel CAD, can result in
balanced reduction and an underestimation of ischemic
burden.
Myocardial perfusion PET is characterized by high spatial
resolution of the photon attenuation–corrected images with
82Rubidium or 13N-ammonia used as myocardial blood flow
tracers. Although less well studied than myocardial perfusion
SPECT, a meta-analysis of 19 studies suggests that PET has
a slightly higher (uncorrected) sensitivity for detection of
CAD,191,192 including in women and obese patients.193
2.2.3.4. Pharmacological Stress CMR
Wall Motion/Perfusion
In recent years, more centers have used pharmacological
stress CMR in the diagnostic evaluation of SIHD patients.
The imaging endpoint depends on the stress agent: develop-
ment of a new wall motion abnormality for cine CMR with
dobutamine stress or a new perfusion abnormality with
vasodilator stress. From a contemporary meta-analysis of 37
studies, the uncorrected diagnostic sensitivity and specificity
of dobutamine-induced CMR wall motion imaging were 83%
and 86%, whereas the uncorrected diagnostic sensitivity and
specificity of vasodilator stress–induced CMR MPI were
91% and 81%.153 Several small comparative series have
reported accuracy data in relation to stress echocardiography
and nuclear imaging. Importantly, normal CMR perfusion has
a high negative predictive value for obstructive CAD.194 One
multicenter study that enrolled 234 patients demonstrated
similar diagnostic accuracy between CMR perfusion and
SPECT MPI in detecting obstructive CAD.172 More recently,
a randomized study of 752 patients directly compared phar-
macological stress CMR with SPECT MPI and reported
higher sensitivity by pharmacological stress CMR than
SPECT MPI in the detection of angiographically significant
coronary stenosis (87% versus 67%; P,0.0001).169 With
dobutamine stress, CMR wall motion had high accuracy for
detection of obstructive CAD in patients with suboptimal
echocardiographic acoustic window.170 CMR dobutamine
wall motion imaging demonstrated higher accuracy than
dobutamine echocardiography wall motion.171 Although wall
motion and perfusion imaging are used to assess the presence
and extent of ischemia, most experienced centers also acquire
late gadolinium enhancement (LGE) imaging in the same
session to delineate the extent and severity of scarred
myocardium.
2.2.3.5. Hybrid Imaging
Current imaging is based largely on the use of a single
modality, but combined or hybrid applications increasingly
are available, which include both PET and CT or SPECT and
CT, thus allowing for combined anatomic and functional
testing. In addition, newer scanning techniques have allowed
assessment of perfusion and FFR by CCTA alone, in addition
to coronary anatomy.195–201 Notably, these combined assess-
ments allow for a fused image in which the physiological
assessment of flow is coupled with the anatomic extent and
severity of CAD and also provides information on plaque
composition and arterial remodeling. Limited evidence is
available on hybrid imaging, although several reports have
reported prognostic accuracy for cardiac events with both
ischemic and anatomic markers.202–206 Other combinations of
imaging modalities also are being developed, including PET/
CMR, which is currently a research application. The strength
e378 Circulation December 18/25, 2012
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
of combined imaging is the added value of anatomy guiding
interpretation of ischemic and scarred myocardium as well as
providing information to guide therapeutic decision making.
Hybrid imaging also can overcome technical limitations of
myocardial perfusion SPECT or myocardial perfusion PET
by providing anatomic correlates to guide interpretative
accuracy207 and can provide the functional information that
an anatomic technique like CCTA or magnetic resonance
angiography lacks; however, radiation dose is increased.
2.2.4. Diagnostic Accuracy of Anatomic Testing for the
Initial Diagnosis of SIHD
2.2.4.1. Coronary CT Angiography
With improvements in temporal and spatial resolution as well
as volume coverage, evaluation of coronary arteries with
CCTA is now possible with a high degree of image quality.208
The extent and severity of angiographic CAD are 2 of the
most important prognostic factors and remain essential for
revascularization decision making.209 Five meta-analyses and
3 controlled clinical trials have reported the diagnostic
accuracy of CCTA with 64-slice CT, yielding sensitivity
values ranging from 93% to 97% and specificity values
ranging from 80% to 90%159–166 for detecting obstructive
CAD on invasive coronary angiography, unadjusted for
referral bias. In a small series of women, the diagnostic
accuracy of CCTA was similarly high.210 Prior reports in-
cluded subsets of patients who already had been referred for
invasive angiography, and as such, test performance would be
altered by the biases inherent in a preselected population.
Factors related to diminished accuracy include image quality,
the extent of coronary calcification, and body mass index
(BMI).208
A potential advantage of CCTA over standard functional
testing is its very high negative predictive value for obstruc-
tive CAD, which can reassure caregivers that providing
GDMT and deferring consideration of revascularization con-
stitute a sensible strategy. In addition to documentation of
stenotic lesions, CCTA can qualitatively visualize arterial
remodeling and nonobstructive plaque, including calcified,
noncalcified, or mixed plaque.211–216 The presence of nonob-
structive plaque has been shown to be helpful to guiding risk
assessment and can aid in discerning the etiology of patient
symptoms.211,215,216 CT information has been correlated with
functional stress testing.203,204,215 Not every obstructive lesion
produces ischemia, and ischemia can be present in the
absence of a significant stenosis in epicardial vessels, which
results in discordance between anatomic imaging with CCTA
and functional stress testing. Several series have reported the
positive predictive value of an anatomic lesion detected on
CCTA to range from 29% to 44% when ischemia on a stress
study is used as a reference standard.203,204 The evidence on
concordance, however, remains incomplete, with current
research showing the highest degree of concordance between
ischemia and mixed plaque. Because the presence of signif-
icant calcification often can preclude the accurate assessment
of lesion severity or cause a false positive study, CCTA
should not be performed in patients who have known exten-
sive calcification or a high risk of CAD.
2.2.4.2. CAC Scoring
CT also provides measurement of a CAC score, calculated as
the product of the CAC area by maximal plaque density (in
Hounsfield units).217 The CAC score frequently has been
applied for risk assessment in asymptomatic individuals,5 and
it also has been used to predict the presence of high-grade
coronary stenosis as the cause of chest pain in symptomatic
patients. When the data from 2 large multicenter registries,
including a total of 3615 symptomatic patients, were com-
bined, the estimated diagnostic sensitivity for the CAC score
to predict obstructive CAD on invasive angiography was
85%, with a specificity of 75%.218 In a recent meta-analysis
of 18 studies, which included 10 355 symptomatic patients,
the presence of nonzero CAC score had a pooled sensitivity
and specificity of 98% and 40%, respectively, for detection of
significant CAD on invasive coronary angiography.174
Although the diagnostic sensitivity of CAC to detect
obstructive CAD is fairly high, the frequency of false nega-
tive exams (ie, significant CAD in the absence of CAC) is not
well established. In small single-center studies, perfusion
defects on nuclear MPI or high-grade coronary stenosis on
coronary angiography can be present in 0% to 39% of
symptomatic patients with a calcium score of zero.219–223 In
the recent large, multicenter, CONFIRM (Coronary CT An-
giography Evaluation For Clinical Outcomes: An Interna-
tional Multicenter Registry) registry, CCTA showed mild,
nonobstructive CAD in 13%, stenosis $50% in 3.5%, and
stenosis $70% in 1.4% of the 10 037 symptomatic patients
without known CAD who had a CAC score of zero.214
Documentation of obstructive CAD without CAC occurs
more often in younger patients in whom atherosclerotic
plaque has not advanced to the stage of calcification.
Previous official documents from the AHA and ACCF218
concluded that “patients considered to be at low risk of
coronary disease by virtue of atypical cardiac symptoms may
benefit from CAC testing to help in ruling out the presence of
obstructive coronary disease”218 or that “coronary calcium
assessment may be reasonable for the assessment of symp-
tomatic patients, especially in the setting of equivocal tread-
mill or functional testing (Class IIb, LOE: B).” The present
writing committee believed that additional evidence in suffi-
ciently large cohorts of patients establishing the uncorrected
diagnostic accuracy of CAC to rule in or rule out high-grade
coronary artery stenosis in symptomatic patients was needed.
2.2.4.3. CMR Angiography
Although not widely applied, CMR angiography has been
performed for the detection of the extent and severity of
obstructive CAD. As a result of small coronary artery size,
tortuosity, and motion, the diagnostic accuracy of CMR
angiography is reduced as compared with CCTA.224 A
multicenter, controlled clinical trial of patients referred to
invasive angiography revealed that magnetic resonance an-
giography had an 81% negative predictive value for exclud-
ing CAD.225 Several meta-analyses that included a total of 59
studies have reported diagnostic sensitivity and specificity
ranging from 87% to 88% and 56% to 70%, respec-
tively,158,226 with reports of a lower accuracy than that of
CCTA.164 Variability in diagnostic accuracy with CMR
Fihn et al Stable Ischemic Heart Disease: Full Text e379
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
angiography has been attributed to a lack of uniformity in
pulse sequences and the application of varying analytic
methods.227 Recent improvements applying 32-channel 3.0-T
CMR have shown comparable abilities to detect CAD as
compared with CCTA.228 No recommendations for the use of
CMR angiography are included in this guideline.
3. Risk Assessment
3.1. Clinical Assessment
3.1.1. Prognosis of IHD for Death or Nonfatal MI:
General Considerations
IHD is a chronic disorder with a natural history that spans
multiple decades. The disease typically cycles through clini-
cally defined phases: asymptomatic, stable angina, accelerat-
ing angina, and ACS (UA or AMI), although the progression
from one state to another is not necessarily linear. The
specific approach to assessing risk of subsequent adverse
outcomes varies according to the patient’s clinical phase,
even though for those with SIHD, there is no universally
accepted approach. This represents a key area for future
research. The approach recommended in the present guideline
is informed by the treatment goals of prolonging survival and
optimizing health status and by the concept that the benefits
of treatment are often proportional to the patient’s underlying
risk. From this perspective, it is essential to quantify the
patient’s prognosis as accurately as possible. Several ap-
proaches to estimating the risk of cardiovascular mortality or
events are provided later in this guideline. In the absence of
an established prognostic model, the following considerations
are highlighted:
1. Sociodemographic characteristics: Age is the single
strongest determinant of survival, whereas ethnicity and
sex have conflicting and less important effects on risk.
Lower socioeconomic status also is associated with
worse outcomes.229
2. Cardiovascular risk factors: Smoking, hypertension,
dyslipidemia, family history of premature CAD, obe-
sity, and sedentary lifestyle confer a greater risk of
complications.
3. Coexisting medical conditions: Diabetes mellitus,230
chronic kidney disease (CKD),231 chronic pulmonary
disease, and malignancy are the most important noncar-
diac conditions to influence prognosis.232–234
4. Cardiovascular comorbidities: Heart failure, PAD, and
cerebrovascular diseases are strong prognostic risk fac-
tors for mortality.
5. Psychosocial characteristics: Depression repeatedly
has been demonstrated to be strongly and independently
associated with worse survival, and anxiety has also
been implicated.235–242 Poor social support, poverty,
and stress also are associated with adverse
prognosis.236,243–245
6. Health status: Patients’ symptoms, functional capacity,
and quality of life are associated significantly with
survival and the incidence of subsequent ACS.246,247 In
a large, prospective cohort of patients in the Veterans
Affairs healthcare system, physical limitations due to
angina were second only to age in predicting
mortality.246
7. Anginal frequency: Frequency of angina is a very strong
predictor of subsequent ACS hospitalizations.246
8. Cardiac disease severity: The degree and distribution of
stenoses measured by coronary angiography, findings
on exercise testing and stress imaging, and LV function
measured with a variety of technologies all provide
meaningful prognostic information that supplements
more clinical information.
3.1.2. Risk Assessment Using Clinical Parameters
Although there are several models to predict the likelihood of
complications and survival in asymptomatic, general popula-
tions and in patients with ACS, there is a relative paucity of
information about models for assessing the risk of patients
with known SIHD that incorporate a broad range of relevant
data. Accurate risk assessment according to clinical variables
is essential to determining optimal treatment strategies. Lauer
and colleagues developed a risk index that incorporates
variables from the history and exercise test on the basis of
data from .32 000 individuals.248 They found that their
index, which can be calculated by using a nomogram (Figure
8), was better able to predict individuals with a low (,3%)
risk of death than was the Duke treadmill score. Daly and
colleagues reported an index to estimate risk of death or
nonfatal AMI derived from data on an international sample of
approximately 3000 patients who presented with angina and
were followed up for 18 months (Figures 9 and 10). Obstruc-
tive CAD was documented in one third, whereas another third
had negative evaluations. The c statistic for the model was
0.74, which indicates a relatively high level of accuracy.57
Several risk-assessment schemes have been developed to
assist in identifying patients with severe CAD, including left
main disease, although several of these studies are up to 2
decades old. One study70 identified 8 clinical characteristics
that are important in estimating the likelihood of severe IHD:
typical angina, previous MI, age, sex, duration of chest pain
symptoms, risk factors (hypertension, diabetes mellitus, hy-
perlipidemia, and smoking), carotid bruit, and chest pain
frequency. A subsequent study71 provided detailed equations
to predict both severe IHD and survival on the basis of
clinical parameters. One study249 developed a simple risk
score for predicting severe (left main or 3-vessel) CAD that
was based on 5 clinical variables: age, sex, history of MI,
presence of typical angina, and diabetes mellitus with or
without insulin use. This same score was validated subse-
quently for prognostic purposes.250,251 This score can be
easily memorized and calculated (Figure 11) and yields an
integer ranging from 0 to 10.57 The score can be applied to
determine if a patient is more suitable for stress testing or
possibly (in appropriate patients who are at highest risk) for
proceeding directly to coronary angiography. Each curve
shows the probability of severe IHD as a function of age for
a given cardiac risk score. As shown on the Figure 11 graph,
some patients have a high likelihood (.50%) of having
severe disease for which revascularization might improve
survival on the basis of clinical parameters alone. For
example, a 50-year-old male patient who has diabetes melli-
tus, is taking insulin, and has typical angina and a history of
previous MI has a likelihood of severe coronary stenosis
.60% and thus might proceed directly to angiography if
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warranted by his preferences and other clinical factors,
although in most circumstances stress testing will assist in
planning further tests and treatments.87,252 Creation of valid,
quantitative models on the basis of data from current regis-
tries and trials to accurately identify patients with anatomic
distributions of CAD for which revascularization has been
shown to improve survival, such as left main disease, should
be a research priority.
Studies have suggested that addition of levels of novel
biomarkers such as C-reactive protein and brain natriuretic
peptide can improve prediction of mortality and cardiovas-
cular events.5,57 Considerable controversy remains; however,
as to whether these tests truly provide incremental informa-
tion beyond more well-accepted risk factors, and few of the
studies have focused on patients with SIHD.253–255 Inflamma-
tory biomarkers, such as myeloperoxidase,256 biochemical
markers of lipid-related atherogenic processes [lipoprotein(a),
apolipoprotein B, small dense LDL, and lipoprotein-
associated phospholipase A2],257,258 and low levels of circu-
lating troponin detected by high-sensitivity assays259 also are
under investigation as indices of risk in patients with SIHD.
3.2. Advanced Testing: Resting and Stress
Noninvasive Testing
3.2.1. Resting Imaging to Assess Cardiac Structure and
Function: Recommendations
Class I
1. Assessment of resting LV systolic and diastolic ven-
tricular function and evaluation for abnormalities of
myocardium, heart valves, or pericardium are rec-
ommended with the use of Doppler echocardiogra-
phy in patients with known or suspected IHD and a
prior MI, pathological Q waves, symptoms or signs
suggestive of heart failure, complex ventricular ar-
Figure 8. Nomogram to predict risk of
death based on clinical data and results
of exercise testing. To determine risk,
draw a vertical line from each risk
marker to the top line, labeled
“POINTS,” to calculate points for each
risk marker. The sum of all these points
is then marked on the line labeled
“TOTAL POINTS.” Drop vertical lines
from there to yield the 3- and 5-year sur-
vival probabilities. For binary variables, 1
means yes and 0 means no. MET indi-
cates metabolic equivalent. Reproduced
from Lauer et al.248
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rhythmias, or an undiagnosed heart mur-
mur.21,57,58,260,261 (Level of Evidence: B)
Class IIb
1. Assessment of cardiac structure and function with
resting echocardiography may be considered in pa-
tients with hypertension or diabetes mellitus and an
abnormal ECG. (Level of Evidence: C)
2. Measurement of LV function with radionuclide im-
aging may be considered in patients with a prior MI
or pathological Q waves, provided there is no need to
evaluate symptoms or signs suggestive of heart fail-
ure, complex ventricular arrhythmias, or an undi-
agnosed heart murmur. (Level of Evidence: C)
Class III: No Benefit
1. Echocardiography, radionuclide imaging, CMR,
and cardiac CT are not recommended for routine
Figure 9. Euro heart score sheet to calculate risk score for patients presenting with stable angina (derived from 3779 patients with
newly diagnosed SIHD). *$1 of previous cerebrovascular event; hepatic disease defined as chronic hepatitis or cirrhosis, or other
hepatic disease causing elevation of transaminases $3 times upper limit of normal; PVD defined as claudication either at rest or on
exertion, amputation for arterial vascular insufficiency, vascular surgery (reconstruction or bypass) or angioplasty to the extremities,
documented aortic aneurysm, or noninvasive evidence of impaired arterial flow; chronic renal failure defined as chronic dialysis or renal
transplantation or serum creatinine .200 mmol/L; chronic respiratory disease defined as a diagnosis previously made by physician or
patient receiving bronchodilators or FEV1 ,75%, arterial PO2 ,60%, or arterial PCO2 .50% predicted in previous studies; chronic
inflammatory conditions defined as a diagnosis of rheumatoid arthritis, systemic lupus erythematosus or other connective tissue dis-
ease, polymyalgia rheumatica, and so on; malignancy defined as a diagnosis of malignancy within a year of active malignancy. FEV1
indicates forced expiratory volume; PO2, partial pressure of oxygen; PCO2, partial pressure of carbon dioxide; and PVD, peripheral vas-
cular disease. Reproduced from Daly et al.57
Figure 10. Risk of death or MI over 1 year after diagnosis of
SIHD according to Euro heart score. Plot to assign estimated
probability of death or nonfatal MI within 1 year of presentation
according to combination of clinical and investigative features in
patients with stable angina. MI indicates myocardial infarction.
Reproduced from Daly et al.57
Figure 11. Nomogram showing the probability of severe
(3-vessel or left main) coronary disease based on a 5-point
score. One point is awarded for each of the following variables:
male sex, typical angina, history and electrocardiographic evi-
dence of MI, and diabetes mellitus and use of insulin. Each
curve shows the probability of severe coronary disease as a
function of age. Reproduced from Hubbard et al.249
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assessment of LV function in patients with a normal
ECG, no history of MI, no symptoms or signs
suggestive of heart failure, and no complex ventric-
ular arrhythmias. (Level of Evidence: C)
2. Routine reassessment (<1 year) of LV function with
technologies such as echocardiography radionuclide
imaging, CMR, or cardiac CT is not recommended
in patients with no change in clinical status and for
whom no change in therapy is contemplated. (Level
of Evidence: C)
See Online Data Supplement 2 for additional data on using
resting imaging to assess cardiac structure and function.
In the presence of signs or symptoms suggestive of heart
failure, it is imperative to obtain an objective measure of LV
function if a prognosis-altering change in therapy could be
based on the findings. For example, a rest ejection fraction
(EF) ,35% is associated with an annual mortality rate .3%
per year.260 Resting 2-dimensional echocardiography with
Doppler echocardiography is the preferred approach because
it provides a thorough assessment of all aspects of cardiac
structure and function, including identifying the mechanism
of heart failure and differentiating systolic LV from diastolic
dysfunction.
Rest imaging also can provide valuable therapeutic
guidance and prognostic information in patients without
symptoms or signs of ventricular dysfunction or changing
clinical status, especially in those with evidence of other
forms of heart disease (eg, hypertensive, valvular). For
example, echocardiography can identify LV or left atrial
dilation; identify aortic stenosis (a potential non-CAD
mechanism for angina-like chest pain); measure pulmo-
nary artery pressure; quantify mitral regurgitation; identify
a LV aneurysm; identify a LV thrombus, which increases
the risk of death262; and measure LV mass and the ratio of
wall thickness to chamber radius—all of which predict
cardiac events and mortality.20,117,263–267
Although nuclear imaging accurately measures EF, it does
not provide additional information on valvular or pericardial
disease and requires exposure to ionizing radiation.21,268
Although CMR is applied less widely, it also accurately
measures LV performance and provides insight into myocar-
dial and valvular structures.269 Use of delayed hyperenhance-
ment techniques can identify otherwise undetected scarred as
well as viable myocardium. Cardiac CT also provides high-
resolution detection of cardiac structures and EF. Neverthe-
less, all 3 tests generally are more expensive than a resting
echocardiogram. Although the amount of ionizing radiation
required in cardiac CT and nuclear MPI has been lowered
over the years and will continue to reduce, the use of these
tests for risk assessment is discouraged in patients with low
pretest probability of CAD and in young patients.
3.2.2. Stress Testing and Advanced Imaging in Patients
With Known SIHD Who Require Noninvasive Testing for
Risk Assessment: Recommendations
See Table 12 for a summary of recommendations from this
section.
3.2.2.1. Risk Assessment in Patients Able to Exercise
Class I
1. Standard exercise ECG testing is recommended for
risk assessment in patients with SIHD who are able
to exercise to an adequate workload and have an
interpretable ECG.106–110,112–114,132–134 (Level of Evi-
dence: B)
2. The addition of either nuclear MPI or echocardiog-
raphy to standard exercise ECG testing is recom-
mended for risk assessment in patients with SIHD
who are able to exercise to an adequate workload
but have an uninterpretable ECG not due to LBBB
or ventricular pacing.7,111,264–266,270,299,300 (Level of
Evidence: B)
Class IIa
1. The addition of either nuclear MPI or echocardi-
ography to standard exercise ECG testing is rea-
sonable for risk assessment in patients with SIHD
who are able to exercise to an adequate workload
and have an interpretable ECG.271–279 (Level of
Evidence: B)
2. CMR with pharmacological stress is reasonable for
risk assessment in patients with SIHD who are able
to exercise to an adequate workload but have an
uninterpretable ECG.279–284 (Level of Evidence: B)
Class IIb
1. CCTA may be reasonable for risk assessment in
patients with SIHD who are able to exercise to an
adequate workload but have an uninterpretable
ECG.285,286 (Level of Evidence: B)
Class III: No Benefit
1. Pharmacological stress imaging (nuclear MPI,
echocardiography, or CMR) or CCTA is not rec-
ommended for risk assessment in patients with
SIHD who are able to exercise to an adequate
workload and have an interpretable ECG. (Level
of Evidence: C)
3.2.2.2. Risk Assessment in Patients Unable to Exercise
Class I
1. Pharmacological stress with either nuclear MPI or
echocardiography is recommended for risk assess-
ment in patients with SIHD who are unable to
exercise to an adequate workload regardless of
interpretability of ECG.7,264–266,287–290 (Level of
Evidence: B)
Class IIa
1. Pharmacological stress CMR is reasonable for
risk assessment in patients with SIHD who are
unable to exercise to an adequate workload re-
gardless of interpretability of ECG.280 –284,291
(Level of Evidence: B)
2. CCTA can be useful as a first-line test for risk
assessment in patients with SIHD who are unable to
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exercise to an adequate workload regardless of
interpretability of ECG.286 (Level of Evidence: C)
3.2.2.3. Risk Assessment Regardless of Patients’ Ability
to Exercise
Class I
1. Pharmacological stress with either nuclear MPI or
echocardiography is recommended for risk assess-
ment in patients with SIHD who have LBBB on
ECG, regardless of ability to exercise to an adequate
workload.287–290,292 (Level of Evidence: B)
2. Either exercise or pharmacological stress with imag-
ing (nuclear MPI, echocardiography, or CMR) is
recommended for risk assessment in patients with
SIHD who are being considered for revasculariza-
tion of known coronary stenosis of unclear physio-
logical significance.266,278,293,294 (Level of Evidence: B)
Class IIa
1. CCTA can be useful for risk assessment in patients
with SIHD who have an indeterminate result from
functional testing.286 (Level of Evidence: C)
Class IIb
1. CCTA might be considered for risk assessment in
patients with SIHD unable to undergo stress imaging
or as an alternative to invasive coronary angiogra-
phy when functional testing indicates a moderate- to
Table 12. Using Stress Testing and Advanced Imaging for Patients With Known SIHD Who Require Noninvasive Testing for
Risk Assessment
Test
Exercise
Status
ECG
Interpretable
COR LOE References
Additional
ConsiderationsAble Unable Yes No
Patients able to exercise*
Exercise ECG X X I B (106–110, 112–114, 132–134)
Exercise with nuclear MPI or Echo X X I B (7, 111, 264–266, 270, 299, 300) Abnormalities other than LBBB
or ventricular pacing
Exercise with nuclear MPI or Echo X X IIa B (271–279)
Pharmacological stress CMR X X IIa B (279–284)
CCTA X X IIb B (285, 286)
Pharmacological stress imaging
(nuclear MPI, Echo, CMR) or CCTA
X X III: No Benefit C N/A
Patients unable to exercise
Pharmacological stress with
nuclear MPI or Echo
X Any I B (7, 264–266, 287–290)
Pharmacological stress CMR X Any IIa B (280–284, 291)
CCTA X Any IIa C (286) Without prior stress test
Regardless of patient’s ability
to exercise
Pharmacological stress with
nuclear MPI or Echo
Any X I B (287–290, 292) LBBB present
Exercise/pharmacological stress
with nuclear MPI, Echo, or CMR
Any Any I B (266, 278, 293, 294) Known coronary stenosis of
unclear physiological significance
being considered
for revascularization
CCTA Any Any IIa C N/A Indeterminate result from
functional testing
CCTA Any Any IIb C N/A Unable to undergo stress imaging
or as alternative to coronary
catheterization when functional
testing indicates moderate to high
risk and angiographic coronary
anatomy is unknown
Requests to perform multiple
cardiac imaging or stress
studies at the same time
Any Any III: No Benefit C N/A
*Patients are candidates for exercise testing if they are capable of performing at least moderate physical functioning (ie, moderate household, yard, or recreational
work and most activities of daily living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predicted maximum heart rate.
CCTA indicates cardiac computed tomography angiography; CMR, cardiac magnetic resonance imaging; COR, class of recommendation; ECG, electrocardiogram;
Echo, echocardiography; LBBB, left bundle-branch block; LOE, level of evidence; MPI, myocardial perfusion imaging; and N/A, not available.
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high-risk result and knowledge of angiographic cor-
onary anatomy is unknown. (Level of Evidence: C)
Class III: No Benefit
1. A request to perform either a) more than 1 stress
imaging study or b) a stress imaging study and a
CCTA at the same time is not recommended for risk
assessment in patients with SIHD. (Level of
Evidence: C)
See Online Data Supplement 2 for additional data on risk
assessment.
3.2.2.4. Exercise ECG
To assess the risk of cardiovascular events in patients who are
able to exercise to an adequate workload and have an
interpretable resting ECG, exercise is the preferred stressor
because it provides an objective assessment of functional
capacity and correlative information with activities of daily
living. The occurrence of ST-segment depression at a reduced
workload or persisting into recovery coupled with exertional
symptoms is associated with a high risk of cardiovascular
mortality.302 Other risk markers for mortality include low
exercise capacity (generally defined as less than stage II of
the Bruce protocol or #20% age- and sex-predicted val-
ues),118 failure to increase systolic BP to .120 mm Hg or a
sustained .10–mm Hg decrease from resting values during
exercise, complex ventricular ectopy or arrhythmias during
stress or recovery, and delayed heart rate recovery (eg, ,10-
or 12-beats-per-minute reduction in the first minute).303 The
Duke treadmill score and the Lauer nomogram score are
validated predictive instruments that incorporate parameters
from an exercise ECG test. The Duke treadmill score includes
duration of exercise, severity of ST-depression or elevation,
and angina (limiting and nonlimiting); has been demonstrated
to be highly predictive across an array of patient populations,
including women and men with suspected and known SIHD;
and has been shown to provide independent risk information
beyond clinical data, coronary anatomy, and LVEF.126,177 It
stratifies patients into risk groups that could prove useful for
patient management, as follows: no further testing for low-
risk patients, consideration for invasive testing for high-risk
patients, and stress imaging for the intermediate-risk patients.
By comparison, the Lauer score incorporates clinical vari-
ables, which results in more effective classification of low-
risk (,1% annual mortality rate) patients.248
3.2.2.5. Exercise Echocardiography and Exercise
Nuclear MPI
Evidence from thousands of patients evaluated in multiple
large registries and clinical trials and meta-analyses confirm
that a normal exercise echocardiogram or exercise nuclear
MPI is associated with a very low risk of death due to
cardiovascular causes or AMI.111,265,304 The extent and sever-
ity of inducible abnormalities in wall motion or perfusion are
directly correlated with the degree of risk. For nuclear MPI,
reversible perfusion defects encompassing 10% of the myo-
cardium (determined either semiquantitatively with summed
scores or quantitatively) to assess defect extent and severity
are considered moderately abnormal, and reversible perfusion
defects encompassing $15% of the myocardium are consid-
ered severely abnormal.277,305,306 Other findings also indica-
tive of elevated risk include a reduction in reduced post-stress
LVEF $5% or a global LVEF ,45%, transient ischemic LV
dilation, increased lung or right ventricular uptake, or abnor-
mal coronary reserve (detected on myocardial perfusion
PET). For echocardiography, a wall motion abnormality
extending beyond 2 to 3 segments as well as the presence of
change in .1 coronary territory are suggestive of higher risk.
For both tests, multiple defects in different coronary territo-
ries with either moderately reduced perfusion (or $10% of
the myocardium) or inducible wall motion abnormalities with
transient ischemic dilatation are suggestive of severe CAD.
Currently, the National Institutes of Health–National Heart,
Lung, and Blood Institute–sponsored ISCHEMIA trial is
under way and is comparing the effectiveness of a conserva-
tive versus catheterization-based initial management strategy
for patients with moderate–severe ischemia.
Several large single-center and multicenter registries
have demonstrated consistently that both stress nuclear
MPI and stress echocardiography provide incremental
prognostic value beyond that provided by a standard
ECG.115,272,299,305,307–315 The addition of imaging is manda-
tory for patients who have an uninterpretable baseline ECG
(including the presence of LBBB or ventricular pacing, LV
hypertrophy, use of digitalis or electrolyte abnormalities,
coexisting resting ST-segment abnormality, or preexcitation
syndromes) and might be of value in patients with equivocal
stress-induced316 ECG ST changes317 or an intermediate
Duke treadmill score.316 Poornima et al, demonstrated that
nuclear MPI has independent prognostic value even in pa-
tients with low-risk Duke treadmill scores, but only if there is
increased clinical risk, such as a history of typical angina, MI,
diabetes mellitus, and advanced age.318,319 Similarly, infor-
mation from exercise echocardiography appears to provide
improved prediction of mortality among patients with low-
risk Duke treadmill scores.311,318 From a large registry, the
extent of ischemic myocardium as quantified by summed
difference score by nuclear MPI has been shown to form an
effective prognostic score for the prediction of cardiac mor-
tality.320 Results from exercise nuclear MPI and exercise
stress echocardiography appear to provide accurate estimates
of the likelihood of death among men and women with
suspected and known SIHD and for patients from different
ethnic groups.314,321,322
From a review of large single- and multicenter registries
and meta-analyses,111,115,272 the following conclusions can be
made:
1. A normal exercise nuclear MPI study or a normal
exercise stress echocardiogram during which the age-
predicted target heart rate is achieved is associated with
a very low annual risk of cardiac death and AMI
(generally ,1%) in both men and women.
2. Normal and mildly abnormal nuclear MPI or exercise
stress echocardiography is associated with a low fre-
quency of referral for coronary revascularization or
worsening clinical status and UA admission (1.3% and
1% annually, respectively).141
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3. Rates of cardiac ischemic events increase in proportion
to the degree of abnormalities on stress nuclear MPI or
echocardiography, with moderate to severe abnormali-
ties associated with an annual risk of cardiovascular
death or MI $5%.115,278,279,284,305,306,310,313,314,323–330
4. For patients with mild abnormalities, coronary angiog-
raphy might be considered if the patient exhibits other
features that might indicate the likelihood of “high-risk”
CAD, including low EF on gated nuclear MPI or
echocardiographic imaging331 or transient ischemic dil-
atation of the left ventricle.332
5. Moderate to severe abnormalities, such as abnormal
wall motion in $4 segments or multivessel abnormali-
ties, indicate an increased risk (range: 6- to 10-fold)
over that of patients with a normal stress imaging
study.271
Nonetheless, the current literature with regard to exercise
nuclear MPI or exercise echocardiography should be clarified
in several ways. Although a normal exercise nuclear MPI or
exercise echocardiogram usually is associated with a low
annual risk of cardiac death or AMI, the negative predictive
value is reduced among patients with a higher pretest likeli-
hood of CAD.111,115,279,284,305,306,310,313,314,323–328,330 Further-
more, although trials have shown that imaging is useful to
detect ischemia and guide intervention in patients with SIHD
and that a reduction in ischemia by stress nuclear MPI is
associated with an observed (unadjusted) event-free sur-
vival,306,333 there is no trial evidence comparing the effective-
ness of a strategy of imaging testing for risk stratification
versus a strategy of nontesting in patients with SIHD.
3.2.2.6. Dobutamine Stress Echocardiography and
Pharmacological Stress Nuclear MPI
In one third to one half of patients who undergo risk
assessment, exercise stress is not recommended because of an
inability to exercise or an abnormal ECG. Similar to exercise
echocardiography, multiple large single-center reports have
shown that dobutamine stress echocardiography accurately
classifies patients into high-risk and very-low-risk groups. A
normal dobutamine echocardiogram is associated with a risk
of an adverse cardiac event of 1% to 2%.312,334 Classification
as high risk by dobutamine stress echocardiography is most
reliable when ischemia is detected in the territory of the LAD
and is somewhat less reliable in patients with diabetes
mellitus.335 In specialized centers, either quantification of
strain rate or myocardial contrast enhancement on dobuta-
mine echocardiography has been shown to provide informa-
tion that supplements the wall motion score alone in predict-
ing cardiac mortality.336 Dobutamine echocardiography also
has been used extensively in risk-stratifying patients with
SIHD undergoing noncardiac vascular surgery. Because the
risk of a cardiac event in the perioperative period is quite low,
the positive predictive value of dobutamine echocardiography
is also low, although the negative predictive value of a normal
result is very high and is associated with a very low likelihood
of a perioperative event.337,338
Similar to exercise SPECT, vasodilator stress nuclear MPI
has been shown to effectively assess risk of subsequent
events in patients with SIHD, with a low annualized event
rate of 1.6% observed in patients with a normal adenosine
SPECT versus 10.6% in patients with a severely abnormal
study (summed stress score .13).339 This event rate also was
observed in elderly patients with normal pharmacological
SPECT.340,341 Because of greater comorbidity in patients who
cannot exercise, the annualized event rate of patients who had
a normal pharmacological stress nuclear MPI increase the
event rate nearly 2-fold higher than that of exercising patients
who had a normal nuclear MPI, after adjustment for age and
comorbidity.342 Additional nonperfusion risk markers can be
derived from pharmacological stress, including an abnormal
ECG, high resting heart rate, and low peak/rest heart rate
ratio.276,332 To facilitate clinical risk assessment, a nomogram
based on robust risk markers, including LV function and
extent of myocardial ischemia by SPECT, has been devel-
oped and validated (Appendix 4).276
3.2.2.7. Pharmacological Stress CMR Imaging
Although clinical experience with using stress CMR for risk
assessment is substantially less than with stress echocardiog-
raphy and nuclear MPI, available evidence indicates that
stress CMR can provide highly accurate prognostic informa-
tion. On the basis of 16 single-site studies providing data
from 7200 patients283 (8 of these studies used vasodilator
stress perfusion imaging, 6 dobutamine stress CMR cine
imaging, and 2 combined stress perfusion and cine imaging),
the following general conclusions can be drawn:
1. A normal stress CMR study with either vasodilator
myocardial perfusion or inotropic stress cine imaging is
associated with a low annual rate of cardiac death or MI,
ranging from 0.01% to 0.6%,280,283 and provides accu-
rate risk assessment in patients of either sex.281,343
2. Detection of myocardial ischemia (by either perfusion
or cine imaging) and LGE imaging of infarction appear
to provide complementary information.
3. An abnormal stress CMR with evidence of ischemia is
associated with elevated likelihood of cardiac death or
MI, with hazard ratios ranging from 2.2 to 12.279,282
The current evidence related to CMR for risk assessment of
patients is limited by the predominance of data collection
from tertiary care centers with high experience in CMR,
heterogeneity of imaging techniques and equipment, and
evolution of interpretative standards.
3.2.2.8. Special Patient Group: Risk Assessment in Patients
Who Have an Uninterpretable ECG Because of LBBB or
Ventricular Pacing
Isolated “false-positive” reversible perfusion defects of the
septum on nuclear MPI due to abnormal septal motion
causing a reduction in diastolic filling time have been
reported in patients with LBBB without significant coronary
stenosis. Compared to patients without LBBB, use of exercise
stress in patients with LBBB or ventricular pacing substan-
tially reduced diagnostic specificity.289,292 Although a normal
nuclear perfusion scan in this clinical setting is highly
accurate in indicating the absence of a significant coronary
stenosis and a low risk of subsequent cardiac events,288 an
abnormal study can be nondiagnostic.148,287 In patients with
LBBB on a rest ECG, dobutamine stress echocardiography is
less sensitive but more specific than nuclear MPI in detecting
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coronary stenosis and provides prognostic information that is
incremental to clinical findings.344 One meta-analysis dem-
onstrated that abnormal stress nuclear MPI and stress echo-
cardiography each confer an up to 7-fold increased risk of
adverse cardiovascular events.148
3.2.3. Prognostic Accuracy of Anatomic Testing to Assess
Risk in Patients With Known CAD
3.2.3.1. Coronary CT Angiography
Given the high accuracy in detecting angiographically signif-
icant coronary stenosis, estimates of cardiovascular risk
according to the Duke CAD index with data obtained via
CCTA appear to be as accurate as those obtained from cardiac
catheterization. However, the actual event rates in patients
undergoing CCTA have been substantially lower because of
differences in the underlying risk profiles of patient groups
that have been referred for these 2 procedures.345 Further-
more, data from CONFIRM suggest that the finding of
nonobstructive CAD on CCTA supplements clinical informa-
tion in predicting risk of mortality.286 For example, 20% to
25% of patients with an intermediate pretest likelihood of risk
(1% to 3% annual mortality rate) based on clinical informa-
tion (without EF) were reassigned to a different risk category
according to information from CCTA. Given that failed
bypass grafts can result in unprotected CAD, which confers a
higher risk, the assessment of the extent of graft patency by
CCTA is also of prognostic value.346,347 Although exercise
stress testing in general is preferred in risk assessment, for
patients unlikely to achieve conclusive results, consensus
opinion suggests that it is reasonable to proceed with a CCTA
for risk-assessment purposes.
Several ongoing trials are comparing the prognostic values
of CCTA and functional imaging modalities such as nuclear
MPI and stress echocardiography.348 At present, there are no
prospectively gathered trial data demonstrating that CCTA
leads to better patient selection for medical or invasive
intervention or to better clinical outcomes.
3.3. Coronary Angiography
3.3.1. Coronary Angiography as an Initial Testing
Strategy to Assess Risk: Recommendations
Class I
1. Patients with SIHD who have survived sudden car-
diac death or potentially life-threatening ventricular
arrhythmia should undergo coronary angiography
to assess cardiac risk.349–351 (Level of Evidence: B)
2. Patients with SIHD who develop symptoms and
signs of heart failure should be evaluated to
determine whether coronary angiography should
be performed for risk assessment.352–355 (Level of
Evidence: B)
3.3.2. Coronary Angiography to Assess Risk After Initial
Workup With Noninvasive Testing: Recommendations
Class I
1. Coronary arteriography is recommended for pa-
tients with SIHD whose clinical characteristics and
results of noninvasive testing indicate a high likeli-
hood of severe IHD and when the benefits are
deemed to exceed risk.59,126,260,310,356–362 (Level of
Evidence: C)
Class IIa
1. Coronary angiography is reasonable to further as-
sess risk in patients with SIHD who have depressed
LV function (EF <50%) and moderate risk criteria
on noninvasive testing with demonstrable ische-
mia.363–365 (Level of Evidence: C)
2. Coronary angiography is reasonable to further as-
sess risk in patients with SIHD and inconclusive
prognostic information after noninvasive testing or
in patients for whom noninvasive testing is contra-
indicated or inadequate. (Level of Evidence: C)
3. Coronary angiography for risk assessment is reason-
able for patients with SIHD who have unsatisfactory
quality of life due to angina, have preserved LV
function (EF >50%), and have intermediate risk
criteria on noninvasive testing.306,366 (Level of
Evidence: C)
Class III: No Benefit
1. Coronary angiography for risk assessment is not
recommended in patients with SIHD who elect not to
undergo revascularization or who are not candidates
for revascularization because of comorbidities or
individual preferences.306,366 (Level of Evidence: B)
2. Coronary angiography is not recommended to fur-
ther assess risk in patients with SIHD who have
preserved LV function (EF >50%) and low-risk
criteria on noninvasive testing.306,366 (Level of
Evidence: B)
3. Coronary angiography is not recommended to assess
risk in patients who are at low risk according to
clinical criteria and who have not undergone nonin-
vasive risk testing. (Level of Evidence: C)
4. Coronary angiography is not recommended to
assess risk in asymptomatic patients with no evi-
dence of ischemia on noninvasive testing. (Level of
Evidence: C)
Coronary angiography defines coronary anatomy, including
the location, length, diameter, and contour of the epicardial
coronary arteries; the presence and severity of coronary
luminal obstruction(s); the nature of the obstruction; the
presence and extent of angiographically visible collateral
flow; and coronary blood flow. Despite the ability of newer
noninvasive imaging modalities such as CT angiography to
visualize and characterize the coronary tree, invasive coro-
nary angiography currently remains the “gold standard.”
Coronary angiography has 2 clinical goals: 1) to assess a
patient’s risk of death and future cardiovascular events
through characterization of the presence and extent of ob-
structive CAD and 2) to ascertain the feasibility of percuta-
neous or surgical revascularization. The likelihood that re-
vascularization might decrease angina and improve a
patient’s quality of life should be considered when a patient
deems his or her quality of life unsatisfactory despite a
conscientious program of evidence-based medical therapy.
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The most commonly used nomenclature for defining cor-
onary anatomy is that which was developed for CASS367 and
further modified by the BARI study group.368 This scheme is
based on the assumption that there are 3 major coronary
arteries: the LAD, the circumflex, and the right coronary
artery, with a right-dominant, left-dominant, or codominant
circulation. The extent of disease is defined as 1-vessel,
2-vessel, 3-vessel, or left main disease, with a significant
stenosis $70% diameter reduction. Left main disease, how-
ever, also has been defined as a stenosis $50%.
Despite being recognized as the traditional “gold standard”
for clinical assessment of coronary atherosclerosis, coronary
angiography is not without limitations. First, the technical
quality of angiograms in many settings can make accurate
interpretation difficult or impossible. In a random sample of
.300 coronary angiograms performed in New York State
during the 1990s, 4% were of unacceptable quality, and 48%
exhibited technical deficiencies that could interfere with
accurate interpretation.369 Although more modern techniques
and equipment likely have eliminated some of these deficien-
cies, few studies have addressed this issue, particularly in
patients who present technical challenges, such as those who
are obese. Second, problems also exist with interobserver
reliability. These investigators also found only 70% overall
agreement among readers with regard to the severity of
stenosis, and this was reduced to 51% when restricted to
coronary vessels rated as having some stenosis by any reader.
Third, angiography in isolation provides only anatomic data
and is not a reliable indicator of the functional significance of
a given coronary stenosis unless a technique such as FFR
(discussed below) is used to provide information about the
physiological significance of an anatomic stenosis. Lastly,
coronary angiography does not distinguish between a vulner-
able plaque, with a large lipid core, thin fibrous cap, and
increased macrophages, and a stable plaque that does not
exhibit these features. Serial angiographic studies performed
before and after acute events and early after MI suggest that
plaques resulting in UA and MI commonly were found to
be ,50% obstructive before the acute event and were
therefore angiographically “silent.”370,371 Diagnostic test-
ing to determine vulnerable plaque, and therefore the
subsequent risk for MI, remains intensely studied, but no
“gold standard” yet has emerged.372 Despite these limita-
tions of coronary angiography, the extent and severity of
CAD remain very significant predictors of long-term
patient outcomes (Table 13).55,70,71,373,374
For patients who are found to be at high risk of coronary
events or death on the basis of clinical data and noninvasive
testing, coronary angiography is often warranted to provide a
more complete risk assessment even though cardiac symp-
toms might not be severe. Certain clinical characteristics,
though relatively infrequent in patients with IHD, have been
associated with a high likelihood of severe disease, including
the following: chest pain leading to pulmonary edema, chest
pain associated with lightheadedness, syncope or hypoten-
sion, exertional syncope, and an exercise-induced gallop
sound on cardiac auscultation. In addition to clinical signs
and symptoms, findings on noninvasive studies could also
suggest that certain patients are at high risk of serious cardiac
events. These findings include abnormal physiological re-
sponse to exercise or imaging studies that suggest extensive
myocardial ischemia (Table 14). Some examples from Table
14 (high-risk category) which may suggest somewhat less
extensive myocardial ischemia: CCTA 2-vessel disease, CAC
score .400 Agatston units, severe resting LV dysfunction
(LVEF ,35%) not readily explained by noncoronary causes,
stress defects at 10% level, 2 coronary beds wall motion
abnormality on stress echocardiography but only 2 segments.
Coronary angiography helps to quantify risk on the basis of
an anatomic prognostic index; the simplest and most widely
used is the classification of disease into 1-, 2-, or 3-vessel or
left main CAD.358,375–377 In the CASS registry364 of medically
treated patients, the 12-year survival rate of patients with
normal coronary arteries was 91%, compared with 74% for
those with 1-vessel disease, 59% for those with 2-vessel
disease, and 40% for those with 3-vessel disease. The
probability of survival declines progressively with the num-
ber of coronary arteries that are occluded. The presence of
severe proximal LAD artery disease significantly reduces the
survival rate. The 5-year survival rate with 3-vessel disease
plus .95% proximal LAD stenosis was reported to be 59%,
as compared with a rate of 79% for 3-vessel disease without
LAD stenosis (Table 13).
With the use of data accumulated in the 1980s, a nomogram
was developed to predict 5-year survival rate on the basis of
clinical history, physical examination, coronary angiography,
and LVEF (Figure 12). The importance of considering clinical
factors and especially LV function in estimating the risk of a
given coronary angiographic finding is illustrated by comparing
the predicted 5-year survival rate of a 65-year-old man with
stable angina, 3-vessel disease, and normal ventricular function
with that of a 65-year-old man with stable angina, 3-vessel
disease, heart failure, and an EF of 30%. The 5-year survival rate
for the former was estimated to be 93%, whereas patients with
the same characteristics but with heart failure and reduced EF
had a predicted survival rate of only 58%. Because of advances
Table 13. CAD Prognostic Index
Extent of CAD
Prognostic
Weight
(0–100)
5-Year
Survival
Rate (%)*
1-vessel disease, 75% 23 93
1-vessel disease, 50% to 74% 23 93
1-vessel disease, $95% 32 91
2-vessel disease 37 88
2-vessel disease, both $95% 42 86
1-vessel disease, $95% proximal LAD artery 48 83
2-vessel disease, $95% LAD artery 48 83
2-vessel disease, $95% proximal LAD artery 56 79
3-vessel disease 56 79
3-vessel disease, $95% in $1 vessel 63 73
3-vessel disease, 75% proximal LAD artery 67 67
3-vessel disease, $95% proximal LAD artery 74 59
*Assuming medical treatment only. CAD indicates coronary artery disease;
LAD, left anterior descending.
Reproduced from Califf et al.55
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in treatment, it is almost certain that the survival rate has
improved since these studies were conducted, but the relative
differences in survival likely persist.
The development of symptomatic LV failure in a patient
with SIHD is often an indication of severe, obstructive CAD
and demands expeditious evaluation for the presence of
active ischemia. Depending on the acuity and severity of
symptoms, angiography or evaluation for ischemia with
noninvasive testing is warranted.
An additional, but less quantifiable, benefit of coronary
angiography and LV function assessment derives from the
ability of experienced angiographers to integrate the findings on
coronary angiography and left ventriculography to estimate the
potential benefit of revascularization strategies discussed below.
The characteristics of coronary lesions (eg, stenosis severity,
length, complexity, and presence of thrombus), the number of
lesions posing jeopardy to regions of contracting myocardium,
the possible role of collaterals, and the mass of jeopardized
viable myocardium also can afford some insight into the conse-
quences of subsequent vessel occlusion. For example, a patient
with a noncontracting inferior or lateral wall and severe proxi-
mal stenosis of a very large LAD artery is presumably at
substantial risk of developing cardiogenic shock if the LAD
artery were to become occluded.
In view of the importance of proximal versus distal coronary
stenoses, a “jeopardy score” has been developed, which takes the
prognostic significance of a lesion’s location into consider-
ation.378 Angiographic studies indicate that a direct correlation
also exists between the angiographic severity of CAD and the
amount of angiographically insignificant plaque buildup else-
where in the coronary tree. These studies suggest that the higher
mortality rate of patients with multivessel disease could occur
because they have more mildly stenotic or nonstenotic plaques
that are potential sites for acute coronary events than do patients
with 1-vessel disease.379
For many years, it has been known that patients with severe
stenosis of the left main coronary artery have a poor progno-
sis when treated medically. A gradation of worsening risk
also has been found with increasing degrees of stenosis of the
left main in medically managed patients.380–382 Angiographic
determination of the significance of left main disease can be
difficult, with suboptimal intraobserver agreement with re-
gard to the degree of severity of any given stenosis.381,383,384
However, multiple other modalities are available to the
angiographer to assist in accurately determining the signifi-
cance of a left main lesion (ie, FFR and intravascular
ultrasound). Despite the challenges posed by angiographic
determination of left main disease, it remains the best option
for the diagnosis and reevaluation of left main disease if
concern exists about progression of previously diagnosed
disease because of the inability to consistently detect and
evaluate this condition with noninvasive testing or clinical
assessment.385–390
4. Treatment
4.1. Definition of Successful Treatment
The paramount goals of treating patients with SIHD are to
minimize the likelihood of death while maximizing health
and function. The more specific objectives are to:
Table 14. Noninvasive Risk Stratification
High risk (3% annual death or MI)
1. Severe resting LV dysfunction (LVEF 35%) not readily explained by
noncoronary causes
2. Resting perfusion abnormalities 10% of the myocardium in patients
without prior history or evidence of MI
3. Stress ECG findings including 2 mm of ST-segment depression at
low workload or persisting into recovery, exercise-induced
ST-segment elevation, or exercise-induced VT/VF
4. Severe stress-induced LV dysfunction (peak exercise LVEF 45% or
drop in LVEF with stress 10%)
5. Stress-induced perfusion abnormalities encumbering 10%
myocardium or stress segmental scores indicating multiple vascular
territories with abnormalities
6. Stress-induced LV dilation
7. Inducible wall motion abnormality (involving 2 segments or
2 coronary beds)
8. Wall motion abnormality developing at low dose of dobutamine
(10 mg/kg/min) or at a low heart rate (120 beats/min)
9. CAC score 400 Agatston units
10. Multivessel obstructive CAD (70% stenosis) or left main stenosis
(50% stenosis) on CCTA
Intermediate risk (1% to 3% annual death or MI)
1. Mild/moderate resting LV dysfunction (LVEF 35% to 49%) not readily
explained by noncoronary causes
2. Resting perfusion abnormalities in 5% to 9.9% of the myocardium in
patients without a history or prior evidence of MI
3. 1 mm of ST-segment depression occurring with exertional
symptoms
4. Stress-induced perfusion abnormalities encumbering 5% to 9.9% of
the myocardium or stress segmental scores (in multiple segments)
indicating 1 vascular territory with abnormalities but without LV
dilation
5. Small wall motion abnormality involving 1 to 2 segments and only
1 coronary bed
6. CAC score 100 to 399 Agatston units
7. One vessel CAD with 70% stenosis or moderate CAD stenosis
(50% to 69% stenosis) in 2 arteries on CCTA
Low risk (1% annual death or MI)
1. Low-risk treadmill score (score 5) or no new ST segment changes
or exercise-induced chest pain symptoms; when achieving maximal
levels of exercise
2. Normal or small myocardial perfusion defect at rest or with stress
encumbering 5% of the myocardium*
3. Normal stress or no change of limited resting wall motion
abnormalities during stress
4. CAC score 100 Agatston units
5. No coronary stenosis 50% on CCTA
*Although the published data are limited; patients with these findings will
probably not be at low risk in the presence of either a high-risk treadmill score
or severe resting LV dysfunction (LVEF 35%).
CAC indicates coronary artery calcium; CAD, coronary artery disease; CCTA,
coronary computed tomography angiography; LV, left ventricular; LVEF, left
ventricular ejection fraction; and MI, myocardial infarction.
Adapted from Gibbons et al.7
Fihn et al Stable Ischemic Heart Disease: Full Text e389
  
Adapted from Snow et al.377a
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
● Reduce premature cardiovascular death;
● Prevent complications of SIHD that directly or indirectly
impair patients’ functional well-being, including nonfatal
AMI and heart failure;
● Maintain or restore a level of activity, functional capacity,
and quality of life that is satisfactory to the patient;
● Completely, or nearly completely, eliminate ischemic
symptoms; and
● Minimize costs of health care, in particular by eliminating
avoidable adverse effects of tests and treatments, by pre-
venting hospital admissions, and by eliminating unneces-
sary tests and treatments.
These goals are pursued with 5 fundamental, complemen-
tary, and overlapping strategies:
1. Educate patients about the etiology, clinical manifesta-
tions, treatment options, and prognosis of IHD, to
support active participation of patients in their treatment
decisions.
2. Identify and treat conditions that contribute to, worsen,
or complicate IHD.
3. Effectively modify risk factors for IHD by both phar-
macological and nonpharmacological methods.
4. Use evidence-based pharmacological treatments to im-
prove patients’ health status and survival, with attention
to avoiding drug interactions and side effects.
5. Use revascularization by percutaneous catheter-based
techniques or CABG when there is clear evidence of the
potential to improve patients’ health status and survival.
4.2. General Approach to Therapy
The writing committee has constructed these guidelines from
the perspective that when making decisions about diagnostic
tests and therapeutic interventions, their potential effects on
improving survival and health status should be considered
independently. Although treatment choices often are intended
to achieve both goals simultaneously, circumstances exist in
which a treatment is administered in pursuit of only one of
these goals. For example, when pharmacotherapy such as
aspirin or angiotensin-converting enzyme (ACE) inhibitors is
prescribed, the goal is to improve survival but not necessarily
quality of life. Similarly, revascularization can be performed
to improve symptoms, even when there is no expectation of
Figure 13. Cumulative incidence of MACE in patients with 3-vessel CAD based on SYNTAX score at 3-year follow-up in the SYNTAX
trial treated with either CABG (blue) or PCI (gold). CABG indicates coronary artery bypass graft; CAD, coronary artery disease; MACE,
major adverse cardiovascular event; PCI, percutaneous coronary intervention; and SYNTAX, Synergy between Percutaneous Coronary
Intervention with TAXUS and Cardiac Surgery. Adapted from Kappetein.980
Figure 12. Nomogram for prediction of
5-year survival from clinical, physical
examination, and cardiac catheterization
findings. Asymp indicates asymptomatic;
CAD, coronary artery disease; MI, myo-
cardial infarction; and Symp, symptom-
atic. Reproduced from Califf et al.55
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improved survival. Occasionally, treatment recommendations
related to achieving these goals can be at odds, such as when
a patient is encouraged to take a medication that significantly
reduces the risk of death even though it causes mild or
moderate adverse side effects.
It might also be the case that a patient expresses a
preference for a treatment approach (eg, PCI) when the
practitioner believes another approach (eg, GDMT) would be
preferable. Although practitioners always should engage
patients in a detailed discussion about their individual goals
and values in order to tailor therapy, this is particularly
important when therapeutic goals or the patient’s or provid-
er’s preferences are not aligned. It is essential that these
discussions be conducted in a location and atmosphere that
permits adequate time for discussion and contemplation.
Initiating a discussion about the relative merits of medical
therapy versus revascularization while a patient is in the
midst of procedure, for example, is not usually consistent
with these principles.
Reducing the risk of mortality should be pursued as
intensively as is sensible for all patients with SIHD. It has
been estimated that nearly half of the dramatic decline in
cardiovascular mortality observed during the past 40 years is
attributable to interventions directed at modifying risk fac-
tors. Of this change, 47% can be attributed to treatments,
including risk factor reduction after AMI, other guideline-
based treatments for UA and heart failure, and revasculariza-
tion for chronic angina.391 An additional 44% reduction in
age-adjusted death is attributed to population-based changes
in risk factors.391 Unfortunately, these changes have been
offset somewhat by increases in BMI and type 2 diabetes
mellitus, which result in an increased number of deaths.391
The 2011 secondary prevention and risk reduction therapy
statement8 summarizes the key interventions known to im-
prove survival and prevent subsequent cardiac events. World-
wide, it has been estimated that 90% of the risk of MI is
attributable to 9 measureable risk factors, including smoking,
diabetes mellitus, hypertension, obesity, impaired psycholog-
ical well-being, poor diet, lack of exercise, alcohol consump-
tion, and dyslipidemia.392 The initial approach to all patients
should be focused on eliminating unhealthy behaviors such as
smoking and effectively promoting lifestyle changes (eg,
maintaining a healthy weight, engaging in physical activity,
adopting a healthy diet [Figure 4]). In addition, for most
patients, an evidence-based set of pharmacological interven-
tions is indicated to reduce the risk of future events. The
presumed mechanism by which these interventions work is
stabilization of the coronary plaque to prevent rupture and
thrombosis.8 These include antiplatelet agents,393 st-
atins,394 – 401 and beta blockers, along with other agents if
indicated, to control hypertension.402,403 ACE inhibitors
are indicated in many patients with SIHD, especially those
with diabetes mellitus or LV dysfunction.296,301,404 Simi-
larly, tight glycemic control not only has not been shown
to reduce the risk of macrovascular complications in
patients with type 2 diabetes mellitus, it also appears to
increase the risk of cardiovascular death and complications.
Nonetheless, weight loss, aerobic exercise, an AHA Step II diet,
and ACE inhibitors in patients with diabetes mellitus with
proteinuria all can improve patients’ risks of microvascular
complications and, potentially, cardiac events.
For the purposes of this guideline, the writing committee
elected to retain the classification for risk of cardiovascular
events that has been accepted by consensus over the past 2
decades. Patients with a predicted annual cardiac mortality
rate of ,1% per year are considered to be at low risk, those
with a predicted rate of 1% to 3% per year are considered to
be at intermediate risk, and those with a predicted average
.3% per year are considered to be at high risk.
For patients at high risk of mortality, the prevalence of
severe CAD (eg, left main coronary occlusion) is higher, and
coronary angiography can define the coronary anatomy and
help to plan further therapy beyond standard GDMT (Figure
5). If the patient is at low or intermediate risk for mortality,
therapeutic decisions should be directed toward improving
symptoms and function, and catheterization may be deferred
if symptoms can be controlled with medical therapy alone.
For patients in whom angiography is performed and who are
determined to be at low or intermediate risk, evidence
reaffirms that it is safe to defer revascularization and institute
a program of evidence-based medical therapy, because nei-
ther survival nor adverse cardiac events are averted by
proceeding immediately to revascularization.366,397,405–409 If a
patient in this category has symptoms that are completely or
almost completely relieved with medical therapy, it is usually
prudent to continue with medical therapy without proceeding to
revascularization. If symptoms persist, however, then a discus-
sion with the patient to elicit his or her preferences and goals is
necessary, along with a frank discussion of the benefits and risks
of PCI and CABG, to ascertain whether the symptoms have been
ameliorated sufficiently to warrant simply continuing with med-
ical therapy alone (Figures 4 and 5).
Coronary revascularization generally improves survival
among certain subgroups of patients, particularly those with
severe left main coronary stenosis. When revascularization is
being considered on an elective basis solely for reducing the
risk of death, the healthcare provider should engage the
patient in an explicit consideration of the estimated improve-
ment in survival relative to the potential risks and costs of the
procedure and related interventions. Because reliable esti-
mates of benefit, such as absolute risk reduction, are fre-
quently unavailable for many specific subgroups, the risk for
death can be estimated before treatment and the anticipated
absolute risk reduction calculated (obtained by multiplying
the RR reduction by the pretreatment risk). In the STICH
(Surgical Treatment for Ischemic Heart Failure) trial, in
which 1212 patients with an LVEF #35% and CAD amena-
ble to revascularization were randomized to CABG or med-
ical therapy, there was no significant difference in overall
mortality rate, but during a median follow-up of 56 months,
28% of those assigned to CABG died of a cardiovascular
cause, compared with 33% of those receiving medical ther-
apy.410 This information can be converted to a more interpre-
table framework, such as the average reduction in risk of
events or number needed to treat. In this example, the average
reduction in cardiovascular events was 19%, and it would be
necessary to perform bypass surgery on about 5 patients with
LV dysfunction to prevent 1 cardiovascular death at 5 years
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(ie, number needed to treat 5 5, calculated as 1 4 absolute
risk reduction, or 1/0.19 [although there would be no effect
on overall mortality rate]). This process complies with the
Institute of Medicine’s goals for transparently sharing evi-
dence with patients so that they can control (or more actively
participate in) their own decisions.411 In general, a beneficial
effect of revascularization on survival has been demonstrated
most clearly among patients with the highest cardiovascular
risk.412 Although traditional methods of risk stratification
have relied on coronary anatomy and LV function, other
strategies described in this guideline can be used (Figure 5).
The specific anatomic features of the patient and the
likelihood of procedural success often influence the approach
to a patient for whom revascularization is being considered.
For example, a given patient with 1-vessel disease might have
coronary anatomic features that would make the risk of PCI
high enough and the likelihood of success low enough that
CABG or medical therapy would be preferred. In general,
complete revascularization leads to better outcomes than
incomplete revascularization.413–418 In patients with chronic
total occlusion, CABG could be preferable to PCI,419 but this
is still controversial. Although the technology and techniques
for PCI of chronic total occlusions are improving, there
remains no current evidence that survival is improved after
successful PCI of a chronic total occlusion. Some patients
with diabetes mellitus can have such diffuse disease that
neither CABG nor PCI is likely to produce sustained benefits.
Other patients can have small-caliber arteries or diffuse
disease that is likely to lead to early graft failure. Still others
can have long, complex lesions that are very likely to undergo
restenosis after PCI, although use of drug-eluting stents
(DES) can reduce this risk.
The majority of patients with SIHD have clinical features
indicating that revascularization is unlikely to improve life
expectancy or the risk of subsequent MI. For such patients,
antianginal therapy and intensive treatment for risk factors
are recommended before consideration of PCI or CABG to
relieve symptoms. A broad range of highly effective drugs is
available, including beta blockers, calcium channel blockers,
long-acting nitrates, and newer agents such as ranolazine.
Comparative trials among these medications are relatively
few and for the most part small.420 On the basis of the
available data, however, all of the classes of agents appear to
be relatively similar in antianginal efficacy, and all have very
acceptable profiles of safety and tolerability. Beta blockers
have been shown to improve survival in patients after AMI
and in patients with hypertension; they provide 24-hour
coverage and have a long history of clinical use. For these
reasons, the writing committee recommends these agents as
first-line drugs for treating angina. In patients who do not
tolerate or adequately respond to beta blockers, calcium
channel blockers and/or long-acting nitrates may be substi-
tuted or added. Ranolazine has been shown to inhibit the late
sodium current in humans and has demonstrated lusitropic
properties.421 Clinical trials have shown that this agent is
comparable to other agents in alleviating angina. Although
this agent has been approved by the US Food and Drug
Administration (FDA) for first-line use in patients with
chronic angina, the writing committee recommends that
ranolazine be considered in circumstances in which beta
blockers, calcium channel blockers, and nitrates are not
adequately effective or are not tolerated.
4.2.1. Factors That Should Not Influence
Treatment Decisions
The 2 medical indications for revascularization are to prevent
death and cardiovascular complications and to improve
symptoms and quality of life. Nonetheless, the use of revas-
cularization has risen dramatically in the past 3 decades.
Much of this increase appears to be for indications for which
benefits in survival or symptoms in comparison with nonin-
vasive therapies are unlikely.422 National data suggest that
about 12% of PCIs could be inappropriate because they lack
evident potential to improve either survival or symptoms.423
Several reasons influence patients and physicians to prefer
revascularization when the likelihood of benefit is less than
the potential risk of the procedure. An ingrained preference
for action (ie, revascularization) over perceived inaction (ie,
medical therapy alone) likely often influences the decision
making of both patients and physicians.252 Moreover, some
healthcare professionals are unduly pessimistic about survival
with conservative medical therapy and inaccurately optimis-
tic about the survival benefits of revascularization proce-
dures.424 As indicated earlier, patients often believe mistak-
enly that PCI has the potential to prevent AMI and prolong
survival.423,425 In addition, the attendant expense and risk of
combined antiplatelet therapy for an uncertain period of time
might not be fully considered. Physicians are professionally
obligated to provide accurate estimates of the risks, benefits,
and costs of various therapeutic options that are based on the
best available scientific data. Other factors can induce phy-
sicians to recommend revascularization. These include med-
icolegal concerns (often exaggerated) and feeling compelled
to satisfy the expectations of patients and referring physicians
(which are sometimes misinformed or unrealistic).426 Addi-
tionally, there are well-documented regional variations in
the use and appropriateness of cardiac procedures that
appear to reflect local practice styles.427 This might partly
reflect a mistaken belief by some physicians that “more
care is better care.”428 Although successful procedures can
be psychologically satisfying to the physician and the
patient, this does not justify the attendant economic costs
and risk of complications of procedures that offer minimal,
if any, genuine benefit.429 – 431
Although rarely discussed explicitly, financial incentives
seem to affect the willingness of a minority of physicians and
institutions to recommend certain procedures or drug thera-
pies. Strong incentives created by the payment system en-
courage overutilization. Also, a small number of physicians
might have financial relationships with the manufacturers of
devices or drugs that might represent apparent conflicts that
ought to be disclosed to patients. At a higher level, those
responsible for the payment system, the manufacturers of
devices and drugs, and physicians making clinical decisions
must commit to supporting guideline-based interventions.
Any and all conflicts of interest must be revealed to patients
in the process of informed consent before any invasive or
noninvasive procedure.
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4.2.2. Assessing Patients’ Quality of Life
In addition to interventions undertaken to improve survival
and prevent cardiovascular complications, therapy also is
prescribed to improve patients’ health status, a general term
that incorporates many facets, including severity of symp-
toms, functional limitations, and quality of life. Assessment
of health status is often unstructured and exclusively quali-
tative, but efforts to standardize this assessment are recom-
mended, beginning with a structured inventory of activity,
symptoms, and quality of life, supplemented by the use of
simple, semiquantitative scales such as the CCS and New
York Heart Association classifications.432,433
The CCS and New York Heart Association classifications
are limited, however, because they quantify health status
from the physicians’ perspective, rather than directly report-
ing patients’ experiences, and they are known to have limited
reproducibility and sensitivity to important clinical changes.
Furthermore, even these simple classifications of health status
are recorded infrequently in health records.432,434 One ap-
proach to directly eliciting perceptions of health status from
patients with IHD is to use the self-administered Seattle
Angina Questionnaire (SAQ), a valid, sensitive, and prognos-
tically important questionnaire, to quantify the symptoms,
functional limitations, and quality of life of patients with
SIHD.246,247,435 Although such instruments typically are used
in research trials, they are readily applicable to clinical
practice and can be used serially to assess and monitor the
effectiveness of therapy, including antianginal medications
and revascularization.434 The formal assessment of a patient’s
disease-specific health status, through either the CCS or the
SAQ, has been endorsed as a performance measure of
healthcare quality.436
4.3. Patient Education: Recommendations
Class I
1. Patients with SIHD should have an individualized
education plan to optimize care and promote well-
ness, including:
a. education on the importance of medication adher-
ence for managing symptoms and retarding dis-
ease progression437–439 (Level of Evidence: C);
b. an explanation of medication management and
cardiovascular risk reduction strategies in a man-
ner that respects the patient’s level of under-
standing, reading comprehension, and ethnic-
ity8,440–444 (Level of Evidence: B);
c. a comprehensive review of all therapeutic op-
tions8,441–444 (Level of Evidence: B);
d. a description of appropriate levels of exercise,
with encouragement to maintain recommended
levels of daily physical activity8,445–448 (Level of
Evidence: C);
e. introduction to self-monitoring skills445,447,448
(Level of Evidence: C); and
f. information on how to recognize worsening car-
diovascular symptoms and take appropriate ac-
tion. (Level of Evidence: C)
2. Patients with SIHD should be educated about the
following lifestyle elements that could influence
prognosis: weight control, maintenance of a BMI of
18.5 to 24.9 kg/m2, and maintenance of a waist
circumference less than 102 cm (40 inches) in men
and less than 88 cm (35 inches) in women (less for
certain racial groups)8,440,449 – 452; lipid manage-
ment18; BP control17,453; smoking cessation and
avoidance of exposure to secondhand smoke8,454,455;
and individualized medical, nutrition, and lifestyle
changes for patients with diabetes mellitus to sup-
plement diabetes treatment goals and education.456
(Level of Evidence: C)
Class IIa
1. It is reasonable to educate patients with SIHD about:
a. adherence to a diet that is low in saturated
fat, cholesterol, and trans fat; high in fresh
fruits, whole grains, and vegetables; and re-
duced in sodium intake, with cultural and
ethnic preferences incorporated8,17,18,457,458
(Level of Evidence: B);
b. common symptoms of stress and depression to
minimize stress-related angina symptoms459
(Level of Evidence: C);
c. comprehensive behavioral approaches for the
management of stress and depression237,460–462
(Level of Evidence: C); and
d. evaluation and treatment of major depressive
disorder when indicated.237,238,437,461,463,464,467,468
(Level of Evidence: B)
Multiple risk factors for heart disease, vascular disease,
and stroke are typically present in persons with SIHD,
including hypertension, smoking, dyslipidemia, diabetes mel-
litus, overweight, and physical inactivity.27,392 At a national
level, in 2000, only 5% of individuals without IHD and 7% of
those with IHD were fully adherent to recommendations for
physical activity, fruit and vegetable consumption, and
nonsmoking.
The approach to managing risk factors usually requires
partnerships among the healthcare team, the patient, their
family, and their community. The goal of this partnership is
to assure an effective exchange of information, sharing of
concerns, and an improved understanding of treatments, with
the aim of improving quality of life and health outcomes. The
American Academy of Family Physicians defines patient
education as “the process of influencing patient behavior
through the provision of information and counseling that is
designed to produce changes in knowledge, attitudes, and
skills necessary to maintain or improve health.”469 The Joint
Commission mandates patient education as a principal guid-
ing policy to improve health outcomes. Effective patient
education and counseling are based on a collaborative ap-
proach that acknowledges individual patient needs through an
understanding of cognitive, behavioral, and sociodemo-
graphic factors. Patients actively involved in care decisions
are more likely to follow a treatment plan and engage in
behaviors that can improve their health.
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When educating patients, it is important to communicate an
understanding of a specific disease process, the need for
laboratory testing, medication management and adherence,
reporting of efficacy and side effects, and behavioral lifestyle
change.8 Unfortunately, the type, intensity, frequency, and
duration of educational programs are not well established for
individual risk factors. For example, the Ask, Advise, Assess,
Assist, and Arrange algorithm for smoking cessation often is
used, although supporting data from RCTs are lacking.470 In
addition, who should deliver education programs and how to
evaluate efficacy are not well studied. In smoking cessation,
the most effective intervention continues to be a physician’s
recommendation for the patient “to quit.” However, quit rates
for smoking are also dependent on the appropriate use of
medical therapies and group support programs.442,471 In dia-
betes care, patient education has the potential to be as
effective as or more effective than medical therapies.472 The
management of hypertension, heart failure, dyslipidemia,
type 2 diabetes mellitus, weight loss, and physical activity is
enhanced by ongoing health education and support in addi-
tion to physician office visits.
Factors that complicate effective patient education include
low literacy, adverse sociodemographic factors (eg, poverty,
social isolation, and emotional disorders such as depression),
cultural beliefs and language barriers, environmental factors,
advanced age, and the presence of complex comorbidities.
These factors and others play an important role in the
adoption of healthy lifestyles and adherence to recommended
medical therapies. In addition, how to best provide cost-
effective educational strategies remains a challenge in today’s
healthcare environment.473 The lack of payment for these
activities remains an important barrier. Clinic-based educa-
tion generally consists of the following:
1. Individual counseling. This educational format com-
monly is used in the context of a routine clinic visit. It
tends to be directive and didactic, generally not inter-
active or behaviorally oriented, relatively brief, and
sometimes supported with written materials. Follow-up
to ascertain effectiveness is not commonly practiced.
2. Group education. Group care or shared office visits
have been tested in multispecialty group practices. They
offer the benefit of providing education to larger num-
bers of patients with similar diagnoses (eg, type 2
diabetes mellitus), combined with an individualized
physician visit. They tend to be behaviorally oriented
with planned follow-up for effectiveness and outcomes.
3. Self-monitoring. Self-monitoring skills enhance patient
education and behavior change. Examples such as home
BP and blood glucose monitoring and tracking daily
calories and physical activity minutes can support
important lifestyle change. Review of self-monitoring
logs by patient and provider at subsequent clinic visits
supports the continued importance of and attention to
behavior change. In some healthcare plans, these data
can be entered via web portals for patients.474
4. Internet- and computer-based education. A growing
number of health plans provide health information via
websites and special programs. This approach is often
low in cost to the patient but requires adequate com-
puter access and skills, higher reading levels, and
self-motivation to change behavior (eg, AHA Choose to
Move).475
5. Hand-held computer devices, smartphones, and other
portable devices. Portable devices have the potential to
provide motivational reminders and prompts for life-
style change but have not yet been thoroughly tested.
Present efforts to improve the effectiveness of patient
education and lifestyle interventions integrate key constructs
related to behavior change theory. A summary of the most
common models is provided below:
1. Motivational interviewing, a social learning theory,
promotes behavioral change through empathetic and
reflective listening, encouraging patients to determine
their reasons for change, helping healthcare profession-
als deal with resistance, and supporting self-efficacy.476
2. Self-efficacy theory posits that the ability to change
behavior depends upon one’s self-confidence to per-
form a specific action (such as walking 30 minutes
daily) and the belief that one can persist with this action.
Low self-efficacy predicts poor ability to achieve a
specified lifestyle change. Improving one’s self-
efficacy will improve the ability to change a particular
lifestyle.477
3. The Transtheoretical Model of behavior change is based
on “stages of change.” The theory relies on the obser-
vation that many individuals traverse 5 distinct temporal
processes in achieving permanent change. These in-
clude precontemplation, contemplation, preparation, ac-
tion, and maintenance. Application of this model of
change entails categorizing an individual’s progress in
the process of change and recognizing that cycling
through phases is common in the process of achieving
permanent change.478
The interventions described above should be provided
within a medical environment that provides coordinated,
team-based care. Data accumulating from interventions that
incorporate principles of the chronic care model,479 such as
the patient-centered medical home, have demonstrated bene-
ficial effects not only on intermediate outcomes such as
glycemic and BP but also on cost, utilization, and mortality
rate.480,481 This approach depends on the active participation
of an engaged, informed patient, which in turn relies on the
patient’s understanding of his or her condition, ability to
adhere safely to complex medical therapies, and willingness
to communicate on a regular basis with the healthcare team.
In addition to counseling about the approach to management
of SIHD and risk reduction, patients often seek information
about other aspects of their health, particularly issues that are
often not directly addressed by healthcare providers.
One such topic that commonly arises is possible restric-
tions on sexual activity. Regrettably, there are relatively
limited scientific data on the cardiovascular demands and
potential risks of sexual activity in patients with heart disease,
some of it dating back 3 or 4 decades and nearly all of it
dealing with men. In general, sexual activity is equivalent to
mild to moderate physical activity requiring 3 to 5 METs (ie,
the equivalent of climbing 2 flights of stairs or walking
briskly).482 The few available studies suggest that AMI within
1 to 2 hours of sexual activity is associated with an average
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RR of 2.7 among middle-aged men, with the greatest risk
among those who are sedentary.483–486 Because the overall
incidence of AMI is low in the population and periods of
exposure relatively infrequent, it has been postulated that the
absolute risk is exceedingly low for any individual.487 How-
ever, ECG monitoring during sexual activity in 1 study of
men with IHD revealed that nearly a third developed ST
depression and nearly half developed arrhythmias. It ap-
peared, however, that these findings also were found during
similarly stressful activities that did not involve sex, and the
arrhythmias were largely benign. Moreover, these patients
were not initially on anti-ischemic medications, and it was
reported that the ischemic changes on ECG resolved when
subjects took beta blockers. Thus, it seems that sexual activity
should not necessarily be regarded as appreciably different
from other types of physical activity that impose equivalent
metabolic demands. Needless to say, patients should be
treated to maximize their capacity for physical activity, as
described subsequently in this guideline.
Patients often express concerns that medications given to
treat symptoms or reduce cardiovascular risk could cause
erectile dysfunction. Although these perceptions are often
firmly and widely held, studies and reviews have not delin-
eated a clear association between these drugs, including beta
blockers, and sexual dysfunction.488–492
A related issue that could arise is use of phosphodiesterase
5 inhibitors, such as sildenafil, vardenafil, or tadalafil, to
improve erectile function. Although, as discussed in the
section on treatment of SIHD, current evidence has shown
that these drugs do not raise the risk of adverse cardiovascular
events in men with SIHD,493,494 there is a clear risk of serious
hypotension when they are taken in conjunction with nitrates,
and the combination is absolutely contraindicated. There are
also potential drug–drug interactions with alpha-blockers that
are sometimes used to treat hypertension.495
4.4. Guideline-Directed Medical Therapy
4.4.1. Risk Factor Modification: Recommendations
4.4.1.1. Lipid Management
Class I
1. Lifestyle modifications, including daily physical ac-
tivity and weight management, are strongly recom-
mended for all patients with SIHD.18,496 (Level of
Evidence: B)
2. Dietary therapy for all patients should include re-
duced intake of saturated fats (to <7% of total
calories), trans fatty acids (to <1% of total calories),
and cholesterol (to <200 mg/d).18,497–500 (Level of
Evidence: B)
3. In addition to therapeutic lifestyle changes, a mod-
erate or high dose of a statin therapy should be
prescribed, in the absence of contraindications or
documented adverse effects.18,398,400,458,501 (Level of
Evidence: A)
Class IIa
1. For patients who do not tolerate statins, LDL cho-
lesterol–lowering therapy with bile acid seques-
trants,* niacin,† or both is reasonable.502,504,505 (Level
of Evidence: B)
Epidemiological studies have established serum cholesterol
as an important coronary heart disease risk factor. The
Framingham Heart Study, Multiple Risk Factor Intervention
trial, and the Lipid Research Clinics trials all found a
continuous, graded increase in coronary events with increas-
ing LDL cholesterol in men and women who were initially
free of IHD.502,506–508 A similar relationship has been ob-
served among patients with SIHD.509–511 The association
between LDL cholesterol and cardiovascular risk is curvilin-
ear, or log-linear, meaning that the decrease in RR for a given
1-mg/dL decrease in LDL cholesterol seems to be the same at
any level of baseline LDL cholesterol. The principal lipid
modification strategy recommended by the NCEP ATP-III
(National Cholesterol Education Program Adult Treatment
Panel III) in patients with SIHD is the reduction of LDL
cholesterol.18,24 This should start with therapeutic lifestyle
changes, including dietary therapy, daily physical activity,
and weight management. Most patients also will benefit from
cholesterol-lowering drug therapy, preferably with a statin.
Effective dietary approaches to lowering LDL cholesterol
include replacing saturated and trans fatty acids with dietary
carbohydrates or unsaturated fatty acids and reducing dietary
cholesterol. Although the response to dietary interventions is
variable, a diet low in saturated fat and cholesterol typically
lowers LDL cholesterol by 10% to 15%.497–500 Other benefi-
cial dietary interventions can include addition of plant sta-
nols/sterols (2 g/d), which trials suggest lower LDL choles-
terol by 5% to 15%, and addition of viscous fiber (.10 g/d),
which reduces LDL cholesterol by 3% to 5%.512–515 A 10-lb
weight loss reduces LDL cholesterol by 5% to 8%.496 Regular
physical activity is also a key component of therapeutic
lifestyle modification. Although exercise does not reliably
lower LDL cholesterol, it facilitates weight loss and has other
beneficial effects on the lipid profile.516–518
Controlled clinical trials of lipid-lowering drug therapy
have demonstrated that lowering of LDL cholesterol is
associated with a reduced risk of adverse cardiovascular
events. Earlier trials used bile acid sequestrants (cholesty-
ramine), fibric acid derivatives (gemfibrozil and clofibrate),
or niacin. More contemporary studies have convincingly
established the efficacy of statins in the primary and second-
ary prevention of coronary events.394–396,398,400,501,519–522 In a
prospective meta-analysis published by the Cholesterol Treat-
ment Trialist Collaborators in 2010 that examined data from
26 randomized trials of statin therapy (comparing higher- to
lower-dose statin therapy or statin therapy to a control
regimen), the mean difference in LDL cholesterol was 31
mg/dL, ranging from 12 to 68 mg/dL. Each 40-mg/dL
reduction in LDL cholesterol was associated with a 10%
reduction in all-cause mortality and a 20% reduction in
coronary mortality, with corresponding reductions in nonfatal
MI, need for coronary revascularization, and first nonfatal
ischemic stroke.458 The absolute benefit of therapy was a
*The use of bile acid sequestrant is relatively contraindicated when triglycerides are
$200 mg/dL and is contraindicated when triglycerides are $500 mg/dL.
†Dietary supplement niacin must not be used as a substitute for prescription
niacin.
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function of an individual’s absolute risk of fatal MI.458 In
trials comparing higher- to lower-dose statin therapy, the
average, weighted reduction in LDL cholesterol at 1 year was
20 mg/dL among those receiving higher-dose regimens.
Among patients assigned to more intensive regimens, there
was a 15% lower incidence of major vascular events (95% CI:
11 to 18; P,0.0001), which reflected a 13% lower risk of
coronary death or nonfatal MI (95% CI: 7 to 19; P,0.0001),
a 19% lower risk of undergoing coronary revascularization
(95% CI: 15 to 24; P,0.0001), and a 16% lower risk of
ischemic stroke (95% CI: 5 to 26; P50.005). The reductions
in serum LDL cholesterol and in cardiovascular risk were
similar in magnitude to those observed in trials comparing
statin therapy to a control regimen. The absolute benefit of
therapy was defined chiefly by an individual’s absolute risk
of death due to coronary occlusion.458 Appropriate treatment
goals for patients with SIHD have been informed by several
trials of intensive lipid-lowering therapy. The HPS (Heart
Protection Study) compared simvastatin 40 mg daily to
placebo in patients with IHD, other occlusive vascular dis-
ease, or diabetes mellitus. On-treatment LDL cholesterol
levels averaged 88 mg/dL in those allocated to simvastatin
and 127 mg/dL in those randomized to placebo. A consistent
and early benefit of therapy was demonstrated, with a 13%
reduction in mortality rate and an 18% reduction in coronary
death rate.398 Similar reductions in RR were observed regard-
less of baseline levels of LDL cholesterol, including in those
with initial levels ,116 mg/dL or ,97 mg/dL. (Of note, LDL
cholesterol levels in the HPS were not drawn with patients in
the fasting state and were measured values rather than the
calculated values used in clinical practice and in most trials;
measured LDL cholesterol is generally about 15% higher
than calculated LDL cholesterol.)398 In the TNT (Treating to
New Targets) trial, patients with clinically apparent IHD and
LDL cholesterol .130 mg/dL were randomly assigned to
either 10 mg or 80 mg of atorvastatin per day. The mean LDL
cholesterols were 77 mg/dL during treatment with 80 mg of
atorvastatin and 101 mg/dL during treatment with 10 mg of
atorvastatin. There was a 22% reduction in a composite
cardiovascular endpoint and a 20% reduction in cardiac
deaths with more intensive therapy but no reduction in
all-cause mortality.400 In the IDEAL (Incremental Decrease
in End Points Through Aggressive Lipid Lowering) study
patients with a past history of MI were randomly assigned to
intensive lipid-lowering therapy with atorvastatin 80 mg daily
or simvastatin 20 mg daily. During treatment, mean LDL
cholesterol levels were 104 mg/dL in the simvastatin group
and 80 mg/dL in the atorvastatin group. The results showed a
nonsignificant trend toward reduction of the primary com-
posite endpoint of coronary death, nonfatal MI, or cardiac
arrest (hazard ratio: 0.89; 95% CI: 0.78 to 1.01); significant
reductions in some secondary endpoints such as nonfatal MI
and coronary revascularization; and no effect on all-cause
mortality.501 It should be noted that both these trials com-
pared 2 drug regimens and did not directly test the benefit of
achieving a given level of LDL cholesterol and that, to date,
there is no clear evidence that treating to a specific target, as
opposed to treating with a higher dose of a higher-potency
statin, is beneficial. The mean achieved LDL cholesterol
levels among patients treated in the high-dose atorvastatin
arms of the TNT and IDEAL studies were 77 and 81 mg/dL,
respectively.
These data support intensive LDL cholesterol lowering
with statins in patients with SIHD. An update of the
ATP-III report18,24 recommends treatment to an LDL
cholesterol level ,100 mg/dL in patients with established
CAD or other high-risk features, with an LDL cholesterol
goal of ,70 mg/dL as a therapeutic option in patients at
very high risk. However, as discussed above, although the
presence of data confirming the use of a specific, numeric
target LDL cholesterol level for all patients with SIHD has
been challenged, the benefit of therapy with moderate- to
high-dose statin therapy is well established.458 For this
reason, the recommendations in this guideline stress the
importance of prescribing a statin in at least a moderate
dose. The ATP-IV report is anticipated later in 2012 and is
expected to provide guidance for the treatment of LDL
cholesterol levels on the basis of the results of an extensive
systematic review. Factors that identify patients at very
high risk in the ATP-III update include the presence of
established coronary vascular disease, plus 1) multiple
major risk factors, especially diabetes mellitus; 2) severe
and poorly controlled risk factors, especially continued
tobacco use; and 3) multiple risk factors for the metabolic
syndrome. Again, it should be acknowledged that no
studies have assessed the benefits of titrating lipid-
lowering drugs to achieve a specific LDL cholesterol
target. In addition, trials of intensive lipid lowering for
secondary prevention have used statins alone. Although
the addition of other agents could lower LDL cholesterol in
patients in whom a target level cannot be achieved with a
statin, the utility of this approach in reducing risk of
cardiovascular morbidity and mortality has not been firmly
established.
A secondary target of therapy introduced by ATP-III is
non–HDL cholesterol in patients with elevated triglycer-
ides.18,24 Non–HDL cholesterol is defined as the difference
between total cholesterol and HDL cholesterol. It includes all
cholesterol and lipoprotein particles that are considered
atherogenic, including LDL cholesterol, lipoprotein,
intermediate-density lipoprotein, and very-low-density lipo-
protein, and is a predictor of cardiovascular death.523 Because
statins lower LDL cholesterol and non–HDL cholesterol to a
similar extent, the relative benefits of lowering these 2 lipid
measures cannot be distinguished from recent clinical trials.
Fibrates could reduce the risk of coronary events in patients
with high triglycerides and low HDL cholesterol levels and
could have an adjunctive role in these patients in combination
with statins.503,524 Nicotinic acid raises HDL cholesterol, and
several trials support the efficacy of niacin when used alone
or in combination with statins.504,505,525
Observational studies and treatment trials suggest that
consumption of omega-3 fatty acids reduces cardiovascular
risk. Cohort and case–control studies have found an RR
reduction of about 15% for fish consumption versus little or
no fish consumption.526 In the GISSI (Gruppo Italiano per lo
Studio della Sopravvivenza nell’Infarto Miocardico) Preven-
tion study in patients with prior MI, 1 g daily of fish oil
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supplement resulted in a 20% reduction in mortality at 42
months.527 Pharmacological treatment with fish oil at higher
doses (2 to 4 g daily) is effective in reducing triglyceride
levels.528
4.4.1.2. Blood Pressure Management
Class I
1. All patients should be counseled about the need for
lifestyle modification: weight control; increased
physical activity; alcohol moderation; sodium reduc-
tion; and emphasis on increased consumption of
fresh fruits, vegetables, and low-fat dairy prod-
ucts.17,529–537 (Level of Evidence: B)
2. In patients with SIHD with BP 140/90 mm Hg or
higher, antihypertensive drug therapy should be
instituted in addition to or after a trial of lifestyle
modifications.538–543 (Level of Evidence: A)
3. The specific medications used for treatment of high
BP should be based on specific patient characteris-
tics and may include ACE inhibitors and/or beta
blockers, with addition of other drugs, such as
thiazide diuretics or calcium channel blockers, if
needed to achieve a goal BP of less than 140/
90 mm Hg.544,545 (Level of Evidence: B)
Hypertension is an important independent risk factor for
ischemic cardiovascular events. Observational studies
have demonstrated a continuous and graded relationship
between BP and cardiovascular risk. In a collaborative
meta-analysis of prospective studies of nearly 1 million
adults without preexisting vascular disease, the risk of a
vascular death increased linearly over the BP range of
115/75 mm Hg to 185/115 mm Hg, without a threshold
effect. Each increment of 20 mm Hg in systolic BP or
10 mm Hg in diastolic BP was associated with a doubling
of risk.546 RCTs indicate that treatment results in a
reduction of cardiovascular risk consistent with predictions
from epidemiological studies.538 –543,547
Treatment of high BP should begin with lifestyle measures.
Maintenance of an appropriate body weight (BMI ,25
kg/m2) is a key element of the nonpharmacological strategies
recommended to improve BP control; weight loss of 10 kg
typically results in a decrease in BP of 5 to 20 mm
Hg.529–531,548,549 Consumption of a diet rich in fruits, vegeta-
bles, and low-fat dairy products532,533; reduction of dietary
sodium intake529,531,533,534,550; regular physical activity535; and
moderation of alcohol consumption536 also result in signifi-
cant lowering of BP.
In many patients with SIHD, therapy with medications will
be required to lower BP to the desired level. Treatment trials
have definitively demonstrated a beneficial effect of antihy-
pertensive drug therapy on cardiovascular disease risk. An
overview of 17 placebo-controlled trials, most of which
focused on lowering diastolic BP, showed that reducing
diastolic BP 5 to 6 mm Hg (or an estimated 10 to 20 mm Hg
in systolic BP) within a population was associated with a
significant reduction in vascular mortality, with approxi-
mately 40% reduction in stroke and 20% reduction in
coronary events.547 This benefit of treatment also has been
observed in studies of older adult patients with isolated
systolic hypertension.539,551,552
Despite the plethora of clinical studies, the appropriate BP
threshold for initiating medical therapy and specific treatment
goals for patients with chronic IHD remain controversial.
RCTs have demonstrated a benefit from antihypertensive
therapy in patients with a diastolic BP .90 mm Hg547 and
also in patients with isolated systolic hypertension and a
systolic BP .160 mm Hg.539,551,552 The Seventh Report of the
Joint National Committee on Prevention, Detection, Evalua-
tion, and Treatment of High Blood Pressure recommends a
target BP of ,140/90 mm Hg in patients with uncomplicated
hypertension and of ,130/80 mm Hg in patients with
diabetes mellitus or CKD.17 Observations from epidemiolog-
ical studies and the relatively high absolute risk of cardiovas-
cular events in patients with vascular disease have led some
to suggest that a lower BP target might also be appropriate in
individuals with SIHD.553
On the other hand, excessive reduction in diastolic BP
could compromise coronary perfusion in SIHD patients, and
some studies have demonstrated a J-shaped relationship
between diastolic BP and coronary events.554 The ACCORD
(Action to Control Cardiovascular Risk in Diabetes) BP
trial,555 which enrolled patients with type 2 diabetes mellitus
at high risk of cardiovascular events, found no benefit of
targeting a systolic BP of 120 mm Hg compared with a
systolic BP of 140 mm Hg in reducing a composite endpoint
of MI, stroke, or death from cardiovascular causes. In a
related vein, in AASK (African-American Study of Kidney
Diseases and Hypertension),556 1094 black patients with
hypertensive kidney disease (diastolic pressure .95 mm Hg
and glomerular filtration rate of 20 to 60 mL/min) and no
diabetes mellitus were randomly assigned to achieve a mean
arterial pressure target #92 mm Hg (corresponding to 130/
80 mm Hg) or to a target of 102 to 107 mm Hg (correspond-
ing to 140/90 mm Hg). Overall, there was no advantage to
more intensive BP control with regard to progression to
end-stage kidney disease or death.556
Although in patients with uncomplicated hypertension
there are a variety of considerations in selecting a medication,
effective BP lowering is the most important factor in prevent-
ing stroke and MI. Clinical trials have failed to convincingly
demonstrate superiority of any single antihypertensive drug
class in preventing cardiovascular events.544,545 In many
patients with SIHD, the choice of medications is guided by
compelling indications for specific classes of drugs, as
discussed elsewhere in this guideline (Table 15).557 ACE
inhibitors improve outcomes in most patients with CAD,
especially those with a history of MI, LV dysfunction and
heart failure, or CKD or diabetes mellitus.295,296,301,558–562
Angiotensin-receptor blockers (ARBs) are beneficial in the
same spectrum of patients.563–566 Beta blockers are recom-
mended in patients with angina pectoris, a history of MI, or
LV dysfunction.567–571 Aldosterone antagonists improve
prognosis in patients with LV dysfunction and heart fail-
ure.572,573 Calcium antagonists are useful in the treatment of
angina. Many patients with SIHD will require a combination
of drugs, including a diuretic, to achieve optimal BP control.
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The role of emotional stress in relationship to hypertension
has yet to be fully elucidated. It might be important to
acknowledge the potential relationship of stress to many of
the cardiovascular risk factors, particularly hypertension,
when counseling patients.
4.4.1.3. Diabetes Management
Class IIa
1. For selected individual patients, such as those with a
short duration of diabetes mellitus and a long life
expectancy, a goal hemoglobin A1c (HbA1c) of 7%
or less is reasonable.574–576 (Level of Evidence: B)
2. A goal HbA1c between 7% and 9% is reasonable for
certain patients according to age, history of hypo-
glycemia, presence of microvascular or macrovascu-
lar complications, or presence of coexisting medical
conditions.577,578 (Level of Evidence: C)
Class IIb
1. Initiation of pharmacotherapy interventions to
achieve target HbA1c might be reasonable.456,579–588
(Level of Evidence: A)
Class III: Harm
1. Therapy with rosiglitazone should not be initiated in
patients with SIHD.589,590 (Level of Evidence: C)
Diabetes mellitus is an important independent risk factor for
cardiovascular disease. Type 1 diabetes mellitus is associated
with at least a 10-fold increase in cardiovascular events,591,592
and patients with type 2 diabetes mellitus have a risk of death
from cardiovascular causes that is 2 to 6 times that of persons
without diabetes mellitus.593–595 The complications of athero-
sclerosis account for 80% of deaths among patients with
diabetes mellitus, and IHD is responsible for the majority of
deaths.574,596 Diabetes mellitus is associated with a poor
outcome in patients with SIHD, even after the extent of
disease and other clinical characteristics are taken into ac-
count. In the CASS registry, for example, patients with
diabetes mellitus had a 57% greater risk of death after
adjustment for other risk factors.597
Clinical trials have demonstrated a salutary effect of
intensive glycemic control on the development of microvas-
cular complications of diabetes mellitus, such as retinopathy,
nephropathy, and peripheral and autonomic neuropa-
thy,574,575,598 with secondary analyses suggesting a benefit
extending into the normal range of HbA1c. However, the
efficacy of intensive diabetes therapy in reducing cardiovas-
cular disease is less well established. In the DCCT (Diabetes
Control and Complications Trial), patients with type 1 dia-
betes mellitus were randomized to intensive (mean achieved
HbA1c 7.4%) or conventional (mean achieved HbA1c 9.1%)
therapy. During the mean 6.5 years of observation, fewer
cardiovascular events occurred in the intensive-treatment
group, but the number of events was small, and the difference
between groups did not reach statistical significance.574 In a
long-term follow-up study of this population, however, inten-
sive therapy reduced the risk of cardiovascular events by
42%.579 Intensive glycemic controlled to a reduction in
microvascular complications (primarily the need for retinal
laser photocoagulation) but not cardiovascular events in the
patients with type 2 diabetes mellitus who participated in the
UKPDS (UK Prospective Diabetes Study).575 In a secondary
analysis, treatment with metformin seemed to confer most of
the benefit, whereas treatment with a sulfonylurea was not
associated with a significant improvement in any endpoint.599
Patients in UKPDS treated with metformin had a lower
median HbA1c (7.4% versus 8.0%) and a 37% reduction in
$1 diabetes endpoints compared with those in the conven-
tional therapy (diet alone) group.580 In the PROactive (Pros-
pective Pioglitazone Clinical Trial in Macrovascular Events)
study, patients with type 2 diabetes mellitus and evidence of
vascular disease were randomized to pioglitazone or placebo.
HbA1c averaged 7.8% at baseline and decreased by 0.3% in
the placebo group and by 0.8% in those on active therapy.
There was no significant difference between treatment groups
in the primary study endpoint, although pioglitazone resulted
in a statistically significant 16% relative reduction in a
secondary endpoint of mortality, nonfatal MI, and stroke.581
Three studies in patients with type 2 diabetes mellitus
suggest that even more intensive glucose lowering fails to
reduce the incidence of cardiovascular events and could cause
harm.576,578,600 The ADVANCE (Action in Diabetes and
Vascular Disease: Preterax and Diamicron Modified Release
Controlled Evaluation) trial tested a strategy of intensive
glucose control with a target HbA1c of 6.5%, with the
Table 15. Indications for Individual Drug Classes in the Treatment of Hypertension in Patients With SIHD*
Indication
Recommended Drugs
Diuretic Beta Blocker ACE Inhibitor ARB
Calcium-Channel
Blocker
Aldosterone
Antagonist
Heart failure ● ● ● ● ●
LV dysfunction ● ●
After myocardial infarction ● ● ● ●
Angina ● ●
Diabetes mellitus ● ● ●
Chronic kidney disease ● ●
*Table indicates drugs that should be considered and does not indicate that all drugs should necessarily be prescribed in an individual patient (eg, ACE inhibitors
and ARB typically are not prescribed together).
ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; and LV, left ventricular.
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sulfonylurea gliclazide (modified release) and other drugs
used as required.576 After a median 5 years of follow-up,
HbA1c averaged 6.5% in the intensive-control group and
7.3% in the standard-control group. Intensive control reduced
the incidence of microvascular events but had no effect on a
composite of macrovascular events that included nonfatal MI,
nonfatal stroke, or death from cardiovascular causes.576 In the
ACCORD study, patients were assigned to receive intensive
therapy with a goal of normalizing the HbA1c (to ,6%) or
standard therapy targeting a level of 7.0% to 7.9%.600 Median
achieved HbA1c levels at 1 year were 6.4% and 7.5% in the
2 groups, respectively. Over 3.5 years, the use of intensive
therapy did not significantly reduce major cardiovascular
events (nonfatal MI, nonfatal stroke, and death from cardio-
vascular causes) but was associated with a 22% greater
all-cause mortality.578,600 The VADT (Veterans Affairs Dia-
betes Trial) examined macrovascular complications in pa-
tients randomized to standard glycemic control or to intensive
therapy (goal HbA1c of ,6%), with a planned HbA1c
separation of $1.5%.578 Median HbA1c levels were 8.4%
and 6.9% in the standard- and intensive-therapy groups,
respectively. There were no differences in the primary end-
point of time to occurrence of a cardiovascular event or
all-cause mortality in the 2 groups over a median follow-up of
5.6 years.
In summary, the most appropriate goal level for HbA1c in
patients with diabetes mellitus has not been established
definitively by clinical trials. A goal HbA1c ,7%—a level
approximating that achieved in the intensive-therapy arms of
the DCCT, UKPDS, and PROactive studies—is reasonable
for many younger patients, depending on their duration of
diabetes mellitus, comorbidities, adherence, and personal
preferences. Secondary analyses of the DCCT and UKPDS
and microvascular data from the ADVANCE trial suggest
that even lower HbA1c levels could be beneficial in selected
individuals. On the other hand, treatment to achieve a HbA1c
,7% might not be safe or practical for some patients, and
factors such as life expectancy, advanced microvascular or
macrovascular complications, cognitive function, comorbidi-
ties, and risk of hypoglycemia should be considered in every
patient before intensifying the therapeutic regimen.
Regardless of the degree of glycemic control, treatment of
other modifiable risk factors that often accompany diabetes
mellitus, such as hypertension and dyslipidemia, results in a
substantial reduction in cardiovascular risk. The benefits of a
target-driven, multifactorial intervention in patients with type
2 diabetes mellitus were demonstrated in the Steno-2
study.601 Behavioral modification and pharmacological ther-
apy targeting hyperglycemia, hypertension, dyslipidemia, and
microalbuminuria lowered the risk of cardiovascular disease
by .50%.601
When the patient and provider elect to use pharmacological
therapy to improve glycemic control, several factors should
be considered in selecting an agent, including acceptability
and safety. Although head-to-head comparisons of different
pharmacological regimens are largely lacking, limited evi-
dence suggests that all agents are not equivalent. For exam-
ple, long-term follow-up from the UKPDS indicates that
patients receiving metformin, particularly those who were
overweight, had a lower incidence of diabetic complications,
MI, and death than those who received insulin plus a
sulfonylurea.588 In addition, available information suggests
that certain agents lack an acceptable safety profile. The
FDA, for example, has imposed restrictions on use of
rosiglitazone, a thiazolidinedione, because of data that sug-
gest an increased risk of cardiovascular complications. Pre-
scriptions for rosiglitazone should not be initiated for patients
with SIHD. Patients who are already receiving this agent and
whose blood glucose is well controlled should be counseled
about the potential hazards, and switching to a different agent
should be strongly considered. In this light, when deciding
whether to prescribe newer hypoglycemic agents, providers
should bear in mind the potential for safety concerns that
could emerge when these drugs are adopted into wider use.
4.4.1.4. Physical Activity
Class I
1. For all patients, the clinician should encourage 30 to
60 minutes of moderate-intensity aerobic activity,
such as brisk walking, at least 5 days and preferably
7 days per week, supplemented by an increase in
daily lifestyle activities (eg, walking breaks at work,
gardening, household work) to improve cardiorespi-
ratory fitness and move patients out of the least-fit,
least-active, high-risk cohort (bottom 20%).602–604
(Level of Evidence: B)
2. For all patients, risk assessment with a physical
activity history and/or an exercise test is recom-
mended to guide prognosis and prescription.605–608
(Level of Evidence: B)
3. Medically supervised programs (cardiac rehabilita-
tion) and physician-directed, home-based programs
are recommended for at-risk patients at first diag-
nosis.602,609,610 (Level of Evidence: A)
Class IIa
1. It is reasonable for the clinician to recommend
complementary resistance training at least 2 days
per week.611,612 (Level of Evidence: C)
Physical activity counseling is an integral component of a
comprehensive coronary risk factor modification strategy in
patients with SIHD. Consistent with the American College of
Sports Medicine and AHA recommendations for healthy
adults,603 most patients with CAD should be encouraged to
engage in 30 to 60 minutes of moderate-intensity aerobic
activity, such as brisk walking, on most, and preferably all,
days of the week. Similar recommendations (2 hours and 30
minutes of moderate-intensity aerobic activity and muscle-
strengthening activities on $2 days a week) have been
advanced by the Centers for Disease Control and Preven-
tion.18,613 Many patients benefit from participation in a
cardiac rehabilitation program that incorporates super-
vised exercise into a comprehensive secondary prevention
program.614
Multiple controlled clinical trials have examined the ben-
efits of exercise training and cardiac rehabilitation in patients
with IHD. Most of these studies have been relatively small,
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but in aggregate they demonstrate that regular exercise
reduces mortality in patients with IHD. A systematic review
and meta-analysis published in 2004 examined 48 RCTs of
exercise interventions in a total of 8940 patients with IHD.602
The median intervention duration was 3 months (range, 0.25
to 30 months), and the median duration of follow-up was 15
months (range, 6 to 72 months). Exercise training resulted in
a 20% reduction in all-cause mortality and a 26% reduction in
total cardiac mortality; favorable but nonsignificant trends
were noted in nonfatal MI, CABG, and percutaneous coro-
nary revascularization procedures. There was no difference
between the mortality rate effects of exercise-only and more
comprehensive cardiac rehabilitation interventions, and the
benefits were independent of actual amount and intensity of
exercise.
Many of the studies demonstrating the efficacy of exercise-
based cardiac rehabilitation enrolled patients after an AMI or
coronary revascularization procedure. Clear benefits of exer-
cise training also have been shown in patients with stable
angina. Controlled trials consistently have demonstrated an
improvement in functional capacity and a delay in the onset
of ischemia in anginal patients who complete an exercise
training program.444,615–620 Exercise-based cardiac rehabilita-
tion could also reduce subjective evidence of ischemia and
could ameliorate symptoms.615,619,621,622
The reduction in mortality rate associated with exercise
interventions might be explained partially by modification of
traditional cardiovascular risk factors. Controlled trials have
demonstrated reductions in total cholesterol, triglycerides,
and BP, although these findings have not been uniform.
Exercise also can enhance smoking quit rates. Other potential
mechanisms include decreased fibrinogen and coagulabil-
ity,623 moderation of inflammation,624 improved endothelial
function,625–627 and improved autonomic regulation.628,629
Several studies have documented the safety of exercise-
based cardiac rehabilitation in patients with documented
SIHD.630–633 The 2007 AHA Scientific Statement on Exer-
cise and Acute Cardiovascular Events estimates the risk of a
major adverse cardiac event (MACE) at 1 in 80 000 patient-
hours.447 This low event rate applies to medically supervised
programs that evaluate patients before participation, provide
serial surveillance, and are equipped to handle emergencies.
Specific strategies for reducing exercise-related cardiovascu-
lar events have not been evaluated. It seems prudent, how-
ever, that patients at high risk of cardiac complications (ie,
those with a history of multiple MIs or cardiac arrest, New
York Heart Association functional class III or IV or exercise
capacity ,6 METs, or significant exercise-induced ischemia
on treadmill testing) participate in a medically supervised
program for at least 8 to 12 weeks to establish the safety of
the prescribed exercise regimen.
The value of resistance exercise increasingly is recognized
for improving functional capacity, independence, and quality
of life in patients with and without cardiovascular disease.
Although the risks and benefits of resistance therapy have not
been evaluated extensively in patients with SIHD, several
small studies have indicated that resistance therapy is well
tolerated and is associated with improvements in quality of
life, strength, and endurance when added to a program of
regular aerobic exercise.611,612
Although previous guidelines have recommended that all
patients undergo an exercise test before participating in a
cardiac rehabilitation program, according to the World Health
Organization,634 an exercise test is not considered necessary
for medical and economic reasons if the patient enters a low-
or moderate-intensity-level training program.
4.4.1.5. Weight Management
Class I
1. BMI and/or waist circumference should be assessed
at every visit, and the clinician should consistently
encourage weight maintenance or reduction through
an appropriate balance of lifestyle physical activity,
structured exercise, caloric intake, and formal be-
havioral programs when indicated to maintain or
achieve a BMI between 18.5 and 24.9 kg/m2 and a
waist circumference less than 102 cm (40 inches) in
men and less than 88 cm (35 inches) in women (less
for certain racial groups).257,449,635–642 (Level of
Evidence: B)
2. The initial goal of weight loss therapy should be to
reduce body weight by approximately 5% to 10%
from baseline. With success, further weight loss can
be attempted if indicated. (Level of Evidence: C)
Population studies consistently have demonstrated an associ-
ation of increased BMI with ischemic cardiac events. In a
meta-analysis of 21 cohort studies including .300 000
persons, the risks for cardiovascular events in patients who
were overweight (BMI 25.0 to 29.9 kg/m2) and obese (BMI
.30 kg/m2) compared with those of normal weight were 32%
and 81% higher, respectively, after adjustment for age, sex,
physical activity, and smoking.635 Cardiovascular risk is
increased particularly in patients with central obesity, which
can be identified by a waist circumference .102 cm (40
inches) in men or .88 cm (35 inches) in women,643,644 and in
those with extreme obesity, defined as a BMI .40 kg/m2.645
Obesity likely contributes to increased cardiovascular risk
through multiple pathophysiological pathways. Obesity is
associated with traditional cardiovascular risk factors, such as
diabetes mellitus, dyslipidemia, and hypertension, but in and
of itself obesity increases sympathetic tone, induces a hyper-
coagulable state, and is associated with markers of inflam-
mation.646 Curiously, despite the strong association of BMI
with cardiovascular risk in population studies, a similar
relationship between BMI and death is not observed consis-
tently in cohorts with established IHD.647 This could be due
to weaknesses of BMI as a measure of adiposity; confounding
factors such as age, smoking, or medications; or weight loss
in association with advanced chronic illness.
No clinical trials have examined specifically the effects of
weight loss on cardiovascular event rates in patients with
SIHD. In the SOS (Swedish Obese Subjects) study, however,
weight losses of 20% to 32% at 1 year achieved with bariatric
surgery were associated with a 24% reduction in mortality
rate.648 The association of adiposity with other cardiovascular
risk factors suggests that weight reduction is indicated in all
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overweight or obese patients. Reducing caloric intake is a
cornerstone of weight management therapy. Referral to an
experienced dietitian or to a reputable weight loss program
for nutritional counseling and behavioral modification ther-
apy can be helpful. The effects of caloric restriction are
potentiated by regular aerobic physical activity. Therapy with
medications or bariatric surgery may be considered in se-
lected patients who are unable to achieve adequate weight
loss by conventional lifestyle modifications.649
4.4.1.6. Smoking Cessation Counseling
Class I
1. Smoking cessation and avoidance of exposure to
environmental tobacco smoke at work and home
should be encouraged for all patients with SIHD.
Follow-up, referral to special programs, and phar-
macotherapy are recommended, as is a stepwise
strategy for smoking cessation (Ask, Advise, Assess,
Assist, Arrange, Avoid).650–652 (Level of Evidence: B)
Observational studies over the past 4 decades have fur-
nished incontrovertible evidence that smoking increases
the risk of cardiovascular disease events.653,654 A dose–
response relationship exists between cigarettes smoked
and cardiovascular risk, with an RR approaching 5.5 for
cardiovascular events among heavy smokers compared
with nonsmokers.654 Potential mechanisms by which
smoking predisposes to cardiovascular events include ad-
verse effects on fibrinogen levels,655 platelet adhesion,656
and endothelial function657; reduced HDL cholesterol lev-
els658; and coronary artery vasoconstriction.659
Although RCTs have not been performed in patients with
SIHD, results of observational studies strongly suggest that
smoking cessation is an effective strategy for secondary
prevention of coronary events. A meta-analysis of 20 pros-
pective cohort studies found a 30% reduction in RR of
mortality for those who quit compared with those who
continued smoking, and a similar reduction was noted in
nonfatal MIs.650 Some studies suggest that most of the
reduction in risk occurs within 2 or 3 years of quitting.660,661
The most effective smoking-cessation therapies include
both nonpharmacological and medical interventions. Physi-
cian advice has a significant effect on quit rates.662 Self-help
programs, telephone counseling, behavioral therapy, and
perhaps exercise programs also have modest efficacy in
increasing cessation rates.663–667 Nicotine-replacement ther-
apy (gum, patch, tablet, lozenge, or nasal spray) approxi-
mately doubles the chances of success of a quit attempt.668
Similar efficacy has been demonstrated with bupropion
sustained-release.669 Varenicline, a partial agonist of the
a4b2 nicotinic receptor, is the most recent FDA-approved
agent for smoking cessation and compares favorably with
placebo and with bupropion in clinical trials.670,671 There
have, however, been concerns about possible worsening of
preexisting depression and the risk of suicide due to vareni-
cline, and the FDA has issued an alert warning that serious
neuropsychiatric symptoms can occur in patients taking this
drug.672,673
Physicians should approach smoking cessation by using
the 6 A’s framework:
● Ask each patient about tobacco use at every visit;
● Advise each smoker to quit;
● Assess each smoker’s willingness to make a quit attempt;
● Assist each smoker in making a quit attempt by offering
medication and referral for counseling;
● Arrange for follow-up; and
● Avoid exposure to environmental tobacco smoke.
4.4.1.7. Management of Psychological Factors
Class IIa
1. It is reasonable to consider screening SIHD patients
for depression and to refer or treat when indi-
cated.237,239,323,457,463,674,675 (Level of Evidence: B)
Class IIb
1. Treatment of depression has not been shown to
improve cardiovascular disease outcomes but might
be reasonable for its other clinical benefits.237,238,676
(Level of Evidence: C)
Depression is a major cause of disability in developed
countries and often coexists with SIHD.677,678 About 20% of
patients with angiographic evidence of CAD and a similar
percentage of those recovering from AMI have comorbid
depression.679–682
Multiple observational studies have demonstrated an asso-
ciation between depression and cardiovascular events. In
several studies involving $1000 outpatients with SIHD,
those with symptoms of depression had more physical limi-
tation, more frequent angina, and lower perceived quality of
life than patients without depressive symptoms.239,683 One
meta-analysis examined 21 prospective studies in healthy
populations and 34 studies in patients with existing IHD.684
The studies in healthy cohorts demonstrated an 81% greater
incidence of ischemic events (MI or fatal IHD) among
patients with symptoms of depression over an average
follow-up period of 10.8 years. A similarly increased risk was
observed in patients with established IHD who had symptoms
of depression. Relatively few studies, however, have reported
estimates of risk that have been adjusted for traditional risk
factors or severity of CAD. Although in aggregate the
observational cohort studies suggest that depression confers a
significant risk for adverse cardiovascular outcomes, con-
founding by other risk factors or by disease severity is
difficult to exclude. Moreover, most studies in patients with
CAD have enrolled patients after recent MI or CABG, and the
relevance to patients with SIHD is uncertain.
Putative mechanisms for a contribution of depression to
atherogenesis and adverse cardiovascular events include both
behavioral and biological effects. Depression is associated
with poor compliance with risk factor–modification strategies
and with poor adherence to prescribed medication regi-
mens.460,462 Patients diagnosed with this disorder are 2- to
4-fold less likely to adhere to medications and lifestyle
recommendations, engage in self-management practices, or
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comply with recommendations for testing and follow-
up.462,675,685–691 Alternatively, some studies suggest the pos-
sibility of more direct pathophysiological links, including
platelet activation,692–695 endothelial dysfunction,696 reduced
heart rate variability,697–699 and inflammation.700
Despite the association of depression with adverse cardio-
vascular outcomes, no clinical trials have established a
reduction in cardiovascular risk with either counseling or
antidepressant therapy. In the ENRICHD (Enhancing Recov-
ery in Coronary Heart Disease) trial, 2481 patients with
depression or low social support after MI were randomized to
usual care or cognitive behavioral therapy, supplemented by
a selective serotonin reuptake inhibitor when indicated. Ac-
tive therapy was associated with improvements in depression
and low social support but with no improvement in event-free
survival after a mean 24 months of follow-up.237 A secondary
analysis, however, demonstrated a significantly lower risk of
death or MI in patients treated with a selective serotonin
reuptake inhibitor.676 The safety and efficacy of sertraline in
patients with a recent ACS were demonstrated in SADHART
(Sertraline Antidepressant Heart Attack Randomized Trial).
Patients were randomized to sertraline or placebo for 24
weeks. Sertraline resulted in improved depressive symptoms
and no change in LVEF, ventricular ectopy, or QT interval.
The study was not powered to detect a difference in cardio-
vascular outcomes.238 Similarly, citalopram, a selective sero-
tonin reuptake inhibitor, and mirtazapine, a dual-acting
antidepressant, improved depression in postinfarction pa-
tients.463,674 Thus, treatment of depression in patients with
SIHD by cognitive therapy or medication is safe and contrib-
utes to relief of depressive symptoms but does not have
proven efficacy in reducing cardiovascular morbidity and
mortality rates.
Either the 2-item Patient Health Questionnaire (PHQ)-2 or
the 9-item PHQ-9 can be used as a screening tool for
depression701,702 (Tables 16 and 17). Patients who respond
affirmatively to either item on the PHQ-2 or to item 9 on the
PHQ-9 or who have a score $10 on the PHQ-9 should be
referred for a more comprehensive clinical evaluation701,702
(Table 17).
Patients with SIHD report high levels of psychosocial
stress, and indices of stress are associated with an increased
risk of cardiovascular events.245 Counseling to reduce psy-
chological stress is recommended as a core component of
comprehensive cardiac rehabilitation programs. Stress-
management interventions use relaxation techniques and
provide instruction in specific skills to reduce cognitive,
behavioral, and psychological stress levels. Although stress-
management programs are not of proven value in reducing
the risk of cardiovascular events, they are effective in
relieving anxiety and reducing depressive symptoms.461
4.4.1.8. Alcohol Consumption
Class IIb
1. In patients with SIHD who use alcohol, it might be
reasonable for nonpregnant women to have 1
drink (4 ounces of wine, 12 ounces of beer, or 1
ounce of spirits) a day and for men to have 1 or
2 drinks a day, unless alcohol is contraindicated
(such as in patients with a history of alcohol abuse
or dependence or with liver disease).703–705 (Level
of Evidence: C)
Observational studies suggest that light to moderate alcohol
consumption is associated with a lower risk of IHD and
all-cause mortality. Most studies report a J-shaped relation-
ship between alcohol consumed and cardiovascular event rate
or mortality; light to moderate drinkers have less risk than
abstainers, but heavy drinkers are at greatest risk. A meta-
analysis of 34 prospective studies found mortality rate reduc-
tions of 17% in men and 18% in women with low levels of
alcohol intake, with the lowest mortality rate at 6 g of alcohol
(approximately one half drink) per day.703 Most of these
studies were performed in healthy cohorts, and data in
patients with IHD are limited. One study704 examined sur-
vival rate among early survivors of MI and found that
moderate alcohol consumption in the year before presentation
was predictive of lower all-cause mortality. Similarly, among
participants in the Physician’s Health Study who experienced
a self-reported MI, moderate drinkers had a 30% lower risk of
death than abstainers.705
Light to moderate alcohol consumption might confer pro-
tection against cardiovascular disease through beneficial ef-
fects on the lipid profile and on insulin sensitivity. Alcohol
intake modestly increases HDL cholesterol in a dose-
dependent fashion.706,707 Consumption of 2 drinks per day
lowers fasting and postprandial insulin levels and increases
insulin sensitivity in healthy subjects.708 Light to moderate
alcohol consumption might also have antiinflammatory ef-
Table 16. Patient Health Questionnaire-2
Over the past 2 weeks, how often have you been bothered by any of the
following problems?
1) Little interest or pleasure in doing things
2) Feeling down, depressed, or hopeless
Reproduced from Kroenke et al.702
Table 17. Patient Health Questionaire-9: Depression
Screening Scales
Over the past 2 weeks, how often have you been bothered by any of the
following problems?
1) Little interest or pleasure in doing things
2) Feeling down, depressed, or hopeless
3) Trouble falling asleep, staying asleep, or sleeping too much
4) Feeling tired or having little energy
5) Poor appetite or overeating
6) Feeling bad about yourself, feeling that you are a failure, or feeling
that you have let yourself or your family down
7) Trouble concentrating on things such as reading the newspaper or
watching television
8) Moving or speaking so slowly that other people could have noticed. Or
being so fidgety or restless that you have been moving around a lot
more than usual
9) Thinking that you would be better off dead or that you want to hurt
yourself in some way
Reproduced from Kroenke et al.702
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fects, as reflected by a reduction in C-reactive protein.709,710
Alternatively, the apparent cardioprotective effects of modest
alcohol consumption reported in observational studies could
represent uncontrolled confounding, as many coronary risk
factors are more prevalent in nondrinkers than in light to
moderate drinkers.711
There are no RCTs in either healthy individuals or in
patients with SIHD demonstrating improved clinical out-
comes with alcohol consumption. Because of the many health
and societal consequences of alcohol abuse, patients who do
not already drink alcohol should not be encouraged to start.
Patients who do consume alcoholic beverages should be
counseled to do so in moderation: no more than 1 drink (4
ounces of wine or 1 ounce of spirits) per day for women and
no more than 2 drinks per day for men.
4.4.1.9. Avoiding Exposure to Air Pollution
Class IIa
1. It is reasonable for patients with SIHD to avoid
exposure to increased air pollution to reduce the risk
of cardiovascular events.712–715 (Level of Evidence: C)
Although they are seldom an explicit focus in provision of
care to individual patients, environmental influences such as
exposure to air pollution can increase the risk of cardiovas-
cular events, possibly because of progression of atheroscle-
rosis due to oxidative stress and inflammation.715 In particu-
lar, fine particulate matter, defined as particulate matter ,2.5
microns in diameter (PM2.5), is associated with a heightened
risk of death due to cardiovascular causes.714 In nonsmokers,
the relative odds of AMI death rise 22% for each 10 mcg
increase in PM2.5.712 Short-term exposure to higher concen-
trations of pollution, for example after a forest fire, also is
associated with the risk for ACS and death.713 Thus, patients
with SIHD may be advised to avoid exposure to increased air
pollution (ie, by remaining indoors during transient elevations
of air pollution). Public policy efforts to minimize small
particulate matter (ie, through tighter regulations on the
emissions from coal-fired power plants) have the potential to
reduce cardiac complications among patients with SIHD.
4.4.2. Additional Medical Therapy to Prevent MI and
Death: Recommendations
4.4.2.1. Antiplatelet Therapy
Class I
1. Treatment with aspirin 75 to 162 mg daily should be
continued indefinitely in the absence of contraindi-
cations in patients with SIHD.716,717 (Level of
Evidence: A)
2. Treatment with clopidogrel is reasonable when as-
pirin is contraindicated in patients with SIHD.718
(Level of Evidence: B)
Class IIb
1. Treatment with aspirin 75 to 162 mg daily and
clopidogrel 75 mg daily might be reasonable in
certain high-risk patients with SIHD.719 (Level of
Evidence: B)
Class III: No Benefit
1. Dipyridamole is not recommended as antiplatelet
therapy for patients with SIHD.720–722 (Level of
Evidence: B)
4.4.2.1.1. Antiplatelet Agents. Because platelet aggregation is
a key element of the thrombotic response to plaque disrup-
tion, platelet inhibition is recommended in patients with
SIHD unless contraindicated. Aspirin is a cyclooxygenase
inhibitor that produces irreversible blockade of prostaglandin
endoperoxide formation. Among 2920 patients with SIHD, a
comprehensive meta-analysis of source data revealed an
association of aspirin use with a 37% reduction in the risk of
serious vascular events, including a 46% decrease in the risk
for UA and a 53% decrease in the risk of requiring coronary
angioplasty.716 Almost two thirds of the patients included in
this meta-analysis were participants in SAPAT (Swedish
Angina Pectoris Aspirin Trial), in which patients with SIHD
were assigned randomly to aspirin 75 mg per day or placebo
for a median of 15 months.717 Aspirin in a dose of 75 to 162
mg daily is equally as effective as 325 mg in secondary
prevention and is associated with a lower risk of bleeding.
Doses ,75 mg have less proven benefit.716,723 Aspirin is
relatively contraindicated in patients with known allergies to
nonsteroidal antiinflammatory drugs and in patients with the
syndrome of asthma, rhinitis, and nasal polyps.
Clopidogrel, a thienopyridine derivative, inhibits platelet
aggregation via selective and irreversible inhibition of the
adenosine diphosphate P2Y12 receptor. Clopidogrel 75 mg
has been compared with aspirin 325 mg in patients with
previous MI, stroke, or symptomatic PAD in the prospective,
randomized CAPRIE (Clopidogrel versus Aspirin in Patients
at Risk of Ischaemic Events) study.718 Although clopidogrel
demonstrated superiority over aspirin in the secondary pre-
vention of MI and death in this group of patients, the
magnitude of difference was small. Because no additional
trials comparing aspirin and clopidogrel in patients with
SIHD have been conducted, clopidogrel remains an accept-
able alternative agent to aspirin.
In certain high-risk patients, combined treatment with
aspirin and clopidogrel has been shown to be beneficial. In
the CURE (Clopidogrel in Unstable Angina to Prevent
Recurrent Events) study, patients with a recent NSTEMI were
randomized to clopidogrel plus aspirin (300 mg/d and 75
mg/d) for an average of 9 months. These patients experienced
fewer deaths from cardiovascular causes, nonfatal MIs, and
strokes than did patients receiving placebo plus aspirin (75 to
325 mg/d).724 Similar results were found in the CREDO
(Clopidogrel for Reduction of Events During Observation)
study. Combined therapy for an average of 1 year signifi-
cantly reduced the risk of death, MI, or stroke.725 In contra-
distinction to these positive results among high-risk patients,
a comparison of aspirin alone versus aspirin combined with
clopidogrel in 15 603 patients with multiple cardiovascular
risk factors (most of whom were without a prior cardiovas-
cular event) in the CHARISMA (Clopidogrel for High
Atherothrombotic Risk Ischemic Stabilization, Management,
and Avoidance) trial demonstrated no differences in the rates
of MI, stroke, or death.393 A post hoc analysis of this study
suggested that a subgroup of patients with documented prior
MI, ischemic stroke, or symptomatic PAD might have had
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better outcomes from dual antiplatelet therapy (DAPT) with
clopidogrel plus aspirin.719 In a meta-analysis of 5 RCTs
comparing clopidogrel plus aspirin to aspirin alone in patients
with IHD, the incidence of all-cause mortality, MI, and stroke
was found to be reduced in the clopidogrel-plus-aspirin
group, whereas the risk of major bleeding increased signifi-
cantly.726 Overall, it appears that the addition of clopidogrel
to aspirin could be beneficial in certain high-risk groups of
patients with SIHD, but data on specific subgroups are
lacking,727 and further research will be required to identify
the ideal target population.
The effectiveness of clopidogrel depends on generation of
the active metabolite in 2 steps that are catalyzed by enzymes
of the cytochrome P450 system, principally CYP2C19. Vari-
ants of the CYP2C19 gene have been identified that are
associated with impaired antiplatelet effects, as measured by
ex vivo platelet aggregation assays, and with higher cardio-
vascular event rates after ACS and percutaneous revascular-
ization procedures.728–731 Poor metabolizers of clopidogrel
can be identified by clinically available tests, but optimal
dosing strategies for these individuals have not been estab-
lished in clinical outcome trials.732,733 Other drugs that are
metabolized by CYP2C19 could competitively inhibit the
enzyme and impair metabolism of clopidogrel. Several stud-
ies have demonstrated a pharmacodynamic interaction be-
tween proton pump inhibitors and clopidogrel.734,735 Obser-
vational studies have suggested that use of a proton pump
inhibitor in combination with clopidogrel is associated with
an approximately 25% increased RR of adverse cardiovascu-
lar events,736,737 although post hoc analyses of several clinical
trials and a recent observational study have failed to demon-
strate a clinically significant interaction.738,739 Pantoprazole is
less likely than other proton pump inhibitors to inhibit
CYP2C19 and does not impair the pharmacodynamic re-
sponse to clopidogrel740–742; alternatively, treatment with an
H2 antagonist or antacid could be sufficient in some patients.
The combination of clopidogrel with a statin can be pre-
scribed safely on the basis of a secondary analysis of the
CHARISMA trial in 10 078 patients with cardiovascular
disease or multiple high-risk coronary risk factors.743 There
was no difference in the composite endpoint of MI, stroke, or
cardiovascular death between the agents, independent of the
metabolism pathway of the statin. Clopidogrel requires a
loading dose to accelerate the onset, intensity, and consisten-
cy of inhibition.744,745
Prasugrel is a third-generation thienopyridine that has
more potent antiplatelet effects and is associated with less
interpatient variability in response than clopidogrel. In
TRITON-TIMI (Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis In Myocardial Infarction) 38, there was a 19%
reduction in RR of the primary efficacy endpoint (cardiovas-
cular death, nonfatal MI, or nonfatal stroke) but an increased
risk of bleeding with prasugrel compared with clopidogrel in
ACS patients scheduled for percutaneous revasculariza-
tion.746 Clinical trials evaluating prasugrel in patients with
SIHD have not been conducted. It has not been tested or
approved for use in patients with SIHD. Ticagrelor is a newly
approved agent that has been shown to be beneficial in
patients with ACS but has not been tested in patients with
SIHD.747
Ticlopidine is a thienopyridine derivative that also inhibits
platelet aggregation but compares less favorably to clopi-
dogrel as an alternative to aspirin, because it has limited
evidence for cardiovascular event reduction among patients
with SIHD and an associated risk of blood dyscrasias.720,721
For these reasons, its use is quite limited for secondary
prevention among patients with SIHD.
The pyrimido-pyrimidine derivative, dipyridamole, pos-
sesses antiplatelet effects but does not have a proven role in
patients with SIHD. The combination of aspirin and dipyri-
damole was not clearly superior to aspirin alone in preventing
reinfarction in the PARIS (Persantine-Aspirin Reinfarction
Study).722 Because dipyridamole vasodilates coronary resis-
tance vessels and can provoke exercise-induced myocardial
ischemia, it is not recommended for secondary prevention in
patients with SIHD.748,749
4.4.2.1.2. Oral Anticoagulant Therapy. Fibrinolytic function
can be disturbed in patients with IHD, particularly related to
activation of the extrinsic coagulation pathway leading to
formation of thrombin. Thrombin, in turn, generates fibrin
and promotes platelet activation and aggregation, thereby
amplifying the activity of both the coagulation and platelet
pathways.750–752 These observations have provided a poten-
tial rationale for antithrombotic therapy in patients with
SIHD. A systematic review of randomized trials of oral
anticoagulants with and without antiplatelet therapy among
20 000 patients with IHD, however, failed to provide evi-
dence of benefit from anticoagulation, and it is not recom-
mended.753 Similarly, there is no evidence that individuals
with defects in the coagulation system, such as G1691A
factor V Leiden, G20201A prothrombin, G455A fibrinogen
chain, G10976A factor VII, or the plasminogen activator
inhibitor-1 4G/5G polymorphisms, are at higher risk of
cardiac events, and they should not receive anticoagulation
therapy solely to prevent such events.754–756
4.4.2.2. Beta-Blocker Therapy
Class I
1. Beta-blocker therapy should be started and continued for
3 years in all patients with normal LV function after MI
or ACS.757–759 (Level of Evidence: B)
2. Beta-blocker therapy should be used in all patients
with LV systolic dysfunction (EF <40%) with heart
failure or prior MI, unless contraindicated. (Use
should be limited to carvedilol, metoprolol succinate,
or bisoprolol, which have been shown to reduce risk
of death.)571,760–763 (Level of Evidence: A)
Class IIb
1. Beta blockers may be considered as chronic therapy
for all other patients with coronary or other vascular
disease. (Level of Evidence: C)
Beta-receptor activation is associated with increases in heart
rate, accelerated AV nodal conduction, and increased con-
tractility, which contribute to increased myocardial oxygen
demand. Decreases in the rate–BP product, AV nodal con-
duction, and myocardial contractility from beta blockers
reduce myocardial oxygen demand, counteracting beta-
receptor activity and contributing to a reduction in angina
onset, with improvement in the ischemic threshold during
exercise and in symptoms.764–769 These agents significantly
reduce deaths and recurrent MIs in patients who have
suffered a MI and are especially effective when a STEMI is
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complicated by persistent or recurrent ischemia or
tachyarrhythmias early after the onset of infarction.757 How-
ever, no large trials have assessed effects of beta blockers on
survival or coronary event rates in patients with SIHD.
Many clinically important differences exist between beta
blockers. These differences relate to cardioselectivity, pres-
ence of intrinsic sympathomimetic activity or vasodilating
properties, and relative lipid solubility in the presence of renal
or hepatic impairment. Despite these differences, all beta
blockers seem to be equally efficacious in SIHD.765–767,770,771
Two large long-term follow-up studies investigating the
prognostic importance of heart rate showed that all-cause
mortality rate progressively increases with higher resting
heart rate after adjustment for exercise capacity, age, diabetes
mellitus, systolic arterial pressure, BMI, and level of physical
activity.772,773 Therefore, it is recommended that beta-blocker
dosing be adjusted to limit the heart rate to 55 to 60 beats per
minute at rest.
In large prospective studies, bisoprolol, carvedilol, and
metoprolol, when administered on a background of ACE
inhibitors and diuretics with or without digoxin, have been
shown to reduce the risk of death and to improve symptoms,
clinical status, and quality of life in patients with chronic
systolic heart failure. Importantly, these benefits were seen in
patients with and without IHD.571,760,761
Studies on multiple polymorphisms in the gene encoding
for the beta-adrenergic receptor have variously shown asso-
ciations with physiological responses to exercise.774–781 Clin-
ical studies with a variety of beta blockers in different patient
populations with hypertension have, however, yielded diver-
gent results in terms of associations with BP and heart
rate,782–785 but it remains to be studied whether this variation
is mainly a function of beta-adrenergic receptor genotype and
whether genotype influences the clinical outcome of beta-
blocker use in patients with SIHD.
Beta blockers have been compared with and combined
with dihydropyridine calcium channel blockers in controlled
clinical trials. The results of the APSIS (Angina Prognosis
Study in Stockholm), TIBBS (Total Ischemic Burden Biso-
prolol Study), and IMAGE (International Multicenter Angina
Exercise) studies showed that a beta blocker was more
effective than a calcium channel blocker in control of angina,
reduction of cardiovascular events, and need for revascular-
ization.786–788 A rationale for combining these agents is a
reduction of dihydropyridine-induced tachycardia by beta-
blockade. When combined, beta blockers and dihydropyri-
dine calcium channel blockers have increased exercise time
and shown a trend toward a lower rate of cardiovascular
outcomes.788,789 Caution is warranted when a beta blocker is
combined with verapamil or diltiazem because of the poten-
tial for development of bradycardia, AV block, or excessive
fatigue.
The combination of a beta blocker with a nitrate could be
an additive combination in patients with SIHD. Nitrates
increase sympathetic tone, which can lead to reflex
tachycardia, which is attenuated by the beta blocker. Beta
blockers can increase LV wall tension associated with de-
creased heart rate, which is counteracted by the concomitant
use of nitroglycerin. Clinical trials have validated this ratio-
nale, showing that the combination is more effective in
controlling angina than is either monotherapy alone.790,791
Absolute contraindications to beta blockers are severe
bradycardia, preexisting high-degree AV block, sick sinus
syndrome (without a pacemaker in place), and refractory
heart failure. Relative contraindications include bronchospas-
tic disease or active PAD (beta blockers without vasodilating
properties or selective agents at low doses may be used).
Because they can mask symptoms of hypoglycemia, beta
blockers should be used with caution in patients with insulin-
dependent diabetes mellitus. Abrupt beta-blocker withdrawal
should be avoided because heightened beta-receptor density
and sensitivity can result in a rebound phenomenon associ-
ated with an increased risk for AMI and sudden death. If
withdrawal is necessary, beta blockers should be tapered over
a 1- to 3-week period, with consideration given to use of
sublingual nitroglycerin or substitution with a nondihydro-
pyridine calcium channel blocker during the withdrawal
period.
The principle adverse effects of beta blockers are fatigue,
exercise intolerance, lethargy, insomnia, nightmares, and
impotence.
4.4.2.3. Renin-Angiotensin-Aldosterone Blocker Therapy
Class I
1. ACE inhibitors should be prescribed in all patients
with SIHD who also have hypertension, diabetes
mellitus, LVEF 40% or less, or CKD, unless contra-
indicated.295–298,301 (Level of Evidence: A)
2. ARBs are recommended for patients with SIHD who
have hypertension, diabetes mellitus, LV systolic
dysfunction, or CKD and have indications for, but
are intolerant of, ACE inhibitors.792–794 (Level of
Evidence: A)
Class IIa
1. Treatment with an ACE inhibitor is reasonable in
patients with both SIHD and other vascular dis-
ease.795,796 (Level of Evidence: B)
2. It is reasonable to use ARBs in other patients who
are ACE inhibitor intolerant.797 (Level of Evidence:
C) (Table 15)
A substantial body of evidence supports the concept that ACE
inhibitors have cardiovascular protective effects, reducing the
risks of future ischemic events. ACE inhibitors result in a
reduction in angiotensin II with an increase in bradykinin.
These changes in the physiological balance between angio-
tensin II and bradykinin could contribute to the reductions in
LV and vascular hypertrophy, atherosclerosis progression,
plaque rupture, and thrombosis; the favorable changes in
cardiac hemodynamics; and the improved myocardial oxygen
supply/demand that result from treatment with ACE inhibi-
tors and ARBs.798–801 Clinical studies have demonstrated
significant reductions in the incidence of AMI, UA, and the
need for coronary revascularization in patients after MI with
LV dysfunction, independent of etiology.559,561,801
The benefits of ACE inhibitors extend to patients with
IHD in the absence of LV dysfunction. In patients with
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atherosclerotic vascular disease or diabetes mellitus and at
least 1 other IHD risk factor, the HOPE (Heart Outcomes
Prevention Evaluation) study301 showed that compared
with placebo, ramipril significantly decreased the primary
composite endpoint of cardiovascular death, AMI, and
stroke by 22%.301 MICRO-HOPE (Microalbuminuria, Car-
diovascular, and Renal Outcomes), a substudy of HOPE,
additionally showed, in middle-aged patients with diabetes
mellitus who were at high risk for cardiovascular events,
significant reductions in MI by 22%, stroke by 33%,
cardiovascular death by 37%, and the combined primary
event outcome by 25%.802 Furthermore, the need for
revascularization and incidence of worsening angina also
were significantly reduced. The EUROPA (European trial
on Reduction Of cardiac events with Perindopril in stable
coronary Artery disease) trial provided added support to
the HOPE trial results in patients with SIHD without
clinical evidence of heart failure.296 In 12 218 patients
followed up for a mean of 4.2 years, there was a 20%
relative increase in the time to the primary composite
endpoint of cardiovascular death, nonfatal MI, or cardiac
arrest with perindopril compared with placebo.296 Perindo-
pril was further tested in the PEACE (Prevention of Events
with Angiotensin-Converting Enzyme Inhibitor) trial,
which enrolled 4158 patients with SIHD and normal or
slightly reduced LV function (ie, absence of LV wall-
motion abnormalities).295 The incidence of the primary
endpoint of death from cardiovascular causes, MI, or
coronary revascularization was equivalent between perin-
dopril and placebo, but the overall rate of cardiovascular
events was lower than in the HOPE and EUROPA trials.
Equivalent results were seen in HOPE and EUROPA when
examined by age, sex, known IHD, LV function, previous
MI, hypertension, or diabetes mellitus. In QUIET
(Quinapril Ischemic Event Trial), there was also no sig-
nificant reduction with quinapril in ischemic events and
progression of CAD in coronary angioplasty patients
without systolic LV dysfunction (RR: 13%; P0.49),
although this finding has been attributed to study design
limitations.797 Similarly, the IMAGINE (Ischemia Man-
agement With Accupril Post-Bypass Graft via Inhibition of
the Converting Enzyme) study demonstrated no reduction
in clinical outcomes in low-risk patients (LVEF 40%)
with quinapril after surgical revascularization.803 In a
meta-analysis of ACE-inhibitor therapy versus placebo in
31 555 patients from HOPE, EUROPA, PEACE, and
QUIET, ACE-inhibitor therapy produced 14% reductions
in all-cause mortality and MI (both P0.0004), a 23%
reduction in stroke (P0.0004), and a 7% reduction in
revascularization procedures (P0.025) compared with
placebo.796
Although the cited studies involved a variety of ACE
inhibitors that differ with regard to structure, bioavailability,
potency, receptor-binding characteristics, tissue distribution,
metabolism, and excretion properties, there is little evidence
that these differences are associated with therapeutic advan-
tages. Because the benefits of ACE inhibitors seem to reflect
a class effect, the selection of a particular agent can be based
on such factors as availability in local formularies, cost, and
tolerability.
ACE inhibitors are recommended for all patients with
SIHD and hypertension, diabetes mellitus, LV dysfunction
(EF 40%), or CKD. Also included in the HOPE301 or
EUROPA296 trials were participants who did not have one of
these conditions but did have multiple cardiac risk factors,
and it seems that they also benefited from use of ACE
inhibitors.797
ARBs also play an important role in vascular protection.
They bind in a competitive or insurmountable manner to the
type 1 angiotensin II receptor, increasing plasma renin
activity, plasma renin, and angiotensin I and II concentra-
tions. In patients with hypertension or cardiovascular disease,
ARBs produce reductions in BP equivalent to those achieved
with ACE inhibitors.804 These agents significantly reduce LV
mass and stroke incidences compared with beta blockers and
improve outcomes in diabetic nephropathy and heart fail-
ure.563,565,792,805 A meta-regression analysis of 26 trials com-
pared the effects of ACE inhibitors and ARBs on major
vascular events by BP effects.804 Treatment with ACE inhib-
itor–based regimens was associated with a reduction in the
risk for stroke (by 19%), IHD (by 16%), and heart failure (by
27%) for each 5–mm Hg reduction in BP; corresponding
figures for the reduction in risk for ARBs were 26%, 17%,
and 12%, respectively. There were no significant differences
between ARB- and ACE inhibitor–based regimens in the risk
of stroke, IHD, and heart failure for each 5–mm Hg reduction
in BP. When these outcomes were assessed at zero BP
reduction, the risk reduction for IHD was significantly greater
for ACE inhibitors than for ARBs (P0.002). Furthermore,
unlike ARBs, ACE inhibitors were associated with a signif-
icant additional risk reduction for IHD of 9% (P0.004),
without differences seen for stroke or heart failure versus
ARBs. It is therefore recommended that ARBs be substituted
for ACE inhibitors in patients with SIHD and hypertension
who are intolerant of ACE inhibitors.563,565,792,804,805
4.4.2.4. Influenza Vaccination
Class I
1. An annual influenza vaccine is recommended for patients
with SIHD.806–810 (Level of Evidence: B)
In patients with chronic medical conditions such as cardio-
vascular disease, influenza contributes to a higher risk for
mortality and hospitalization and exacerbates underlying
medical conditions. The World Health Organization and the
AHA/ACCF recommend annual vaccination with inactivated
vaccine (administered intramuscularly) against seasonal in-
fluenza to prevent all-cause mortality and morbidity in
patients with underlying cardiovascular conditions.806,807 A
cohort study in 1340 elderly (ie, 65 years of age) patients
with heart failure or IHD showed that annual influenza
vaccinations reduced the risk of mortality by 37% during the
winter period (January through April), but not the summer
period (June through September), resulting in a number
needed to treat to prevent 1 death during 1 influenza period of
122 annual vaccinations.808 Further mechanistic and confir-
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matory studies in heart failure and other cardiovascular
disease are needed to confirm these findings. Evidence from
2 prospective randomized clinical studies in patients $65
years of age who were medically stable supports increasing
influenza vaccine doses to achieve higher serum antibody
titers and potentially improved protection from influenza
infection.809,810 This dosing scheme was associated with
higher injection site reactions, including pain and myalgias.
Currently, it is recommended that patients with SIHD receive
an annual influenza vaccination in the standard dose.
4.4.2.5. Additional Therapy to Reduce Risk of MI
and Death
Class III: No Benefit
1. Estrogen therapy is not recommended in postmeno-
pausal women with SIHD with the intent of reducing
cardiovascular risk or improving clinical out-
comes.811–814 (Level of Evidence: A)
2. Vitamin C, vitamin E, and beta-carotene supplemen-
tation are not recommended with the intent of
reducing cardiovascular risk or improving clinical
outcomes in patients with SIHD.398,527,815–818 (Level of
Evidence: A)
3. Treatment of elevated homocysteine with folate or
vitamins B6 and B12 is not recommended with the
intent of reducing cardiovascular risk or improving
clinical outcomes in patients with SIHD.819–822 (Level
of Evidence: A)
4. Chelation therapy is not recommended with the
intent of improving symptoms or reducing cardio-
vascular risk in patients with SIHD.823–826 (Level of
Evidence: C)
5. Treatment with garlic, coenzyme Q10, selenium,
or chromium is not recommended with the intent
of reducing cardiovascular risk or improving clin-
ical outcomes in patients with SIHD. (Level of
Evidence: C)
4.4.2.5.1. Hormone Replacement Therapy. Numerous obser-
vational studies have suggested that estrogen therapy might
provide protection against the development of IHD in post-
menopausal women.827–829 Beneficial effects of exogenous
estrogen include an increase in HDL cholesterol, a decrease
in LDL cholesterol, and enhanced endothelial function.830–833
In light of the epidemiological data and evidence of salutary
physiological effects, postmenopausal estrogen replacement
previously was advocated for the primary and secondary
prevention of CAD in women. Clinical trials in women with
and without established CAD, however, have failed to con-
firm a decrease in cardiovascular events with hormone
therapy. In HERS (Heart and Estrogen/progesterone Replace-
ment Study), 2763 postmenopausal women with CAD were
randomized to therapy with 0.625 mg of conjugated estrogen
plus 2.5 mg of medroxy progesterone acetate or placebo and
were followed up for an average of 4.4 years. Despite an 11%
lower level of LDL cholesterol and a 10% higher level of
HDL cholesterol in the hormone therapy group, there was no
difference in the composite primary endpoint of MI or IHD
death, and an early increase in cardiovascular events was
observed.811 In HERS-II, an unblinded follow-up study of
HERS, the lack of benefit with estrogen/progestin therapy
persisted at an average of 6.8 years.834 A subsequent angio-
graphic study demonstrated a nonsignificant worsening of
coronary stenoses in patients prescribed estrogen therapy.835
The Women’s Health Initiative, a randomized controlled
primary prevention trial, also found no evidence that estrogen
protects against IHD.812–814 Thus, the weight of current
scientific evidence suggests that estrogen/progestin therapy in
postmenopausal women does not reduce the risk of vascular
events or coronary deaths in secondary prevention. Women
who are taking estrogen therapy and who have vascular
disease can continue this therapy if it is prescribed for other
well-established indications and if no better alternative ther-
apies are appropriate, although the FDA recommends use in
the lowest dose and shortest duration acceptable. There is,
however, no basis for adding or continuing estrogens in
postmenopausal women with clinically evident SIHD in an
effort to prevent or retard progression of their atherosclerotic
disease.
4.4.2.5.2. Vitamin C, Vitamin E, and Beta-Carotene. Epide-
miological and population studies have suggested that anti-
oxidant vitamins, such as vitamin E, vitamin C, and beta-
carotene, could lower cardiovascular risk.836,837 Controlled
clinical trials, however, have failed to demonstrate a benefi-
cial effect of antioxidant supplements on risk of cardiovas-
cular morbidity and mortality.398,527,815–817 A meta-analysis of
antioxidant vitamin studies examined 7 trials of vitamin E
treatment and 8 trials of beta-carotene treatment with .1000
subjects in each. Most of these studies were performed in
patients with CAD or at risk of CAD. Vitamin E had no effect
on all-cause mortality or cardiovascular death.838 Beta-
carotene led to a small but statistically significant increase in
all-cause mortality and cardiovascular death. Thus, existing
scientific evidence does not justify routine use of antioxidant
supplements for the prevention or treatment of cardiovascular
disease.
4.4.2.5.3. Folate and Vitamins B6 and B12. Prospective
observational studies have demonstrated that the serum ho-
mocysteine level is a strong, independent risk factor for
ischemic events.839–841 Homocysteine levels can be lowered
with folic acid or B-vitamins. Trials of folate and vitamin B
supplementation, however, consistently have failed to dem-
onstrate a decrease in cardiovascular morbidity or mortality
rates. The VISP (Vitamin Intervention for Stroke Prevention)
trial randomized patients with prior nondisabling stroke to
varying doses of folic acid, B6, and B12. Despite a reduction
in homocysteine that was 2 mmol/L greater in the group
allocated to the high dose of supplementation, there were no
differences in the incidence of recurrent stroke, IHD, or
death.822 Similarly, the HOPE 2 (Heart Outcome in Preven-
tion) trial found no benefit of folate and vitamins B6 and B12
in patients with vascular disease or diabetes mellitus.821 The
NORVIT (Norwegian Vitamin Trial) examined 3 combina-
tions of folate and B vitamins in patients who had an AMI and
observed no decrease in the risk of cardiovascular events.820
A meta-analysis of these and 9 other smaller trials also found
no reduction in cardiovascular events or mortality with folate
supplementation.819 These studies indicate that routine use of
folate and B vitamins for the prevention or treatment of
cardiovascular disease should not be recommended.
4.4.2.5.4. Chelation Therapy. Chelation therapy, which con-
sists of a series of intravenous infusions of disodium ethylene
diamine tetraacetic acid (EDTA) in combination with other
substances, has been promoted as a noninvasive means of
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improving blood flow in atherosclerotic vessels. EDTA
combines with polyvalent cations, such as calcium ions, to
form soluble complexes that can be excreted. Advocates
maintain that this process can result in regression of athero-
sclerotic plaques and relief of angina and that EDTA reduces
oxidative stress in the vascular wall.
Anecdotal reports have suggested that EDTA chelation
therapy can result in relief of angina in patients with SIHD. In
general, however, the efficacy of chelation therapy in athero-
sclerotic disease is not supported by clinical trials. Studies in
patients with intermittent claudication have failed to demon-
strate improvements in exercise measures,823,824 ankle-
brachial index,823,824 or digital subtraction angiograms with
chelation.825 The only RCT examining the effectiveness of
chelation therapy on SIHD826 studied 84 patients with stable
angina and a positive treadmill test for ischemia. Those
randomized to active therapy received weight-adjusted diso-
dium EDTA chelation therapy for 3 hours per treatment,
twice weekly for 15 weeks and then once monthly for an
additional 3 months. There were no differences between
groups in changes in exercise time to ischemia, exercise
capacity, or quality-of-life scores. The National Center of
Complementary and Alternative Medicine and the National
Heart, Lung, and Blood Institute have sponsored TACT (Trial
to Assess Chelation Therapy),842 an RCT comparing chela-
tion to placebo in patients who had experienced an MI. There
is insufficient evidence to support chelation therapy for
improving symptoms or preventing adverse outcomes in
patients with SIHD. Moreover, this therapy is costly and time
consuming, can result in harm, and could result in patients
failing to pursue proven treatment strategies.
4.4.2.5.5. Garlic, Coenzyme Q10, Selenium, and Chromium. Nu-
tritional supplements for the prevention and treatment of
cardiovascular disease have grown increasingly popular in
the United States. These alternative therapies often are
promoted with anecdotal claims of efficacy but have not been
studied rigorously. When data are available, they often
conflict and consist of results of small, open-label trials. At
present, there is no definitive evidence to recommend treat-
ment with garlic, coenzyme Q10, selenium, or chromium for
improving cardiovascular outcomes in patients with SIHD.
4.4.3. Medical Therapy for Relief of Symptoms
4.4.3.1. Use of Anti-ischemic
Medications: Recommendations
Class I
1. Beta blockers should be prescribed as initial
therapy for relief of symptoms in patients with
SIHD.757,765,766 (Level of Evidence: B)
2. Calcium channel blockers or long-acting nitrates
should be prescribed for relief of symptoms when
beta blockers are contraindicated or cause unaccept-
able side effects in patients with SIHD.420,768,769
(Level of Evidence: B)
3. Calcium channel blockers or long-acting nitrates, in
combination with beta blockers, should be pre-
scribed for relief of symptoms when initial treatment
with beta blockers is unsuccessful in patients with
SIHD.420 (Level of Evidence: B)
4. Sublingual nitroglycerin or nitroglycerin spray is
recommended for immediate relief of angina in
patients with SIHD.843–845 (Level of Evidence: B)
Class IIa
1. Treatment with a long-acting nondihydropyridine
calcium channel blocker (verapamil or diltiazem)
instead of a beta blocker as initial therapy for relief
of symptoms is reasonable in patients with SIHD.420
(Level of Evidence: B)
2. Ranolazine can be useful when prescribed as a
substitute for beta blockers for relief of symptoms in
patients with SIHD if initial treatment with beta
blockers leads to unacceptable side effects or is
ineffective or if initial treatment with beta blockers
is contraindicated.846 (Level of Evidence: B)
3. Ranolazine in combination with beta blockers can be
useful when prescribed for relief of symptoms when
initial treatment with beta blockers is not successful
in patients with SIHD.847,848 (Level of Evidence: A)
4.4.3.1.1. Beta Blockers. Beta blockers are recommended as
the initial agents to relieve symptoms in most patients with
SIHD. Beta blockers reduce myocardial oxygen consumption
by reducing heart rate, myocardial contractility, and afterload,
with attenuation of cardiovascular remodeling by decreasing
LV wall tension with long-term use. The reduction in myo-
cardial oxygen demand is directly proportional to the level of
adrenergic tonic stimulation. Furthermore, the reduction in
heart rate also shifts the cardiac cycle, permitting more
diastolic time and greater coronary perfusion, thereby im-
proving myocardial oxygen supply.
Long-term beta-blocker treatment is well tolerated, has
proven benefit in SIHD by reducing ischemic burden and
threshold, and improves survival in patients with LV dys-
function or history of MI.757,765,766 When prescribed in com-
bination with agents that block the renin-angiotensin-aldoste-
rone system, beta blockers are the preferred agents
for the treatment of angina in patients with LV dysfunction
after MI and in patients with heart failure, on the basis of
documented improvements in survival and ventricular
performance.402,571,760,792,801
A meta-analysis of comparison trials between beta block-
ers and calcium channel blockers (dihydropyridine and non-
dihydropyridine agents) showed negligible differences in the
rate of death or MI over relatively brief durations of admin-
istration (ie, 6 wk to 6 mo), although patients with heart
failure, heart block, or significant pulmonary disease were
excluded from the meta-analysis.420 Beta blockers were found
to exhibit an advantage with regard to control of angina and
withdrawals from therapy due to adverse events, a problem
that was most pronounced with nifedipine.420 Calcium chan-
nel blockers, however, have not been shown to improve
survival after MI, as beta blockers have, but have been shown
to offer protection against severe angina and to reduce the risk
of reinfarction after MI.849–851
Adherence to beta-blocker therapy can be influenced by
the occurrence of adverse effects such as fatigue, lethargy,
sexual dysfunction, or sleep disturbances. Although beta
blockers have the potential to worsen symptoms in patients
with significant depressive illness or PAD, these effects are
observed rarely in clinical practice. For patients with severe
PAD or those with vasospastic (Prinzmetal’s) angina, wors-
ening symptoms due to vasoconstriction from unopposed
alpha-adrenergic activity can be avoided by using beta
blockers with alpha-adrenergic blocking (eg, labetalol or
carvedilol) or direct vasodilator (eg, nebivolol) properties.
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4.4.3.1.2. Calcium Channel Blockers. If adverse effects or
contraindications limit the use of beta blockers, calcium
channel blockers are recommended for relief of anginal
symptoms. These agents noncompetitively limit calcium ion
influx through voltage-dependent L-type calcium channels,
resulting in negative inotropic effects, cardiac pacemaker
depression, slowing conduction, and smooth muscle relax-
ation. There are 3 classes of calcium channel blockers: the
dihydropyridines (eg, nifedipine) and 2 types of nondihydro-
pyridines, the phenylalkylamines (eg, verapamil) and the
benzothiazepines (eg, diltiazem). All classes improve myo-
cardial oxygen supply by decreasing coronary vascular resis-
tance and augmenting epicardial conduit vessel and systemic
arterial blood flow. Myocardial demand is decreased by a
reduction in myocardial contractility, systemic vascular resis-
tance, and arterial pressure. However, the phenylalkylamines
and, to a lesser extent, the benzothiazepines also depress
cardiac pacemaker rate and slow conduction. This depressant
effect can cause sinus bradycardia or can worsen preexisting
conduction defects, leading to heart block. Myocardial con-
tractile depression also is a common feature, although the
degree is variable according to drug class. As a result of these
pharmacological properties, the calcium channel blockers are
effective anti-ischemic drugs, but their use must be
individualized.852,853
All classes of calcium channel blockers reduce anginal
episodes, increase exercise duration, and reduce use of
sublingual nitroglycerin in patients with effort-induced an-
gina.854–856 Because all 3 classes also reduce the frequency of
Prinzmetal’s variant angina, they are the drugs of choice,
along with nitrates, used alone or in combination.857–859
Because the 3 classes seem to be equally efficacious in
treating angina, the choice of a particular agent should be
based on potential drug interactions and adverse events. The
dihydropyridine class is preferred over other calcium channel
blockers in patients with cardiac conduction defects such as
sick sinus syndrome, sinus bradycardia, or significant AV
conduction disturbances. Dihydropyridines should be used
with caution in patients with severe aortic valve stenosis.
Short-acting dihydropyridines in patients with fixed lesions
can exacerbate angina, possibly by excessive lowering of
arterial pressure with reflex tachycardia, and therefore should
be avoided. Short-acting nifedipine seems to increase mortal-
ity in patients with hypertension,860 but there is currently no
evidence that these concerns apply to extended-release prep-
arations.861,862 Because of their effects on contractility, none
of the calcium channel blockers are recommended for routine
treatment of patients with current or prior symptoms of heart
failure and a reduced LVEF.21
Many drug interactions associated with calcium channel
blockers occur because of rapid absorption or low bioavail-
ability due to high first-pass metabolism by the cytochrome
P450 (ie, CYP3A4) system. These pharmacokinetic properties
result in high intraindividual and interindividual variability,
necessitating dosage adjustment. These drugs should be used
with caution when combined with cyclosporine, carbamaz-
epine, lithium carbonate, amiodarone, or digoxin (ie, 50% to
70% increase in digoxin concentrations in first week of
therapy). Combining verapamil or diltiazem with beta block-
ers generally should be avoided because of potentially pro-
found adverse effects on AV nodal conduction, heart rate, or
cardiac contractility.
Overall, calcium channel blockers, particularly diltiazem,
are well tolerated. The major adverse effects of dihydropyr-
idines are related to vasodilation and systemic hypotension,
including headache, dizziness, palpitations, and flushing.
Many patients experience peripheral edema because of ex-
cessive arterial vasodilation unmatched to venous dilation.
Verapamil can cause constipation that can be severe, partic-
ularly in the elderly.
4.4.3.1.3. Nitrates. Nitrates are effective in the treatment of
all forms of angina. They relax vascular smooth muscle in the
systemic arteries, inclusive of the coronary arteries, and veins
(predominant effect at lower doses) in patients with SIHD.
Short-term continuous nitroglycerin delivery by the intrave-
nous or transdermal route for only 2 to 4 hours protects the
endothelium from experimental ischemia in healthy volun-
teers and reduces ischemia during coronary angioplasty and
physical exercise in IHD patients.863–865 Oxygen free radical
release seems to be associated with these protective out-
comes. Nitroglycerin causes dilation of the artery wall not
affected by plaque, but independent of an intact endothelium,
leading to reduced resistance across the obstructed lumen.866
Furthermore, nitroglycerin contributes to coronary blood flow
redistribution, by augmenting collateral flow and lowering
ventricular diastolic pressure, from areas of normal perfusion
to ischemic zones.867 Preload is reduced, leading to reduc-
tions in myocardial wall tension and myocardial oxygen
demand, although this effect is offset by increased heart rate
and myocardial contractile state due to reflex sympathetic
activity. Nitroglycerin also has demonstrated antithrombotic
and antiplatelet effects.868,869
Long-term nitrate therapy, however, could offset the
beneficial short-term ischemic preconditioning effects. Long-
term nitroglycerin therapy is associated with endothelial
dysfunction via accumulation of the same oxygen free radi-
cals that seem to be beneficial in short-term administra-
tion.870,871 The oxygen free radical accumulation increases
arterial sensitivity to vasoconstrictors such as angiotensin II,
which can be counteracted by concomitant treatment with an
ACE inhibitor or hydralazine.872–875 Importantly, these phys-
iological changes are independent of dose or the presence or
absence of a nitrate-free interval and can result in a decrease
in the anginal threshold during the nitrate-free interval.876
Further research to better understand the balance between the
long-term benefits and safety concerns of these compounds is
warranted in patients with SIHD.
Despite these physiological observations, nitrates improve
exercise tolerance, time to ST-segment depression, and time
to onset of angina in patients with SIHD, albeit in small
patient studies conducted for relatively short periods.876–878
Comparisons of nitrates to beta blockers or calcium channel
blockers have not shown significant differences with regard
to weekly anginal episodes, time to ST-segment depression,
total exercise time, or sublingual nitroglycerin use.420 With-
drawal for adverse effects was also not statistically different
between the drug classes.
All patients with SIHD should be prescribed sublingual
nitroglycerin tablets or nitroglycerin spray for immediate
relief of angina. Most patients respond within 5 minutes of
taking 1 to 2 sublingual dose(s) of 0.3 to 0.6 mg. Nitroglyc-
erin spray is available in a 0.4-mg metered-dose canister that
dispenses 200 doses. The tablets should be placed under the
tongue and not swallowed. If the spray is used, it should be
applied to the tongue and not swallowed or inhaled. If
additional doses are necessary, they should be taken at
5-minute intervals, for a maximum dose of #1.2 mg within
15 minutes. During this timeframe, if relief does not occur,
Fihn et al Stable Ischemic Heart Disease: Full Text e409
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
the patient should seek immediate medical attention. These
products are also effective for prevention of effort-induced
angina when administered 5 to 10 minutes before activity,
with relief lasting approximately 30 to 40 minutes. The
tablets must be kept in the manufacturer’s bottle (loss of
potency can occur in a few hours if out of the bottle) and
should be stored in a cool, dry place but should not be
refrigerated. The tablets should not be used 6 to 12 months
after opening the bottle. Patients usually are able to detect
when tablets have lost potency by the absence of a burning
sensation beneath the tongue. Nitroglycerin ointment also
may be used for short-term relief of angina. Applied to the
chest in doses of 0.5 to 2.0 inches, with a delay in relief of 30
minutes, this preparation can be effective for 4 to 6 hours.
Absorption can be increased by rotating the application sites,
covering the paste with plastic, or not applying the ointment
continuously (ie, maintenance of a nitrate-free interval).879–881
All short-acting nitrate preparations can cause hypotension,
sometimes severe, and headaches that limit adherence to
these agents. Patients should be counseled about these ad-
verse effects and advised to seek medical treatment if
syncope or resistant chest pain occurs. The ointment can
cause permanent discoloration of clothing.
Long-acting nitrate preparations (eg, nitroglycerin, isosor-
bide dinitrate, isosorbide-5-mononitrate) are recommended
for treatment of angina when initial therapy with a beta
blocker or nondihydropyridine calcium channel blocker is
contraindicated or poorly tolerated or when additional ther-
apy to control angina is necessary. Isosorbide dinitrate
undergoes rapid high first-pass metabolism, resulting in low
bioavailability. However, substantial interpatient variability
exists in the metabolic enzyme systems responsible for
isosorbide dinitrate conversion. Isosorbide mononitrate, the
active metabolite of the dinitrate formulation, is 100% bio-
available. Nitroglycerin also can be delivered through sili-
cone gel or polymer matrix release patch systems. The rate of
release varies between these systems, necessitating individu-
alization of dosing. With all formulations, titration of dose is
important to gain adequate anginal control with the lowest
possible dose to limit the occurrence of headaches, avoid
nitrate tolerance, and facilitate long-term adherence. The
effectiveness of all of these formulations seems to be roughly
equivalent despite differences in the preparation and dosing
schedules.843,882 With all of them, it is necessary to maintain
a daily nitrate-free interval of 10 to 14 hours to avoid
development of nitrate tolerance.843 Nitrate tolerance does not
develop with the sublingual route of administration. Use of
long-acting nitrates also does not result in tolerance to the use
of sublingual products.
Nitrates are relatively well tolerated if a titration schedule
is used at initiation and with discontinuation. The most
common side effects are headache, flushing, and hypotension.
Patients should be instructed to remain seated when taking
rapid-acting nitrate products as a safety precaution to avoid
syncope from vasodilation. Tolerance to the headaches could
develop after a few weeks of continuing the medication.
Prophylactic analgesics can be helpful until headache toler-
ance develops. Methemoglobinemia is a rare adverse effect,
usually seen only with large doses. Nitrates are relatively
contraindicated in hypertrophic obstructive cardiomyopathy
because of the potential to increase the outflow tract obstruc-
tion and mitral regurgitant flow. They should be avoided in
patients with severe aortic valvular stenosis. Coadministra-
tion of the phosphodiesterase inhibitors sildenafil, tadala-
fil, or vardenafil with long-acting nitrates should be strictly
avoided within 24 hours of nitrate administration because
of the risk of profound hypotension (eg, 25–mm Hg drop
in systolic BP). Patients should be advised not to take
phosphodiesterase inhibitors within 24 hours of long-
acting nitrates, and nitrates should not be taken for 24
hours after use of sildenafil or 48 hours after tadalafil; a
suitable time interval after vardenafil has not been deter-
mined. Patients should be made aware of the possibility of
intensification of their angina if nitrates are discontinued
abruptly. This effect could be reduced by concomitant
administration of other antianginals or by tapering of the
long-acting nitrate dosage.
4.4.3.1.4. Ranolazine. Ranolazine inhibits the late inward
sodium current, indirectly reducing the sodium-dependent
calcium current during ischemic conditions and leading to
improvement in ventricular diastolic tension and oxygen
consumption. Minimal changes in mean heart rate (,2 beats
per minute) and systolic BP (,3 mm Hg) occur in controlled
studies. At maximal exercise, the rate–pressure product is not
increased, independent of age, or in the presence of diabetes
mellitus, reactive airway disease, or heart failure.883 Ranola-
zine is currently indicated for the treatment of chronic angina
and may be used in combination with beta blockers, nitrates,
dihydropyridine calcium channel blockers, ACE inhibitors,
ARBs, and antiplatelet and lipid-lowering therapy. It should
be prescribed only in low doses in combination with verap-
amil or diltiazem, as described later. The lack of an effect on
BP and heart rate makes ranolazine an attractive alternative in
patients with bradycardia or low BP. Although ranolazine has
been well studied in SIHD, the agent was not administered in
the COURAGE (Clinical Outcomes Utilizing Revasculariza-
tion and Aggressive Drug Evaluation) study,366 and further
clinical evaluation is needed, especially of ranolazine as an
element of intensive interventions for multiple risk factors.
The ranolazine extended-release preparation reduces the
frequency of angina, improves exercise performance, and
delays the development of exercise-induced angina and ST-
segment depression.847,884 In one study, ranolazine reduced
weekly anginal frequency by 36% and nitroglycerin use by
43% in comparison with placebo.848 Other studies indicated
that among patients with ACS, ranolazine did not reduce the
incidence of MI or death885 but did reduce recurrent ischemia
in the postinfarction period.886 In patients with preexisting
angina, it was superior to placebo in improving patients’
angina and quality of life.887 Ranolazine could exert a
beneficial effect on glycemic control and has demonstrated
consistent reductions in HbA1c in patients with diabetes
mellitus in 2 studies.883,888,889
Ranolazine blocks the delayed rectifier potassium current
and prolongs the QTc interval in a dose-related manner,
resulting in a mean increase in QTc of approximately 6 msec
at maximal recommended dosing. Currently, there is limited
experience with concomitant administration of ranolazine and
other drugs that prolong the QT interval, including Class IA
and III antiarrhythmics and certain antipsychotics (thiorida-
zine and ziprasidone). In 3162 patients with ACS, there was
no increased risk of proarrhythmia or sudden death. In this
study, there was a significantly lower incidence of arrhyth-
mias, including ventricular tachycardia, bradycardia, su-
praventricular tachycardia, and new atrial fibrillation, in
patients treated with ranolazine (80%) versus placebo
(87%).883,885,890,891
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Ranolazine does not require dose adjustment for age, sex,
New York Heart Association class I–IV heart failure, or
diabetes mellitus. Plasma concentrations of ranolazine are
increased by up to 50% in patients with Stage 4 CKD
(creatinine clearance ,30 mL/min).892 The drug is contrain-
dicated in patients with clinically significant hepatic impair-
ment because of increased plasma concentrations and QT
prolongation. In general, dosing in the elderly should start at
the low end of the dosing range.883
Ranolazine is contraindicated in combination with potent
inhibitors of the CYP3A4 pathway, including ketoconazole
(3.2-fold increase in ranolazine plasma levels) and other azole
antifungals, macrolide antibiotics, HIV (human immunodefi-
ciency virus) protease inhibitors, grapefruit products or juice,
diltiazem (1.8- to 2.3-fold increase in ranolazine plasma levels),
itraconazole, clarithromycin, and certain HIV protease inhibi-
tors. When administered with moderate inhibitors of CYP3A
such as diltiazem, verapamil, aprepitant, erythromycin, flucona-
zole, or grapefruit juice, the dose of ranolazine should be limited
to 500 mg twice daily because of an approximately 2-fold
increase in ranolazine plasma levels. No dose adjustment is
required in patients treated with cimetidine or paroxetine. Co-
administration of ranolazine (1000 mg twice daily) with simva-
statin increases the plasma concentration of simvastatin and its
active metabolite 2-fold. Digoxin plasma concentrations are
increased 1.5-fold, but this interaction might not be clinically
relevant with lower digoxin dosing (0.125 mg daily). Coadmin-
istration of ranolazine with drugs that inhibit CYP2D6, with the
exceptions of tricyclic antidepressants and some antipsychotics,
does not require dosage adjustment.
Ranolazine is well tolerated; the major adverse effects are
constipation, nausea, dizziness, and headache. The incidence
of syncope is ,1%.
4.4.3.1.5. Antianginal Agents Not Currently Available in the
United States
4.4.3.1.5.1. Nicorandil. Nicorandil is a nicotinamide ester
with a dual mechanism of action. It activates adenosine
triphosphate–sensitive potassium channels and promotes sys-
temic venous and coronary vasodilation through a nitrate
moiety.893 This dual action increases coronary blood flow,
with reductions in afterload, preload, and oxidative injury.893
The agent does not exhibit effects on contractility or conduc-
tion.894,895 The antianginal efficacy and safety of nicorandil
are similar to those of oral nitrates, beta blockers, and calcium
channel blockers.893,896,897 In a prospective, randomized,
study of 5126 patients with chronic stable angina, the addition
of nicorandil to standard therapy was found to produce a 17%
RR reduction in the composite endpoint of IHD death,
nonfatal MI, or unplanned hospital admission for cardiac
chest pain.898 There was, however, no difference between
nicorandil and placebo with regard to death from IHD or
nonfatal MI.894 Tolerance can develop with long-term dos-
ing.899 Common side effects include flushing; palpitation;
weakness; headache; ulceration of the mouth, perianal, ileal,
and peristomal areas; nausea; and vomiting. The agent is not
currently available in the United States.
4.4.3.1.5.2. Ivabradine. Ivabradine is a specific inhibitor of
the If current of pacemaker cells in the sinoatrial node at
concentrations that do not inhibit other cardiac currents.900
This action results in heart rate reduction, prolonging diastole
and thereby improving myocardial oxygen balance. Ivabra-
dine has no effect on BP, myocardial contractility, or intra-
cardiac conduction parameters.901–903 Ivabradine improves
exercise capacity and reduces anginal frequency in compar-
ison to atenolol among patients with chronic stable an-
gina.904,905 In 5479 patients with IHD and LV systolic
dysfunction, however, ivabradine added to standard treatment
had no effect, when compared with placebo, on the composite
endpoint of cardiovascular death, admission to the hospital
for AMI, and admission to the hospital for new-onset or
worsening heart failure.906 The most common adverse event,
reported in 14.5% of patients, is phosphenes, described as a
transient enhanced brightness in a limited area of the visual
field that typically occurs within the first 2 months of
treatment. Most of these luminous visual-field disturbances
(77%) resolve without discontinuing treatment. The drug is
approved in Europe (not currently available in the United
States) for the symptomatic treatment of chronic stable
angina in patients with normal sinus rhythm with a contrain-
dication or intolerance to beta blockers.
4.4.3.1.5.3. Trimetazidine. Trimetazidine seems to improve
cellular tolerance to ischemia by inhibiting fatty acid metab-
olism and secondarily by stimulating glucose metabolism,
although the exact anti-ischemic mechanisms are un-
known.907 In patients with chronic stable angina, this agent
increases coronary flow reserve, delaying the onset of ische-
mia associated with exercise and reducing the number of
weekly angina episodes and weekly nitroglycerin consump-
tion.908,909 The anti-ischemic effects are not associated with
changes in heart rate or systolic BP. Few data exist on the
effect of trimetazidine on cardiovascular endpoints, mortality,
or quality of life. The most frequently reported adverse events
are gastrointestinal disorders, but the incidence is low. The
agent is not available in the United States but is available in
Europe and reportedly in .80 countries worldwide.
4.4.4. Alternative Therapies for Relief of Symptoms in
Patients With Refractory Angina: Recommendations
Class IIb
1. Enhanced external counterpulsation (EECP) may be
considered for relief of refractory angina in patients
with SIHD.910 (Level of Evidence: B)
2. Spinal cord stimulation may be considered for relief
of refractory angina in patients with SIHD.911,912
(Level of Evidence: C)
3. Transmyocardial revascularization (TMR) may be
considered for relief of refractory angina in patients
with SIHD.913–915 (Level of Evidence: B)
Class III: No Benefit
1. Acupuncture should not be used for the purpose of
improving symptoms or reducing cardiovascular risk in
patients with SIHD.916,917 (Level of Evidence: C)
TMR has been used as either a percutaneous or a surgical
procedure concomitant with CABG or as sole therapy in
patients with angina refractory to medical therapy,913–915,918
although the mechanism by which it might be efficacious is
unknown.919,920 Early studies of the percutaneous approach
demonstrated no therapeutic benefit, and it was promptly
abandoned.921 When used as sole therapy by a surgical
approach, TMR is reserved for the patient with incapacitat-
ing, medically refractory angina and no other feasible thera-
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peutic options. Proposed mechanisms of action include stim-
ulation of microcirculation, creation of myocardial scarring,
and denervation of ischemic myocardium.922 Various energy
sources have been used, including carbon dioxide XeCl
excimer and holmium:YAG lasers.923–925 There is no con-
vincing evidence that one energy source is superior to the
others. TMR also has been combined with cardiac denerva-
tion by thoracic sympathectomy.926
Numerous single-center and a few multicenter randomized
trials have been published that compare TMR with medical
therapy for relief of refractory angina.927–930 Most have
shown better angina relief with TMR but no survival benefit.
The exception is a single multicenter trial that shows a
survival benefit as well as better relief of angina at 5 years.931
A 5-year follow-up of a multicenter, prospectively random-
ized trial reported not only sustained angina relief but also
improved survival in CCS Class IV angina, and patients with
no additional options for therapy who were randomized to
sole-therapy TMR.931 A meta-analysis of 7 RCTs involving
1053 patients evaluated the effect of TMR on survival and
angina relief.932 The conclusion was that at 1 year, TMR
improved angina class but not survival when used as the sole
procedural intervention compared with medical therapy
alone. A number of other series also have reported sustained
angina relief and improved quality of life in randomized
patients receiving TMR at 3 to 5 years after treatment
(Section 5.10 for additional information on TMR in
revascularization).
A growing number of patients with SIHD have refractory
angina, defined as multivessel CAD with ischemia and
symptoms that cannot be controlled with medical therapy or
surgical or percutaneous revascularization. The prevalence of
this syndrome is not well established, but data from registries
suggest that about 10% of patients referred for angiography
for symptomatic SIHD have coronary anatomy that is not
amenable to revascularization.933–935 Other nonpharmacologi-
cal therapies may be considered in these patients in an effort
to improve quality of life.
4.4.4.1. Enhanced External Counterpulsation
EECP is a technique that uses inflatable cuffs wrapped
around the lower extremities to increase venous return and
augment diastolic BP. The cuffs are inflated sequentially
from the calves to the thigh muscles during diastole and are
deflated instantaneously during systole. The resultant diastol-
ic augmentation increases coronary perfusion pressure, and
the systolic cuff depression decreases peripheral resistance.
Treatment is associated with improved LV diastolic filling
and improved endothelial function936 –938; other putative
mechanisms for improvement in symptoms include recruit-
ment of collaterals, release of proangiogenic cytokines, and a
peripheral training effect. A treatment course typically con-
sists of 35 hour-long treatment sessions, given 5 days a week.
Contraindications include decompensated heart failure, se-
vere PAD, and severe aortic regurgitation.
The efficacy of EECP in treating stable angina pectoris has
been evaluated in a single RCT and several observational
registry studies. In MUST-EECP (Multicenter Study of En-
hanced External Counterpulsation), 139 patients with angina,
documented CAD, and evidence of ischemia on exercise
testing were randomized to 35 hours of active counterpulsa-
tion or to inactive counterpulsation.910 Time to $1-mm
ST-segment depression increased significantly in patients
treated with active counterpulsation (from 337618 s to
379618 s) compared with placebo (from 326621 s to
330620 s; P50.01), although there was no difference be-
tween the groups in exercise duration. More active counter-
pulsation patients experienced a decrease in anginal episodes.
Of patients receiving EECP, 55% reported adverse events,
including leg and back pain and skin abrasions, compared
with 26% in the control group, with approximately half of
these events categorized as device related.
In a meta-analysis of 13 observational studies that tracked
949 patients, anginal class as categorized by the CCS classi-
fication was improved by $1 class in 86% (95% CI: 82% to
90%).939 The EECP Consortium reported results in 2289
consecutive patients undergoing EECP therapy at 84 partic-
ipating centers, including a subgroup of 175 patients from 7
centers who underwent radionuclide perfusion stress tests
before and after therapy.940 Treatment was associated with
improved perfusion images and increased exercise duration.
Similarly, the International EECP Registry reported improve-
ment of $1 angina class in 81% of patients immediately after
the last treatment.941
In general, existing data, largely from uncontrolled studies,
suggest a benefit from EECP in patients with angina refrac-
tory to other therapy. Additional data from well-designed
RCTs are needed to better define the role of this therapeutic
strategy in patients with SIHD.942
4.4.4.2. Spinal Cord Stimulation
Spinal cord stimulation at the T1 to T2 level has been
advocated as a therapeutic option for patients with angina
pectoris that is refractory to medical therapy and coronary
revascularization. The stimulation lead is inserted into the
epidural space and is connected to a pulse generator im-
planted subcutaneously. A paresthetic stimulus is delivered in
a continuous, cyclic, or intermittent manner. The mechanisms
by which spinal cord stimulation leads to reduced angina are
not well established. Although inhibition of pain transmission
plays a role, some studies suggest that spinal cord stimulation
also might reduce myocardial ischemia.943–945
The efficacy of spinal cord stimulation has been evaluated in
several observational and cohort studies. The Prospective Italian
Registry described outcomes in 104 patients with severe angina
refractory to medical therapy over an average of 13 months after
initiation of spinal cord stimulation.946 A .50% reduction in
anginal symptoms was observed in 73% of patients. CCS class
improved by $1 class in 80% and by $2 classes in 42% of patients.
Similarly, in a cohort of 51 patients with refractory CCS Class III or
IV angina, spinal cord stimulation was associated with a significant
reduction in anginal episodes in 88% of subjects at 24 months of
follow-up.947 There were no significant complications of therapy in
either series.
The published RCTs of spinal cord stimulation were small. One
study tested the efficacy of spinal cord stimulation in 13 patients
with chronic, intractable angina compared with 12 controls over 6
weeks.912 Patients with spinal cord stimulation demonstrated greater
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exercise duration and time to angina during treadmill testing and
fewer bouts of angina and fewer episodes of ST depression on
ambulatory echocardiographic monitoring. A subsequent trial com-
pared spinal cord stimulation to CABG.911 Subjects included 104
patients with severe angina who would not be expected to derive
survival benefit from revascularization, were at increased risk of
surgical complications, and were unsuitable for PCI. Patients in both
groups had significant symptom relief. Those assigned to bypass
surgery had greater increases in exercise capacity and less ST
depression on treadmill testing than did those treated with spinal
cord stimulation. Mortality and cardiovascular morbidity rates were
lower in the spinal cord stimulation group.
In summary, studies of spinal cord stimulation suggest that
this technique might have some use as a method to relieve
angina in patients with symptoms that are refractory to
standard medical therapy and revascularization. There is a
paucity of data on the mechanisms and long-term risks and
benefits of this therapeutic approach, however.
4.4.4.3. Acupuncture
Acupuncture is used by some practitioners for the relief of
acute and chronic pain. The efficacy of acupuncture in the
treatment of angina pectoris has not been studied rigorously,
however. In part this is due to the difficulty of blinding both
patients and healthcare providers. Twenty-six patients with
severe angina resistant to standard medical therapy were
studied in one of the first randomized trials comparing
acupuncture and sham acupuncture.917 There was no differ-
ence between groups in the frequency of angina or use of
nitroglycerin, although patients treated with acupuncture
achieved a higher pressure–rate product on exercise testing. A
subsequent study by the same investigators in patients with
less severe ischemia failed to show a difference in either
exercise variables or subjective measures between acupunc-
ture and placebo patients.916 In contrast, a decrease in anginal
episodes and an increase in the workload required to induce
ischemia were observed with acupuncture in a crossover
study of 21 patients with stable angina. The control condition
in this trial was a pill placebo, however, so neither subjects
nor investigators were blinded.948
In summary, acupuncture has not been studied sufficiently
to warrant recommendation as a treatment option for relief of
symptoms in patients with SIHD.
5. CAD Revascularization
Recommendations and text in this section are the result of
extensive collaborative discussions between the PCI and
CABG writing committees, as well as key members of the
SIHD and UA/NSTEMI writing committees. Certain issues,
such as older versus more contemporary studies, primary
analyses versus subgroup analyses, and prospective versus
post hoc analyses, have been carefully weighed in designating
COR and LOE; they are addressed in the appropriate corre-
sponding text. The goals of revascularization for patients with
CAD are to 1) improve survival and 2) relieve symptoms.
Revascularization recommendations in this section are based
predominantly on studies of patients with symptomatic SIHD and
should be interpreted in this context. As discussed later in this
section, recommendations on the type of revascularization are, in
general, applicable to patients with UA/NSTEMI. In some cases
(eg, unprotected left main CAD), specific recommendations are
made for patients with UA/NSTEMI or STEMI.
Historically, most studies of revascularization have been
based on and reported according to angiographic criteria.
Most studies have defined a “significant” stenosis as $70%
diameter narrowing; therefore, for revascularization decisions
and recommendations in this section, a “significant” stenosis
has been defined as $70% diameter narrowing ($50% for
left main CAD). Physiological criteria, such as an assessment
of FFR, have been used in deciding when revascularization is
indicated. Thus, for recommendations about revascularization
in this section, coronary stenoses with FFR #0.80 can also be
considered to be “significant.”
As noted, the revascularization recommendations have
been formulated to address issues related to 1) improved
survival and/or 2) improved symptoms. When one method of
revascularization is preferred over the other for improved
survival, this consideration, in general, takes precedence over
improved symptoms. When options for revascularization are
discussed with the patient, he or she should understand when
the procedure is being performed in an attempt to improve
symptoms, survival, or both.
Although some results from the SYNTAX (Synergy be-
tween Percutaneous Coronary Intervention with TAXUS and
Cardiac Surgery) study are best characterized as subgroup
analyses and “hypothesis generating,” SYNTAX nonetheless
represents the latest and most comprehensive comparison of
PCI and CABG.949,950 Therefore, the results of SYNTAX
have been considered appropriately when formulating our
revascularization recommendations. Although the limitations
of using the SYNTAX score for certain revascularization
recommendations are recognized, the SYNTAX score is a
reasonable surrogate for the extent of CAD and its complex-
ity and serves as important information that should be
considered when making revascularization decisions. Recom-
mendations that refer to SYNTAX scores use them as
surrogates for the extent and complexity of CAD.
Revascularization recommendations to improve survival
and symptoms are provided in the following text and are
summarized in Tables 18 and 19. References to studies
comparing revascularization with medical therapy are pre-
sented when available for each anatomic subgroup. When
such studies have been completed only for CABG, RCTs or
cohort studies comparing CABG with PCI are presented, but
the LOE for PCI is downgraded.
See Online Data Supplements 3 and 4 for additional data
regarding the survival and symptomatic benefits with CABG
or PCI for different anatomic subsets.
5.1. Heart Team Approach to Revascularization
Decisions: Recommendations
Class I
1. A Heart Team approach to revascularization is
recommended in patients with unprotected left main
or complex CAD.950–952 (Level of Evidence: C)
Fihn et al Stable Ischemic Heart Disease: Full Text e413
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
Table 18. Revascularization to Improve Survival Compared With Medical Therapy
Anatomic Setting COR LOE References
UPLM or complex CAD
CABG and PCI I—Heart Team approach recommended C (950–952)
CABG and PCI IIa—Calculation of STS and SYNTAX scores B (949, 950, 953–957)
UPLM*
CABG I B (73, 381, 412, 959–962)
PCI IIa—For SIHD when both of the following are present:
● Anatomic conditions associated with a low risk of PCI procedural
complications and a high likelihood of good long-term outcome (eg,
a low SYNTAX score of #22, ostial or trunk left main CAD)
● Clinical characteristics that predict a significantly increased risk of
adverse surgical outcomes (eg, STS-predicted risk of operative
mortality $5%)
B (949, 953, 955, 958, 963–980)
IIa—For UA/NSTEMI if not a CABG candidate B (949, 968–971, 976–979, 981)
IIa—For STEMI when distal coronary flow is TIMI flow grade ,3 and PCI
can be performed more rapidly and safely than CABG
C (965, 982, 983)
IIb—For SIHD when both of the following are present:
● Anatomic conditions associated with a low to intermediate risk of PCI
procedural complications and an intermediate to high likelihood of
good long-term outcome (eg, low-intermediate SYNTAX score of
,33, bifurcation left main CAD)
● Clinical characteristics that predict an increased risk of adverse
surgical outcomes (eg, moderate—severe COPD, disability from prior
stroke, or prior cardiac surgery; STS-predicted operative mortality
.2%)
B (949, 953, 955, 958, 963–980, 984)
III: Harm—For SIHD in patients (versus performing CABG) with unfavorable
anatomy for PCI and who are good candidates for CABG
B (73, 381, 412, 949, 953, 955,
959–964)
3-vessel disease with or without
proximal LAD artery disease*
CABG I B (353, 412, 959, 985–987)
IIa—It is reasonable to choose CABG over PCI in patients with complex
3-vessel CAD (eg, SYNTAX score .22) who are good candidates for
CABG
B (964, 980, 987–989)
PCI IIb—Of uncertain benefit B (366, 959, 980, 985, 987)
2-vessel disease with proximal LAD
artery disease*
CABG I B (353, 412, 959, 985–987)
PCI IIb—Of uncertain benefit B (366, 959, 985, 987)
2-vessel disease without proximal
LAD artery disease*
CABG IIa—With extensive ischemia B (327, 990–992)
IIb—Of uncertain benefit without extensive ischemia C (987)
PCI IIb—Of uncertain benefit B (366, 959, 985, 987)
1-vessel proximal LAD artery disease
CABG IIa—With LIMA for long-term benefit B (412, 987, 993, 994)
PCI IIb—Of uncertain benefit B (366, 959, 985, 987)
1-vessel disease without proximal
LAD artery involvement
CABG III: Harm B (306, 327, 412, 985, 990, 995–998)
PCI III: Harm B (306, 327, 412, 985, 990, 995–998)
LV dysfunction
CABG IIa—EF 35% to 50% B (365, 412, 999–1002)
CABG IIb—EF ,35% without significant left main CAD B (355, 365, 410, 412, 999–1002)
PCI Insufficient data N/A
(Continued)
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Class IIa
1. Calculation of the STS and SYNTAX scores is
reasonable in patients with unprotected left main
and complex CAD.949,950,953–957 (Level of Evidence: B)
One protocol used in RCTs950–952,958 often involves a multi-
disciplinary approach referred to as the Heart Team. Com-
posed of an interventional cardiologist and a cardiac surgeon,
the Heart Team 1) reviews the patient’s medical condition
and coronary anatomy, 2) determines that PCI and/or CABG
are technically feasible and reasonable, and 3) discusses
revascularization options with the patient before a treatment
strategy is selected. Support for using a Heart Team approach
comes from reports that patients with complex CAD referred
specifically for PCI or CABG in concurrent trial registries
have lower mortality rates than those randomly assigned to
PCI or CABG in controlled trials.951,952
The SIHD, PCI, and CABG guideline writing committees
endorse a Heart Team approach in patients with unprotected
left main CAD and/or complex CAD in whom the optimal
revascularization strategy is not straightforward. A collabor-
ative assessment of revascularization options, or the decision
to treat with GDMT without revascularization, involving an
interventional cardiologist, a cardiac surgeon, and (often) the
patient’s general cardiologist, followed by discussion with the
patient about treatment options, is optimal. Particularly in
patients with SIHD and unprotected left main and/or complex
CAD for whom a revascularization strategy is not straight-
forward, an approach has been endorsed that involves termi-
nating the procedure after diagnostic coronary angiography is
completed; this allows a thorough discussion and affords
both the interventional cardiologist and cardiac surgeon
the opportunity to discuss revascularization options with
the patient. Because the STS score and the SYNTAX score
Table 18. Continued
Anatomic Setting COR LOE References
Survivors of sudden cardiac death
with presumed ischemia-
mediated VT
CABG I B (350, 1003, 1004)
PCI I C (1003)
No anatomic or physiological criteria
for revascularization
CABG III: Harm B (306, 327, 412, 985, 990, 995–998)
PCI III: Harm B (306, 327, 412, 985, 990, 995–998)
*In patients with multivessel disease who also have diabetes mellitus, it is reasonable to choose CABG (with LIMA) over PCI30,991,1005–1011 (Class IIa; LOE: B).
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; COR, class of recommendation; EF,
ejection fraction; LAD, left anterior descending; LIMA, left internal mammary artery; LOE, level of evidence; LV, left ventricular; N/A, not available; PCI, percutaneous
coronary intervention; SIHD, stable ischemic heart disease; STEMI, ST-elevation myocardial infarction; STS, Society of Thoracic Surgeons; SYNTAX, Synergy between
Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; TIMI, Thrombolysis In Myocardial Infarction; UA/NSTEMI, unstable angina/non–ST-elevation
myocardial infarction; UPLM, unprotected left main disease; and VT, ventricular tachycardia.
Table 19. Revascularization to Improve Symptoms With Significant Anatomic (>50% Left Main or >70% Non–Left Main CAD) or
Physiological (FFR <0.80) Coronary Artery Stenoses
Clinical Setting COR LOE References
$1 significant stenoses amenable to revascularization and unacceptable angina despite
GDMT
1—CABG A (366, 407, 1012–1020)
1—PCI
$1 significant stenoses and unacceptable angina in whom GDMT cannot be
implemented because of medication contraindications, adverse effects, or patient
preferences
IIa—CABG C N/A
IIa—PCI C N/A
Previous CABG with $1 significant stenoses associated with ischemia and unacceptable
angina despite GDMT
IIa—PCI C (1021–1024)
IIb—CABG C (1025)
Complex 3-vessel CAD (eg, SYNTAX score .22) with or without involvement of the
proximal LAD artery and a good candidate for CABG
IIa—CABG preferred over PCI B (980, 987–989)
Viable ischemic myocardium that is perfused by coronary arteries that are not amenable
to grafting
IIb—TMR as an adjunct to CABG B (923, 927, 929, 1026,
1027)
No anatomic or physiological criteria for revascularization III: Harm—CABG C N/A
III: Harm—PCI C N/A
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COR, class of recommendation; FFR, fractional flow reserve; GDMT, guideline-directed
medical therapy; LOE, level of evidence; N/A, not available; PCI, percutaneous coronary intervention; SYNTAX, Synergy between Percutaneous Coronary Intervention
with TAXUS and Cardiac Surgery; and TMR, transmyocardial revascularization.
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have been shown to predict adverse outcomes in patients
undergoing CABG and PCI, respectively, calculation of
these scores is often useful in making revascularization
decisions.949,950,953–957
5.2. Revascularization to Improve
Survival: Recommendations
Left Main CAD Revascularization
Class I
1. CABG to improve survival is recommended for
patients with significant (>50% diameter stenosis)
left main coronary artery stenosis.73,381,412,959–962
(Level of Evidence: B)
Class IIa
1. PCI to improve survival is reasonable as an alterna-
tive to CABG in selected stable patients with signif-
icant (>50% diameter stenosis) unprotected left
main CAD with: 1) anatomic conditions associated
with a low risk of PCI procedural complications and
a high likelihood of good long-term outcome (eg, a
low SYNTAX score [<22], ostial or trunk left main
CAD); and 2) clinical characteristics that predict a
significantly increased risk of adverse surgical out-
comes (eg, STS-predicted risk of operative mortality
>5%).949,953,955,958,963–979 (Level of Evidence: B)
2. PCI to improve survival is reasonable in patients
with UA/NSTEMI when an unprotected left main
coronary artery is the culprit lesion and the patient
is not a candidate for CABG.949,968–971,976–979,981
(Level of Evidence: B)
3. PCI to improve survival is reasonable in patients
with acute STEMI when an unprotected left main
coronary artery is the culprit lesion, distal coronary
flow is less than TIMI (Thrombolysis In Myocardial
Infarction) grade 3, and PCI can be performed more
rapidly and safely than CABG.965,982,983 (Level of
Evidence: C)
Class IIb
1. PCI to improve survival may be reasonable as an
alternative to CABG in selected stable patients with
significant (>50% diameter stenosis) unprotected
left main CAD with: a) anatomic conditions associ-
ated with a low to intermediate risk of PCI proce-
dural complications and an intermediate to high
likelihood of good long-term outcome (eg, low–
intermediate SYNTAX score of <33, bifurcation left
main CAD); and b) clinical characteristics that
predict an increased risk of adverse surgical out-
comes (eg, moderate–severe chronic obstructive pul-
monary disease, disability from previous stroke, or
previous cardiac surgery; STS-predicted risk
of operative mortality >2%).949,953,955,958,963–979,984
(Level of Evidence: B)
Class III: Harm
1. PCI to improve survival should not be performed in
stable patients with significant (>50% diameter
stenosis) unprotected left main CAD who have un-
favorable anatomy for PCI and who are good can-
didates for CABG.73,381,412,949,953,955,959–964 (Level of
Evidence: B)
Non–Left Main CAD Revascularization
Class I
1. CABG to improve survival is beneficial in patients
with significant (>70% diameter) stenoses in 3
major coronary arteries (with or without involve-
ment of the proximal LAD artery) or in the proximal
LAD artery plus 1 other major coronary ar-
tery.353,412,959,985–987 (Level of Evidence: B)
2. CABG or PCI to improve survival is beneficial in
survivors of sudden cardiac death with presumed
ischemia-mediated ventricular tachycardia caused
by significant (>70% diameter) stenosis in a major
coronary artery. (CABG Level of Evidence:
B350,1003,1004; PCI Level of Evidence: C1003)
Class IIa
1. CABG to improve survival is reasonable in patients
with significant (>70% diameter) stenoses in 2
major coronary arteries with severe or extensive
myocardial ischemia (eg, high-risk criteria on stress
testing, abnormal intracoronary hemodynamic eval-
uation, or >20% perfusion defect by myocardial
perfusion stress imaging) or target vessels supplying
a large area of viable myocardium.327,990–992 (Level of
Evidence: B)
2. CABG to improve survival is reasonable in patients
with mild–moderate LV systolic dysfunction (EF 35% to
50%) and significant (>70% diameter stenosis) multives-
sel CAD or proximal LAD coronary artery stenosis, when
viable myocardium is present in the region of intended
revascularization.365,412,999–1002 (Level of Evidence: B)
3. CABG with a left internal mammary artery (LIMA)
graft to improve survival is reasonable in patients
with significant (>70% diameter) stenosis in the
proximal LAD artery and evidence of extensive
ischemia.412,987,993,994 (Level of Evidence: B)
4. It is reasonable to choose CABG over PCI to im-
prove survival in patients with complex 3-vessel
CAD (eg, SYNTAX score >22), with or without
involvement of the proximal LAD artery who are
good candidates for CABG.964,980,987–989 (Level of
Evidence: B)
5. CABG is probably recommended in preference
to PCI to improve survival in patients with multi-
vessel CAD and diabetes mellitus, particularly if a
LIMA graft can be anastomosed to the LAD
artery.991,1005–1008,1008–1011 (Level of Evidence: B)
Class IIb
1. The usefulness of CABG to improve survival is
uncertain in patients with significant (70%) diame-
ter stenoses in 2 major coronary arteries not involv-
ing the proximal LAD artery and without extensive
ischemia.987 (Level of Evidence: C)
2. The usefulness of PCI to improve survival is uncer-
tain in patients with 2- or 3-vessel CAD (with or
without involvement of the proximal LAD artery) or
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1-vessel proximal LAD disease.366,959,985,987 (Level of
Evidence: B)
3. CABG might be considered with the primary or sole
intent of improving survival in patients with SIHD
with severe LV systolic dysfunction (EF <35%)
whether or not viable myocardium is pres-
ent.355,365,410,412,999–1002 (Level of Evidence: B)
4. The usefulness of CABG or PCI to improve survival
is uncertain in patients with previous CABG and
extensive anterior wall ischemia on noninvasive test-
ing.1021–1025,1029–1032 (Level of Evidence: B)
Class III: Harm
1. CABG or PCI should not be performed with the
primary or sole intent to improve survival in pa-
tients with SIHD with 1 or more coronary stenoses
that are not anatomically or functionally significant
(eg, <70% diameter non–left main coronary artery
stenosis, FFR >0.80, no or only mild ischemia on
noninvasive testing), involve only the left circumflex
or right coronary artery, or subtend only a small
area of viable myocardium.306,327,412,985,990,995–998
(Level of Evidence: B)
5.3. Revascularization to Improve
Symptoms: Recommendations
Class I
1. CABG or PCI to improve symptoms is beneficial in
patients with 1 or more significant (>70% diameter)
coronary artery stenoses amenable to revascularization
and unacceptable angina despite GDMT.366,407,1012–
1018,1020,1033 (Level of Evidence: A)
Class IIa
1. CABG or PCI to improve symptoms is reasonable in
patients with 1 or more significant (>70% diameter)
coronary artery stenoses and unacceptable angina
for whom GDMT cannot be implemented because of
medication contraindications, adverse effects, or pa-
tient preferences. (Level of Evidence: C)
2. PCI to improve symptoms is reasonable in
patients with previous CABG, 1 or more significant
(>70% diameter) coronary artery stenoses associ-
ated with ischemia, and unacceptable angina despite
GDMT.1021,1023,1024 (Level of Evidence: C)
3. It is reasonable to choose CABG over PCI to im-
prove symptoms in patients with complex 3-vessel
CAD (eg, SYNTAX score >22), with or without
involvement of the proximal LAD artery, who are
good candidates for CABG.964,980,987–989 (Level of
Evidence: B)
Class IIb
1. CABG to improve symptoms might be reasonable
for patients with previous CABG, 1 or more signif-
icant (>70% diameter) coronary artery stenoses not
amenable to PCI, and unacceptable angina despite
GDMT.1025 (Level of Evidence: C)
2. TMR performed as an adjunct to CABG to improve
symptoms may be reasonable in patients with viable
ischemic myocardium that is perfused by arteries
that are not amenable to grafting.923,927,929,1026,1027
(Level of Evidence: B)
Class III: Harm
1. CABG or PCI to improve symptoms should not be
performed in patients who do not meet anatomic
(>50% diameter left main or >70% non–left main
stenosis diameter) or physiological (eg, abnormal
FFR) criteria for revascularization. (Level of
Evidence: C)
5.4. CABG Versus Contemporaneous
Medical Therapy
In the 1970s and 1980s, 3 RCTs established the survival
benefit of CABG compared with contemporaneous (although
minimal by current standards) medical therapy without revas-
cularization in certain subjects with stable angina: the Veter-
ans Affairs Cooperative Study,1035 European Coronary
Surgery Study,986 and CASS.1036 Subsequently, a 1994 meta-
analysis of 7 studies that randomized a total of 2649 patients
to medical therapy or CABG412 showed that CABG offered a
survival advantage over medical therapy for patients with left
main or 3-vessel CAD. The studies also established that
CABG is more effective than medical therapy for relieving
anginal symptoms. These studies have been replicated only
once during the past decade. In MASS II (Medicine, Angio-
plasty, or Surgery Study II), patients with multivessel CAD
who were treated with CABG were less likely than those
treated with medical therapy to have a subsequent MI, need
additional revascularization, or experience cardiac death in
the 10 years after randomization.1016
Surgical techniques and medical therapy have improved
substantially during the intervening years. As a result, if
CABG were to be compared with GDMT in RCTs today, the
relative benefits for survival and angina relief observed
several decades ago might no longer be observed. Con-
versely, the concurrent administration of GDMT may sub-
stantially improve long-term outcomes in patients treated
with CABG in comparison with those receiving medical
therapy alone. In the BARI 2D (Bypass Angioplasty Revas-
cularization Investigation 2 Diabetes) trial of patients with
diabetes mellitus, no significant difference in risk of mortality
in the cohort of patients randomized to GDMT plus CABG or
GDMT alone was observed, although the study was not
powered for this endpoint, excluded patients with significant
left main CAD, and included only a small percentage of
patients with proximal LAD artery disease or LVEF ,0.50
(408). The PCI and CABG guideline writing committees
endorse the performance of the ISCHEMIA trial, which will
provide contemporary data on the optimal management strat-
egy (medical therapy or revascularization with CABG or
PCI) of patients with SIHD, including multivessel CAD, and
moderate to severe ischemia.
5.5. PCI Versus Medical Therapy
Although contemporary interventional treatments have low-
ered the risk of restenosis compared with earlier techniques,
meta-analyses have not shown that the introduction of bare
metal stents (BMS) confers a survival advantage over balloon
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angioplasty1037–1039 or that the use of DES confers a survival
advantage over BMS.138,1040
No study to date has demonstrated that PCI in patients with
SIHD improves survival rates.138,366,408,959,985,987,1041–1044 Nei-
ther COURAGE366 nor BARI 2D,408 which treated all pa-
tients with contemporary optimal medical therapy, demon-
strated any survival advantage with PCI, although these trials
were not specifically powered for this endpoint. Although 1
large analysis evaluating 17 RCTs of PCI versus medical
therapy (including 5 trials of subjects with ACS) found a 20%
reduction in death with PCI compared with medical ther-
apy,1043 2 other large analyses did not.138,1042 An evaluation of
13 studies reporting the data from 5442 patients with non-
acute CAD showed no advantage of PCI over medical
therapy for the individual endpoints of all-cause death,
cardiac death or MI, or nonfatal MI.1044 Evaluation of 61
trials of PCI conducted over several decades shows that
despite improvements in PCI technology and pharmacother-
apy, PCI has not been demonstrated to reduce the risk of
death or MI in patients without recent ACS.138
The findings from individual studies and systematic re-
views of PCI versus medical therapy can be summarized as
follows:
● PCI reduces the incidence of angina.366,407,1016,1020,1033,1045
● PCI has not been demonstrated to improve survival in
stable patients.138,1041,1042
● PCI may increase the short-term risk of MI.366,397,1041,1045
● PCI does not lower the long-term risk of
MI.138,366,397,408,1041,1042
5.6. CABG Versus PCI
The results of 26 RCTs comparing CABG and PCI have been
published: Of these, 9 compared CABG with balloon angio-
plasty,30,368,1017,1046–1059 14 compared CABG with BMS im-
plantation,1022,1054,1060–1076 and 3 compared CABG with DES
implantation.950,1077,1078
5.6.1. CABG Versus Balloon Angioplasty or BMS
A systematic review of the 22 RCTs comparing CABG with
balloon angioplasty or BMS implantation concluded the
following1079:
1. Survival was similar for CABG and PCI (with balloon
angioplasty or BMS) at 1 year and 5 years. Survival was
similar for CABG and PCI in subjects with 1-vessel
CAD (including those with disease of the proximal
portion of the LAD artery) or multivessel CAD.
2. Incidence of MI was similar at 5 years after
randomization.
3. Procedural stroke occurred more commonly with
CABG than with PCI (1.2% versus 0.6%).
4. Relief of angina was accomplished more effectively
with CABG than with PCI 1 year after randomization
and 5 years after randomization.
5. During the first year after randomization, repeat coro-
nary revascularization was performed less often after
CABG than after PCI (3.8% versus 26.5%). This was
also demonstrated after 5 years of follow-up (9.8%
versus 46.1%). This difference was more pronounced
with balloon angioplasty than with BMS.
A collaborative analysis of data from 10 RCTs comparing
CABG with balloon angioplasty (6 trials) or with BMS
implantation (4 trials)1080 permitted subgroup analyses of the
data from the 7812 patients. No difference was noted with
regard to mortality rate 5.9 years after randomization or the
composite endpoint of death or MI. Repeat revascularization
and angina were noted more frequently in those treated with
balloon angioplasty or BMS implantation.1080 The major new
observation of this analysis was that CABG was associated
with better outcomes in patients with diabetes mellitus and in
those .65 years of age. Of interest, the relative outcomes of
CABG and PCI were not influenced by other patient charac-
teristics, including the number of diseased coronary arteries.
The aforementioned meta-analysis and systematic re-
view1079,1080 comparing CABG and balloon angioplasty or
BMS implantation were limited in several ways:
1. Many trials did not report outcomes for other important
patient subsets. For example, the available data are
insufficient to determine if race, obesity, renal dysfunc-
tion, PAD, or previous coronary revascularization af-
fected the comparative outcomes of CABG and PCI.
2. Most of the patients enrolled in these trials were male,
and most had 1- or 2-vessel CAD and normal LV
systolic function (EF .50%)—subjects known to be
unlikely to derive a survival benefit and less likely to
experience complications after CABG.412
3. The patients enrolled in these trials represented only a
small fraction (generally ,5% to 10%) of those who
were screened. For example, most screened patients
with 1-vessel CAD and many with 3-vessel CAD were
not considered for randomization.
See Online Data Supplements 5 and 6 for additional data on
CABG versus PCI.
5.6.2. CABG Versus DES
Although the results of 9 observational studies comparing
CABG and DES implantation have been published,964,1081–1088
most of them had short (12 to 24 months) follow-up periods. In
a meta-analysis of 24 268 patients with multivessel CAD
treated with CABG or DES,1089 the incidences of death and
MI were similar for the 2 procedures, but the frequency with
which repeat revascularization was performed was roughly 4
times higher after DES implantation. Only 1 large RCT
comparing CABG and DES implantation has been published.
The SYNTAX trial randomly assigned 1800 patients (of a
total of 4337 who were screened) to receive DES or
CABG.949,950,980 MACE, a composite of death, stroke, MI, or
repeat revascularization during the 3 years after randomiza-
tion, occurred in 20.2% of CABG patients and 28.0% of those
undergoing DES implantation (P,0.001). The rates of death
and stroke were similar; however, MI (3.6% for CABG, 7.1%
for DES) and repeat revascularization (10.7% for CABG,
19.7% for DES) were more likely to occur with DES
implantation.980
In SYNTAX, the extent of CAD was assessed by using the
SYNTAX score, which is based on the location, severity, and
extent of coronary stenoses, with a low score indicating less
complicated anatomic CAD. In post hoc analyses, a low score
was defined as #22; intermediate, 23 to 32; and high, $33.
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The occurrence of MACE correlated with the SYNTAX score
for DES patients but not for those undergoing CABG. At
12-month follow-up, the primary endpoint was similar for
CABG and DES in those with a low SYNTAX score. In
contrast, MACE occurred more often after DES implantation
than after CABG in those with an intermediate or high
SYNTAX score.950 At 3 years of follow-up, the mortality
rate was greater in subjects with 3-vessel CAD treated with
PCI than in those treated with CABG (6.2% versus 2.9%).
The differences in MACE between those treated with PCI
or CABG increased with an increasing SYNTAX score
(Figure 12).980
Although the utility of using a SYNTAX score in everyday
clinical practice remains uncertain, it seems reasonable to
conclude from SYNTAX and other data that outcomes of
patients undergoing PCI or CABG in those with relatively
uncomplicated and lesser degrees of CAD are comparable,
whereas in those with complex and diffuse CAD, CABG
appears to be preferable.949,980
See Online Data Supplements 6 and 7 for additional data
comparing CABG with DES.
5.7. Left Main CAD
5.7.1. CABG or PCI Versus Medical Therapy for Left
Main CAD
CABG confers a survival benefit over medical therapy in
patients with left main CAD. Subgroup analyses from RCTs
performed 3 decades ago included 91 patients with left main
CAD in the Veterans Administration Cooperative Study.961 A
meta-analysis of these trials demonstrated a 66% reduction in
RR of death with CABG, with the benefit extending to 10
years.412 The CASS Registry381 contained data from 1484
patients with $50% diameter stenosis left main CAD initially
treated surgically or nonsurgically. Median survival duration
was 13.3 years in the surgical group and 6.6 years in the
medical group. The survival benefit of CABG over medical
therapy appeared to extend to 53 asymptomatic patients with
left main CAD in the CASS Registry.962 Other therapies that
subsequently have been shown to be associated with im-
proved long-term outcome, such as the use of aspirin, statins,
and internal mammary artery grafting, were not widely used
in that era.
RCTs and subgroup analyses that compare PCI with
medical therapy in patients with “unprotected” left main
CAD do not exist.
5.7.2. Studies Comparing PCI Versus CABG for Left
Main CAD
Of all subjects undergoing coronary angiography, approxi-
mately 4% are found to have left main CAD,1090 .80% of
whom have significant ($70% diameter) stenoses in other
epicardial coronary arteries.
Published cohort studies have found that major clinical
outcomes are similar with PCI or CABG 1 year after
revascularization and that mortality rates are similar at 1, 2,
and 5 years of follow-up; however, the risk of needing
target-vessel revascularization is significantly higher with
stenting than with CABG.
In the SYNTAX trial, 45% of screened patients with
unprotected left main CAD had complex disease that pre-
vented randomization; 89% of these underwent CABG.949,950
In addition, 705 of the 1800 patients who were randomized
had revascularization for unprotected left main CAD. The
majority of patients with left main CAD and a low SYNTAX
score had isolated left main CAD or left main CAD plus
1-vessel CAD; the majority of those with an intermediate
score had left main CAD plus 2-vessel CAD; and most of
those with a high SYNTAX score had left main CAD plus
3-vessel CAD. At 1 year, rates of all-cause death and MACE
were similar for the 2 groups.949 Repeat revascularization
rates were higher in the PCI group than the CABG group
(11.8% versus 6.5%), but stroke occurred more often in the
CABG group (2.7% versus 0.3%). At 3 years of follow-up,
the incidence of death in those undergoing left main CAD
revascularization with low or intermediate SYNTAX scores
(#32) was 3.7% after PCI and 9.1% after CABG (P50.03),
whereas in those with a high SYNTAX score ($33), the
incidence of death after 3 years was 13.4% after PCI and
7.6% after CABG (P50.10).949 Because the primary endpoint
of SYNTAX was not met (ie, noninferiority comparison of
CABG and PCI), these subgroup analyses need to be consid-
ered in that context.
In the LE MANS (Study of Unprotected Left Main
Stenting Versus Bypass Surgery) trial,958 105 patients with
left main CAD were randomized to receive PCI or CABG.
Although a low proportion of patients treated with PCI
received DES (35%) and a low proportion of patients treated
with CABG received internal mammary grafts (72%), the
outcomes at 30 days and 1 year were similar between the
groups. In the PRECOMBAT (Premier of Randomized Com-
parison of Bypass Surgery versus Angioplasty Using
Sirolimus-Eluting Stent in Patients with Left Main Coronary
Artery Disease) trial of 600 patients with left main disease,
the composite endpoint of death, MI, or stroke at 2 years
occurred in 4.4% of patients treated with PCI and 4.7% of
patients treated with CABG, but ischemia-driven target-
vessel revascularization was more often required in the
patients treated with PCI (9.0% versus 4.2%).984
The results from these 3 RCTs suggest (but do not
definitively prove) that major clinical outcomes in selected
patients with left main CAD are similar with CABG and PCI
at 1- to 2-year follow-up, but repeat revascularization rates
are higher after PCI than after CABG. RCTs with extended
follow-up of $5 years are required to provide definitive
conclusions about the optimal treatment of left main CAD. In
a meta-analysis of 8 cohort studies and 2 RCTs,973 death, MI,
and stroke occurred with similar frequency in the PCI- and
CABG-treated patients at 1, 2, and 3 years of follow-up.
Target-vessel revascularization was performed more often in
the PCI group at 1 year (OR: 4.36), 2 years (OR: 4.20), and
3 years (OR: 3.30).
See Online Data Supplements 8 to 13 for additional data
comparing PCI with CABG for left main CAD.
5.7.3. Revascularization Considerations for Left
Main CAD
Although CABG has been considered the “gold standard” for
unprotected left main CAD revascularization, more recently
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PCI has emerged as a possible alternative mode of revascu-
larization in carefully selected patients. Lesion location is an
important determinant when PCI is considered for unpro-
tected left main CAD. Stenting of the left main ostium or
trunk is more straightforward than treating distal bifurcation
or trifurcation stenoses, which generally requires a greater
degree of operator experience and expertise.1091 In addition,
PCI of bifurcation disease is associated with higher restenosis
rates than when disease is confined to the ostium or
trunk.971,1092 Although lesion location influences technical
success and long-term outcomes after PCI, location exerts a
negligible influence on the success of CABG. In subgroup
analyses, patients with left main CAD and a SYNTAX score
$33 with more complex or extensive CAD had a higher
mortality rate with PCI than with CABG.949 Physicians can
estimate operative risk for all CABG candidates by using a
standard instrument, such as the risk calculator from the STS
database. The above considerations are important factors
when choosing among revascularization strategies for unpro-
tected left main CAD and have been factored into revascu-
larization recommendations. Use of a Heart Team approach
has been recommended in cases in which the choice of
revascularization is not straightforward. As discussed in
Section 5.9.5., the ability of the patient to tolerate and comply
with DAPT is also an important consideration in revascular-
ization decisions.
The 2005 PCI guideline987 recommended routine angio-
graphic follow-up 2 to 6 months after stenting for unprotected
left main CAD. However, because angiography has limited
ability to predict stent thrombosis and the results of SYNTAX
suggest good intermediate-term results for PCI in subjects
with left main CAD, this recommendation was removed in
the 2009 STEMI/PCI focused update.3
Experts have recommended immediate PCI for unprotected
left main CAD in the setting of STEMI.983 The impetus for
such a strategy is greatest when left main CAD is the site of
the culprit lesion, antegrade coronary flow is diminished (eg,
TIMI flow grade 0, 1, or 2), the patient is hemodynamically
unstable, and it is believed that PCI can be performed more
quickly than CABG. When possible, the interventional car-
diologist and cardiac surgeon should decide together on the
optimal form of revascularization for these subjects, although
it is recognized that these patients are usually critically ill and
therefore not amenable to a prolonged deliberation or discus-
sion of treatment options.
5.8. Proximal LAD Artery Disease
A cohort study985 and a meta-analysis412 from the 1990s
suggested that CABG confers a survival advantage over
contemporaneous medical therapy for patients with disease in
the proximal segment of the LAD artery. Cohort studies and
RCTs412,1050,1062,1063,1065,1077,1093–1095 as well as collaborative
analyses and meta-analyses1080,1096–1098 showed that PCI and
CABG result in similar survival rates in these patients.
See Online Data Supplements 6 and 14 for additional data
on proximal LAD artery disease.
5.9. Clinical Factors That May Influence the
Choice of Revascularization
5.9.1. Completeness of Revascularization
Most patients undergoing CABG receive complete or nearly
complete revascularization, which seems to influence long-
term prognosis positively.1099 In contrast, complete revascu-
larization is accomplished less often in subjects receiving PCI
(eg, in ,70% of patients), and the extent to which the absence
of complete initial revascularization influences outcome is
less clear. Rates of late survival and survival free of MI
appear to be similar in patients with and without complete
revascularization after PCI. Nevertheless, the need for subse-
quent CABG is usually higher in those whose initial revas-
cularization procedure was incomplete (compared with those
with complete revascularization) after PCI.1100–1102
5.9.2. LV Systolic Dysfunction
Several older studies and a meta-analysis of the data from
these studies reported that patients with LV systolic dysfunc-
tion (predominantly mild to moderate in severity) had
better survival with CABG than with medical therapy
alone.365,412,999–1002 For patients with more severe LV systolic
dysfunction, however, the evidence that CABG results in
better survival compared with medical therapy is lacking. In
the STICH trial of subjects with LVEF ,35% with or without
viability testing, CABG and GDMT resulted in similar rates
of survival (death from any cause, the study’s primary
outcome) after 5 years of follow-up. For several secondary
outcomes at this time point, including 1) death from any
cause or hospitalization for heart failure, 2) death from any
cause or hospitalization for cardiovascular causes, 3) death
from any cause or hospitalization for any cause, or 4) death
from any cause or revascularization with PCI or CABG,
CABG was superior to GDMT. Although the primary out-
come (death from any cause) was similar in the 2 treatment
groups after an average of 5 years of follow-up, the data
suggest the possibility that outcomes would differ if the
follow-up were longer in duration; as a result, the study is
being continued to provide follow-up for up to 10 years.355,410
Only very limited data comparing PCI with medical
therapy in patients with LV systolic dysfunction are avail-
able.1002 In several ways, these data are suboptimal, in that
many studies compared CABG with balloon angioplasty,
many were retrospective, and many were based on cohort or
registry data. Some of the studies demonstrated a similar
survival rate in patients having CABG and PCI,988,1080,1103–1105
whereas others showed that those undergoing CABG had better
outcomes.964 The data that exist at present on revascularization
in patients with CAD and LV systolic dysfunction are more
robust for CABG than for PCI, although data from contempo-
rary RCTs in this patient population are lacking. Therefore, the
choice of revascularization in patients with CAD and LV
systolic dysfunction is best based on clinical variables (eg,
coronary anatomy, presence of diabetes mellitus, presence of
CKD), magnitude of LV systolic dysfunction, patient prefer-
ences, clinical judgment, and consultation between the interven-
tional cardiologist and the cardiac surgeon.
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5.9.3. Previous CABG
In patients with recurrent angina after CABG, repeat revas-
cularization is most likely to improve survival in subjects at
highest risk, such as those with obstruction of the proximal
LAD artery and extensive anterior ischemia.1021–1025,1029–1032
Patients with ischemia in other locations and those with a
patent LIMA to the LAD artery are unlikely to experience a
survival benefit from repeat revascularization.1023
Cohort studies comparing PCI and CABG among post-
CABG patients report similar rates of mid- and long-term
survival after the 2 procedures.1022,1024,1025,1029,1031,1032,1106 In
the patient with previous CABG who is referred for revascu-
larization for medically refractory ischemia, factors that may
support the choice of repeat CABG include vessels unsuitable
for PCI, number of diseased bypass grafts, availability of the
internal mammary artery for grafting chronically occluded
coronary arteries, and good distal targets for bypass graft
placement. Factors favoring PCI over CABG include limited
areas of ischemia causing symptoms, suitable PCI targets, a
patent graft to the LAD artery, poor CABG targets, and
comorbid conditions.
5.9.4. Unstable Angina/Non–ST-Elevation
Myocardial Infarction
The main difference between management of the patient with
SIHD and the patient with UA/NSTEMI is that the impetus
for revascularization is stronger in the setting of UA/
NSTEMI, because myocardial ischemia occurring as part of
an ACS is potentially life threatening, and associated anginal
symptoms are more likely to be reduced with a revascular-
ization procedure than with GDMT.1107–1109 Thus, the indi-
cations for revascularization are strengthened by the acuity of
presentation, the extent of ischemia, and the ability to achieve
full revascularization. The choice of revascularization method
is generally dictated by the same considerations used to
decide on PCI or CABG for patients with SIHD.
5.9.5. DAPT Compliance and Stent
Thrombosis: Recommendation
Class III: Harm
1. PCI with coronary stenting (BMS or DES) should
not be performed if the patient is not likely to be able
to tolerate and comply with DAPT for the appropri-
ate duration of treatment based on the type of stent
implanted.1110–1113 (Level of Evidence: B)
The risk of stent thrombosis is increased dramatically in
patients who prematurely discontinue DAPT, and stent
thrombosis is associated with a mortality rate of 20% to
45%.1110 Because the risk of stent thrombosis with BMS is
greatest in the first 14 to 30 days, this is the generally
recommended minimum duration of DAPT therapy for these
individuals. Consensus in clinical practice is to treat DES
patients for $12 months with DAPT to avoid late (after 30
days) stent thrombosis.1110,1114 Therefore, the ability of the
patient to tolerate and comply with $30 days of DAPT with
BMS treatment and $12 months of DAPT with DES treat-
ment is an important consideration in deciding whether to use
PCI to treat patients with CAD.
5.10. Transmyocardial Revascularization
A single randomized multicenter comparison of TMR (with a
holmium:YAG laser) plus CABG and CABG alone in pa-
tients in whom some myocardial segments were perfused by
arteries considered not amenable to grafting1026 showed a
significant reduction in perioperative mortality rate (1.5%
versus 7.6%, respectively), and the survival benefit of the
TMR–CABG combination was present after 1 year of follow-
up.1026 At the same time, a large retrospective analysis of data
from the STS National Cardiac Database, as well as a study
of 169 patients from the Washington Hospital Center who
underwent combined TMR–CABG, showed no difference in
adjusted mortality rate compared with CABG alone.1027,1115
In short, a TMR–CABG combination does not appear to
improve survival compared with CABG alone. In selected
patients, however, such a combination may be superior to
CABG alone in relieving angina.
5.11. Hybrid Coronary
Revascularization: Recommendations
Class IIa
1. Hybrid coronary revascularization (defined as the
planned combination of LIMA-to-LAD artery graft-
ing and PCI of >1 non-LAD coronary arteries) is
reasonable in patients with 1 or more of the follow-
ing1116–1122 (Level of Evidence: B):
a. Limitations to traditional CABG, such as heavily
calcified proximal aorta or poor target vessels for
CABG (but amenable to PCI);
b. Lack of suitable graft conduits;
c. Unfavorable LAD artery for PCI (ie, excessive
vessel tortuosity or chronic total occlusion).
Class IIb
1. Hybrid coronary revascularization (defined as the
planned combination of LIMA-to-LAD artery
grafting and PCI of >1 non-LAD coronary arter-
ies) may be reasonable as an alternative to multi-
vessel PCI or CABG in an attempt to improve the
overall risk– benefit ratio of the procedures. (Level
of Evidence: C)
Hybrid coronary revascularization, defined as the planned
combination of LIMA-to-LAD artery grafting and PCI of $1
non-LAD coronary arteries,1123 is intended to combine the
advantages of CABG (ie, durability of the LIMA graft) and
PCI.1124 Patients with multivessel CAD (eg, LAD and $1
non-LAD stenoses) and an indication for revascularization
are potentially eligible for this approach. Hybrid revascular-
ization is ideal in subjects in whom technical or anatomic
limitations to CABG or PCI alone may be present and for
whom minimizing the invasiveness (and therefore the risk of
morbidity and mortality) of surgical intervention is pre-
ferred1118 (eg, patients with severe preexisting comorbidities,
recent MI, a lack of suitable graft conduits, a heavily calcified
ascending aorta, or a non-LAD coronary artery unsuitable for
bypass but amenable to PCI, and situations in which PCI of
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the LAD artery is not feasible because of excessive tortuosity
or chronic total occlusions).
Hybrid coronary revascularization may be performed in a
hybrid suite in one operative setting or as a staged procedure
(ie, PCI and CABG performed in 2 different operative suites,
separated by hours to 2 days, but typically during the same
hospital stay). Because most hospitals lack a hybrid operating
room, staged procedures are usually performed. With the
staged procedure, CABG before PCI is preferred, because
this approach allows the interventional cardiologist to 1)
verify the patency of the LIMA-to-LAD artery graft before
attempting PCI of other vessels and 2) minimize the risk of
perioperative bleeding that would occur if CABG were
performed after PCI (ie, while the patient is receiving DAPT).
Because minimally invasive CABG may be associated with
lower graft patency rates compared with CABG performed
through a midline sternotomy, it seems prudent to angio-
graphically image all grafts performed through a minimally
invasive approach to confirm graft patency.1118
To date, no RCTs involving hybrid coronary revascular-
ization have been published. Over the past 10 years, several
small, retrospective series of hybrid revascularization using
minimally invasive CABG and PCI have reported low mor-
tality rates (0% to 2%) and event-free survival rates of 83%
to 92% at 6 to 12 months of follow-up. The few series that
have compared the outcomes of hybrid coronary revascular-
ization with standard CABG report similar outcomes at 30
days and 6 months.1116–1122
5.12. Special Considerations
In addition to patients’ coronary anatomy and LV function
and whether they have undergone prior revascularization,
clinical features such as the existence of coexisting chronic
conditions might influence decision making. However, the
paucity of information about special subgroups represents
one of the greatest challenges in developing evidence-based
guidelines applicable to large populations. As is the case for
many chronic conditions, studies specifically geared toward
answering clinical questions about the management of SIHD
in women, older adults, and individuals with diabetes mellitus
or CKD are lacking. Moreover, clinicians are often guided by
misconceptions and biases that serve to deprive patients of
potentially beneficial therapies. ACCF/AHA guidelines for
the management of patients with UA/NSTEMI4,4a address
special subgroups by recommending that diagnostic, pharma-
cological and revascularization strategies be congruent with
those in men, the young, and those without diabetes mellitus.
This section echoes those management recommendations.
Although this section will briefly review some special con-
siderations in diagnosis and therapy in certain groups of
patients, the general approach should be to apply the recom-
mendations in this guideline consistently among groups.
5.12.1. Women
Women generally have a lower incidence of SIHD than men
until older age, but their outcomes after MI are worse.1125
Microvascular disease, typically with preserved LV function,
is more common among women, particularly those who are
younger, whereas obstructive epicardial CAD is less preva-
lent. Up to 50% of women with typical or atypical anginal
symptoms undergoing cardiac catheterization are found not to
have obstructive CAD.1126,1127 Contrary to earlier percep-
tions, the prognosis of women with chest pain and nonob-
structive disease is not necessarily better.1128,1129 As women
age, the prevalence of obstructive CAD increases.
Stable angina is the most frequent initial manifestation of
SIHD in women, as opposed to AMI and sudden death in
men.35,1130 Atypical chest pain and angina-equivalent symp-
toms such as dyspnea are more common in women, although
women still present with similar patterns, duration, and
frequency of symptoms. The lower prevalence of obstructive
disease in conjunction with technical challenges makes the
interpretation of ischemia on imaging studies somewhat more
difficult. Accumulating evidence suggests that vascular reac-
tivity related to abnormalities in microvascular and endothe-
lial function and possibly plaque erosion or distal microem-
bolization contribute to ischemia to a greater extent in women
than in men.75
On exercise testing, ST-segment changes are less accurate
for the detection of CAD in women than in men,175 although
marked ST-segment changes (a visual interpretation $1 mm
of horizontal or downsloping ST-segment depression or
elevation for $60 to 80 ms after the end of the QRS complex)
remain diagnostic for all patients. Challenges with exercise
testing in women include their generally lower physical work
capacity and the high prevalence of obesity, diabetes mellitus,
frailty, and other comorbid conditions. Numerous re-
ports14,315,1131,1132 and an expert consensus statement175 have
examined the diagnostic accuracy of the exercise ECG and
various imaging modalities in large cohorts of women.
Overall, most reports document an improvement in diagnostic
accuracy with imaging when compared to a standard exercise
ECG,175 although that improvement does not necessarily
translate into improved clinical outcomes.147 From a meta-
analysis, the diagnostic sensitivity and specificity were 72%
and 88% for women undergoing dobutamine stress echocar-
diography.149 From a small controlled clinical trial, diagnostic
specificity was improved considerably when using gated
Tc-99m myocardial perfusion SPECT over Tl-201 myocar-
dial perfusion SPECT (92% versus 67%) because of im-
proved image quality.1133 Overall, sensitivity and specificity
of myocardial perfusion SPECT were reported as 88% and
96% for women.86,175,1134 For CMR, one study reported a
diagnostic sensitivity and specificity of 92% and 80%
with vasodilator stress magnetic resonance myocardial
perfusion.281
In part related to differing pathophysiology and clinical
presentation, substantial differences in provision of clinical
care have been observed between men and women with
CAD.1135 Despite increasing recognition of the risks of
worsening IHD and attendant complications in women, the
frequency with which they are prescribed important risk-
modifying therapies such as statins, aspirin, and beta blockers
after episodes of ACS remains significantly lower than
among men.1136,1137 Among patients with documented SIHD,
however, the differences between men and women appear to
be much smaller with regard to prescription of these
therapies.1138
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Data from COURAGE suggest that the benefits of GDMT
alone in comparison with GDMT plus PCI were similar for
men and women.366,1138 Moreover, the outcomes of revascu-
larization appear to be less favorable among women than
men,1139–1142 although very few women were enrolled in
COURAGE. In various risk models, the odds of in-hospital
death after PCI have ranged from 25% to 80% higher for
women than for men,1143–1147 although this trend might have
improved in recent years after the higher incidence of
diabetes mellitus and hypertension in women is taken into
account.1148 The risk of procedural complications also ap-
pears to be significantly higher in women.1149 Although fewer
data on the experience of women after CABG are available,
in the New York State registry, the odds of in-hospital death
for women were 2-fold higher than for men.1149,1150 On the
basis of these observations, the initial approach to therapy for
women with SIHD should be to prescribe a full regimen of
GDMT and to reserve consideration of revascularization for
patients who do not obtain a satisfactory response or who
experience unacceptable adverse effects. On the basis of the
higher risk associated with PCI in women, it might be
reasonable to adopt a more conservative approach in under-
taking this procedure than in men, although the general
principle of using revascularization in patients whose symp-
toms are refractory to medical therapy and who are not
satisfied with their current level of angina persists.
5.12.2. Older Adults
In older adults, often defined as .75 years of age, coronary
stenoses are likely to be more diffuse and more severe, with
a higher prevalence of 3-vessel and left main disease. Several
factors complicate the diagnosis and treatment of SIHD in
this age group. Common coexisting conditions of the pulmo-
nary, gastrointestinal, and musculoskeletal systems can cause
chest pain, making diagnosis more difficult, even in patients
with documented IHD. Physiological changes in older adults,
including alterations in cardiac output through various mech-
anisms, muscle loss and deconditioning, neuropathies, lung
disease, and degenerative joint disease, make stress testing
more difficult. Thus, many elderly patients are incapable of
responding to graded increases in workload as required by
standard exercise ECG protocols.118,1151 For patients who are
unable to exercise, pharmacological stress imaging is indi-
cated. Although the majority of investigations have focused
on prognosis by markers of ischemia in the elderly, the results
generally reveal a similar accuracy of testing when compared
with younger individuals presenting with SIHD.1152–1155
Baseline ECG changes, arrhythmias, and LV hypertrophy,
which are more common in older adults who have accumu-
lated cardiac comorbidities, also limit the value of stress
testing.1156,1157 The higher prevalence of SIHD in older adults
results in more tests that are falsely negative, and the
prognostic value of the Duke treadmill score in older adults
might be limited.1158
Data based on RCTs to guide therapy in older adults are
relatively sparse because of the common exclusion of older
patients from early clinical trials. Several studies have shown
less frequent use of evidence-based therapies in older adults,
such as early invasive procedures, anticoagulants, beta block-
ers, and glycoprotein IIb/IIIa inhibitors.1156,1159,1160 The find-
ings are likely related to several factors. Pharmacotherapy is
more difficult in older adults because of changes in drug
bioavailability and elimination. Drug–drug interactions are
more common because of polypharmacy. A more conserva-
tive approach to coronary angiography is often appropriate
given the higher risk of contrast-induced nephropathy in older
adults.1161 Moreover, the risks of morbidity and mortality
associated with CABG are increased in older adults.
Despite the complexities and concerns related to evaluating
and treating elderly patients with SIHD, findings from the
COURAGE trial indicated that initial medical therapy was
not significantly less effective than medical therapy plus PCI
in relieving angina (73% in the GDMT group at 60 months,
versus 80% in the medical therapy–plus–PCI group).1162
Although the mortality rate was 50% higher among patients
.65 years of age than among younger patients, there were no
significant differences between the 2 treatment groups in
either patients younger or older than 65 years. Furthermore,
although the incidence of MI and stroke was also higher in
older patients, there were no significant differences between
treatment groups. In the TIME (Trial of Invasive versus
Medical Therapy in the Elderly) trial, 301 patients $75 years
of age with chronic angina with CCS Class II or higher
despite treatment with $2 antianginal drugs were randomized
to GDMT or to an invasive strategy of coronary angiography
followed by revascularization with PCI or CABG, if feasi-
ble.1163 Patients who were assigned to the early revascular-
ization group experienced greater improvement in symptoms
at 6 months. This difference disappeared by 12 months, at
which time both groups had shown a 2-class improvement in
their CCS scores and similar results on other quality-of-life
measures. It should be noted that 45% of the group assigned
to medical therapy ultimately underwent revascularization
because of refractory symptoms.
Considerable evidence indicates that elderly patients have
higher mortality following PCI and CABG than do younger
patients, and the risk appears to rise monotonically when .65
years of age.1144–1147,1164–1166 Compared with patients #65
years of age, adjusted odds of short-term mortality after PCI
among patients between the ages of 60 and 80 have ranged
from 2.2 to 7.6 in various registries, and the odds of death
among those $80 years have ranged from 2.7 to .13.
Unfortunately, far fewer data are available on the outcomes of
elderly patients undergoing CABG, and much of it could be
outdated. On the basis of data from 16 120 patients entered
into the New York State registry, the odds of in-hospital
mortality rose 8% per year of age .60 years (OR: 1.08; 95%
CI: 1.06 to 1.09).1150 On the other hand, in an analysis of 505
645 records from the registry maintained by the STS, age was
not found to be a predictor of mortality.1167 In older studies,
elderly patients were reported to have favorable results after
CABG,1168,1169 and long-term survival rates for elderly pa-
tients with SIHD treated medically versus surgically were
similar.406
Older adults constitute a growing proportion of patients
with SIHD. On the basis of the available data, it is recom-
mended that management by GDMT be the initial approach
in most patients. Given concerns about higher mortality rate,
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particularly in patients .75 or 80 years of age, decisions to
recommend revascularization should be undertaken only after
careful consideration of patient preferences, functional capac-
ity, quality-of-life and end-of-life issues, as well as therapeu-
tic alternatives.4,4a
5.12.3. Diabetes Mellitus
Type 1 and type 2 diabetes mellitus are associated with a
greater risk of SIHD, and the effects of other risk factors such
as hypercholesterolemia are magnified.1170 Cardiovascular
mortality rate is 3-fold higher in men with diabetes mellitus
and between 2- and 5-fold higher in women with diabetes
than in patients without diabetes mellitus.1171,1172 Sudden
cardiac death occurs more frequently in patients with diabetes
mellitus. Although direct evidence is lacking, asymptomatic
ischemia could be more prevalent in patients with diabetes
mellitus, possibly because of autonomic neuropathy.1173
The risk of death in a patient with SIHD and diabetes
mellitus has been equated to the risk of death in a patient with
SIHD and a previous MI.1171,1174 Aggressive management of
cardiovascular risk factors, including hypercholesterolemia,
hypertension, smoking, low physical activity, and obesity, is
essential, along with appropriate glycemic control.
Among patients with IHD, the presence of concomitant
diabetes mellitus increases the risk of adverse events, irre-
spective of whether the patient is treated medically or with
revascularization. Two studies have suggested that survival
among patients with diabetes mellitus is more favorable after
bypass surgery than with medical therapy, although these
results are based on subgroup analyses from observational
data.991,1175 Of 2 studies comparing PCI and medical therapy
in patients with diabetes mellitus, one reported longer sur-
vival,1175 but the other did not.991
A subgroup analysis of data from the BARI trial suggested
that patients with diabetes mellitus who underwent CABG
with 1 arterial conduit had improved survival compared with
those who underwent PCI.368 Several retrospective cohort
studies have compared outcomes among patients with diabe-
tes mellitus undergoing PCI versus CABG. Three observa-
tional studies have reported a survival advantage for CABG
over PCI, whereas a fourth found no significant difference,
and no studies located reported better outcomes after PCI.
In the BARI 2D study, 2368 patients with type 2 diabetes
mellitus and SIHD were initially selected as candidates for
either PCI or CABG on the basis of clinical and angiographic
assessment and then were randomly assigned to undergo
either prompt revascularization with intensive medical ther-
apy or intensive medical therapy alone and to undergo either
insulin-sensitization or insulin-provision therapy.408 The
study was not designed to compare PCI with CABG. At 5
years, overall survival was similar between the revasculariza-
tion and medical-therapy groups (88.3% versus 87.8%), as
was the incidence of MACE (77.2% versus 75.9%).409 Pa-
tients with the most severe CAD were assigned to the CABG
stratum and those with the least severe CAD to the PCI
stratum. In the PCI stratum, there was no significant differ-
ence in primary endpoints between the revascularization
group and the medical-therapy group. In the 763 patients
randomized to the CABG stratum, survival was similar but
AMI less frequent among those assigned to revascularization
plus intensive medical therapy compared with intensive
medical therapy (10.0% versus 17.6%; P50.003), and the
composite endpoints of all-cause death or MI (21.1% versus
29.2%; P50.010) and cardiac death or MI (P50.03) were
also less frequent. Compared with those selected for PCI,
patients in the CABG stratum had more 3-vessel disease
(20% versus 52%), more total occlusions (32% versus 61%),
more proximal LAD stenoses .50% (10% versus 19%), and
a significantly higher myocardial jeopardy score.409
One-year follow-up data from the SYNTAX study demon-
strated a higher rate of repeat revascularization in patients
with diabetes mellitus treated with PCI than in those treated
with CABG, driven by a tendency for higher repeat revascu-
larization rates in those with higher SYNTAX scores under-
going PCI.1006
A large meta-analysis that included the BARI trial but not
BARI 2D failed to identify any significant difference in
mortality rate after CABG versus PCI for patients with
diabetes mellitus.1079 In a more recent, collaborative analysis
that pooled patient-level data from 10 randomized trials
(again, not including BARI 2D), Hlatky and colleagues found
that of the 1233 patients with diabetes mellitus, 23% of those
assigned to CABG died, compared with 29% of those
assigned to PCI.1080 By contrast, of the 6561 patients without
diabetes mellitus, 13% and 14% died, respectively (P50.014
for interaction). The interaction between diabetes mellitus
and treatment remained highly significant after adjustment
for multiple patient characteristics and after exclusion of
patients enrolled in the BARI 2D trial.
Some evidence indicates that the presence of diabetes
mellitus adversely affects the outcomes of revascularization.
An analysis of the 2009 data on 7812 patients (1233 with
diabetes mellitus) in 10 RCTs demonstrated a worse long-
term survival rate in patients with diabetes mellitus after
balloon angioplasty or BMS implantation than after
CABG.1080 Analyses from 3 registries found significantly
elevated adjusted ORs for short-term mortality after PCI that
ranged from 1.25 to 1.54 in relation to patients without
diabetes mellitus.1144,1146,1165 Data from the STS registry
indicated that patients with diabetes mellitus on oral therapy
had an adjusted OR of 1.15 for death within 30 days (95% CI:
1.09 to 1.21), as well as significantly higher odds of stroke,
renal failure, or sternal wound infection than those of patients
without diabetes mellitus.1167 For patients on insulin, the
adjusted OR for death within 30 days was 1.50 (95% CI: 1.42
to 1.58), and the risks for other complications were also
correspondingly higher.
In summary, in subjects requiring revascularization for
multivessel CAD, current evidence supports diabetes mellitus
as an important factor to consider when deciding on a
revascularization strategy, particularly when complex or ex-
tensive CAD is present (Figure 14).
The basis of the currently available data, an intensive
approach to reducing cardiovascular risk and symptoms in
patients with diabetes mellitus by using GDMT should be the
initial approach. For patients whose symptoms are inade-
quately managed or who experience intolerable adverse
effects, revascularization should be considered. CABG might
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be associated with lower risk of mortality in patients with
diabetes mellitus and multivessel disease than PCI, but this
remains uncertain. The ongoing FREEDOM (Future Revas-
cularization Evaluation in patients with Diabetes mellitus:
Optimal management of Multivessel disease) trial could help
resolve this question.1177
5.12.4. Obesity
Obese individuals frequently have reduced physical work
capacity and exaggerated dyspnea on exertion. Furthermore,
weight limits of exercise and imaging equipment preclude
testing the very obese.1178,1179 Because of limitations in
exercise testing and challenges with imaging through in-
creased breast tissue or chest girth, reduced diagnostic accu-
racy has been reported for obese patients.1180 Because of
breast tissue artifact, myocardial perfusion PET is more
accurate than myocardial perfusion SPECT for the obese
patient,191,193,323 although attenuation-correction algorithms
or prone imaging can help improve myocardial perfusion
SPECT accuracy.187,188 Intravenous contrast enhancement
improves image quality in obese patients and results in
improved diagnostic certainty for stress echocardiography.181
5.12.5. Chronic Kidney Disease
CKD confers greater risk for developing SIHD, for its
progression, and for poor outcomes after interventions for
AMI.1181–1183 The mortality rate for patients on hemodialysis
is .20% per year, and approximately 50% of deaths among
these patients are due to a cardiovascular cause.27,1184 To
avoid worsening underlying kidney disease, physicians
should consider creatinine clearance in pharmacotherapy and
should apply risk scores for predicting the likelihood of
contrast-induced nephropathy1161,1185 in conjunction with the
use of renal protective strategies such as isosmolar contrast
agents during angiography.3,4,4a
Unfortunately, studies evaluating the outcomes of revascu-
larization in patients with renal disease have not applied a
consistent definition of renal disease. Only one study identi-
fied by the writing committee used the Kidney Disease
Outcome Quality Definition of renal disease grades: Stage 1,
creatinine clearance of 90 to 120 mL/min; Stage 2, 60 to 89
mL/min; Stage 3, 30 to 59 mL/min; Stage 4, 15 to 29
mL/min; and Stage 5, ,15 mL/min or ongoing dialysis
(1186). Others studies simply described patients as receiving
dialysis1187,1188 or defined renal disease as any creatinine
clearance ,60 mL/min1189,1190 or any serum creatinine above
approximately 2.3 mg/dL.1191,1192 Ongoing studies are begin-
ning to use the AKIN (Acute Kidney Injury Network) or
RIFLE (Risk, Injury, Failure, Loss, and End-stage) criteria
and should ensure more consistency in the study of peripro-
cedural complications of percutaneous revascularization.
Among patients who were enrolled in the COURAGE trial,
the presence of CKD was associated with odds of 1.48 for
death, MI, or new heart failure relative to patients without
kidney disease.1193 Medical therapy, however, was effective
and associated with the same BP and lipid levels as in patients
without CKD. Patients with CKD also experience significant
and sustained improvement in angina with both PCI and
GDMT, and there was no significant interaction between the
presence of CKD and treatment assignment in survival rate,
incidence of AMI, or improvement in symptoms.
To date, randomized comparisons of coronary revascular-
ization (with CABG or PCI) and medical therapy in patients
with CKD have not been reported. Some, but not all,
observational studies or subgroup analyses have demon-
strated an improved survival rate with revascularization
compared with medical therapy in patients with CKD and
multivessel CAD,1191,1193,1194 despite the fact that the inci-
dence of periprocedural complications (eg, death, MI, stroke,
infection, renal failure) is higher in patients with CKD than in
those without renal dysfunction. In 2 cohort studies involving
patients with a spectrum of kidney disease ranging from mild
to severe, adjusted survival was superior for those who
underwent bypass surgery compared with those who received
only medical therapy.1191,1194 In 1 study, survival after PCI
was improved (compared with medical therapy) in patients
with mild, moderate, or severe kidney disease but not in those
with end-stage kidney disease. The other study yielded
opposite results, with longer survival after PCI in patients
with end-stage renal disease but not in those with mild,
moderate, or severe kidney disease.
Some studies have shown that CABG is associated with a
greater survival benefit than PCI among patients with severe
renal dysfunction.1187–1192,1194 Five studies have suggested
that survival is prolonged among patients with CKD after
CABG compared with after PCI,1187,1188,1191,1192,1194 whereas
3 other studies indicated that survival is similar after either of
the 2 revascularization strategies, regardless of the severity of
underlying renal disease.1189,1190,1192
Figure 14. One-year mortality rates in randomized trials of patients with diabetes and multivessel CAD, comparing PCI (experimental)
with CABG (control). An OR .1 suggests an advantage of CABG over PCI. ARTS1 indicates Arterial Revascularization Therapy Study
I1033; BARI I, Bypass Angioplasty Revascularization Investigation I1005; CARDia, Coronary Artery Revascularization in Diabetes1176; CI,
confidence interval; DM, diabetes mellitus; MASS II, Medicine, Angioplasty, or Surgery Study II1008; OR, odds ratio; SYNTAX, Synergy
between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; and W, weighted.1006
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5.12.6. HIV Infection and SIHD
HIV infection appears to be associated with an increased risk
of premature coronary and cerebrovascular atherosclerosis,
which is often accelerated, diffuse, and circumferential,
involving whole arteries.1195,1196 AMI is often the initial
manifestation.1197 The etiology is likely multifactorial and
related to both the underlying infection and antiretroviral
therapy. The former appears to promote proliferation of
smooth muscle cells and elastin leading to luminal obstruc-
tion, although there is poor correlation between CD4 cell
counts and severity of CAD. Of the therapeutic agents used to
treat HIV infection, protease inhibitors in particular have
been epidemiologically linked to dyslipidemia and insulin
resistance.1198–1200 The protease inhibitors amprenavir/fosam-
prenavir with or without ritonavir and lopinavir with ritonavir
have the strongest association with risk of AMI, although
saquinavir and nelfinavir do not appear to be associated with
MI.1201,1202 The nucleoside reverse-transcriptase inhibitors
didanosine and abacavir also are associated with risk of
AMI.1202 Other agents, such as nonnucleoside reverse-
transcriptase inhibitors (nevirapine and efavirenz), entry in-
hibitors, and integrase inhibitors, do not appear to be associ-
ated with an increased risk of IHD.
Despite the increase in prevalence of IHD among patients
with HIV, the absolute increase in incidence of AMI is
relatively low, and overall mortality does not appear to be
increased.1198,1203 It is likely that this reflects the otherwise
enormous benefit conferred by treatment with highly active
antiretroviral therapy in the course of HIV infection. None-
theless, patients receiving highly active antiretroviral therapy
should be assessed for cardiovascular risk factors and moni-
tored for signs and symptoms of IHD. It is prudent to
recommend a healthy diet, regular physical activity, and
avoidance of smoking. Patients with hypercholesterolemia
should be managed in a fashion similar to other patients at
risk for IHD.1204
5.12.7. Autoimmune Disorders
Connective tissue disease represents a less well-studied issue
in SIHD. In rheumatoid arthritis, findings from at least one
study show increased inflammation in the coronary artery
walls, with increased frequency of vulnerable plaques.1205
Accelerated atherosclerosis in systemic lupus erythematosis,
due to impaired endothelial function and novel atherogenic
and thrombotic risk factors, requires special attention inas-
much as the adjusted rate of SIHD in systemic lupus
erythematosis is $50-fold higher than in patients without
it.1206,1207 A younger population is more frequently affected in
systemic lupus erythematosis,1208 and coronary artery spasm
is a frequent complication in connective tissue disease.1209
5.12.8. Socioeconomic Factors
Low socioeconomic status is highly associated with the risk
of cardiovascular disease.1210 Men 30 to 59 years of age with
low socioeconomic status are at 55% higher risk of death due
to IHD than are those of higher status (RR: 1.55; 95% CI:
1.51 to 1.60), and the risk is .2-fold higher among women
(RR: 2.13; 95% CI: 1.98 to 2.29).1211
In addition to lower socioeconomic status being associated
with a higher prevalence of IHD, it has been amply demon-
strated that patients of lower socioeconomic status and those
who are members of an ethnic or racial minority (in particular
African Americans and Hispanics) are less likely to receive a
wide variety of diagnostic and therapeutic interventions.
These disparities have been observed with regard to cardiac
procedures as well as access to cardiologists.1212 Moreover,
African Americans and Hispanics are 10% to 40% less likely
to receive outpatient secondary prevention therapies for
cardiovascular disease.1213 Although lower rates of diagnostic
and interventional services have not been adequately ex-
plained,1214,1215 it is clear that individuals of lower socioeco-
nomic status and ethnic minorities typically have fewer
healthcare resources, have worse general health and cardiac
risk profiles, and are less knowledgeable about SIHD symp-
toms. Healthcare providers and systems should strive to
eliminate or ameliorate barriers to care for patients who have
SIHD and are of low socioeconomic class or ethnic
minorities.
5.12.9. Special Occupations
Although not recommended for the general population, rou-
tine surveillance with functional testing is recommended in a
few occupations in which the presence of even asymptomatic
cardiac disease could endanger others, such as commercial
pilots, police, firefighters, and bus drivers. The general
parameters of test performance noted above apply in these
circumstances, with the caveat that most of these individuals
are at low risk and therefore could be more likely to have
false positive results.
6. Patient Follow-Up: Monitoring of
Symptoms and Antianginal Therapy
The goals of clinical follow-up of patients with SIHD are to
maximize function and to minimize long-term mortality and
morbidity. In this context, the primary goal of follow-up
testing should be to reassess residual or new ischemic burden
in the setting of persistent or worsening (but not unstable)
symptoms. Thus, follow-up assessment and testing will vary
according to the clinical status of the patient and with the
evolution of evidence-based practice. Unnecessary testing
should be avoided. For patients with SIHD who show no
change in symptoms or functional capacity, periodic
follow-up serves multiple purposes:
● Ongoing reassessment of adherence to and effectiveness of
the therapeutic regimen, including clinical response, occur-
rence of adverse effects, and treatment goals, on the basis
of evolving scientific evidence and preferences of the
patient.
● Evaluation of the effectiveness of interventions to modify
risk factors such as exertional hypertension.
● Assessment of the status of coexisting chronic medical
conditions that could directly or indirectly affect the
management of stable cardiac ischemia.
Patients with SIHD who have accelerating symptoms or
decreasing functional capacity require prompt reassessment.
Patients with SIHD who develop new ACS should
be evaluated and treated according to established
guidelines.3,4,4a,9,10 Patients who have been treated for an ACS
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(ie, AMI or UA) within the previous 6 months and who
develop chest pain within 30 days of the AMI should be
evaluated according to the STEMI or UA/NSTEMI guide-
lines as warranted.2–4,4a Patients who have undergone revas-
cularization with either PCI or CABG within 6 months should
be monitored according to the PCI and CABG guidelines.9,10
Patients with SIHD should be evaluated before elective or
emergent surgery according to established perioperative
guidelines.4,4a,9,10
6.1. Clinical Evaluation, Echocardiography During
Routine, Periodic Follow-Up: Recommendations
Class I
1. Patients with SIHD should receive periodic follow-
up, at least annually, that includes all of the follow-
ing (Level of Evidence: C):
a. Assessment of symptoms and clinical function;
b. Surveillance for complications of SIHD, including
heart failure and arrhythmias;
c. Monitoring of cardiac risk factors; and
d. Assessment of the adequacy of and adherence to
recommended lifestyle changes and medical
therapy.
2. Assessment of LVEF and segmental wall motion by
echocardiography or radionuclide imaging is recom-
mended in patients with new or worsening heart
failure or evidence of intervening MI by history or
ECG. (Level of Evidence: C)
Class IIb
1. Periodic screening for important comorbidities that
are prevalent in patients with SIHD, including dia-
betes mellitus, depression, and CKD, might be rea-
sonable. (Level of Evidence: C)
2. A resting 12-lead ECG at 1-year or longer intervals
between studies in patients with stable symptoms
might be reasonable. (Level of Evidence: C)
Class III: No Benefit
1. Measurement of LV function with a technology such
as echocardiography or radionuclide imaging is not
recommended for routine periodic reassessment of
patients who have not had a change in clinical status
or who are at low risk of adverse cardiovascular
events.117 (Level of Evidence: C)
Standard risk-assessment tools that have been developed
from clinical and laboratory evaluation of ambulatory popu-
lations with suspected CAD, as discussed in detail in Section
2 of this guideline, include patients who have noncardiac
causes of presenting symptoms. However, the performance of
these same tools in predicting short-term and long-term risk
for coronary mortality and coronary events might vary in
patients with known SIHD as compared with patients without
known disease who present with chest pain syndromes that
might or might not represent angina. Although mortality and
morbidity rates intuitively might be considered to be higher in
patients with documented as opposed to suspected CAD,
evidence-based medical management, including adherence to
appropriate lifestyle changes, and possibly appropriate revas-
cularization in patients with ACS or patients identified as
high risk with worsening clinical status or persistent symp-
toms despite GDMT, might explain the generally low mor-
tality risk that has been found in several studies of patients
with established SIHD.57,58,366,1216,1217 The incidence of ad-
verse events during longitudinal follow-up of SIHD has
declined and can be expected to vary with evolving medical
management and with accruing information about the out-
comes of revascularization.295,898,1163,1217–1219
Although data on serial testing are limited, one approach to
identifying candidates for follow-up testing is to apply
prognostic scores for detection of patients with SIHD who are
at high risk of MACE. The findings of studies that have
examined the prognostic value of testing among patients with
known stable CAD who are receiving contemporary
GDMT306,1220–1223 could provide clues for identifying candi-
dates and appropriate intervals for follow-up testing. In the
TIBET (Total Ischemic Burden European Trial) study group,
which comprised 682 patients with stable angina and positive
exercise ECG tests, adverse outcome was predicted by time to
ischemia during exercise, prior infarction or prior CABG,
ECG evidence for LV hypertrophy, and LV enlargement by
echocardiography.58 Easily available clinical characteristics
have been the strongest predictors of risk during follow-up of
patients with SIHD in other studies. The Euro Heart Survey
found that a score based on the cumulative presence of
comorbidity, diabetes mellitus, severity of angina, onset of
recurrent symptoms ,6 months previously, abnormal ven-
tricular function, and resting ECG repolarization abnormali-
ties was associated with an increase in the 1-year risk of death
or nonfatal infarction that ranged nearly 100-fold (from 0.5%
to 47%) among .3000 outpatients.57 The ACTION (A
Coronary Disease Trial Investigating Outcome with Nifedi-
pine Gastrointestinal Therapeutic System) trial derived a
clinical risk score that separated 5-year risk of death, MI, or
stroke from 4% to 35% in .7300 patients with stable angina
on the basis of commonly available clinical variables. In
order of decreasing importance, the variables included age,
LVEF, smoking, white blood cell count, presence of diabetes
mellitus, casual (any time of day without regard to time since
the last meal) blood glucose concentration, creatinine, prior
stroke, frequent angina, findings at coronary angiography,
lipid-lowering treatment, QT interval on the resting ECG,
systolic hypertension, number of drugs used for angina, prior
infarction, and sex.1216 Because the populations enrolled in
these studies varied and the results have not been indepen-
dently validated, additional prospective studies of patients
with established SIHD are required to establish appropriate
follow-up evaluation strategies and to establish efficient time
intervals for evaluation in stable patients.307,320,1223,1224
6.2. Follow-Up of Patients With SIHD
Standard risk assessment tools that have been developed from
clinical and laboratory evaluation of ambulatory populations
with suspected CAD, as discussed in detail in Section 2 of
this guideline, include patients who have noncardiac causes
of presenting symptoms. Estimates of the likelihood of future
cardiac events using the Framingham score,508,1225 which was
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derived from populations that included large numbers of
low-risk individuals without disease in their low-risk subsets,
are not generally useful when applied to patients with known
SIHD. In fact, prediction of risk for coronary mortality and
coronary events during short-term and long-term follow-up of
patients with SIHD differs from risk stratification in less-
ascertained populations with chest pain syndromes. Although
mortality and morbidity rates intuitively might be considered
to be higher in patients with documented as opposed to
suspected IHD, several circumstances serve to confound this
assumption. Patients at highest risk, for example, are often
identified and aggressively treated during the course of ACS
or during initial risk assessment of chest pain. After being
treated, asymptomatic patients are typically at low risk for
adverse events. Moreover, patients with recognized SIHD
could be more likely to receive and adhere to effective
therapies than are those whose disease has not been docu-
mented. Finally, patients who have been stable for long
periods of time could be less prone to development of ACS
than are newly ascertained patients with SIHD. Thus,
evidence-based medical management, including adherence to
appropriate lifestyle changes and possibly appropriate revas-
cularization in patients with ACS or patients identified as
high risk with worsening clinical status or persistent symp-
toms despite GDMT, could explain the generally low mor-
tality risk that has been found in several studies of patients
with established but stable SIHD.57,58,366,1216,1217 Moreover,
large trials conducted during the past decade have shown a
declining mortality rate among patients with established
SIHD.295,898,1163,1217,1218 Accordingly, risk could change with
advances in therapy and patient management, and these
advances could alter risk-prediction models.
A key component in following up patients with SIHD is to
systematically and reproducibly monitor their symptoms and
functional status. This should be done, at a minimum, yearly
and ideally at each visit. Even though the CCS classification
system is the most common metric with which to quantify
patients’ symptoms and function, as noted previously, it is
limited by being from the physician’s perspective rather than
the patient’s. Moreover, it has limitations in its reproducibil-
ity and interrater reliability. To obtain a valid, reliable,
reproducible, and sensitive assessment of patients’ symp-
toms, function, and quality of life from patients’ perspectives,
the SAQ can be used.435,1226 The SAQ is a 19-item, self-
reported questionnaire that takes approximately 5 minutes for
most patients to complete and explicitly quantifies patients’
angina frequency, recent changes in their angina, their phys-
ical limitations due to angina, their satisfaction with treat-
ment, and their perceptions of how their angina limits their
quality of life. Scores on the SAQ have been shown to be
associated with subsequent survival. ACS admissions and
costs246,247,1227 can be integrated into prognostic models to
identify patients warranting more aggressive treatment be-
cause of an adverse prognosis. In the CADENCE (Coronary
Artery Disease in General Practice) study, conducted in 207
primary care clinics throughout Australia,1228 Beltrame and
colleagues found wide variation in anginal symptoms accord-
ing to the SAQ. Routine use of the SAQ has been endorsed as
a performance measure of quality in SIHD.407,436
6.2.1. Focused Follow-Up Visit: Frequency
Patients with SIHD should receive regular follow-up to
monitor symptoms and progression or complications of dis-
ease. Regular visits with a healthcare provider are also
necessary to evaluate patients’ adherence to and effectiveness
of therapy as well as occurrence of any adverse effects.
Although there are scant data on which to base a definitive
recommendation, the writing committee recommends a clin-
ical follow-up evaluation every 4 to 12 months. A more
precise interval cannot be recommended because many fac-
tors influence the length of the follow-up period, including
sharing of care by family physicians, internists, and cardiol-
ogists, which will vary with regional practice patterns, patient
preference, and physician availability. During the first year of
therapy, evaluations every 4 to 6 months are recommended.
After the first year of therapy, evaluations every 6 to 12
months are recommended if the patient is stable and reliable
enough to call or make an appointment when symptoms or
functional capacity become worse. Limited data from obser-
vational studies indicate that outcomes might be better for
patients who receive follow-up from a cardiologist.1229,1230
When patients are managed jointly by their primary care
physician and cardiologist, effective communication between
physicians is essential. This ultimately will be facilitated by
effective implementation of accessible electronic medical
records. Periodic office visits can be supplemented by tele-
phone, e-mail, or other types of contact between the patient
and the healthcare team.
6.2.2. Focused Follow-Up Visit: Interval History and
Coexisting Conditions
Although follow-up of patients with SIHD often is focused on
periodic testing, the most crucial element is a careful interval
history. Key elements of the history are:
● Changes in physical activity or symptoms;
● Response to therapy, adverse effects, and adherence to
recommendations; and
● Development of relevant, new chronic conditions or
changes in existing conditions.
Symptomatic change and decreasing functional capacity
are important markers for increased risk in patients with
SIHD, particularly with increasing age and additional comor-
bidities. The evaluation of symptoms should be detailed and
directed, as many patients are reluctant to volunteer such
information. It should be noted whether patients have reduced
their activity, perhaps in an effort to ameliorate anginal
symptoms or as a symptom of ventricular dysfunction. The
adverse prognostic importance of frequent, typical angina in
patients with SIHD is evident in both older and newer studies
of risk.57,126,127,1231,1232 Motivation and compliance with risk-
reduction measures should be carefully assessed. In particu-
lar, assistance with smoking cessation by means of a struc-
tured program might be necessary for some patients. Careful
attention must be paid to concomitant conditions, such as
hypertension, diabetes mellitus, dyslipidemia, heart failure,
and depression.
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6.2.3. Focused Follow-Up Visit: Physical Examination
The physical examination should be directed according to the
patient’s history. Every patient should have weight, BP, and
heart rate measured. BMI and waist circumference can
provide signs of additional risk. Signs of heart failure, such as
elevated jugular venous pressure, hepatojugular reflux, pul-
monary crackles, new murmurs or gallops, or edema, should
be sought. The vascular examination should identify any
change in peripheral pulses or new bruits. Coexistence of
SIHD with extracranial carotid disease makes palpation and
auscultation of the carotid arteries particularly important, and
examination of the abdomen should include special attention
to bruits or abnormally prominent pulsations of the abdomi-
nal aorta.
6.2.4. Focused Follow-Up Visit: Resting 12-Lead ECG
An ECG is necessary when there is a change in anginal
pattern, symptoms or findings suggestive of a dysrhythmia or
conduction abnormality, and near or frank syncope. It is
important to recognize that periodic recording of the standard
12-lead ECG has clinical value that is independent of diag-
nostic and prognostic content: It provides a baseline wave-
form against which tracings taken during symptoms reason-
ably can be compared. Because many patients with SIHD
have resting repolarization abnormalities, absence of a timely
tracing for comparison with a tracing taken during atypical
symptoms can lead to overdiagnosis of acute ische-
mia.1233,1234 Conversely, repolarization abnormalities dur-
ing symptoms that might be new or significantly more
marked can also be consistent with old disease and lead to
underdiagnosis or undertreatment of unstable disease.1235
New repolarization abnormalities during serial study have
been shown to predict cardiovascular events during the
longitudinal study of hypertensive patients in the Framing-
ham Heart Study.318 A study of hypertensive patients that
included a subgroup with established SIHD also demon-
strated an increased risk of cardiovascular endpoints after
the development of new repolarization changes during
serial evaluation.318,1236 Although there are no prospective
randomized data demonstrating that intervention based on
routine, periodic evaluation of the ECG alone will alter
outcomes in patients with SIHD, pending such evidence,
the clinical value of a change in the resting ECG is widely
accepted. In patients with established SIHD, a change in a
periodically obtained ECG can be the only evidence of
intercurrent silent infarction, inadequately treated hyper-
tension, or complex arrhythmia that would modify treat-
ment. The timing between routine recordings of the 12-
lead ECG that would be required and adequate to
accomplish these purposes has not been established, but a
consensus recommendation based on expert opinion and
common practice would be not greater than once yearly for
stable patients with SIHD, as well as at the time of any
clinical change.
6.2.5. Focused Follow-Up Visit: Laboratory Examination
Patients not known to have diabetes mellitus should have a
fasting blood glucose measurement every 3 years to detect
new-onset diabetes mellitus, and those with established dia-
betes mellitus should have glycosylated hemoglobin mea-
sured at least annually to assess glycemic control. A lipid
profile should be obtained as clinically warranted. Long-term
studies (up to 7 years) demonstrate sustained benefit from
continued therapy.18,318 Measurement of creatinine kinase
also could be appropriate at these times. In circumstances in
which the patient is not concurrently followed up by a
primary care physician, measurements of hemoglobin, thy-
roid function, serum electrolytes, and renal function should
be obtained annually, or sooner when prompted by a change
in symptoms or signs.
6.3. Noninvasive Testing in Known SIHD
For any patients with known SIHD who have recurrent but
stable symptoms after having been symptom free for a period
of time on GDMT or after revascularization and who do not
fall into any of the categories listed in the previous paragraph,
the concepts underlying the recommendations for “Noninva-
sive Testing for Diagnosis of IHD” from Section 2.2 gener-
ally apply, with the modifications and special consideration
discussed below.
6.3.1. Follow-Up Noninvasive Testing in Patients With
Known SIHD: New, Recurrent, or Worsening Symptoms
Not Consistent With Unstable Angina: Recommendations
See Table 20 for a summary of recommendations from this
section.
6.3.1.1. Patients Able to Exercise
Class I
1. Standard exercise ECG testing is recommended in
patients with known SIHD who have new or wors-
ening symptoms not consistent with UA and who
have a) at least moderate physical functioning and
no disabling comorbidity and b) an interpretable
ECG.114,145–147 (Level of Evidence: B)
2. Exercise with nuclear MPI or echocardiography is rec-
ommended in patients with known SIHD who have new
or worsening symptoms not consistent with UA and who
have a) at least moderate physical functioning or no
disabling comorbidity but b) an uninterpretable
ECG.172,276,278,284,306,313,314,320,324,327–329,1237–1240 (Level of
Evidence: B)
Class IIa
1. Exercise with nuclear MPI or echocardiography is
reasonable in patients with known SIHD who have
new or worsening symptoms not consistent with UA
and who have a) at least moderate physical function-
ing and no disabling comorbidity, b) previously
required imaging with exercise stress, or c) known
multivessel disease or high risk for multivessel dis-
ease.1241,1242 (Level of Evidence: B)
Class III: No Benefit
1. Pharmacological stress imaging with nuclear MPI,
echocardiography, or CMR is not recommended
in patients with known SIHD who have new or
worsening symptoms not consistent with UA and
who are capable of at least moderate physical
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functioning or have no disabling comorbidity.333
(Level of Evidence: C)
6.3.1.2. Patients Unable to Exercise
Class I
1. Pharmacological stress imaging with nuclear MPI
or echocardiography is recommended in patients
with known SIHD who have new or worsening
symptoms not consistent with UA and who are
incapable of at least moderate physical function-
ing or have disabling comorbidity.148 –150,152–156
(Level of Evidence: B)
Class IIa
1. Pharmacological stress imaging with CMR is rea-
sonable in patients with known SIHD who have new
or worsening symptoms not consistent with UA and
who are incapable of at least moderate physical
functioning or have disabling comorbidity.280,281,283
(Level of Evidence: B)
Class III: No Benefit
1. Standard exercise ECG testing should not be per-
formed in patients with known SIHD who have new
or worsening symptoms not consistent with UA and
who a) are incapable of at least moderate physical
functioning or have disabling comorbidity or b) have
an uninterpretable ECG. (Level of Evidence: C)
6.3.1.3. Irrespective of Ability to Exercise
Class IIb
1. CCTA for assessment of patency of CABG or of
coronary stents 3 mm or larger in diameter might be
reasonable in patients with known SIHD who have
new or worsening symptoms not consistent with UA,
irrespective of ability to exercise.1244–1248 (Level of
Evidence: B)
2. CCTA might be reasonable in patients with known
SIHD who have new or worsening symptoms not
consistent with UA, irrespective of ability to exercise,
in the absence of known moderate or severe calcifi-
Table 20. Follow-Up Noninvasive Testing in Patients With Known SIHD: New, Recurrent, or Worsening Symptoms Not Consistent
With UA
Test
Exercise
Status
ECG
Interpretable
COR LOE References
Additional
ConsiderationsAble Unable Yes No
Patients able to exercise*
Exercise ECG X X I B (114, 145–147)
Exercise with nuclear MPI or Echo X X I B (172, 276, 278, 284, 306,
313, 314, 320, 324,
327–329, 1237–1240)
Exercise with nuclear MPI or Echo X Any IIa B (1241, 1242) ● Prior requirement for imaging
with exercise
● Known or at high risk for
multivessel disease
Pharmacological stress nuclear
MPI/Echo/CMR
X X III: No Benefit C (333)
Patients unable to exercise
Pharmacological stress nuclear
MPI or Echo
X Any I B (148–150, 152–156)
Pharmacological stress CMR X Any IIa B (280, 281, 283)
Exercise ECG X X III: No Benefit C N/A
Irrespective of ability to exercise
CCTA Any Any IIb B (1244–1248) Patency of CABG or coronary
stent $3 mm diameter
CCTA Any Any IIb B (158, 161, 1244) In the absence of known moderate or
severe calcification and intent to assess
coronary stent ,3 mm in diameter
CCTA Any Any III: No Benefit B (1244–1248) Known moderate or severe native
coronary calcification or assessment
of coronary stent ,3 mm in diameter
in patients who have new or worsening
symptoms not consistent with UA
*Patients are candidates for exercise testing if they are capable of performing at least moderate physical functioning (ie, moderate household, yard, or recreational
work and most activities of daily living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predicted maximum heart rate.
CABG indicates coronary artery bypass graft surgery; CCTA, cardiac computed tomography angiography; CMR, cardiac magnetic resonance; COR, class of
recommendation; ECG, electrocardiogram; Echo, echocardiography; LOE, level of evidence; MPI, myocardial perfusion imaging; N/A, not available; SIHD, stable
ischemic heart disease; and UA, unstable angina.
e430 Circulation December 18/25, 2012
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
cation or if the CCTA is intended to assess coronary
stents less than 3 mm in diameter.158,161,1244 (Level of
Evidence: B)
Class III: No Benefit
1. CCTA should not be performed for assessment of
native coronary arteries with known moderate or
severe calcification or with coronary stents less than
3 mm in diameter in patients with known SIHD who
have new or worsening symptoms not consistent
with UA, irrespective of ability to exercise.1244–1248
(Level of Evidence: B)
See Online Data Supplement 1 for additional data on nonin-
vasive testing in known SIHD: recurrent or worsening
symptoms.
Strategies for the selection and use of noninvasive
testing in the evaluation of new or worsening symptoms in
patients with documented SIHD are similar to those in
suspected SIHD. As always, in patients with interpretable
rest ECGs who are capable of exercise, treadmill exercise
ECG testing remains the first choice. Whenever possible,
initial and follow-up testing should be performed with the
same stress and imaging techniques so that any interval
change can be attributed more reliably to alterations in
clinical status rather than mere differences in technique.
Loss of the ability to exercise on follow-up testing, in and
of itself, suggests deterioration in functional and clinical
status. In general, the diagnostic accuracy of stress testing
is similar in patients with and without known SIHD
(Section 2.2.3). A few meta-analyses examining the effect
of prior MI on diagnostic accuracy have found that the
specificity of exercise ECG was higher in mixed popula-
tions,145 whereas the diagnostic performance of exercise
echocardiography was reduced. In contrast, the specificity
of exercise SPECT was increased because of the predictive
value of total stress perfusion abnormalities, which in-
cludes both the risk of ischemia plus infarcted myocardi-
um.91 Although CMR LGE imaging detects MI, current
evidence indicates that assessment of myocardial ischemia
provides incremental diagnostic1249 and prognostic value
above LGE detection of infarction284 in patients with or
without known SIHD.
In contrast to stress testing, the diagnostic value of
CCTA differs in patients with and without known CAD.
Limitations of image quality relating to coronary calcifi-
cation, coronary stents, or vascular clips can reduce
diagnostic accuracy, and revascularization also affects
results. The large caliber of venous conduits facilitates the
assessment of patients who have undergone CABG with
CCTA and has sensitivities of 89% to 98% and specifici-
ties of 89% to 97% for the identification of .50%
diameter stenoses in grafts on invasive coronary angiog-
raphy.1244 –1246 The accurate evaluation of coronary stents
with CCTA depends on the material and diameter of the
stent, with image artifacts related to the stents’ metallic
structure preventing assessment of 9% to 11% of
stents.1247,1248 Typically, stents .3 mm in diameter can be
assessed,1248 with sensitivities for detecting a .50% di-
ameter in-stent restenosis on invasive coronary angiogra-
phy of 86% to 94% and specificities of 91% to 93%.
6.3.2. Noninvasive Testing in Known
SIHD—Asymptomatic (or Stable
Symptoms): Recommendations
See Table 21 for a summary of recommendations from this
section.
Table 21. Noninvasive Testing in Known SIHD: Asymptomatic (or Stable Symptoms)
Test
Exercise
Status
ECG
Interpretable
Pretest Probability
of Ischemia COR LOE References
Additional
ConsiderationsAble* Unable Yes No
Exercise or pharmacological
stress with nuclear MPI, Echo,
or CMR at $2-y intervals
X X Prior evidence of silent
ischemia or high risk for
recurrent cardiac event.
Meets criteria listed in
additional considerations.
IIa C (10, 12, 15) a) Unable to exercise to
adequate workload or
b) Uninterpretable ECG or
c) History of incomplete
coronary revascularization
Exercise ECG at $1-y intervals X X Any IIb C N/A a) Prior evidence of
silent ischemia OR
b) At high risk for recurrent
cardiac event
Exercise ECG X X No prior evidence of silent
ischemia and not at high risk
of recurrent cardiac event.
IIb C N/A For annual surveillance
Exercise or pharmacological
stress with nuclear MPI,
Echo, or CMR or CCTA
Any Any Any III: No Benefit C (10, 12, 15) a) ,5-y intervals after
CABG, or
b) ,2-y intervals after PCI
*Patients are candidates for exercise testing if they are capable of performing at least moderate physical functioning (ie, moderate household, yard, or recreational
work and most activities of daily living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predicted maximum heart rate.
CABG indicates coronary artery bypass graft surgery; CCTA, cardiac computed tomography angiography; CMR, coronary magnetic resonance; COR, class of
recommendation; CCTA, computed tomography angiography; CMR, cardiac magnetic resonance; ECG, electrocardiogram; Echo, echocardiography; LOE, level of
evidence; MPI, myocardial perfusion imaging; N/A, not available; PCI, percutaneous coronary intervention; and SIHD, stable ischemic heart disease.
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Class IIa
1. Nuclear MPI, echocardiography, or CMR with ei-
ther exercise or pharmacological stress can be useful
for follow-up assessment at 2-year or longer inter-
vals in patients with SIHD with prior evidence of
silent ischemia or who are at high risk for a recur-
rent cardiac event and a) are unable to exercise to an
adequate workload, b) have an uninterpretable
ECG, or c) have a history of incomplete coronary
revascularization.10,12,15 (Level of Evidence: C)
Class IIb
1. Standard exercise ECG testing performed at 1-year
or longer intervals might be considered for follow-up
assessment in patients with SIHD who have had
prior evidence of silent ischemia or are at high risk
for a recurrent cardiac event and are able to exercise
to an adequate workload and have an interpretable
ECG. (Level of Evidence: C)
2. In patients who have no new or worsening symptoms
or no prior evidence of silent ischemia and are not at
high risk for a recurrent cardiac event, the useful-
ness of annual surveillance exercise ECG testing is
not well established. (Level of Evidence: C)
Class III: No Benefit
1. Nuclear MPI, echocardiography, or CMR, with ei-
ther exercise or pharmacological stress or CCTA, is
not recommended for follow-up assessment in pa-
tients with SIHD, if performed more frequently than
at a) 5-year intervals after CABG or b) 2-year
intervals after PCI.10,12,15 (Level of Evidence: C)
See Online Data Supplement 1 for additional data on nonin-
vasive testing in known SIHD: asymptomatic (or stable
symptoms).
6.3.3. Factors Influencing the Use of Follow-Up Testing
The appropriateness of performing noninvasive testing in
patients who either are asymptomatic or have stable symp-
toms (ie, routine surveillance testing) depends on factors
related to the likelihood of significant findings, such as the
patient’s risk for rapidly advancing disease, propensity to
have silent ischemia, and length of time since revasculariza-
tion. The data supporting follow-up testing are sparse and
insufficient to support routine, repeat testing in asymptomatic
individuals. However, evidence exists that persistent ische-
mia on testing is a prognostically poor finding. Exploratory
data from a small cohort of 314 patients with SIHD enrolled
in the COURAGE trial nuclear substudy revealed that a
reduction in the ischemic myocardium is associated with an
(unadjusted) reduction in the incidence of death or MI
combined.306 In the BARI 2D trial, at 1 year of follow-up,
more extensive and severe stress myocardial perfusion
SPECT abnormalities were associated with higher rates of
death or MI.276
There are, however, several circumstances in which a
decision to perform follow-up testing is thought to be
warranted in the absence of a change in clinical status,
although data supporting this approach are limited. These
circumstances include, but are not limited to, evaluation of
incomplete revascularization, assessment of the adequacy of
medical therapy by provocative exercise testing, a substantial
change in risk profile, or the need to reevaluate coronary
status in anticipation of major noncardiovascular surgery
when the patient’s exercise capacity is limited or unknown
(although revascularization in this circumstance has not been
shown to reduce the risk of perioperative cardiovascular
complications), as detailed in the ACCF/AHA Perioperative
Cardiovascular Evaluation and Care for Noncardiac Surgery
Guideline.1250 Care should be taken when interpreting paired
testing results to incorporate not only the change in the extent
and severity of ischemia but also the workload at onset and
total exercise capacity achieved, as these factors relate to the
patient’s symptom burden and functional correlates in daily
life. Outside of such special circumstances, routine periodic
testing is not recommended in patients who are at low risk for
progression or had overt symptoms on initial presentation (ie,
those without known silent ischemia) or very early after
revascularization. In addition to a lack of evidence for testing
to detect ischemia, currently there is also little research to
support exercise stress testing for risk assessment in asymp-
tomatic patients with known CAD, except for cardiac reha-
bilitation and exercise prescription purposes (Section
4.4.1.4.).
6.3.4. Patient Risk and Testing
By using clinical, noninvasive, and invasive data acquired
during the initial evaluation and subsequently, recommenda-
tions about stress testing in patients with known SIHD can be
formulated on the basis of the following considerations: In
the absence of a change in clinical status, patients with a low
projected annual mortality rate (,1%) are those with low-risk
Duke treadmill scores, either without imaging or with nega-
tive imaging findings, whose 4-year cardiovascular survival
rate approximates 99%. The low-risk category also includes
patients with normal stress imaging who lack adverse prog-
nostic characteristics, such as diabetes mellitus or prior MI.
Younger women without diabetes mellitus or a prior MI who
have normal stress nuclear MPI remain at very low risk for as
long as 7 to 9 years,307 depending on specific clinical
characteristics, and probably do not require repeat stress
imaging during that period in the absence of changes in
clinical status.307
Data are more limited with regard to the value of serial
testing strategies in patients at intermediate risk of cardiac
mortality (1% to 3% per year). Follow-up testing probably
should be performed only if decisions about a change in
pharmacological management, level of exercise, or revascu-
larization will be influenced directly by the test result or if the
patient has persistent symptoms despite adequate GDMT.
Thus, in the patient with known SIHD, the goal of repeat
testing is the assessment of residual ischemic burden after
optimization of GDMT or the consideration of revasculariza-
tion as a result of failed optimal medical management.
Furthermore, to be considered significant, findings should be
outside the expected range of variability of test results, which
is approximately 5% for stress nuclear MPI,306,366 such that
patients move into a higher or lower risk category.
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Even for high-risk patients, the value of annual exercise
testing (or serial exercise testing at alternative intervals) in
the absence of a change in symptoms has not been studied
adequately. Yearly exercise testing could be useful in patients
with SIHD who have .3% risk of mortality per year, because
a marked decrease in exercise capacity or a marked increase
in ischemic burden can warrant reevaluation of the medical
regimen or interventional plan. Examples of such patients are
those with a high-risk Duke treadmill score, patients with an
EF ,50% and significant CAD in .1 major vessel, patients
with diabetes mellitus, and those with multivessel disease
who have not undergone CABG. Some data also suggest that
ischemic burden might be useful in targeting ischemia-guided
revascularization. In a substudy of the COURAGE trial, the
overall event-free survival rate was 86.6% in patients with
$5% reduction in ischemic myocardium versus 75.3% in
those without significant reduction in ischemic burden after 6
to 18 months (unadjusted P50.037; adjusted P50.26).306
Although this trial substudy was not powered to examine
differences in clinical outcomes, the results are similar to the
BARI 2D trial, in which patients with high myocardial
jeopardy scores randomized to CABG had fewer cardiovas-
cular events (AMI and composite endpoint of all-cause
mortality or MI and cardiac death or MI) than those with high
scores who received only medical therapy.276,409
6.3.5. Stability of Results After Normal Stress Testing in
Patients With Known SIHD
The durability of information gained from a stress test over
time varies widely according to the characteristics of the
patients and the type of test performed. Among patients with
several clinical risk factors and negative stress imaging
studies, the relative hazard for cardiac death or MI can
increase after a 2-year follow-up time period, whereas among
other groups, the risk remains low through 2 years and can be
safely assumed to remain low for an extended period of time.
In 1 large single-site study, the factors associated with an
earlier increase in risk included diabetes mellitus, male sex,
increased age (ie, $70 years), a history of previous MI or
revascularization, and having undergone a pharmacological
stress test rather than an exercise test327 (Figure 15). The
relationships were, however, complex and covarying. Impor-
tantly, among patients who were younger and female and did
not have diabetes mellitus or a history of MI or revascular-
ization, the annual risk of adverse cardiovascular events was
predicted to remain ,1% for as long as 9 years, on the basis
of hard events observed during the 2-year follow-up period.
In contrast, in an 80-year-old man with a normal pharmaco-
logical stress study, the risk of an adverse event rose to .1%
in ,1 year after an index-negative perfusion evaluation.
6.3.6. Utility of Repeat Stress Testing in Patients With
Known CAD
The interpretation of repeat testing should be based on a
threshold change value that exceeds the expected variability
in test results, even in patients at high risk for recurrent
events, and especially in those with no interval clinical
change.1244 Although the variability of exercise and stress
testing results is not well established,306,1251 factors such as
differences in day-to-day operations in the same laboratory,
interobserver variability, and differences between practices in
different imaging laboratories are important contributory
factors in observed differences in serial testing. A 5% change
in the percent of ischemic myocardium (based on extent and
severity) has been suggested by some investigators as a
threshold that indicates clinically significant change for stress
nuclear MPI.306,1251 The findings from different exercise or
stress imaging modalities (echocardiography versus nuclear
MPI) can be even more difficult to compare, such that
clinicians should use the same imaging modality over time
whenever possible. Despite these concerns, significant
changes in risk category (such as shifting to a lower- or
higher-risk patient subset) may be used to guide interpretabil-
ity of interval change in repeat testing,306,333 and the presence
of significant interval change can alter risk assessment. For
example, in the ACME (Angioplasty Compared to Medicine)
trial, patients whose exercise nuclear MPI normalized after 6
months of randomized treatment had an improved survival
Figure 15. Incidence of cardiac death or
nonfatal MI during follow-up after a nor-
mal stress MPI. Adapted with permission
from Hachamovitch et al.327 MI indicates
myocardial infarction; MPI, myocardial
perfusion imaging.
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rate (92%) compared with those with persistent ischemia
(82%, P50.02).333 The ongoing technical evolution within
imaging modalities is, in part, aimed at minimizing intraob-
server, interobserver, and intertest variability.
6.3.7. Future Developments
Numerous opportunities to improve the diagnosis and man-
agement of SIHD remain. Large registries have the potential
to improve the diagnosis of IHD and to assess risk according
to clinical information and results from noninvasive testing.
Risk-assessment strategies from older databases should be
updated with modern information and statistical techniques.
Technical development across all cardiac imaging modalities
continues to evolve rapidly, often outpacing the ability to
perform rigorous clinical validation and application. Current
and anticipated technical developments of CT scanners and
software are intended to improve the spatial and temporal
resolution of cardiac CT images while reducing the radiation
dose received from a typical examination. They include wider
detector arrays that allow higher numbers of simultaneously
acquired image slices, faster x-ray tube rotation times, and the
use of alternative image reconstruction techniques that target
image noise, all of which could improve the diagnostic value
of CCTA in currently challenging scenarios, such as calcified
coronary arteries and coronary stents. The improvement also
will foster the study and clinical use of newer applications of
cardiac CT, such as coronary plaque characterization, late
enhancement imaging for the detection of myocardial scar,
and MPI to detect myocardial ischemia.1252 Efforts currently
under way to obtain perfusion information from CCTA
images are promising,196–201 with one report also calculating
FFR with CCTA.195 Moreover, plaque quantification soft-
ware is in development and could further guide accurate
detection of atherosclerotic disease burden.1253
Several new developments in stress nuclear MPI have
occurred, including new radioisotopes: 1) an F18 PET perfu-
sion agent (in Phase III trials), which will allow exercise PET
testing; 2) 123I-beta-methyl-iodophenylpentadecanoic acid
SPECT, with the unique ability to document metabolic
alterations representing prior ischemic episodes (ie, ischemic
memory); and 3) 123I-labeled meta-iodobenzylguanidine
SPECT, which could be helpful for assessment of arrhythmic
risk in SIHD patients.1254 Several new SPECT cameras also
have been introduced into the marketplace and offer the
opportunity for improved image quality within a substantially
shorter time period and with a lower radiation dose.1255,1256
Several studies have correlated atherosclerotic plaque char-
acteristics with the extent of ischemic myocardium by stress
nuclear MPI.202–206,215 Finally, the diagnostic and prognostic
value of PET flow reserve data is currently under intense
investigation.185,1257
Echocardiography, being the most portable and widely
available stress imaging technique, has developed novel
methods that are promising in the assessment of SIHD
patient. Speckle-tracking echocardiography provides a
2-dimensional, angle-independent, real-time evaluation of
myocardial strain and has been shown to detect myocardial
ischemia incremental to wall motion analysis.1258,1259 Recent
reports of contrast echocardiography MPI during vasodilating
stress indicate that it is a potentially robust and clinically
viable tool in detection of CAD.1260 Finally, 3-dimensional
techniques can provide an improved assessment of cardiac
size and function in patients with SIHD.
Increasing recognition of the ability of CMR to accurately
assess abnormal myocardial physiology of CAD by combined
imaging of rest and stress ventricular function, perfusion, and
myocardial viability is expected to increase its use in
SIHD.172,1261,1262 With rapid data acquisition by parallel
imaging, real-time cine, or sub-second single-shot imaging
methods, a diagnostically adequate CMR can be obtained
without the need for patient breath-holding or ECG gat-
ing.1263 A routine CMR assessment of CAD can be achieved
in ,30 minutes. These developments likely will improve
diagnostic consistency and patient throughput of CMR. CMR
myocardial perfusion and LGE imaging for ischemia and
scar, respectively, have improved image quality at 3.0T field
strength compared to 1.5T and have been shown to improve
diagnostic accuracy in detecting CAD.1264 Whole-heart
3-dimensional coronary magnetic resonance angiography
with navigator respiratory-gating has shown promising pilot
results and is being evaluated in clinical trials.1265,1266
Further studies on lipid management are warranted to
ascertain the optimal drug regimens for patients with SIHD.
Questions remain as to the optimal dose of statins and the
effectiveness of combining lipid-lowering medications. In
addition, studies that establish the effectiveness of CABG in
comparison with contemporary GDMT are necessary, as are
studies that better define the relative benefits of different
revascularization techniques (Figure 13).
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Appendix 3. Abbreviations List
ACE 5 angiotensin-converting enzyme
ACS 5 acute coronary syndrome
AMI 5 acute myocardial infarction
ARB 5 angiotensin-receptor blocker
AV 5 atrioventricular
BMI 5 body mass index
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CABG 5 coronary artery bypass graft
CAC 5 coronary artery calcium
CAD 5 coronary artery disease
CCS 5 Canadian Cardiovascular Society
CCTA 5 coronary/cardiac computed tomography angiography
CKD 5 chronic kidney disease
CMR 5 cardiac magnetic resonance
CT 5 computed tomography
DAPT 5 dual antiplatelet therapy
DES 5 drug-eluting stent
ECG 5 electrocardiogram
EDTA 5 ethylene diamine tetraacetic acid
EECP 5 enhanced external counterpulsation
EF 5 ejection fraction
FDA 5 US Food and Drug Administration
FFR 5 fractional flow reserve
GDMT 5 guideline-directed medical therapy
HbA1c 5 hemoglobin A1c
HDL 5 high-density lipoprotein
HIV 5 human immunodeficiency virus
IHD 5 ischemic heart disease
LAD 5 left anterior descending
LBBB 5 left bundle-branch block
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LGE 5 late gadolinium enhancement
LIMA 5 left internal mammary artery
LV 5 left ventricular
LVEF 5 left ventricular ejection fraction
MACE 5 major adverse cardiac event
MET 5 metabolic equivalent
MI 5 myocardial infarction
MPI 5 myocardial perfusion imaging
NSTEMI 5 non–ST-elevation myocardial infarction
PAD 5 peripheral artery disease
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PET 5 positron emission tomography
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RCT 5 randomized controlled trial
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(Continued)
Appendix 3. Continued
SPECT 5 single-photon emission computed tomography
STEMI 5 ST-elevation myocardial infarction
TMR 5 transmyocardial revascularization
UA 5 unstable angina
UA/NSTEMI 5 unstable angina/non–ST-elevation myocardial infarction
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Appendix 4. Nomogram for Estimating 2-Year CAD Event-Free Survival (ie, Freedom From CAD Death or Nonfatal MI) by Using
Percent Ischemic Myocardium in Intermediate-Likelihood Patients by Post-Stress LV
CAD indicates coronary artery disease, LVEF, left ventricular ejection fraction; MI, myocardial infarction; and SPECT, single-photon emission computed tomography.
Reproduced with permission from Shaw et al.276
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Correction
e463
In the article by Fihn et al, “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the 
Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the 
American College of Cardiology Foundation/American Heart Association Task Force on Practice 
Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, 
Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and 
Interventions, and Society of Thoracic Surgeons,” which published online November 19, 2012, and 
appeared in the December 18/25, 2012, issue of the journal (Circulation. 2012;126:e354–e471), 
several corrections were needed.
1.  On page e366, in Figure 3, the green diamond-shaped box associated with the “LBBB on ECG” 
box read, “MPI or Echo w/ exercise.” It has been changed to read, “Exercise Echo or Pharm 
Stress MPI/Echo.” The correct figure has been updated in the online article.
2.  On page e384, in Table 12, Row 14, Column 1 “Test,” the sentence read, “Pharmacological stress 
with nuclear MPI or Echo.” It has been changed to read, “Exercise Echo or pharmacological 
stress with MPI or Echo.”
3.  On page e384, in the first column, in Section 3.2.2.3, the Class 1, Recommendation 1 read, 
“Pharmacological stress with either nuclear....” It has been changed to read, “Exercise echo or 
pharmacological stress with either nuclear....”
4.  On page e389, in the Table 14 footnote, the last paragraph read, “Adapted from Gibbons et al.7” 
It has been changed to read, “Adapted from Snow et al.377a”
5.  On page e406, in the first column, in the first paragraph, the sixth sentence read, “Perindopril was 
further tested in the PEACE….” It has been changed to read, “Trandolapril was further tested in 
the PEACE….”
6.  On page e444, in the Reference section, a reference has been added: 377a. Snow V, Barry P, Fihn 
SD, et al. Evaluation of primary care patients with chronic stable angina: guidelines from the 
American College of Physicians. Ann Intern Med. 2004;141:57–64.”
These corrections have been made to the current online version of the article, which is available 
at http://circ.ahajournals.org/content/126/25/e354.
(Circulation. 2013;129:e463.)
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2012 ACCF/AHA Stable Ischemic Heart Disease Guideline Data Supplements 
 
Data Supplement 1 - Imaging 
Study Name, 
Author, Year, 
Citation 
Aim of 
Study 
Study 
Type 
Study 
Size 
Patient Population Endpoints Statistical 
Analysis 
(Results) 
P Values & 
95% CI 
OR: HR: 
RR 
Study 
Limitations 
Findings/ 
Comments 
 Inclusion 
Criteria 
Exclusion 
Criteria 
Primary 
Endpoint 
Secondary 
Endpoint 
 
Standard Exercise ECG Testing 
RCTs 
A randomized trial of 
exercise treadmill 
ECG vs. stress SPECT 
MPI as an initial 
diagnostic strategy in 
stable patients with 
chest pain and 
suspected CAD: cost 
analysis, Sabharwal, 
2007, (1)  
Compare 
Ex ECG vs. 
MPI 
RCT 457 Suspected 
CAD 
N/A Cost to 
diagnosis 
N/A N/A p=NS 
 
N/A No Sens/Spec 
 
Costs similar per ECG 
& MPI 
Comparative 
effectiveness of 
exercise 
electrocardiography 
with or without 
myocardial perfusion 
SPECT in women with 
suspected CAD, 
Women’s Trial, Shaw, 
2011 (2) 
Compare 
Ex ECG vs. 
MPI in 
Women 
RCT 824 Suspected 
CAD 
N/A 2 y incidence of 
MACE 
(composite of 
cardiac death, 
nonfatal MI or 
hospital 
admission for 
ACS or HF) 
Diagnostic 
accuracy 
ETT 98% vs. 
exercise MPI 
97.7% 
 
p=0.59 N/A Limited stat. 
power 
.N/A 
Meta-Analysis 
Meta-analysis of 
exercise testing to 
detect CAD in women, 
Kwok, 1999 (3) 
Diagnostic 
accuracy of 
Ex ECG, 
MPI, and 
Echo in 
women 
Meta-
analysis 
27 
studies 
(4,113 
pts) 
Suspected 
CAD-
Women 
N/A CAD N/A ECG: Sens=61; 
Spec=70           
Echo: Sens=86, 
Spec=79;           
MPI: Sens=61, 
Spec=70 
N/A N/A Planar imaging Moderate diagnostic 
accuracy in women 
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Exercise-induced ST 
depression in the 
diagnosis of CAD, 
Gianrossi, 1989 (4) 
Diagnostic 
accuracy of 
Ex ECG 
Meta-
analysis 
150 
study 
groups 
(24,074 
pts) 
Suspected 
CAD 
N/A CAD N/A Sens=61, 
Spec=77 
N/A N/A N/A Moderate diagnostic 
accuracy 
Pharmacologic Echocardiography, Radionuclide MPI, or MRI 
Clinical Practice Guideline/Expert Consensus Statements 
Myocardial perfusion 
scintigraphy: the 
evidence, Underwood, 
2004, (5, 6) 
Systematic 
Review of 
Cost 
Effectivene
ss of ECG 
and MPI 
Consens
us 
conferen
ce; 
review 
Consens
us 
Confere
nce;  48 
studies 
(7,002 
pts) 
Suspected 
CAD 
N/A Diagnostic 
costs 
N/A N/A N/A N/A N/A Diagnostic costs 
Relationship between 
obstructive CAD and 
abnormal stress testing 
in patients with 
paroxysmal or 
persistent AF, 
Nucifora, 2011 (7) 
Diagnostic 
accuracy of 
ECG in pts 
with 
abnormal 
ECG 
 
Registry  87 AF pts N/A Diagnostic 
Accuracy 
N/A N/A N/A N/A N/A Low diagnostic 
accuracy of ETT in pts 
with abnormal ECG 
Meta-Analysis 
Exercise-induced ST 
depression in the 
diagnosis of CAD, 
Gianrossi, 1989 (4) 
Diagnostic 
accuracy of 
Ex ECG 
Meta-
analysis 
150 
study 
groups 
(24,074 
pts) 
Suspected 
CAD 
N/A CAD N/A Meta-regression: 
Reduced Sens 
with LBBB, 
digitalis 
p=0.002 N/A N/A Moderate diagnostic 
accuracy 
Multicenter Registry 
Economics of MPI in 
Europe—the EMPIRE 
study, Underwood, 
1999 (8) 
Compare 
Ex ECG, 
MPI, vs. 
Angio 
Registry 396 Suspected 
CAD 
N/A Diagnostic Costs N/A N/A N/A N/A N/A Costs higher for 
imaging; emphasis on 
ECG for lower-risk 
patients 
Exercise Echocardiography or MPI with patients who can and cannot exercise and Standard Exercise ECG testing 
Clinical Practice Guideline/Expert Consensus Statements 
Clinical value, cost-
effectiveness and 
safety of myocardial 
Diagnostic 
Accuracy 
of MPI and 
Meta-
analysis  
19 
studies 
(1,405 
Suspecte
d CAD 
N/A CAD N/A Pharm: MPI: 
Sens=87, 
Spec=90;  
N/A N/A N/A High diagnostic 
accuracy 
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perfusion scintigraphy: 
a position statement 
Marcassa, 2008, (9) 
 
Echo pts) Echo: Sens=85, 
Spec=85;           
Ex: MPI: 
Sens=82, 
Spec=88;  
Echo: Sens=70, 
Spec=89 
Myocardial perfusion 
scintigraphy: the 
evidence, Underwood, 
2004 (5, 6) 
 
Diagnostic 
Accuracy 
of MPI 
Consens
us 
conferen
ce; 
review 
Concen
sus 
confere
nce:  48 
studies 
(7,002 
pts) 
Suspecte
d CAD 
N/A CAD N/A Ex: Sens=88, 
Spec=70;           
Dipy: Sens=91, 
Spec=75;            
Ad: Sens=87, 
Spec=81 
N/A N/A N/A High diagnostic 
accuracy 
Meta-analysis 
Ex echo or ex SPECT 
imaging? A meta-
analysis of diagnostic 
test performance, 
Fleischmann, 1998, 
(10) 
Diagnostic 
accuracy of 
Ex Echo 
and MPI 
Meta-
analysis 
44 
articles 
(5,830 
pts) 
Suspected 
CAD 
N/A CAD N/A Echo: Sens=85, 
Spec=77;                      
MPI: Sens=87, 
Spec=64 
N/A N/A N/A N/A 
Cost-effectiveness of 
alternative test 
strategies for diagnosis 
of CAD, Garber, 1999 
(11) 
Diagnostic 
accuracy of 
Echo and 
MP 
Meta-
analysis  
27 
studies 
(2,753 
pts) 
Suspected 
CAD 
N/A CAD N/A Echo: Sens=76, 
Spec=88;     
SPECT: Sens=87, 
Spec=76;           
PET: Sens=88, 
Spec=81 
N/A N/A N/A High diagnostic 
accuracy 
Head-to-head 
comparison of 
dipyridamole echo and 
stress perfusion 
scintigraphy for the 
detection of CAD, 
Imran, 2003 (12) 
Diagnostic 
accuracy of 
Pharmacol
ogic Echo 
and MPI 
Meta-
analysis 
 
10 
studies 
(651 
pts) 
Suspected 
CAD 
N/A CAD N/A Echo: Sens=70; 
Spec=90;               
MPI: Sens=88, 
Spec=67 
N/A N/A  N/A N/A 
Accuracy of 
noninvasive 
techniques for 
diagnosis of CAD and 
prediction of cardiac 
events in patients with 
Diagnostic 
accuracy in 
Patients 
with LBBB 
Meta-
analysis 
55 
studies; 
1,432 
patients 
Suspected 
CAD in LBBB 
N/A Detection of 
CAD and 
prediction of 
cardiac events 
in pts with 
LBBB;  >50% 
N/A Echo: Sens=75; 
Spec=89;               
MPI: Sens=89, 
Spec=41 
N/A N/A N/A N/A 
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LBBB, Biagini, 2006 
(13) 
or >70% 
coronary 
artery stenosis 
on 
angiography 
Diagnostic 
performance of stress 
CMR imaging in the 
detection of CAD: a 
meta-analysis 
Nandular, 2007 (14) 
Diagnostic 
accuracy of 
CMR 
WMA and 
perfusion 
Meta-
analysis 
 
37 
studies 
(2,191 
pts) 
Suspected 
CAD 
N/A CAD N/A WMA: Sens=83, 
Spec=86;       
Perfusion: 
Sens=91, 
Spec=81 
N/A N/A N/A N/A 
DSE for the detection 
of CAD in women, 
Geleijnse, 2007 (15)  
Diagnostic 
accuracy of 
DSE in 
women 
Meta-
analysis 
 
14 
studies 
(91 pts) 
Suspected 
CAD in women 
N/A CAD CAD Sens=72% and 
Spec=88% 
 
 
N/A N/A N/A N/A 
The diagnostic 
accuracy of 
pharmacological stress 
echo for the 
assessment of CAD: a 
meta–analysis, Picano, 
2008 (16) 
Diagnostic 
accuracy of 
Pharmacol
ogic Echo 
Meta-
analysis 
 
5 
studies 
(435 
pts) 
Suspected 
CAD 
N/A CAD CAD Sens=85%, 
Spec=89% 
N/A N/A N/A High diagnostic 
accuracy 
Diagnostic accuracy of 
MPI and stress echo 
for the diagnosis of 
LM and triple vessel 
CAD: a comparative 
meta-analysis,  
Mahajan, 2010 (17) 
Diagnostic 
accuracy of 
Echo and 
MPI for 
3VD/LM 
Meta-
analysis 
 
32 
studies 
(3,533 
pts) 
Suspected 
CAD 
N/A 3 VD/LM N/A Echo: Sens=94, 
Spec=40;  
MPI: Sens=75, 
Spec=48 
N/A N/A N/A High Sens 
CCTA for patients who are and are not able to exercise 
Controlled Clinical Trials 
Diagnostic 
performance of 64-
multidetector row of 
CCTA for evaluation 
of coronary artery 
stenosis in individuals 
without known CAD: 
Diagnostic 
accuracy of 
64-slide 
CCTA 
Prospecti
ve, 
blinded, 
MCS 
230 a) ≥18 y 
b) chest pain 
(typical or 
atypical) 
c) nonemergent 
ICA 
a) known 
CAD 
b) renal 
failure 
c) 
arrhythmia 
d) HR >100 
a) ≥50% 
diameter 
stenosis on 
QCA 
b) ≥70% 
diameter 
stenosis on 
N/A Patient based 
analysis ≥50% 
stenosis 
Sens: 95% 
Spec: 83% 
PPV: 64% 
NPV: 99% 
Patient based 
analysis ≥50% 
stenosis 
(85% to 99%) 
(76% to 88%) 
(53% to 75%) 
(96% to 100%) 
N/A Referred for 
ICA 
≥50% stenosis 
AUC=0.96 (0.94 to 
0.98) 
 
≥70% stenosis 
AUC=0.95 (0.92 to 
0.97)  
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results from the 
prospective 
multicenter 
ACCURACY, Budoff, 
2008 (18) 
mm Hg 
e) SBP 
<100 mm 
Hg 
f) contrast 
allergy 
g) CI to 
BB’s, CCB; 
nitro 
h) 
pregnancy 
QCA  
≥70% stensosis 
Sens: 94% 
Spec: 83% 
PPV:  48% 
NPV: 99% 
 
 
 
≥70% stenosis 
(79% to 99%) 
(77% to 88%) 
(35% to 62%) 
(96% to 100%) 
Diagnostic 
performance of 
coronary angiography 
by 64-row CT, Miller, 
2008 (19) 
Diagnostic 
accuracy of 
64-slide 
MDCTA 
Prospecti
ve, 
blinded, 
internatio
nal, MCS 
291 a)  ≥40 y 
b) chest pain 
c) nonemergent 
ICA 
d) neg. 
pregnancy test 
a) known 
CABG 
b) PCI <6 
mo 
c) AF 
d) renal 
failure 
e) contrast 
allergy 
f) CI to 
BB’s 
g) heart 
failure 
h) BMI >40 
i) aortic 
stenosis 
j) multiple 
myeloma 
a) ≥50% 
diameter 
stenosis on 
QCA 
N/A Visual MCDTA 
Sens: 83% 
Spec: 91% 
PPV: 92% 
NPV: 81% 
 
Quant MDCTA 
Sens: 85% 
Spec: 90% 
PPV: 91% 
NPV: 83% 
Visual MDCTA 
(76% to 88%) 
(85% to 96%) 
(87% to 96%) 
(73% to 87%) 
 
Quant MDCTA 
(79% to 90%)  
(83% to 94%) 
(86% to 95%) 
(75% to 89%) 
 Referred for 
ICA 
Visual MDCTA 
AUC=0.93 (0.89 to 
0.95) 
 
Quant MDCTA 
AUC=0.93 (0.90 to 
0.96) 
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Diagnostic accuracy of 
64-slice computed 
tomography coronary 
angiography: a 
prospective, 
multicenter, 
multivendor study, 
Meijboom, 2008 (20) 
Diagnostic 
accuracy of 
64-slide 
CCTA 
Prospecti
ve, MCS 
360 a) 50 to 70 y 
b) stable angina 
and UA 
referred for 
CCA 
c) chest pain 
d) nonemergent 
ICA 
a) prior PCI 
with stent 
or CABG  
b) renal 
failure (Cr 
>120 
µM/L) 
c) 
arrhythmia 
d) <15 sec 
breath hold 
e) contrast 
allergy 
≥50% 
diameter 
stenosis on 
QCA 
N/A Per patient 
analysis: 
Sens: 99% 
Spec: 64% 
PPV: 86% 
NPV: 97% 
Per patient 
analysis: 
(98% to 100%) 
(55% to 73%) 
(82% to 90%) 
(95% to 100%) 
N/A Referred for 
ICA 
Intraobserver 
(k=0.66) 
 
Iinterobserver 
(k=0.69) 
 
Multivendor 
64-Slice computed 
tomography 
angiography in the 
diagnosis and 
assessment of CAD: 
systematic review and 
meta-analysis, 
Mowatt, 2008 (21) 
Accuracy 
of 64-slice 
CT 
angiograph
y compared 
with ICA 
Meta-
analysis  
18 
studies 
1,286 
patients 
a) 64-slice 
CTA 
b) RCTs 
c) 
nonrandomized 
comparative 
studies 
d) case series 
N/A ≥50% 
diameter 
stenosis 
N/A Sens: 99% 
Spec: 89% 
PPV: 93% 
 
NPV: 100% 
(97% to 99%) 
(83% to 94%) 
(Range: 64% to 
100%) 
(Range: 86% to 
100%)  
N/A N/A N/A 
A systematic review 
on diagnostic accuracy 
of CT-based detection 
of significant CAD, 
Janne d’Othee B, 2008 
(22) 
Diagnostic 
accuracy of 
CCTA 
Meta-
analysis 
5 
studies 
(308 
pts) 
a) 64-slice 
CCTA 
a) CABG 
CTA 
b) stent 
CTA 
≥50% or 
≥70% to 75% 
diameter 
stenosis 
N/A Fixed effects: 
Sens: 92% 
Spec 98% 
 
Random effects: 
Spec: 85% 
Sens 99% 
N/A N/A N/A N/A 
Meta-analysis: 
noninvasive coronary 
angiography using 
computed tomography 
vs. MRI, Schuetz GM, 
2010 (23) 
Determine 
potential of 
CT for 
ruling out 
CAD in 
adults with 
suspected 
or known 
CAD 
Meta-
analysis 
109 
studies 
(8,205 
pts) 
a) 64-slice 
CCTA (9 
studies) 
b) 320-slice 
CCTA (1 
study) 
N/A ≥50% 
diameter 
stenosis 
N/A Sens: 98% 
Spec: 89% 
(97% to 99%)  
(86% to 92%)  
N/A N/A N/A 
Diagnostic 
performance of 
Diagnostic 
accuracy of 
Meta-
analysis 
29 
studies; 
Suspected 
CAD 
N/A CAD; >50% 
diameter 
N/A Sens: 96% 
Spec: 74% 
N/A N/A N/A N/A 
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multislice spiral 
computed tomography 
of coronary arteries as 
compared with 
conventional invasive 
coronary angiography, 
Hamon M, 2006 (24) 
CCTA with 
invasive 
coronary 
angiograph
y 
2,024 
pts 
stenosis  
Meta-analysis of 
comparative 
diagnostic 
performance of MRI 
and multislice 
computed tomography 
for noninvasive 
coronary angiography, 
Schuijf JD, 2006 (25) 
Diagnostic 
accuracy of 
CCTA with 
invasive 
coronary 
angiograph
y 
Meta-
analysis 
51 
studies; 
2,203 
pts;  
Suspected 
CAD 
N/A CAD 
≥50% 
diameter 
stenosis 
N/A Sens: 85% 
Spec: 95% 
N/A 16.9 N/A N/A 
Diagnostic value of 
multislice computed 
tomography 
angiography in CAD: 
a meta-analysis, Sun 
Z, 2006 (26) 
Diagnostic 
accuracy of 
CCTA with 
Invasive 
Coronary 
Angiograp
hy 
Meta-
analysis 
47 
studies; 
3,142 
pts 
Suspected 
CAD 
N/A CAD N/A Sens: 91% 
Spec: 86% 
N/A N/A N/A N/A 
Multidetector 
computed tomography 
for the diagnosis of 
CAD: a meta-analysis,  
Stein PD, 2006 (27) 
Diagnostic 
accuracy of 
CCTA with 
Invasive 
Coronary 
Angiograp
hy 
Meta-
analysis 
33 
studies; 
1,861 
pts 
Suspected 
CAD 
N/A CAD (50% or 
≥50%) 
N/A Sens: 98% 
Spec: 88% 
N/A N/A N/A N/A 
Bypass Graft CT Angiography 
Multi-detector 
computed tomography 
in CABG assessment: 
a meta-analysis, Jones, 
2007 (28) 
Determinat
ion of 
diagnostic 
accuracy of 
8-slice, 16-
slice, and 
54-slice 
MDCT vs. 
Meta-
analysis 
Occlusi
ons: 
14 
studies 
1,791 
grafts 
 
Stenose
Comparison of 
CABG patency 
or stenosis, or 
both, on 
MDCT vs. 
angiography 
Use of 
MDCT was 
unconfirme
d, 
performed 
as 
preoperativ
e work-up, 
a) graft 
occlusion 
b) graft 
stenosis 
N/A Occlusions: 
Sens: 98% 
Spec: 99% 
PPV: 93.6 
NPV:99.4% 
 
 
 
Occlusions: 
(95% to 
99%) 
(98% to 
99%) 
 
 
 
Occlusions
: 
OR=934.2 
(436.4 to 
1999.9) 
 
 
Stenoses: 
N/A Occlusions: 
AUC=0.996 
 
 
 
 
Stenoses:  
AUC=0.867 
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angiograph
y in 
diagnosis 
of graft 
occlusion 
and 
stensosis 
s: 
8 
studies 
878 
grafts 
or 
performed 
on pts with 
conduit 
stenting or 
angioplasty 
Stenoses 
Sens: 89% 
Spec: 97% 
PPV: 77.8% 
NPV: 98.8% 
 
Stenoses: 
(75% to 
95%) 
(96% to 
98%)  
OR=152.0 
(64.0 to 
360.7) 
Diagnostic 
performance of 16- 
and 64-section spiral 
CT for CABG 
assessment: meta-
analysis, Hamon M, 
2008 (29) 
Accuracy 
of 16- and 
64- CT to 
help assess 
CABG 
Meta-
analysis 
15 
studies 
723 pts 
2,023 
grafts 
a) use of 
multisection 
CT as 
diagnostic test 
to sasses 
significant 
lesion 
(occlusion or 
≥50% stenosis) 
of CABG 
b) used 16- or 
64-section 
scanner 
c) used 
coronary 
angiography as 
the reference 
standard 
N/A ≥50% 
diameter 
stenosis 
N/A Sens: 98% 
Spec: 97% 
PPV: 93% 
NPV: 99% 
(96% to 
99%) 
(96% to 
98%) 
(91% to 
95%) 
(97% to 
99%) 
Positive 
LR: 23.42 
(13.69 to 
40.07);  
Negative 
LR: 0.045 
(0.028 to 
0.071);  
Diagnostic 
OR: 
780.32 
(379.12 to 
1,606.01) 
N/A N/A 
64-Slice computed 
tomography 
angiography in the 
diagnosis and 
assessment of CAD: 
systematic review and 
meta-analysis, Mowatt 
G, 2008 (21) 
Accuracy 
of 64-slice 
CT 
angiograph
y compared 
with ICA 
Meta-
analysis 
40 
studies 
(28 
include
d) in 
meta-
analysis 
543 pts 
a) 64-slice 
CCTA 
b) RCTs 
c) non-
randomized 
comparative 
studies 
d) case series 
N/A ≥50% 
diameter 
stenosis 
N/A Patient based 
detection: 
Sens: 99% 
Spec: 89% 
PPV: 93% 
NPV: 100% 
 
Segment-based 
detection: 
Sens: 90% (85% 
to 94%)  
Spec: 97% (95% 
to 98%) 
PPV: 76% (44% 
to 93%)  
(97% to 
99%) 
(83% to 
94%) 
(64% to 
100%) 
(86% to 
100%) 
N/A N/A N/A 
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NPV: 99% (95% 
to 100%)  
In-Stent Restenosis  
Diagnostic accuracy of 
64-slice computed 
tomography 
angiography for the 
detection of in-stent 
restenosis: a meta-
analysis, Carrabba N, 
2010 (30) 
Accuracy 
of 64-slice 
MDCT 
compared 
with 
invasive 
coronary 
angiograph
y to detect 
ISR 
Meta-
analysis 
9 
studies 
598 pts 
978 
stents 
a) 64-MDCT 
used for ISR 
b) Values 
available for 
TP, FP, TN, 
and FN 
a) Post-
CABG 
b) prior 
heart 
transplantati
on 
>50% by 
angiography 
(invasion and 
quantitative)  
N/A Sens: 86% 
Spec: 93% 
Positive LR: 
12.32 
Negative LR: 
0.18 
(80% to 
91%) 
(91% to 
95%)  
(7.26 to 
20.92)  
 
N/A N/A AUC=0.94 per stent 
analysis indicated 
good diagnostic 
agreement between 64-
MDCT and invasive 
coronary angiography 
Diagnostic accuracy of 
64 multislice CT 
angiography in the 
assessment of 
coronary in-stent 
restenosis: a meta-
analysis, Sun, Z, 2010 
(31) 
Accuracy 
of 64-slice 
CT 
angiograph
y compared 
with 
convention
al coronary 
angiograph
y to detect 
ISR  
Meta-
analysis 
14 
studies 
858 pts 
Peer reviewed, 
published in 
English (2004 
to 2008). 
Prospective and 
retrospective 
studies (10 
patient 
minimum), 64-
slice CT used 
for diagnosis 
and invasion 
coronary 
angiography as 
reference 
Review 
article; 
editorials; 
conference 
abstracts; in 
vitro or 
phantomstu
dies; not 
reporting 
numbers of 
TN, TP, FN 
and FP. 
>50% 
stenosis; 
diagnostic 
sensitivity, 
specificity 
using a fixed 
effects model 
(TP, TN, FP, 
FN)  
N/A Assessable stents: 
Sens: 94% 
Spec: 91% 
 
Evaluable and 
unevaluable 
stents (5 studies): 
Sens: 79% 
Spec: 81% 
Assessable 
stents: (86% 
to 94%); 
(90% to 
93%); 
evaluable 
and 
unevaluable 
stents (5 
studies); 
(68% to 
88%); (77% 
to 84%) 
N/A a) Publication 
bias (non-
English studies 
excluded, (under 
way or under 
review studies 
excluded;  
b) lack of 
uniform criteria 
of assessment 
(reporting of 
type and 
diameter of 
stents 
implanted);  
c) Limitation of 
pooled 
sensitivities and 
specificities 
(different pos. 
criteria not 
considered) 
64-slice CT 
angiography has high 
diagnostic accuracy 
(>90% sensitivity and 
specificity) for the 
detection of ISR 
compared to 
conventional coronary 
angiography 
 
*Meta-analyses of the diagnostic accuracy of CCTA from 2006 and earlier include predominantly or exclusively studies done with obsolete scanner technology (16-slice or 4-slice MDCT or electron beam CT (EBCT).  These 
older studies are included here to demonstrate the consistently high diagnostic accuracy of CCTA across all of the available meta-analyses and the evidence and the size of the evidence base supporting its use." 
 
        
	
	
	
	
	
		

         #

ACCURACY indicates Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography; ACS, acute coronary syndrome; AF, atrial fibrillation; Angio, angiography; 
AUC, area under the curve, BB, beta blocker; BMI; body mass index; bpm, beats per minute; CABG, coronary artery bypass surgery; CAD, coronary artery disease; CCA, conventional coronary angiogram/angioplasty, CCB, 
calcium channel blocker; CCTA coronary computer tomography angiography; CE-CCT, contrast enhanced coronary computed tomography; CI, confidence interval; CMR, cardiac magnetic resonance, Cr, creatinine, CRF, 
chronic renal failure; CMR, cardiac magnetic resonance; CT, computed tomography; CTA, computed tomographic angiography; DSE, dobutatmine stress echocardiography; EBCT, electron beam computed tomography; ECG, 
electrocardiogram; Echo, echocardiography; EMPIRE, Economics of myocardial perfusion imaging in Europe; ETT, exercise tolerance test; Ex, exercise; FN, false negative, FP, false positive, HR, hazard  ratio, ICA, invasive 
coronary angiography; ISR, in-stent restenosis, LBBB, left bundle brunch block; LM, left main; LR, likelihood ratio; µM, micromoles MCS, multicenter study; MDCT, multi-detector computed tomography; MDCTA, 
multidetector CT angiography; MI, myocardial infarction; MPI, myocardial perfusion imaging; MRI, magnetic resonance imaging; N/A not applicable; Neg., negative; NLR, negative likelihood ratio; NPV, negative predictive 
value; NS, non-significant; NTG, nitroglycerin; OR, odds ratio; PCI, percutaneous coronary intervention; PET, positron emission tomography; PLR, positive likelihood ratio; Pos., positive; PPV, positive predictive value; 
PTCA, percutaneous transluminal coronary angioplasty; QCA, quantitative coronary angiography; Quant., quantitative; RCT, randomized controlled trial; RR, relative risk; SBP, systolic blood pressure; sec, second; Sens., 
sensitivity; Spec., specificity; SPECT, single photon emission computed tomography; Stat., statistical; TN, true negative, TP, true positive; UA, unstable angina; VD, vessel disease; vs., versus; and WMA, wall motion 
abnormality. 
 
 
Data Supplement 2 - Imaging 
Risk Assessment  
Study Name, 
Author, Year 
Aim of 
study 
Study 
Type 
Study 
Size Patient Population Endpoints 
Statistical 
Analysis 
(Results) 
P Values &  
95% CI: 
Main Study 
Findings 
 Study 
Limitations 
Findings/ 
Comments 
        
Inclusion 
Criteria 
Exclusion 
Criteria 
Primary 
Endpoint 
Secondary  
Endpoint           
Stress Cardiac MRI-prognostic studies in patients with suspected CAD 
Assessment of 
myocardial wall 
motion and 
perfusion, 
Korosoglou, 2010 
(32) 
Prognosis by 
dobutamine 
stress MRI 
Single-
center 
trial 
1,493 Suspected 
Ischemia 
MRI 
related 
exclusions 
Cardiac death 
and AMI  
Late coronary 
revascularizati
on 
Multivariable 
Cox Regression 
p<0.001 Adj. HR of stress 
wall motion for 
primary endpoints: 
5.9 (95% CI: 2.5 to 
13.6); for late  
revascularization 
HR 3.1: (95% CI: 
1.7 to 5.6)                       
Adjusted HR of 
perfusion for 
primary endpoints: 
5.4 (95% CI: 2.3 to 
12.9); for late 
revascularization 
Single center 
observational 
study  
Very low hard event 
rates by negative 
dobutamine 
combined stress 
function and 
perfusion 
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adj. HR: 6.2 (95% 
CI: 3.3 to 11.3) 
Long-term 
prognostic value 
of dobutamine 
stress CMR,  
Kelle S, 2011 (33) 
 
Prognosis by 
dobutamine 
stress MRI 
Single-
center 
trial 
1,463 Suspected 
Ischemia 
MRI 
related 
exclusions 
Cardiac death 
and AMI 
None Multivariable 
Cox Regression 
p<0.001  
(1.8 to 5.9) 
HR of inducible 
wall motion 
abnormality for 
primary endpoints: 
3.31 
Single-center 
observational 
study 
Negative 
dobutamine stress 
CMR conveys 
96.8% 6-y event-
free survival 
Incremental 
prognostic 
significance of 
combined CMR 
imaging, 
adenosine stress 
perfusion, delayed 
enhancement, and 
LV function over 
preimaging 
information for the 
prediction of 
adverse events. 
Bingham SE, 2011 
(34) 
Prognosis by 
adenosine 
stress MRI 
Single-
center 
trial 
908 Suspected 
Ischemia 
MRI 
related 
exclusions 
Death, AMI, and 
late coronary 
revascularization 
Cardiac death 
and MI 
Multivariable 
Cox Regression 
p=0.02 HR of 2.2 for 
primary endpoint 
Referral bias 
of a single-
center 
observational 
study 
Ventricular volume, 
aortic flow, 
myocardial viability, 
and stress perfusion 
all add incremental 
value for prediction 
of adverse events 
over pre-CMR data 
and can be 
combined to further 
enhance 
prognostication.  
Prognostic value 
of CMR stress 
tests: adenosine 
stress perfusion 
and dobutamine 
stress wall motion 
imaging. 
Jahnke C, 2007 
(35) 
Prognosis by 
adenosine 
stress MRI 
Single-
center 
trial 
513 Symptoms 
suspicious of 
ischemia and 
no history of 
MI 
MRI 
related 
exclusions  
Cardiac death or 
AMI 
None Multivariable 
Cox Regression 
p<0.001; 95% 
CI: 3.6 to 43 
HR of 12.5 for 
primary endpoint 
Single-center 
observational 
study 
Both adenosine and 
dobutamine MRI 
were effective in 
cardiac 
prognostication with 
high negative event 
rate. 
Stress MPI by 
CMR provides 
strong prognostic 
value to cardiac 
events regardless 
of patient's sex.  
Coelho-Filho OR, 
Prognosis by 
adenosine 
stress MRI in 
women 
Single-
center 
trial 
424 Symptoms 
suspicious of 
ischemia 
MRI 
related 
exclusions 
Death or AMI None Multivariable 
Cox Regression 
p<0.001 Unadjusted HR of 
presence of 
ischemia: 6.4 for 
primary endpoints 
Single-center 
observational 
study 
Negative annual 
hard event rate 
99.4% in women. 
Stress CMR risk 
stratify women 
effectively 
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2011 
(36) 
Prognostic value 
of dipyridamole 
stress 
cardiovascular 
MRI in pts with 
known or 
suspected CAD. 
Bodi V, 2007  
(37) 
 
Prognosis by 
dipyridamole 
stress MRI 
Single-
center 
trial 
420 Symptoms 
suspicious of 
ischemia 
MRI 
related 
exclusions 
Cardiac death 
and AMI 
None Multivariable 
Cox Regression 
p=0.0006 Stress wall motion 
abnormality carries 
a OR of 5.3 for 
primary endpoints 
Single-center 
observational 
study 
N/A 
MRI 
determination of 
cardiac prognosis.  
Hundley WG,  
2002 
(38) 
Prognosis by 
dobutamine 
stress MRI 
Single-
center 
trial 
279 Symptoms 
suspicious of 
ischemia 
MRI 
related 
exclusions 
Cardiac death 
and AMI 
None  Multivariable 
Cox Regression 
p=0.0004; 
95% CI: 1.1 to 
9.7 
Stress wall motion 
abnormality had a 
HR: 3.3 for 
primary endpoint, 
independent of 
LVEF 
Single-center 
observational 
study 
First study that 
illustrated the 
prognostic 
significance of 
dobutamine stress 
MRI 
Dobutamine 
cardiac magnetic 
resonance results 
predict cardiac 
prognosis in 
women with 
known or 
suspected IHD. 
Wallace EL, 2009 
(39) 
Prognosis by 
dobutamine 
stress MRI in 
women 
Single-
center 
trial 
266 Symptoms 
suspicious of 
ischemia, 
women 
MRI 
related 
exclusions 
Cardiac death 
and AMI 
None Multivariable 
Cox Regression 
p<0.0001; 
95% CI: 1.8 to 
4.3 
Stress wall motion 
abnormality had a 
HR: of 2.7 for 
primary endpoints. 
Single-center 
observational 
study 
Dobtamine stress 
MRI effectiveness 
prognosticate in 
women 
Prognostic value 
of adenosine stress 
cardiovascular 
magnetic 
resonance and 
DSE in pts with 
low-risk chest 
pain. Hartlage G, 
2011 
(40) 
Compare 
prognosis by 
adenosine 
stress CMR 
and DSE 
Single-
center 
trial 
255 Suspected 
ischemia 
N/A Cardiac death, 
AMI, 
obstructive CAD 
on angiography, 
and 
rehospitalization 
None Multivariable 
Cox Regression 
N/A Negative event rate 
(for primary 
endpoints) was 
100% for stress 
CMR. 
Single-center 
observational 
study 
Negative event rate 
100% by stress 
CMR and 99% by 
DSE 
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Complementary 
prognostic values 
of stress 
myocardial 
perfusion and late 
gadolinium 
enhancement 
imaging by CMR 
in pts with known 
or suspected CAD. 
Steel K, 2009 
(41) 
Prognosis by 
combining 
stress 
perfusion and 
late 
gadolinium 
enhancement 
imaging 
Single-
center 
trial 
254 Symptoms 
suspicious of 
ischemia 
MRI 
related 
exclusions 
Cardiac death 
and AMI 
Late 
revascularizati
on and UA 
hospitalization 
Multivariable 
Cox Regression 
p<0.0001 
(2.79 to 16.89) 
Stress CMR had a 
HR: 6.88 for 
primary endpoints 
Referral bias 
of a single-
center clinical 
study 
Demonstrated that 
stress perfusion and 
late gadolinium 
enhancement 
imaging provide 
complement cardiac 
prognostication. 
Prognostic value 
of normal 
adenosine-stress 
CMR imaging. 
Pilz G, 2008 (42) 
Prognosis by 
adenosine 
stress MRI 
Single-
center 
trial 
218 Suspected 
ischemia but 
negative stress 
CMR perfusion 
MRI 
related 
exclusions 
Cardiac death, 
AMI, 
revascularization
, and 
hospitalization 
at 12 mo 
None Logistic 
regression, 
ROC analysis 
N/A Negative event rate 
(for primary 
endpoints) at 12 
mo: 99.1% 
Small study 
with short-
term follow-up 
composite 
events 
CMR 12 mos 
negative predictive 
value 99.1% 
Prognostic value 
of adenosine stress 
myocardial 
perfusion by CMR 
imaging in pts 
with known or 
suspected CAD. 
Lo KY, 2011 (43) 
Prognosis by 
adenosine 
stress MRI 
Single-
center 
trial 
203 Suspected 
ischemia 
N/A Cardiac death 
and nonfatal MI 
None Multivariable 
Cox Regression 
p<0.001; 95% 
CI: 3.18 to 
27.3 
Stress CMR had a 
HR of 9.31 for 
primary events 
Single-center, 
small size 
N/A 
Prediction of 
cardiac events in 
pts with reduced 
LVEF with 
dobutamine 
cardiovascular 
magnetic 
resonance 
assessment of wall 
motion score 
index.  
Dall'Armellina E, 
2008 (44) 
Prognosis by 
dobutamine 
stress MRI as 
modified by 
LVEF. 
Single-
center 
trial 
200 Suspected 
ischemia, 
LVEF ≤55% 
MRI 
related 
exclusions 
Cardiac death 
and AMI 
UA or HF 
admission 
Multivariable 
Cox Regression 
p=0.003 Stress CMR had a 
HR: 3.01for 
primary events 
Single center 
observational 
study 
Induced ischemia by 
dobutamine stress 
MRI was primarily 
in those with LVEF 
>40% 
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Prognosis of 
Negative 
Adenosine Stress 
Magnetic 
Resonance in Pts 
Presenting to an 
Emergency 
Department With 
Chest Pain. 
Ingkanisorn WP, 
2006 (45) 
Prognosis by 
adenosine 
stress MRI in 
pts with acute 
chest pain 
Single-
center 
trial 
135 Suspected 
ischemia, acute 
chest pain pts 
from the ER, 
with no ECG 
changes and 
negative 
troponins/CK 
MRI 
related 
exclusions 
Cardiac death, 
AMI, and late 
revascularization 
None Logistic 
regression, 
ROC analysis 
p<0.002 Negative event rate 
(for primary 
endpoints) at 12 
mo was 100%. 
Single-center 
observational 
study 
12 mos negative 
event rate 100% 
Prognostic value 
of adenosine stress 
cardiovascular 
magnetic 
resonance in pts 
with low-risk 
chest pain. Lerakis 
S, 2009 (46) 
Prognosis by 
dobutamine 
stress MRI in 
low risk chest 
pain 
Single-
center 
trial 
103 Suspected 
ischemia, acute 
chest pain with 
no ECG 
changes and 
negative 
troponins/CK 
MRI 
related 
exclusions 
Cardiac death, 
AMI, 
revascularization
, and 
rehospitalization 
None  Logistic  
regression 
N/A Negative event rate 
(for primary 
endpoints) at 12 
mo was 100%. 
Single-center 
observational 
study, small 
study size 
Negative event rate 
100% 
Risk stratification 
by adenosine 
stress CMR in pts 
with coronary 
artery stenoses of 
intermediate 
angiographic 
severity. Doesch 
C, 2009 (47) 
Prognosis by 
stress MRI in 
pts with 
intermediate 
stenosis 
Single-
center 
trial 
81 Stable angina, 
intermediate 
angiographic 
severity 
MRI 
related 
exclusions 
Death, stroke, 
and ACS 
Target vessel 
revascularizati
on, angina, 
dyspnea 
Multivariable 
Cox Regression 
p=0.003 Pts who 
experienced 
MACE had 
ischemic extent 
1.64 fold larger in 
size 
Single-center 
observational 
study, small 
study size 
Evaluate prognosis 
in setting of 
intermediate 
coronary stenosis 
Stress CMR—multicenter or comparative studies to detect CAD 
Combined 
assessment of 
myocardial 
perfusion and late 
gadolinium 
enhancement in 
pts after 
percutaneous PCI 
or bypass grafts: a 
Multicenter 
study by 
adenosine 
stress CMR 
in detecting 
coronary 
stenosis after 
PCI or CABG 
Multi-
center 
trial 
3 
centers 
(477) 
Suspected 
ischemia 
MRI 
related 
exclusions 
≥70% angiographic 
coronary stenosis 
N/A Logistic regression 
and ROC, analysis 
N/A NPV of stress 
CMR for 
angiographic 
significant 
coronary stenosis 
was 96%.  Sens. 
was 94% and 
spec. was 87%. 
Selection bias 
due to entry 
criteria of a 
clinical 
indication for 
X-ray coronary 
angiography 
N/A 
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multicenter study 
of an integrated 
cardiovascular 
magnetic 
resonance 
protocol. 
Bernhardt P, 2009 
(48) 
 
MR-IMPACT, 
Comparison of 
perfusion-CMR 
with single-photon 
emission CT for 
the detection of 
CAD in a 
multicentre, 
multivendor, 
randomized trial. 
Schwitter J, 2008, 
(49) 
First 
multicenter 
study in 
evaluating 
diagnostic 
accuracy of 
stress cardiac 
MRI and 
compared to 
SPECT 
Multi-
center 
trial 
18 cts 
(241) 
Symptoms 
suspicious of 
ischemia 
MRI 
related 
exclusions 
Angiographic 
significant CAD 
(≥50%) 
None Logistic regression 
and ROC analysis  
p=0.01 Stress CMR for 
diagnosis of 
angiographic 
significant CAD: 
Sens. 87%, Spec. 
86% 
N/A Vasodilating 
stress MRI has 
similar 
diagnostic 
utility as 
SPECT overall, 
but more 
sensitive that 
SPECT in pts 
with 
multivessel 
disease 
Noninvasive 
diagnosis of 
ischemia-induced 
wall motion 
abnormalities with 
the use of high-
dose dobutamine 
stress MRI: 
comparison with 
DSE.  
Nagel E, 1999 
(50) 
Compare 
diagnostic 
utility of 
dobutamine 
MRI with 
DSE 
Single-
center 
trial 
208 Suspected 
ischemia 
MRI 
related 
exclusions 
Angiographic 
significant CAD 
(≥50% diameter 
stenosis) 
None Logistic regression 
and ROC analysis 
p<0.05 Dobutamine 
stress CMR has 
higher sens. and 
speci. for 
diagnosis of 
significant CAD 
than DSE: sens. 
86% vs. 74%; 
spec. 86% vs. 
70% (both 
p<0.05) 
N/A N/A 
CE-MARC study. 
Clinical evaluation 
of magnetic 
resonance imaging 
in coronary heart 
disease: the CE-
MARC study. 
Compare 
CAD 
diagnosis and 
prognosis by 
stress MRI 
and SPECT 
Single-
center 
trial 
750 Suspected 
ischemia 
MRI 
related 
exclusions 
≥70% angiographic 
coronary stenosis 
None Logistic regression 
and ROC analysis 
N/A Stress CMR: 
Sens. 87% (95% 
CI: 82 to 91), 
Speci. 83% (95% 
CI: 80 to 87) 
SPECT sens. 
67% (95% CI: 60 
N/A First 
randomized 
trial comparing 
the diagnostic 
utilities of 
stress CMR and 
stress SPECT 
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Greenwood JP, 
2009   
(51) 
to 72), Spec. 
=83% (95% CI: 
79 to 86) 
Stress CMR-Meta Analysis to Diagnose CAD  
Diagnostic 
performance of 
stress CMR 
imaging in the 
detection of CAD: 
a meta-analysis. 
Nandalur KR, 
2007 
(14) 
To evaluate 
stress cardiac 
MRI in the 
diagnosis of 
CAD 
 
Meta-
analysis 
37 
studies 
(2,191 
pts) 
Suspected 
ischemia (use 
of stress MRI 
as diagnostic 
test for CAD 
≥50% diameter 
stenosis and 
use of catheter 
X-ray 
angiography as 
reference 
standard 
 
MRI 
related 
exclusions 
≥70% angiographic 
coronary stenosis 
None Logistic regression 
and ROC, analysis  
N/A Stress induced 
wall motion 
abnormalities 
imaging:  
Sens. 0.83, Spec. 
0.86, Disease 
prevalence: 
70.5%.  
                                       
Perfusion 
imaging:  
Sens. 0.91 (0.88 
to 0.94), Spec. 
0.81 (0.77 to 
0.85), Disease 
prevalence 
=57.4% 
N/A N/A 
Meta-analysis of 
the diagnostic 
performance of 
stress perfusion 
cardiovascular 
magnetic 
resonance for 
detection of CAD. 
Hamon M, 2010 
(52) 
Studies (from 
2001-2008) 
presented on 
patient-based 
analysis 
Meta-
analysis 
35 
studies 
(2,125 
pts) 
Suspected 
ischemia.  
Studies using 
(a) ≥1.5 Tesla 
MR scanner; 
(b) employed 
invasive 
coronary 
angiography as 
reference 
standard for 
diagnosing 
significant 
obstructive 
CAD (≥ 50% 
diameter 
stenosis), and 
MRI 
related 
exclusions 
≥70% angiographic 
coronary stenosis 
None Logistic regression, 
ROC analysis.   
Stress perfusion 
CMR: pt based 
analysis:  Sensitivity 
89% (88 to 91), 
Specificity 80% (78 
to 83), Disease 
prevalence 57%, 
PLR 4.18 (3.31 to 
5.27), NLR 0.15 
(0.11 to 0.20), AUC 
0.92 
N/A Diagnostic OR: 
33.65 (95% CI: 
22.09 to 51.27) 
N/A N/A 
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(c) provided 
sufficient data 
to permit 
analysis. 
ACS indicates acute coronary syndrome; Adj, adjusted; AMI; acute myocardial infarction; AUC, area under the curve; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; CE-MARC, Clinical 
Evaluation of Magnetic Resonance Imaging in Coronary heart disease; CI, confidence interval; CK, creatine kinase; CMR, contract magnetic resonance; CT, computed tomography; CTA, computed tomography 
angiography; DSE, dobutatmine stress echo; DSMR, dobutamine stress magnetic resonance; ECG, electrocardiogram; Echo, echocardiogram; ER, emergency room; HF, heart failure; HR, hazard ratio; LV, left 
ventricular; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events; MI, myocardial infarction; MR-IMPACT, Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary 
Artery Disease Trial; MR, magnetic resonance; MRI, magnetic resonance imaging; N/A, not applicable; NLR, negative likelihood ratio; OR, odds ratio; pts, patients; PCI, percutaneous coronary intervention; PLR, 
positive likelihood ratio; ROC, receiver operator characteristics; Sens., sensitivity; Spec., specificity; SPECT, single-photon emission computed tomography; UA, unstable angina and vs., versus. 
 
Data Supplements 3 to 17 pertain to the Revascularization Section  
 
Data Supplement 3. Evidence for Survival Benefit After PCI or CABG (With LIMA Grafting to the LAD) in Patients With SIHD Who Are Receiving Medical Therapy 
and Are Suitable Candidates for Revascularization  
Anatomic Subgroups 
 
Evidence Supporting CABG for 
Survival 
Evidence Supporting PCI  
for Survival 
Evidence Supporting Superiority 
of Either CABG or PCI for 
Survival 
Evidence Supporting Equivalence 
of CABG and PCI for Survival 
Unprotected left main CAD 
 
 
 
 
 
 
 
 
 
 
 
 
SYNTAX score <33 
 
SYNTAX score ≥33 
CASS Registry* (53, 54) 
CASS† (55) 
VA Cooperative† (56, 57) 
Yusuf et al.† (58) 
Dzavik et al.* (59) 
None found CABG better: 
Wu* (60) 
 
PCI better: 
None found 
 
 
 
 
 
 
 
 
SYNTAX†(61) 
 
SYNTAX† (61) 
SYNTAX† (62) 
LE MANS† (63) 
Boudriot et al.† (64) 
Chieffo et al.* (65, 66) 
Lee et al.* (67) 
Lee et al.§ (68) 
Naik et al.§ (69) 
White et al.* (70) 
Palmerini et al.* (71) 
Park et al.* (72) 
Sanmartín et al.* (73) 
Brener et al.* (74) 
Mäkikallio et al.* (75) 
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3-vessel disease with or without 
proximal LAD disease 
 
 
For: 
Dzavik et al.* (59) 
ECSS† (76) 
Jones et al.* (77) 
MASS II* (78) 
Myers et al.† (79) 
Smith et al.* (80) 
SYNTAX†(61) 
Yusuf et al.† (58) 
For: 
Dzavik et al.* (59) 
Smith et al.* (80) 
 
Against: 
Boden et al.† (81) 
 
 
CABG better: 
Bair et al.* (82) 
Booth et al.† (83) 
Hannan et al.* (84) 
Hannan et al.* (85) 
Jones et al.* (77) 
MASS II* (78) 
Malenka et al.* (86) 
 
Bravata et al.† (87) 
Daemen et al.† (88) 
Dzavik et al.* (59) 
ERACI II† (89)  
Mercado et al.† (90) 
RITA I† (91) 
Van Domburg et al.* (92) 
2-vessel disease with proximal LAD 
disease 
 
For: 
ECSS† (76) 
Jones et al.* (77) 
Smith et al.* (80) 
Yusuf et al.† (58) 
For: 
Dzavik et al.* (59) 
Jones et al.* (77) 
Smith et al.* (80) 
 
Against: 
Boden et al.† (81) 
CABG better: 
Hannan et al.* (84) 
Hannan et al.* (85) 
Hannan et al.* (93) 
Jones et al.* (77) 
 
Berger et al.† (94) 
ERACI II† (89)  
Malenka et al.* (86) 
 
2-vessel disease without proximal LAD 
disease 
For: 
Smith et al.* (80) 
 
For: 
Jones et al.* (77) 
Smith et al.* (80) 
 
Against: 
Boden et al.† (81) 
Cecil et al.† (95) 
Pitt et al.† (96) 
CABG better: 
Bair et al.* (82) 
Booth et al.† (83) 
Dzavik et al.* (59) 
Hannan et al.* (93) 
Hannan et al.* (85) 
Jones et al.* (77) 
 
Bravata et al.† (87) 
Daemen et al.† (88) 
Dzavik et al.* (59) 
Jones et al.* (77) 
Mercado et al.† (90) 
van Domburg et al.* (92) 
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1-vessel proximal LAD disease 
 
For: 
Smith et al.* (80) 
 
Against: 
Greenbaum et al.* (97) 
 
For: 
Jones et al.* (77) 
Smith et al.* (80) 
 
Against: 
Greenbaum et al.* (97) 
 
CABG better: 
Hannan et al. (84) 
Aziz et al.† (98) 
Ben-Gal et al.* (99) 
Bravata et al.† (87) 
Cisowski et al.§ (100) 
Diegeler et al.† (101) 
Drenth et al.† (102) 
Fraund et al.* (103) 
Goy et al.† (104, 105) 
Greenbaum et al.* (97) 
Hong et al.† (106) 
Jaffery et al.† (107) 
Jones et al.* (77) 
Kapoor et al.† (108) 
MASS I† (109) 
1-vessel disease without proximal LAD 
involvement 
 
Against: 
Jones et al.* (77) 
Smith et al.* (80) 
Yusuf et al.† (58) 
Against: 
Jones et al.* (77) 
PCI better: 
Hannan et al.* (84) 
Jones et al * (77) 
Jones et al.* (77) 
 
Multivessel CAD, DM present For: 
MASS II† (110) 
Sorajja et al.* (111) 
 
No benefit: 
BARI 2D† (112) 
For: 
MASS II† (110) 
 
No effect: 
BARI 2D† (112) 
Sorajja et al.* (111) 
 
CABG better: 
BARI I† (113, 114) 
Brener et al.* (115) 
Hlatky et al.† (116) 
Javaid et al.* (117) 
Malenka et al.* (86) 
Niles et al.* (118) 
Pell et al.* for 3-V CAD (119) 
Weintraub et al.† (120) 
ARTS I* (121) 
Bair et al.* (82) 
Barsness et al.* (122) 
Bravata et al.† (87) 
CARDia† (123) 
Dzavik et al.* (59) 
MASS II† (110) 
Pell et al.* for 2-V CAD  
(119) 
*Observational study, including articles on long-term follow-up, clinical trials not specified as randomized, comparative registry studies, comparative studies, prospective cohort studies, prospective observational studies, prospective 
registries, and prospective studies. †Randomized controlled trials, including meta-analyses. ‡Reviews (systematic or not). §Unknown study design.  
 
ARTS indicates Arterial Revascularization Therapies Study Part; AWESOME, Angina With Extremely Serious Operative Mortality Evaluation; BARI I,  Bypass Angioplasty Revascularization Investigation I; BARI 2D, Bypass 
Angioplasty Revascularization Investigation 2 Diabetes; CAD, coronary artery disease; CARDIA, Coronary Artery Revascularization in Diabetes; DM, diabetes mellitus; ECSS, European Coronary Surgery Study; ERACI II, Argentine 
Randomized Trial of Percutaneous Transluminal Coronary Angioplasty versus Coronary Artery Bypass Surgery in Multivessel Disease II; LAD,  left anterior descending; LIMA, left internal mammary artery; MASS,  Medicine, 
Angioplasty, or Surgery Study;  RITA, Randomised Intervention Treatment of Angina; SIHD, stable ischemic heart disease; SYNTAX, Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; V, vessel; 
and VA, Veterans Administration. 
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Data Supplement 4. Evidence for Relief of Unacceptable Angina in Subsets of Patients With SIHD Who are Receiving GDMT and Have Anatomy Suitable for 
Revascularization 
Anatomic Subgroups Evidence Supporting CABG + 
GDMT for Angina 
Evidence Supporting PCI + GDMT 
for Angina 
Evidence Supporting Superiority 
of either CABG or PCI for Angina
Evidence Supporting Equivalence of 
CABG and PCI for Angina 
Multivessel CAD Benefit: 
Benzer et al.* (124) 
Bonaros et al.* (125) 
Favaroto et al.† (126) 
Hofer et al.* (127) 
Lukkarinen et al.* (128) 
MASS II† (78) 
RITA I† (129) 
 
No benefit: 
Lukkarinen et al.* (128) 
 
Benefit: 
Benzer et al.* (124) 
COURAGE† (81, 130) 
Hambrecht et al.‡ (131) 
Hofer et al.* (127) 
MASS II† (78) 
RITA I† (129) 
RITA II† (132) 
Wijeysundera et al.‡ (133) 
CABG better:    
Benzer et al.* (124) 
Bonaros et al.* (125) 
Lukkarinen et al.* (128) 
RITA I† (129) 
 
PCI better:   
None found 
 
 
Hofer et al.* (127) 
MASS II et al.† (78) 
Takagi et al.‡ (134) 
1-vessel CAD excluding the proximal 
LAD 
No data found Hambrecht et al.† (131) 
Parisi et al.† (135) 
Pitt et al.† (96) 
Pocock et al.† (132) 
No data found No data found 
1-vessel CAD involving the proximal 
LAD 
MASS I† (109) 
 
Hambrecht et al.† (131) 
Parisi et al.† (135) 
Pitt et al.† (96) 
Pocock et al.† (132) 
 
CABG better: 
Ben-Gal et al.* (99) 
Cisowski et al.† (100) 
Diegeler et al.‡ (101) 
Goy et al.† (104) 
Toutouzas et al.* (130) 
MASS I† (109) 
Cisowski et al.† (136) 
Drenth et al.§ (137) 
Thiele et al.† (138) 
Special Circumstances 
 
Patients with prior CABG and small or 
moderate sized area of ischemia 
No data found Gurfinkel et al.§ (139) 
Pfautsch et al.* (140) 
Subramanian et al.* (141) 
CABG better: 
Weintraub et al.† (142) 
Stephan et al.* (143) 
*Observational study, including articles on long-term follow-up, clinical trials not specified as randomized, comparative registry studies, comparative studies, prospective cohort studies, prospective observational studies, prospective 
registries, and prospective studies. †Randomized controlled trials, including meta-analyses. ‡Reviews (systematic or not). §Unknown study design.  
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ARTS indicates Arterial Revascularization Therapies Study Part; AWESOME, Angina With Extremely Serious Operative Mortality Evaluation; BARI 2D,  Bypass Angioplasty Revascularization Investigation 2 Diabetes; CABG, coronary 
artery bypass graft; CAD, coronary artery disease; CARDia, Coronary Artery Revascularization in Diabetes; COURAGE, Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation; GDMT, guideline-directed medical 
therapy; LAD, left anterior descending artery; LOE, level of evidence; MASS, Medicine, Angioplasty or Surgery Study; PCI, percutaneous coronary intervention; RITA, Randomised Intervention Treatment of Angina; SIHD, stable 
ischemic heart disease; and TIME, Trial of invasive versus medical therapy in elderly patients. 
 
 
 
Data Supplement 5. RCTs of CABG Versus Balloon Angioplasty 
 
Acute Outcome Late Outcome 
 
 
Death % Q Wave MI 
% 
Death % Q Wave MI % Angina % Repeat 
Revascularization % 
Primary 
Endpoint 
Primary 
Endpoint 
Follow-Up i
Years 
Trial No. Age (y) Female CAD CABG/ 
PCI 
CABG/ 
PCI 
CABG/ 
PCI 
CABG/ 
PCI 
CABG/ 
PCI 
CABG/ 
PCI 
 
CABG/ 
PCI 
 
BARI (114, 144, 
145, 146) 
1,829 61 26% MV 1.3/1.1 4.6/2.1 26.5/29 36/36 NA/NA 20/77* D 26.5/29 10 
EAST (147, 
148) 
392 61 26% MV 1.0/1.0 10.3/3.0* 17/21 19.6/16.6 12/20* 27/65* D+MI+T 27.3/28.8 8a 
GABI (149) 359 NA 20% MV 2.5/1.1 8/2.3* 22/25 9.4/4.5 26/29 59/83* A 26/29 13
b 
Toulouse et al. 
(150) 
152 67 23% MV 1.3/1.3 6.6/3.9 10.5/13.2 1.3/5.3 5.3/21.1* 9/29* A 5.2/21.1* 5 
RITA I (91, 129, 
151) 
1,011 57 19% SV/MV 1.2/0.8 
RR: 0.88 (95% 
CI: 0.59 to 
1.29) 
2.4/3.5 9.0/7.7 7.4/10.8 52/78* 11/44* D+MI+T 8.6/9.8 5 
ERACI (152, 
153) 
127 58 13% MV 4.6/1.5 6.2/6.3 4.7/9.5 7.8/7.8 3.2/4.8 6/37* D+MI+A+Revasc 23/53* 3 
MASS (109, 
154) 
142 56 42% SV (LAD) 1.4/1.4 1.4/0 2.9/5.7 7/11 23/25 0/30* D+MI+Revasc 3/24* 3 
Goy et al. (104) 
134 56 20% SV (LAD) 0/0 0/0 2/9 4/15* 
RR: 2.6 (95% 
CI: 1.1 to 5.4; 
p=0.00004)c 
29/26 9/38* D+MI+Revasc 7.6/36.8* 5 
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CABRI (155, 
156) 
1,054 60 22% MV 1.3/1.3 N/A/N/A 2.7/3.9 
RR: 1.42 (95% 
CI: 0.731 to 
2.76; p=0.297) 
3.5/4.9 
RR: 1.42 (95% 
CI: 0.80 to 
2.54; p=0.234) 
10.1/13.9* 
RR: 1.54 (95% CI: 
1.09 to 2.16; 
p=0.012) 
 
9/36* 
RR: 5.23 (95% CI: 
3.90 to 7.03; p<0.001) 
D 2.7/3.9 1 
*Statistically significant; aMortality and repeat revascularization at 8 y, other endpoints at 3 y; bMortality and repeat revascularization at 13 y, other endpoints at 1 y; c Relative risk for combined endpoint cardiac death and MI.  
 
A indicates angina; BARI, Bypass Angioplasty Revascularization Investigation; CAD, coronary artery disease; CABG, coronary artery bypass graft; CABRI, Coronary Angioplasty versus Bypass Revascularization Investigation; CI, 
confidence interval; D, death; EAST, Emory Angioplasty versus Surgery Trial; ERACI, Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty versus Coronary Artery Bypass Surgery in Multivessel Disease; 
GABI, German Angioplasty Bypass Surgery Investigation; LAD, left anterior descending; MASS, Medicine, Angioplasty, or Surgery Study; MI, myocardial infarction; MV, multivessel; NA, not available; No., number; PCI, percutaneous 
coronary intervention; RITA, Randomized Intervention Treatment of Angina; Revasc, repeat revascularization; RR, relative risk; SV, single-vessel; and T, thallium defect. 
 
 
 
Data Supplement 6. RCTs of CABG Versus BMS 
      
Death % Q Wave MI 
% 
Angina 
% 
Repeat 
Revascularization % 
Primary 
Endpoint 
Primary Endpoint % Follow-Up in 
Years 
Trial No. Age (y) Female CAD Enrollment 
Period 
CABG/ 
PCI 
CABG/ 
PCI 
CABG/ 
PCI 
CABG/PCI 
 
CABG/ 
PCI 
 
SIMA (157) 121 59 21% SV 1994-1998 4/2 4/5 5/9 8/24 D+MI+Rep Revasc 
7/31* 2.4 
AWESOME 
(158, 159) 
454 67 NA MV 1995-2000 21/18 NA NA 22/43* D 21/20 5 
MASS II (78) 
408 60 32% MV 1995-2000 25/24 10/13 NA 7.5/41.9 D+MI+Rep 
Revasc 
HR: 1.85 (95% 
CI: 1.39 to 2.47) 
33/42* 10 
ERACI II (153, 
160) 
450 62 21% MV 1996-1998 11.6/7.2 6.2/2.8 18/14 7.2/28.4* D+MI+CVA+Rep 
Revasc 
23.6/34.7* 5 
SoS (161) 
988 61 21% MV 1996-1999 6.8/10.9* 
HR: 2.91 (95% 
CI: 1.29 to 6.53; 
p=0.01) 
8.2/4.9 NA 6/21* 
HR: 3.85 (95% CI: 2.56 to 
5.79; p<0.0001) 
Rep Revasc 6/21* 6 
ARTS I  (162) 
1205 61 24% MV 1997-1998 7.6/8.0 
RR: 1.05 (95% 
CI: 0.71 to 1.55; 
p=0.83) 
5.6/6.7 
RR: 1.19 (95% 
CI: 0.76 to 1.85; 
p=0.47) 
NA 8.8/30.3* 
RR: 3.46 (95% CI: 2.61 to 
4.60; p<0.001) 
D+MI+CVA+Rep 
Revasc 
21.8/41.7* 
RR: 1.91 (95% CI: 1.60 
to 2.28; p<0.001) 
5 
Drenth et al. 
(102, 137) 
102 61 24% SV 1997-1999 2/0 2/10 15/33 4/16 D+MI+CVA+Rep 
Revasc 
14/29 4 
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Leipzig (101, 
163) 
220 62 25% SV 1997-2001 12/10 
RR: 0.85 (95% 
CI: 0.37 to 1.93; 
p=0.54) 
7/5 
RR: 0.71 (95% 
CI: 0.20 to 2.43; 
p=0.46) 
NA 10/32* 
RR: 3.18 (95% CI: 1.67 to 
6.39; p<0.001) 
 
D+MI+Rep 
Revasc 
29/47* 
RR: 1.64 (95% CI: 1.13 
to 2.42; p=0.02) 
5 
Myoprotect (164) 44 70 30% MV 1998-2001 24/22 0/4 NA 5/30 D+MI+Rep Revasc 
29/48* 1 
Octostent (165) 
280 60 29% MV 1998-2000 2.8/0 4.9/4.4 13/22 4.2/15.2 D+MI+CVA+Rep 
Revasc 
9.5/14.5 
RR: 0.93 (95% CI: 0.86 
to 1.02) 
1 
AMIST (166) 100 57 22% SV 1999-2001 25/30 0/4 8/10 0/4 D+MI+Rep Revasc+T 
28/34 1 
Cisowski et  al. 
(100, 136)  
100 54 17% SV 2000-2001 0/3.6 0/0 0/20 0/20 D+MI 0/4 1 
Kim et al. (167) 100 62 35% SV 2000-2001 4.0/4.0 NA 6/19 2/14 NA NA 1 
*Statistically significant. AMIST indicates Angioplasty versus Minimally Invasive Surgery Trial; ARTS, Arterial Revascularization Therapies Study; AWESOME, Angina with Extremely Serious Operative Mortality Evaluation; 
BMS, bare-metal stent; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CI, confidence interval; CVA, cerebrovascular accident; D, death; ERACI, Argentine Randomized Trial of Percutaneous Transluminal 
Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease; MASS, Medicine, Angioplasty, or Surgery Study; MI, myocardial infarction; MIDCAB, minimally invasive direct coronary artery bypass; MV, 
multivessel; NA, not available; Octostent, Long-term comparison of stenting versus off-pump; PCI, percutaneous coronary intervention; RITA, Randomized Intervention Treatment of Angina; RR, relative risk; Rep Revasc, repeat 
revascularization; SIMA, Stenting versus Internal Mammary Artery Study; SoS, Stent or Surgery; SV, single-vessel; and T, thallium defect. 
 
 
 Data Supplement 7.  RCTs of CABG Versus DES 
 
Death % MI % Repeat 
Revascularization % 
Primary Endpoint RR and 95% CI Follow-Up in 
Months 
Trial No. Age 
(y) 
Female CAD Enrollment 
Period 
CABG/PCI CABG/PCI CABG/PCI 
 
CABG/PCI 
  
Hong et al. 
(106) 189 61 36% SV 2003 2.9/0 2.9/1.7 5.9/1.7 
D, MI, Rep 
Revasc 11.7/4.3 N/A 6 
Leipzig (138) 130 66 30% SV 2003-2007 0/0 7.7/1.5* 0/6.2 D+MI+Rep Revasc 7.7/7.7 N/A 12 
SYNTAX 
(168, 169) 1800 65 22% MV 2005-2007 6.7/8.6 3.6/7.1 10.7/19.7 
D+MI+CVA+Rep 
Revasc 20.2/28.0 
MACCE 12 mo 
follow-up; RR: 
1.44 95% CI: 1.15 
to 1.81 
36 
*Statistically significant. CABG indicates coronary artery bypass surgery; CAD, coronary artery disease; CI, confidence interval; CVA, cerebrovascular accident; D, death; MACCE, major adverse cardiac and cerebrovascular events; 
MI, myocardial infarction; N/A, not applicable; No., number of patients; MV, multivessel; PCI, percutaneous coronary intervention; RR, relative risk; Rep Revasc, repeat revascularization; SV, single vessel; and SYNTAX,  Synergy 
Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery. 
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Data Supplement 8. Hazard Ratios in Observational Studies Comparing PCI-DES to CABG  
Study Location No. Patients 
(CABG/PCI) 
Average 
Age (y) 
Female 
Patients % 
CAD Enrollment 
Period 
Combined 
Death/MI/CVA  
HR and 95% CI 
Repeat 
Revascularization  
HR and 95% CI 
MACCE  
HR and 95% CI 
Follow-Up in 
Months 
Park et al. (170) Korea 1,495/1,547 62 29% MVD 2003-2005 
0.7* 
0.53 to 0.91 
2.56* 
1.96 to 3.4 
1.37* 
1.16 to 1.63 31 
Hannan et al. (85) USA 7,437/9,964 66 30% MVD 2003-2004 
0.99 
0.89 to 1.098 
5.88* 
5.31 to 6.51 
2.89* 
2.72 to 3.08 19 
Briguori et al. (171) Italy 149/69 65 29% MVD 2002-2004 
1.03 
0.53 to 1.99 
4.01* 
1.67 to 9.60 
1.48* 
0.91 to 2.43 12 
Yang et al. (172) China 231/235 65 22% MVD 2003-2004 
0.7 
0.33 to 1.49 
13.26* 
4.15 to 42.34 
3.09* 
1.80 to 5.30 25 
Lee et al. (173) USA 103/102 68 35% MVD 2003-N/A 
1.29 
0.68 to 2.46 
6.73* 
2.06 to 21.95 
2.25* 
1.36-3.72 12 
Yang et al. (174) Korea 390/441 63 29% MVD 2003-2004 
0.75 
0.43 to 1.31 
4.26* 
1.78 to 10.15 
1.41* 
0.93 to 2.13 12 
Javaid et al. (117) USA 701/979 65 33% MVD N/A 
1.93 
1.37 to 2.73 
2.43* 
1.73 to 3.41 
2.44* 
1.87 to 3.19 12 
Varani et al. (175) Italy 95/111 65 31% MVD 2003-2005 
0.47* 
0.16 to 1.37 
5.91* 
1.39 to 25.6 
1.52* 
0.70 to 3.28 12 
Tarantini et al. (176) Italy 127/93 66 18% MVD 2005-2005 
0.56 
0.20 to 1.56 
1.91* 
0.62 to 5.83 
0.96* 
0.48 to 1.92 24 
  
         
  
Pooled HR      0.94 4.06 1.86   
              p=0.66 p<0.001 p<0.001   
*Statistically significant. CABG, coronary artery bypass surgery; CAD, coronary artery disease; CI, confidence interval; CVA, cerebrovascular accident; DES, drug-eluting stent; HR, hazard ratio; MACCE, major adverse cardiac 
and cerebrovascular events; MI, myocardial infarction; Mo, months; MVD, multivessel disease; N/A, not available; No, number; PCI, percutaneous coronary intervention, and y, year.  
 
 
 
 
  
        
	
	
	
	
	
		

         

Data Supplement 9. Evidence from RCTs and Cohort Studies Comparing PCI with CABG for Unprotected Left Main CAD 
Study Type of Study/ 
Years of Recruitment 
PCI/CABG  
No. of Patients 
Early Results for PCI Versus CABG 1 to 5-Y Results for PCI Versus CABG 
SYNTAX (62) Randomized/2005-2007 
45% of screened pts with LM disease 
not randomized, 89% of these had 
CABG 
357/348 30-d outcomes not reported 3-y follow-up: MACCE 13.0% vs. 14.3% 
(p=0.60); repeat revascularization 20.0% 
vs. 11.7% (p=0.004); all-cause death 7.3% 
vs. 8.4% (change -0.2%, p=0.64). 
LE MANS (63) Randomized/2001-2004 
65% of screened pts excluded as not 
suitable for both procedures 
52/53 30-d outcomes: death  0% vs. 0%; MI 2% vs. 4% 
(p=NS)  MACCE 2% vs. 14% (p=0.01)                                      
MAE RR: 0.78, p=0.006; MACCE RR: 0.88, p=0.03 
1 y follow-up: death 2% vs. 8% (p=NS); 
MI 2% vs. 6% (p=NS); revascularization 
30% vs. 10% (p=0.01); MACCE 32% vs. 
26% (p=NS); MACCE RR: 1.09 (95% CI: 
0.85 to 1.38); MAE RR: 0.89 (95% CI: 
0.64 to 1.23) 
Boudriot et al. (64) Randomized/2003-2009 
53% of screened pts excluded 
100/201 Early outcomes not reported 12 mo outcomes: death 2.0% vs. 5.0% 
(p<0.001 for noninferiority); death, MI or 
revascularization 19.0% vs. 13.9% 
(p=0.19 for noninferiority) 
Brener et al. (74) Cohort/1997-2006 97/190 In-hospital outcomes: death 3% vs. 4% (p=NS) 3 y follow-up: survival 80% vs. 85%;          
OR: 1.42 (95% CI: 0.56 to 3.63; p=0.14) 
Cedars-Sinai (67, 69, 70) Cohort/2003-2005 67/67 30-d outcomes: death 2% vs. 5% (p=NS); MI 0% vs. 
2% (p=NS); stroke 0% vs. 8% (p=0.03); MACCE 
17% vs. 2%; (p<0.01) 
1-2 y follow-up: propensity-adjusted HR 
for death HR: 1.93 (95% CI: 0.89 to 4.19; 
p=0.10), MACCE HR: 1.83 (95% CI: 1.01 
to 3.32; p=0.05) 
Chieffo et al. (65, 66) Cohort/2002-2004 107/142 In-hospital outcomes: death 0% vs. 2.1% (p=NS);           
MI 9.3% vs. 26.1% (p=0.0009); stroke 0% vs. 2% 
(p=NS) 
5 y adjusted cardiac death OR: 0.50 (95% 
CI: 0.16 to 1.46; p=0.24), cardiac death or 
MI   OR: 0.41 (95% CI: 0.15 to 1.06; 
p=0.06); death, MI, or stroke OR: 0.40 
(95% CI: 0.15 to 0.99; p=0.04); TVR OR: 
4.41(95% CI: 1.83 to 11.37; p=0.0004), 
MACCE OR: 1.58 (95% CI: 0.83 to 3.05; 
p=0.18) 
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MAIN-COMPARE (72, 177) Cohort/2000-2006 1102/1138 30-d outcomes not reported 5-y adjusted risk of death HR: 1.13 (95% 
CI: 0.88 to 1.44, p=0.35), combined 
adjusted risk of death, Q-wave MI, or 
stroke HR: 1.07          ( 95% CI: 0.84 to 
1.37,p=0.59); TVR HR: 5.11  (95% CI: 
3.52 to 7.42,p<0.001) 
Mäkikallio et al. (75) Cohort/2005-2207 49/238 30-d outcomes: death 2% vs. 7% (p=0.13)                                                1-y follow-up: death 4% vs. 11% 
(p=0.14);                             PCI vs. CABG 
(using 1o and 2o endpoint) HR: 2.1 (95% 
CI: 0.7 to 5.8, p= 0.180) 
Palmerini et al. (71) Cohort/2002-2005 157/154 30-d outcomes: death 3.2% vs. 4.5% (p=NS); MI 
4.5% vs. 1.9%,(p=NS); revascularization 0.6% vs. 
0.6% (p=NS) 
1-2 y follow-up: death 13.4% vs. 12.3% 
(p=0.8); MI 8.3% vs. 4.5% (p=0.17); 
revascularization 25.5% vs. 2.6% 
(p=0.0001); PCI vs. CABG mortality HR:  
0.95 (95% CI: 0.51 to 1.77, p=0.861); 
cardiac mortality HR: 0.99, (95% CI: 0.49 
to 2.04, p=0.994); MI  HR: 0.53 (95% CI: 
0.21 to 1.32; p=0.170) 
 
Rodés-Cabau et al. (178) Cohort/2002-2008  104/145 30-d outcomes: MACCE 18.3% vs. 27.6%; death 
6.7% vs. 8.3%; MI 12.5% vs. 17.2%; stroke 1.0% vs. 
5.5% (all p=NS) 
1-2-y follow-up: MACCE 43.3% vs. 35%; 
death 16.3% vs. 12.4%; MI 23.1% 19.3%; 
revascularization 9.6% vs. 4.8%; stroke 
8.75 vs. 6.2% (all NS).                                     
Survival free of cardiac death or MI 
adjusted HR: 1.28 (95% CI: 0.64 to 2.56; 
p=0.47); MACCE-free survival adjusted 
HR: 1.11(95% CI: 0.59 to 2.0; p= 0.73). 
 
Sanmartín et al. (73) Cohort/2000-2005 96/245 30-d outcomes: MACCE after surgery 2.1% vs. 9.0% 
(p=0.03). 
1-y follow-up: MACCE 10.4% vs. 11.4%, 
(p=0.50), repeat revascularization 5.2% 
vs. 0.8% (p=0.02) 
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Wu et al. (60) Cohort/2000-2004 135/135 30-d outcomes: death 5.2% vs. 2.2% (p=0.33) 1-y follow-up: death 16.1% vs. 5.9% OR: 
3.06 (95% CI: 0.99 to 9.45) 
2-y follow-up: death 18.0% vs. 5.9%; HR: 
3.1 (95% CI: 1.42 to 7.14; p=0.005); 
revascularization 37.3% vs. 6.3%; HR: 
6.7; (95% CI: 3.0 to 14.3; p<0.001) 
CABG indicates coronary artery bypass grafting; CI, confidence interval; d, day; HR, hazard ratio; LEMANS, Study of Unprotected Left Main Stenting Versus Bypass Surgery; LM, left main; MACCE, Major adverse cardiac and 
cardiovascular events; MAE, major adverse events; MAIN-COMPARE, Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty versus Surgical Revascularization; MI, 
myocardial infarction; NS, not significant; OR, odds ratio; pts, patients; PCI, percutaneous coronary intervention; RR, relative risk; SYNTAX, Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; 
TVR, target vessel revascularization; and y, year. 
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Data Supplement 10. Forest Plot of 1-Year MACCE Rates After PCI or CABG for Unprotected Left Main CAD 
 
References: (62-67, 69, 70, 72, 177, 178). OR >1 suggest an advantage of CABG over PCI.  
CABG indicates coronary artery bypass surgery; CAD, coronary artery disease; CI, confidence interval; LEMANS, Study of Unprotected Left Main 
Stenting Versus Bypass Surgery; MAIN-COMPARE, Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of 
Percutaneous Coronary Angioplasty versus Surgical Revascularization; MACCE, major adverse cardiac and cerebrovascular event; OR, odds ratio; PCI, 
percutaneous coronary intervention; SYNTAX, Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; and W, 
weighted. 
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Data Supplement 11. Forest Plot of 1-Year Mortality Rates After PCI or CABG for Unprotected Left Main CAD 
 
References: (60, 62-67, 69-72, 75, 177, 178). OR >1 suggest an advantage of CABG over PCI.  
CABG indicates coronary artery bypass surgery; CAD, coronary artery disease; CI, confidence interval; LEMANS, Study of Unprotected Left Main Stenting Versus Bypass Surgery;  
MACCE, major adverse cardiac and cerebrovascular event; MAIN-COMPARE, Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous  
Coronary Angioplasty versus Surgical Revascularization; OR, odds ratio; SYNTAX, Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; and W, weighted. 
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 Data Supplement 12. Forest Plot of 2-Year Mortality Rates After PCI or CABG for Unprotected Left Main CAD 
 
References: (60, 63, 71, 72, 177-179). OR >1 suggest an advantage of CABG over PCI.  
CABG indicates coronary artery bypass surgery; CAD, coronary artery disease; CI, confidence interval; MAIN-COMPARE, Revascularization for Unprotected Left Main Coronary Artery Stenosis:  
Comparison of Percutaneous Coronary Angioplasty versus Surgical Revascularization; OR, odds ratio; PCI, percutaneous coronary intervention; SYNTAX, Synergy Between Percutaneous Coronary  
Intervention with TAXUS and Cardiac Surgery; and W, weighted. 
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Data Supplement 13. Forest Plot of 3-Year Mortality Rates After PCI or CABG (for Unprotected Left Main CAD) 
 
References: (72, 74).  OR >1 suggest an advantage of CABG over PCI.  
CABG indicates coronary artery bypass surgery; CAD, coronary artery disease; CI, confidence interval; MAIN-COMPARE, Revascularization for Unprotected Left Main Coronary Artery Stenosis:  
Comparison of Percutaneous Coronary Angioplasty versus Surgical Revascularization; OR, odds ratio; PCI, percutaneous coronary intervention; and W, weighted.  
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Data Supplement 14. Forest Plot of 5-Year Mortality Rates After PCI or CABG for Unprotected Left Main CAD 
 
 
References: (66, 72). OR >1 suggest an advantage of CABG over PCI.  
CABG indicates coronary artery bypass surgery; CAD, coronary artery disease; CI, confidence interval; MAIN-COMPARE, Revascularization for Unprotected Left Main Coronary  
Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty versus Surgical Revascularization; OR, odds ratio; PCI, percutaneous coronary intervention; and W, weighted. 
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Data Supplement 15. Outcomes of PCI Versus CABG for Patients With Single-Vessel Coronary Disease Involving the Proximal Left Anterior Descending Artery 
Author Type of Study/  
Years of Recruitment 
Number of 
Patients 
PCI/CABG 
Short-Term Results for                                           
PCI Versus CABG 
Long-Term Results for  
PCI Versus CABG 
Greenbaum et al. (97) Retrospective cohort 
1986-1994 
754/149 At 1 y, HR for event-free survival for CABG to 
PCI: 0.20; p<0.0001 
At 2 to 7 y, HR for event-free survival for CABG to PCI: 0.62; 
p=NS 
Goy et al. (104, 105, 180) Randomized  
1994-1998 
68/66 At 2.4 y: death, MI, revascularization 31% vs. 7% 
(p<0.001); death or MI 12% vs. 7% 
At 5 y: death 9% vs. 3% (p=0.09).  
At 10 y: death 10% vs. 10% (p=1.0) 
Cisowski et al. (100) Randomized  
2000-2001 
50/50 At 6 mo: death or MI:  0% vs. 0%; 
 revascularization 12% vs. 2% (p<0.05) 
N/A 
Diegeler et al. (101) Randomized  
1997- 2001 
110/110 At 6 mo: death or MI 3% vs. 6% (p=NS); 
revascularization 29% vs. 8% (p=0.02) 
N/A 
Drenth et al. (102, 137) Randomized 
1997-99 
51/51 At 6 mo: death or MI 6% vs. 10% (p=NS); 
revascularization 4% vs. 8% (p=NS) 
N/A 
Reeves et al. (166) Randomized 
1999-2001 
50/50 In-hospital: death or MI 0% vs. 0% At 1.5 y: death 0% vs. 2% (p=NS); MI 4% vs. 0% (p=NS); 
revascularization 4% vs. 0% (p=NS). 
Survival analysis for MIDCAB vs. PTCA HR: 0.77 (95% CI: 
0.38 to 1.57; p=0.47) 
 
Thiele et al. (138) 
 
Randomized 
1997-2001 
110/110 N/A At 5 y: death 10% vs. 12%  (p=0.54); MI 5% vs. 7% (p=0.46); 
revascularization: 32% vs. 10% (p<0.001) 
Hong et al. (106) Randomized 
2003 
119/70 In-hospital: death or MI 5.1% vs. 4.3% (p=1.00) At 6 mo: death or MI:  6.8% vs. 10.1% (p=NS); 
revascularization 5.9% vs. 1.7% (p=NS) 
MASS I (109, 181) Randomized 
 
72/70 N/A At 3 y: death, MI or revascularization 24% vs. 3% (p=0.006) 
Fraund et al. (103) Cohort 
1998-2001 
256/206 In-hospital death or MI 0.8% vs. 2 % (p=NS) At 3 y: death or MI 4.7% vs. 5.8% (p=NS); 
 revascularization 7.8% vs. 28.9% (p<0.01) 
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Ben-Gal et al. (99) Matched cases from 
prospective cohort  
2002-2003 
(PCI were all DES) 
83/83 30 d death: 0% vs. 1.1% (p=NS) At 22 mo: death 1.1% vs. 5.5% (p=NS); revascularization 16.8% 
vs. 3.6% (p=0.005); independent predictors of MACE (Cox 
analysis) were assignment to the Cypher group (HR:  4.1; 95% 
CI: 1.26 to 13.16), multivessel disease (HR: 4.3; 95% CI: 1.44 to 
13.16), and prior PCI (HR: 4.36; 95% CI: 1.28 to 14.90) 
 
Toutouzas et al. (182) Cohort 147/110 Inhospital: death or MI or revascularization 0% 
vs. 0% 
At 2 y: death:  2.0% vs. 1.8% (p=NS); MI 0% vs. 0.9%; (p=NS); 
revascularization  2% vs. 0% (p=0.51) 
CABG indicates coronary artery bypass graft; CI, confidence interval; d, day; DES, drug-eluting stents; HR, hazard ratio; MASS, Medicine, Angioplasty, or Surgery Study; MIDCAB, minimally invasive direct coronary artery bypass ;MI, 
myocardial infarction; mo, month; NS, not significant; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty and y, year. 
 
 
Data Supplement 16. Cohort Studies Comparing CABG to PCI in Patients With Diabetes 
Author Type of Study/ 
Year of Recruitment 
Number of Patients PCI/CABG Long-Term Results for PCI Versus CABG 
Barsness et al. (122) 
 
Retrospective cohort 
1984-1990 
770 pts with diabetes total At 5 y: Similar mortality for PCI and CABG pts: unadjusted 
86% vs. 89%; p=NS; adjusted 92% vs. 93% 
Weintraub et al. (120) 
 
Cohort 
1981-1994 
834/1,805 At 10 y: death:  64% vs. 53%; p=0.045 for insulin-requiring 
pts with diabetes ONLY                                                      
Insulin-requiring subgroup multivariate HR: 1.35; 95% CI: 
1.01 to 1.79 for PTCA vs. CABG 
Niles et al. (118) 
 
Retrospective cohort 
1992-1996 
2,766 pts with diabetes total At 2 y: higher mortality in PCI pts (HR: 2.0; p=0.038) with 
3-vessel disease. Trend to higher mortality in PCI pts (HR: 
1.3; p=0.2) with 2-vessel disease, compared to CABG 
Van Domburg et al. (92) Cohort 
1970-1985 
76/82 At 20 y: survival similar for PCI vs. CABG pts                       
Mortality for CABG vs. PTCA  RR: 1.03; 95% CI: 0.87 to 
1.24 
 
Brener et al. (115) 
 
Retrospective cohort 
1995-1999 
265/2,054 At 6 y: deaths for NIDDM: 21% vs. 17%; p=0.008 
Deaths for IDDM:  31% vs. 23%; p<0.0001                            
Unadjusted HR: 1.13; 95% CI: 1.0  to 1.4; p=0.07 
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Javaid et al. (117) Retrospective cohort 
DES era 
601 pts with diabetes total 
344/257 
At 1 y: death, stroke, MI, revascularization HR: 3.5; 
(p<0.001) for 2-vessel CAD 
HR: 4.8 (p<0.001) for 3-vessel CAD 
Hueb et al. (110) 
 
Cohort 
1995-2000 
120/221 At 5 y: incidence of cardiac death 11.1% vs. 11.8% (p=NS), 
revascularization 27.5% vs. 3.2% (p<0.001)                            
The incidence of cardiac death was NS different between 
PCI and MT groups  
Bair et al. (82) Subset of large cohort 
1992-2000 
353/1,267 At 15 y: death HR: 0.81; p=0.03 
Hannan et al. (85) 
 
Subset of large cohort 
2003-2004 
2,844/3,256 At 18 mo: death HR: 1.03, p=0.75; death or MI HR: 1.19;  
p=0.07 
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; CI, confidence interval; DES, drug-eluting stent; HR, hazard ratio; IDDM, insulin-dependent diabetes mellitus; MI, myocardial infarction; MT, medical therapy; 
NIDDM, noninsulin-dependent diabetes mellitus; NS, not significant; pts, patients; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; RR, relative risk, and y, year. 
 
 
Data Supplement 17. RCTs of PCI With CABG in Patients With Multivessel CAD and Diabetes 
Author Type of Study in Year of 
Recruitment 
Number of 
Patients PCI/ 
CABG 
Primary Endpoint for PCI and CABG Comments 
SYNTAX (183) Randomized 2005-2007 Overall 903/897 
DM 231/221 
DM: 12-mo death, stroke, MI, or revascularization: 
26.0% vs. 14.2% (HR: 1.83, 95% CI: 1.22 to 1.73; 
p=0.003) 
Criterion for noninferiority of PCI to 
CABG was not met in overall study. 
CARDIa (123) Randomized 2002-2007 DM 256/254 DM: 1-y death, stroke or MI: 13.0% vs. 10.5% 
([OR: 1.25, 95% CI: 0.75 to 2.09; p=0.39) 
Criterion for noninferiority of PCI to 
CABG was not met. 
BARI 2D (112) Prestratified/randomized to 
revascularization-medical therapy 
DM 798/807 Death from any cause: 
•  Medical:  87.8% 
•  Revascularization:  88.3% 
•  P=0.97 
5-y freedom from MACE:  
• PCI vs. medical (77.0% vs. 78.9; 
p=0.15) 
• CABG vs. medical (77.6% vs. 
69.5%; p=0.01) 
•  interaction p=0.002 
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ARTS I (121, 162, 184) Randomized 1997-1998 Overall 600/605 
DM 112/96 
Overall: 5-y overall freedom from death, stroke, or 
MI 18.2% vs. 14.9% (RR: 1.22; 95% CI: 0.95 to 
1.58; p=0.14) 
DM: 1-y freedom from death, stroke, MI, or 
revascularization (63.4% vs. 84.4%; p< 0.001) 
 
MASS II (110) Randomized 1995-2000 Overall 205/203 
DM 56/59 
DM: 1-y death 5.3% vs. 6.8% (p=0.5) 
 
*ARTS indicates Arterial Revascularization Therapies Study; BARI 2D, Bypass Angioplasty Revascularization Investigation 2 Diabetes; CABG, coronary artery bypass graft; CAD, coronary artery disease; CARDIA, Coronary Artery 
Revascularization in Diabetes; CI,  confidence interval; DM, diabetes mellitus; HR, hazard ratio; LAD, left anterior descending artery; LOE, level of evidence; MACE, major adverse cardiac event; MASS II, Medicine, Angioplasty, or 
Surgery Study (MASS II); OR, odds ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention; RR, relative risk; SYNTAX, Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; and y, 
year. 
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